<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21368062</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>9</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept).</ArticleTitle><Pagination><StartPage>3500</StartPage><EndPage>3507</EndPage><MedlinePgn>3500-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5242-10.2011</ELocationID><Abstract><AbstractText>Several mouse models of Alzheimer's disease (AD) with abundant &#x3b2;-amyloid and/or aberrantly phosphorylated tau develop memory impairments. However, multiple non-mnemonic cognitive domains such as attention and executive control are also compromised early in AD individuals. Currently, it is unclear whether mutations in the &#x3b2;-amyloid precursor protein (APP) and tau are sufficient to cause similar, AD-like attention deficits in mouse models of the disease. To address this question, we tested 3xTgAD mice (which express APPswe, PS1M146V, and tauP301L mutations) and wild-type control mice on a newly developed touchscreen-based 5-choice serial reaction time test of attention and response control. The 3xTgAD mice attended less accurately to short, spatially unpredictable stimuli when the attentional demand of the task was high, and also showed a general tendency to make more perseverative responses than wild-type mice. The attentional impairment of 3xTgAD mice was comparable to that of AD patients in two aspects: first, although 3xTgAD mice initially responded as accurately as wild-type mice, they subsequently failed to sustain their attention over the duration of the task; second, the ability to sustain attention was enhanced by the cholinesterase inhibitor donepezil (Aricept). These findings demonstrate that familial AD mutations not only affect memory, but also cause significant impairments in attention, a cognitive domain supported by the prefrontal cortex and its afferents. Because attention deficits are likely to affect memory encoding and other cognitive abilities, our findings have important consequences for the assessment of disease mechanisms and therapeutics in animal models of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Romberg</LastName><ForeName>Carola</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Experimental Psychology, University of Cambridge, Cambridge CB2 3EB, United Kingdom. carola.romberg@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Mughal</LastName><ForeName>Mohamed R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Bussey</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Saksida</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0001354</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000312</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000317</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000313</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000314</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003216" MajorTopicYN="N">Conditioning, Operant</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21368062</ArticleId><ArticleId IdType="mid">NIHMS277798</ArticleId><ArticleId IdType="pmc">PMC3066152</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5242-10.2011</ArticleId><ArticleId IdType="pii">31/9/3500</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Artero S, Ritchie K. The detection of mild cognitive impairment in the general practice setting. Aging Ment Health. 2003;7:251&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">12888436</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley A, Cocchini G, Della Sala S, Logie RH, Spinnler H. Working memory and vigilance: evidence from normal aging and Alzheimer's disease. Brain Cogn. 1999;41:87&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">10536087</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley AD, Baddeley HA, Bucks RS, Wilcock GK. Attentional control in Alzheimer's disease. Brain. 2001;124:1492&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459742</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, Nurra M, Pietropoli A, Samanin R, Carli M. Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635. Psychopharmacology (Berl) 2003;167:28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">12618916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartko SJ, Vendrell I, Saksida LM, Bussey TJ. A computer-automated touchscreen paired-associates learning (PAL) task for mice: impairments following administration of scopolamine or dicyclomine and improvements following donepezil. Psychopharmacology (Berl) 2010 doi: 10.1007/s00213-010-2050-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-010-2050-1</ArticleId><ArticleId IdType="pubmed">21086119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley P, Vuilleumier P, Thiel CM, Driver J, Dolan RJ. Cholinergic enhancement modulates neural correlates of selective attention and emotional processing. Neuroimage. 2003;20:58&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">14527570</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley P, Driver J, Dolan RJ. Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health. Brain. 2008;131:409&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605268</ArticleId><ArticleId IdType="pubmed">18077465</ArticleId></ArticleIdList></Reference><Reference><Citation>Berardi AM, Parasuraman R, Haxby JV. Sustained attention in mild Alzheimer's disease. Dev Neuropsychol. 2005;28:507&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2383280</ArticleId><ArticleId IdType="pubmed">15992254</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Blin J, Ivanoiu A, De Volder A, Michel C, Bol A, Verellen C, Seron X, Duprez T, Laterre EC. Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease. Psychopharmacology (Berl) 1998;136:256&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">9566811</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel A, Sanger DJ, Moser PC. Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies. Psychopharmacology (Berl) 2000;149:293&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">10823411</ArticleId></ArticleIdList></Reference><Reference><Citation>Carli M, Robbins TW, Evenden JL, Everitt BJ. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res. 1983;9:361&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">6639741</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudasama Y, Muir JL. Visual attention in the rat: a role for the prelimbic cortex and thalamic nuclei? Behav Neurosci. 2001;115:417&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">11345966</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudasama Y, Robbins TW. Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. Psychopharmacology (Berl) 2004;174:86&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">15071717</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudasama Y, Passetti F, Rhodes SE, Lopian D, Desai A, Robbins TW. Dissociable aspects of performance on the 5-choice serial reaction time task following lesions of the dorsal anterior cingulate, infralimbic and orbitofrontal cortex in the rat: differential effects on selectivity, impulsivity and compulsivity. Behav Brain Res. 2003;146:105&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643464</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalley JW, McGaughy J, O'Connell MT, Cardinal RN, Levita L, Robbins TW. Distinct changes in cortical acetylcholine and noradrenaline efflux during contingent and noncontingent performance of a visual attentional task. J Neurosci. 2001;21:4908&#x2013;4914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762350</ArticleId><ArticleId IdType="pubmed">11425918</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalley JW, Theobald DE, Bouger P, Chudasama Y, Cardinal RN, Robbins TW. Cortical cholinergic function and deficits in visual attentional performance in rats following 192 IgG-saporin-induced lesions of the medial prefrontal cortex. Cereb Cortex. 2004;14:922&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">15084496</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403.</Citation><ArticleIdList><ArticleId IdType="pubmed">63862</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruin NM, Fransen F, Duytschaever H, Grantham C, Megens AA. Attentional performance of (C57BL/6J &#xd7; 129Sv)F2 mice in the five-choice serial reaction time task. Physiol Behav. 2006;89:692&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987534</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermaut B, Kumar-Singh S, Rademakers R, Theuns J, Cruts M, Van Broeckhoven C. Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. Trends Genet. 2005;21:664&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16221505</ArticleId></ArticleIdList></Reference><Reference><Citation>Foldi NS, White RE, Schaefer LA. Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease. Int J Geriatr Psychiatry. 2005a;20:485&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852461</ArticleId></ArticleIdList></Reference><Reference><Citation>Foldi NS, Schaefer LA, White RE, Johnson R, Jr, Berger JT, Carney MT, Macina LO. Effects of graded levels of physical similarity and density on visual selective attention in patients with Alzheimer's disease. Neuropsychology. 2005b;19:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15656758</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, Neary D, Snowden JS, Wilcock GK. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N Engl J Med. 1985;313:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">2582256</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9:532&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568014</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, Haxby JV, Horwitz B, Sundaram M, Berg G, Schapiro M, Friedland RP, Rapoport SI. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol. 1988;10:576&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">3265710</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. Presenilins: genes for life and death. Neuron. 1997;18:687&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">9182794</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008;1216:92&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">18486110</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff FJ, Growdon JH, Corkin S, Rosen TJ. Age at onset and rate of progression of Alzheimer's disease. J Am Geriatr Soc. 1987a;35:27&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">3794143</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff FJ, Becker JT, Belle SH, Nebes RD, Holland AL, Boller F. Cognitive deficits and clinical diagnosis of Alzheimer's disease. Neurology. 1987b;37:1119&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">3601078</ArticleId></ArticleIdList></Reference><Reference><Citation>Humby T, Laird FM, Davies W, Wilkinson LS. Visuospatial attentional functioning in mice: interactions between cholinergic manipulations and genotype. Eur J Neurosci. 1999;11:2813&#x2013;2823.</Citation><ArticleIdList><ArticleId IdType="pubmed">10457178</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DN, Higgins GA. Effect of scopolamine on visual attention in rats. Psychopharmacology (Berl) 1995;120:142&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">7480545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992;108:485&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">1410164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkby DL, Higgins GA. Characterization of perforant path lesions in rodent models of memory and attention. Eur J Neurosci. 1998;10:823&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">9753151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamar M, Podell K, Carew TG, Cloud BS, Resh R, Kennedy C, Goldberg E, Kaplan E, Libon DJ. Perseverative behavior in Alzheimer's disease and subcortical ischemic vascular dementia. Neuropsychology. 1997;11:523&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambourne SL, Humby T, Isles AR, Emson PC, Spillantini MG, Wilkinson LS. Impairments in impulse control in mice transgenic for the human FTDP-17 tauV337M mutation are exacerbated by age. Hum Mol Genet. 2007;16:1708&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pubmed">17517691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence AD, Sahakian BJ. Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord. 1995;9(Suppl 2):43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">8534423</ArticleId></ArticleIdList></Reference><Reference><Citation>Levinoff EJ, Saumier D, Chertkow H. Focused attention deficits in patients with Alzheimer's disease and mild cognitive impairment. Brain Cogn. 2005;57:127&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15708202</ArticleId></ArticleIdList></Reference><Reference><Citation>McGaughy J, Dalley JW, Morrison CH, Everitt BJ, Robbins TW. Selective behavioral and neurochemical effects of cholinergic lesions produced by intrabasalis infusions of 192 IgG-saporin on attentional performance in a five-choice serial reaction time task. J Neurosci. 2002;22:1905&#x2013;1913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758873</ArticleId><ArticleId IdType="pubmed">11880520</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Cherrier MM, Perryman KM. Differences between Alzheimer's disease and vascular dementia on information processing measures. Brain Cogn. 1997;34:301&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">9220093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirza NR, Stolerman IP. The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacology (Berl) 2000;148:243&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">10755737</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir JL, Dunnett SB, Robbins TW, Everitt BJ. Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp Brain Res. 1992;89:611&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">1644125</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir JL, Everitt BJ, Robbins TW. AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. J Neurosci. 1994;14:2313&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577145</ArticleId><ArticleId IdType="pubmed">7512637</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, Brown M, Martin B, Iyun T, Maudsley S, Clark RF, Mattson MP. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007;205:166&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1979096</ArticleId><ArticleId IdType="pubmed">17368447</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003a;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003b;24:1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643377</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y, Leslie FM, LaFerla FM. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2005;102:3046&#x2013;3051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549455</ArticleId><ArticleId IdType="pubmed">15705720</ArticleId></ArticleIdList></Reference><Reference><Citation>Passetti F, Chudasama Y, Robbins TW. The frontal cortex of the rat and visual attentional performance: dissociable functions of distinct medial prefrontal subregions. Cereb Cortex. 2002;12:1254&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427677</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Stolerman IP, Asherson P, Sluyter F. Attentional performance of C57BL/6 and DBA/2 mice in the 5-choice serial reaction time task. Behav Brain Res. 2006;170:197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">16616787</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattij T, Janssen MC, Loos M, Smit AB, Schoffelmeer AN, van Gaalen MM. Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains. Genes Brain Behav. 2007;6:579&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116168</ArticleId></ArticleIdList></Reference><Reference><Citation>Pekkala S, Albert ML, Spiro A, 3rd, Erkinjuntti T. Perseveration in Alzheimer's disease. Dement Geriatr Cogn Disord. 2008;25:109&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">18075249</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholineterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978;4:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">703927</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RJ, Hodges JR. Attention and executive deficits in Alzheimer's disease. A critical review. Brain. 1999;122:383&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10094249</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RJ, Hodges JR. Differentiating frontal and temporal variant frontotemporal dementia from Alzheimer's disease. Neurology. 2000;54:2277&#x2013;2284.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881252</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RJ, Hodges JR. Dissociation between top-down attentional control and the time course of visual attention as measured by attentional dwell time in patients with mild cognitive impairment. Eur J Neurosci. 2003;18:221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887404</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RJ, Watson P, Hodges JR. The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia. 2000;38:252&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678692</ArticleId></ArticleIdList></Reference><Reference><Citation>Piquard A, Lacomblez L, Derouesn&#xe9; C, Si&#xe9;roff E. Problems inhibiting attentional capture by irrelevant stimuli in patients with frontotemporal dementia. Brain Cogn. 2009;70:62&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">19162388</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid W, Broe G, Creasey H, Grayson D, McCusker E, Bennett H, Longley W, Sulway MR. Age at onset and pattern of neuropsychological impairment in mild early-stage Alzheimer disease. A study of a community-based population. Arch Neurol. 1996;53:1056&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">8859068</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins TW. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002;163:362&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">12373437</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins TW, Granon S, Muir JL, Durantou F, Harrison A, Everitt BJ. Neural systems underlying arousal and attention. Implications for drug abuse. Ann N Y Acad Sci. 1998;846:222&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">9668410</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Black SE, Robillard A, Lussier I. Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey. Int J Geriatr Psychiatry. 2004;19:954&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">15449367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 1989;154:797&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">2597885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahakian BJ, Coull JT. Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB. Acta Neurol Scand. 1993;(Suppl 149):29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">8128835</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Crockford HA, Crooks M, Hill K, Levy R. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl) 1993;110:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">7870908</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8:447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Hansen LA, Alford M, Masliah E, Thal LJ, Corey-Bloom J. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology. 2000;55:1278&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087768</ArticleId></ArticleIdList></Reference><Reference><Citation>Traykov L, Baudic S, Raoux N, Latour F, Rieu D, Smagghe A, Rigaud AS. Patterns of memory impairment and perseverative behavior discriminate early Alzheimer's disease from subcortical vascular dementia. J Neurol Sci. 2005;229&#x2013;230:75&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">15760623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Greig NH, Yu QS, Mattson MP. Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices. Neurobiol Aging. 2009;30:1061&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717610</ArticleId><ArticleId IdType="pubmed">18068871</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh KA, Butters N, Hughes JP, Mohs RC, Heyman A. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's disease. Arch Neurol. 1992;49:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">1580805</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Au KS. Cholinergic receptors in aging and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:665&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">3541056</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuede CM, Dong H, Csernansky JG. Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol. 2007;18:347&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666934</ArticleId><ArticleId IdType="pubmed">17762506</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahs KR, Ashe KH. &#x2018;Too much good news&#x2019;&#x2014;are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 2010;33:381&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">20542579</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21368173</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells.</ArticleTitle><Pagination><StartPage>4441</StartPage><EndPage>4446</EndPage><MedlinePgn>4441-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1100650108</ELocationID><Abstract><AbstractText>Frontotemporal lobar degeneration is a progressive neurodegenerative syndrome that is the second most common cause of early-onset dementia. Mutations in the progranulin gene are a major cause of familial frontotemporal lobar degeneration [Baker M, et al. (2006) Nature 442:916-919 and Cruts M, et al. (2006) Nature 442:920-924]. Although progranulin is involved in wound healing, inflammation, and tumor growth, its role in the nervous system and the mechanism by which insufficient levels result in neurodegeneration are poorly understood [Eriksen and Mackenzie (2008) J Neurochem 104:287-297]. We have characterized the normal function of progranulin in the nematode Caenorhabditis elegans. We found that mutants lacking pgrn-1 appear grossly normal, but exhibit fewer apoptotic cell corpses during development. This reduction in corpse number is not caused by reduced apoptosis, but instead by more rapid clearance of dying cells. Likewise, we found that macrophages cultured from progranulin KO mice displayed enhanced rates of apoptotic-cell phagocytosis. Although most neurodegenerative diseases are thought to be caused by the toxic effects of aggregated proteins, our findings suggest that susceptibility to neurodegeneration may be increased by a change in the kinetics of programmed cell death. We propose that cells that might otherwise recover from damage or injury are destroyed in progranulin mutants, which in turn facilitates disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kao</LastName><ForeName>Aimee W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Departments of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenhut</LastName><ForeName>Robin J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Lauren Herl</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bagley</LastName><ForeName>Josh A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>de Luis</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Neukomm</LastName><ForeName>Lukas J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Cabello</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Farese</LastName><ForeName>Robert V</ForeName><Initials>RV</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Kenyon</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS059604</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG11816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS59604</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029742">Caenorhabditis elegans Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077155">Granulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120204">Grn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029742" MajorTopicYN="N">Caenorhabditis elegans Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004625" MajorTopicYN="N">Embryo, Nonmammalian</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077155" MajorTopicYN="N">Granulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21368173</ArticleId><ArticleId IdType="pmc">PMC3060230</ArticleId><ArticleId IdType="doi">10.1073/pnas.1100650108</ArticleId><ArticleId IdType="pii">1100650108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neary D, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GD, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet. 2005;37:806&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15:2988&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950801</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, et al. French Research Network on FTD/FTD-MND Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat. 2007;28:846&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">17436289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, Mackenzie IR. Progranulin: Normal function and role in neurodegeneration. J Neurochem. 2008;104:287&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">17953663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71:1235&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18768919</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132:583&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664450</ArticleId><ArticleId IdType="pubmed">19158106</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65:603&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">19288468</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007;64:1436&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923627</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology. 2008;71:656&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">18565828</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, et al. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology. 2008;71:253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184915</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan J, et al. An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:747&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">19016491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman A, Bennett HP. The granulin gene family: From cancer to dementia. Bioessays. 2009;31:1245&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">19795409</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel R, He Z, Carmichael KP, Halper J, Bateman A. Cellular localization of gene expression for progranulin. J Histochem Cytochem. 2000;48:999&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">10858277</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D, Lippa CF, Rosso A. Progranulin (PGRN) expression in ALS: An immunohistochemical study. J Neurol Sci. 2009;276:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">18848708</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol. 2008;181:37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2287280</ArticleId><ArticleId IdType="pubmed">18378771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan CL, et al. Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci. 2009;10:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779192</ArticleId><ArticleId IdType="pubmed">19860916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187:761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulston JE, Schierenberg E, White JG, Thomson JN. The embryonic cell lineage of the nematode Caenorhabditis elegans. Dev Biol. 1983;100:64&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">6684600</ArticleId></ArticleIdList></Reference><Reference><Citation>L'Etoile ND, Bargmann CI. Olfaction and odor discrimination are mediated by the C. elegans guanylyl cyclase ODR-1. Neuron. 2000;25:575&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774726</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddien PW, Cameron S, Horvitz HR. Phagocytosis promotes programmed cell death in C. elegans. Nature. 2001;412:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">11449278</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaham S, Reddien PW, Davies B, Horvitz HR. Mutational analysis of the Caenorhabditis elegans cell-death gene ced-3. Genetics. 1999;153:1655&#x2013;1671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1460877</ArticleId><ArticleId IdType="pubmed">10581274</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeppner DJ, Hengartner MO, Schnabel R. Engulfment genes cooperate with ced-3 to promote cell death in Caenorhabditis elegans. Nature. 2001;412:202&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">11449279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinchen JM, et al. Two pathways converge at CED-10 to mediate actin rearrangement and corpse removal in C. elegans. Nature. 2005;434:93&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">15744306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurwitz ME, et al. Abl kinase inhibits the engulfment of apoptotic [corrected] cells in Caenorhabditis elegans. PLoS Biol. 2009;7:e99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672617</ArticleId><ArticleId IdType="pubmed">19402756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Sonstein J, Christensen PJ, Punturieri A, Curtis JL. Deficient in vitro and in vivo phagocytosis of apoptotic T cells by resident murine alveolar macrophages. J Immunol. 2000;165:2124&#x2013;2133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513940</ArticleId><ArticleId IdType="pubmed">10925298</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Ong CH, Halper J, Bateman A. Progranulin is a mediator of the wound response. Nat Med. 2003;9:225&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">12524533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009;64:110&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834890</ArticleId><ArticleId IdType="pubmed">19840553</ArticleId></ArticleIdList></Reference><Reference><Citation>Albeck JG, et al. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell. 2008;30:11&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858979</ArticleId><ArticleId IdType="pubmed">18406323</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm M, Huber HJ, Dussmann H, Prehn JH. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J. 2006;25:4338&#x2013;4349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1570423</ArticleId><ArticleId IdType="pubmed">16932741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanocco-Marani T, et al. Biological activities and signaling pathways of the granulin/epithelin precursor. Cancer Res. 1999;59:5331&#x2013;5340.</Citation><ArticleIdList><ArticleId IdType="pubmed">10537317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nykjaer A, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature. 2004;427:843&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron. 2010;68:654&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990962</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggests a role for progranulin in successful aging. Am J Pathol. 2010;177:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: A mouse model of frontotemporal dementia. FASEB J. 2010 10.1096/fj.10-161471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci. 2010;13:411&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072212</ArticleId><ArticleId IdType="pubmed">20305648</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77:71&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnabel R, Hutter H, Moerman D, Schnabel H. Assessing normal embryogenesis in Caenorhabditis elegans using a 4D microscope: Variability of development and regional specification. Dev Biol. 1997;184:234&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">9133433</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21376239</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Astrocyte-neuron lactate transport is required for long-term memory formation.</ArticleTitle><Pagination><StartPage>810</StartPage><EndPage>823</EndPage><MedlinePgn>810-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2011.02.018</ELocationID><Abstract><AbstractText>We report that, in the rat hippocampus, learning leads to a significant increase in extracellular lactate levels that derive from glycogen, an energy reserve selectively localized in astrocytes. Astrocytic glycogen breakdown and lactate release are essential for long-term but not short-term memory formation, and for the maintenance of long-term potentiation (LTP) of synaptic strength elicited in vivo. Disrupting the expression of the astrocytic lactate transporters monocarboxylate transporter 4 (MCT4) or MCT1 causes amnesia, which, like LTP impairment, is rescued by L-lactate but not equicaloric glucose. Disrupting the expression of the neuronal lactate transporter MCT2 also leads to amnesia that is unaffected by either L-lactate or glucose, suggesting that lactate import into neurons is necessary for long-term memory. Glycogenolysis and astrocytic lactate transporters are also critical for the induction of molecular changes required for memory formation, including the induction of phospho-CREB, Arc, and phospho-cofilin. We conclude that astrocyte-neuron lactate transport is required for long-term memory formation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Akinobu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Bozdagi</LastName><ForeName>Ozlem</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Huntley</LastName><ForeName>George W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Ruth H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Magistretti</LastName><ForeName>Pierre J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Alberini</LastName><ForeName>Cristina M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-MH065635</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH074736</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH065635</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH087004</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH074736</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32-MH087004</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050113">Imino Furanoses</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027501">Monocarboxylic Acid Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009124">Muscle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498648">Slc16a4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013402">Sugar Alcohols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027981">Symporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C421223">monocarboxylate transport protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>100937-53-9</RegistryNumber><NameOfSubstance UI="C058137">1,4-dideoxy-1,4-iminoarabinitol</NameOfSubstance></Chemical><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-79-2</RegistryNumber><NameOfSubstance UI="D006003">Glycogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>B40ROO395Z</RegistryNumber><NameOfSubstance UI="D001089">Arabinose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2011 Mar 4;144(5):644-5. doi: 10.1016/j.cell.2011.02.027.</RefSource><PMID Version="1">21376229</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001089" MajorTopicYN="N">Arabinose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006003" MajorTopicYN="N">Glycogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050113" MajorTopicYN="N">Imino Furanoses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057567" MajorTopicYN="Y">Memory, Long-Term</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027501" MajorTopicYN="N">Monocarboxylic Acid Transporters</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009124" MajorTopicYN="N">Muscle Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013402" MajorTopicYN="N">Sugar Alcohols</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027981" MajorTopicYN="N">Symporters</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21376239</ArticleId><ArticleId IdType="mid">NIHMS274885</ArticleId><ArticleId IdType="pmc">PMC3073831</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2011.02.018</ArticleId><ArticleId IdType="pii">S0092-8674(11)00132-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol. Rev. 2009;89:121&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883056</ArticleId><ArticleId IdType="pubmed">19126756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamburg JR, McGough A, Ono S. Putting a new twist on actin: ADF/cofilins modulate actin dynamics. Trends Cell. Biol. 1999;9:364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">10461190</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozdagi O, Nagy V, Kwei KT, Huntley GW. In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. J. Neurophysiol. 2007;98:334&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4415272</ArticleId><ArticleId IdType="pubmed">17493927</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramham CR, Worley PF, Moore MJ, Guzowski JF. The immediate early gene arc/arg3.1: regulation, mechanisms, and function. J. Neurosci. 2008;28:11760&#x2013;11767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615463</ArticleId><ArticleId IdType="pubmed">19005037</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks GA. Cell-cell and intracellular lactate shuttles. J. Physiol. 2009;587:5591&#x2013;5600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805372</ArticleId><ArticleId IdType="pubmed">19805739</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AM, Baltan Tekkok S, Ransom BR. Energy transfer from astrocytes to axons: the role of CNS glycogen. Neurochem. Int. 2004;45:529&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15186919</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LY, Rex CS, Casale MS, Gall CM, Lynch G. Changes in synaptic morphology accompany actin signaling during LTP. J. Neurosci. 2007;27:5363&#x2013;5372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672340</ArticleId><ArticleId IdType="pubmed">17507558</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke DD, Sokoloff L. Circulating and energy metabolism of the brain. In: Siegle GJ, Agranoff BW, Albers RW, Molinoff PB, editors. In Basic Neurosciemistry. Raven Press; New York: 1994. pp. 645&#x2013;680.</Citation></Reference><Reference><Citation>DiNuzzo M, Mangia S, Maraviglia B, Giove F. Glycogenolysis in astrocytes supports blood-borne glucose channeling not glycogen-derived lactate shuttling to neurons: evidence from mathematical modeling. J. Cereb. Blood Flow Metab. 2010;30:1895&#x2013;1904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3002884</ArticleId><ArticleId IdType="pubmed">20827264</ArticleId></ArticleIdList></Reference><Reference><Citation>Dringen R, Gebhardt R, Hamprecht B. Glycogen in astrocytes: possible function as lactate supply for neighboring cells. Brain Res. 1993;623:208&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221102</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudai Y. The neurobiology of consolidations, or, how stable is the engram? Annu. Rev. Psychol. 2004;55:51&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744210</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedulov V, Rex CX, Simmons DA, Palmer L, Gall CM, Lynch G. Evidence That Long-Term Potentiation Occurs within Individual Hippocampal Synapses during Learning. J. Neurosci. 2007;27:8031&#x2013;8039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672739</ArticleId><ArticleId IdType="pubmed">17652593</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Schrick C, Spiess J, Radulovic J. Distinct roles of hippocampal de novo protein synthesis and actin rearrangement in extinction of contextual fear. J. Neurosci. 2004;24:1962&#x2013;1966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730386</ArticleId><ArticleId IdType="pubmed">14985438</ArticleId></ArticleIdList></Reference><Reference><Citation>Fray AE, Forsyth RJ, Boutelle MG, Fillenz M. The mechanisms controlling physiologically stimulated changes in rat brain glucose and lactate: a microdialysis study. J. Physiol. 1996;496:49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160823</ArticleId><ArticleId IdType="pubmed">8910195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Cheung YY, Mansfield BC, Chou JY. Brain contains a functional glucose-6-phosphatase complex capable of endogenous glucose production. J. Biol. Chem. 2005;280:11114&#x2013;11119.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs ME, Anderson DG, Hertz L. Inhibition of glycogenolysis in astrocytes interrupts memory consolidation in young chickens. Glia. 2006;54:214&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">16819764</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs ME, Lloyd HG, Santa T, Hertz L. Glycogen is a preferred glutamate precursor during learning in 1-day-old chick: biochemical and behavioral evidence. J. Neurosci. Res. 2007;85:3326&#x2013;3333.</Citation><ArticleIdList><ArticleId IdType="pubmed">17455305</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon GR, Choi HB, Rungta RL, Ellis-Davies GC, MacVicar BA. Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature. 2008;456:745&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4097022</ArticleId><ArticleId IdType="pubmed">18971930</ArticleId></ArticleIdList></Reference><Reference><Citation>Halassa MM, Florian C, Fellin T, Munoz JR, Lee SY, Abel T, Haydon PG, Frank MG. Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. Neuron. 2009;61:213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673052</ArticleId><ArticleId IdType="pubmed">19186164</ArticleId></ArticleIdList></Reference><Reference><Citation>Halassa MM, Haydon PG. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 2010;72:335&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117429</ArticleId><ArticleId IdType="pubmed">20148679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamprecht B, Verleysdonk S, Wiesinger H. Enzymes of carbohydrate and energy metabolism. In: Kettenmann H, Ransom BR, editors. Neuroglia. 2nd ed. Oxford University Press; New York: 2005. pp. 202&#x2013;215.</Citation></Reference><Reference><Citation>Hashimoto T, Hussien R, Oommen S, Gohil K, Brooks GA. Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis. FASEB J. 2007;21:2602&#x2013;2612.</Citation><ArticleIdList><ArticleId IdType="pubmed">17395833</ArticleId></ArticleIdList></Reference><Reference><Citation>Henneberger C, Papouin T, Oliet SH, Rusakov DA. Long-term potentiation depends on release of D-serine from astrocytes. Nature. 2010;463:232&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807667</ArticleId><ArticleId IdType="pubmed">20075918</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrero-Mendez A, Almeida A, Fern&#xe1;ndez E, Maestre C, Moncada S, Bola&#xf1;os JP. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat. Cell Biol. 2009;11:747&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">19448625</ArticleId></ArticleIdList></Reference><Reference><Citation>Impey S, Smith DM, Obrietan K, Donahue R, Wade C, Storm DR. Stimulation of cAMP response element (CRE)-mediated transcription during contextual learning. Nat. Neurosci. 1998;1:595&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196567</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahanshahi M, Sadeghi Y, Hosseini A, Naghdi N, Marjani A. The effect of spatial learning on the number of astrocytes in the CA3 subfield of the rat hippocampus. Singapore Med. J. 2008a;49:388&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">18465048</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahanshahi M, Sadeghi Y, Hosseini A, Naghdi N, Piriaie A. Working memory learning method and astrocytes number of different subfields of rat's hippocampus. Am. J. Anim. Vet. Sci. 2008b;3:28&#x2013;31.</Citation></Reference><Reference><Citation>Jourdain P, Bergersen LH, Bhaukaurally K, Bezzi P, Santello M, Domercq M, Matute C, Tonello F, Gundersen V, Volterra A. Glutamate exocytosis from astrocytes controls synaptic strength. Nat. Neurosci. 2007;10:331&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">17310248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001;294:1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">11691980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasischke KA, Vishwasrao HD, Fisher PJ, Zipfel WR, Webb WW. Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science. 2004;305:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15232110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Ransom BR. Neuroglia. 2nd ed. Oxford University Press; New York: 2005.</Citation></Reference><Reference><Citation>Klann E, Sweatt JD. Altered protein synthesis is a trigger for long-term memory formation. Neurobiol. Learn. Mem. 2008;89:247&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323606</ArticleId><ArticleId IdType="pubmed">17919940</ArticleId></ArticleIdList></Reference><Reference><Citation>Leutgeb JK, Frey JU, Behnisch T. Single cell analysis of activity-dependent cyclic AMP-responsive element-binding protein phosphorylation during long-lasting long-term potentiation in area CA1 of mature rat hippocampal-organotypic cultures. Neuroscience. 2005;131:601&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">15730866</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J. Exp. Biol. 2006;209:2304&#x2013;2311.</Citation><ArticleIdList><ArticleId IdType="pubmed">16731806</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ. Brain energy metabolism. In: Squire LR, Berg D, Bloom FE, du Lac S, Ghosh A, Spitzer NC, editors. Fundamental Neuroscience. 3rd ed. Academic Press; San Diego: 2008. pp. 271&#x2013;293.</Citation></Reference><Reference><Citation>Magistretti PJ, Morrison JH. Noradrenaline- and vasoactive intestinal peptide-containing neuronal systems in neocortex: functional convergence with contrasting morphology. Neuroscience. 1988;24:367&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">2834663</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science. 1999;283:496&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">9988650</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantzura L, Joelsa G, Lamprecht R. Actin polymerization in lateral amygdala is essential for fear memory formation. Neurobiol. Learn. Mem. 2009;91:85&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">18812227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell. Biol. 2001;2:599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483993</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna MC, Rolf Gruetter R, Sonnewald U, Waagepetersen HS, Schousboe A. Energy Metabolism of the Brain. In: Siegel G, Albers RW, Brady S, Price DL, editors. Basic Neurochemistry. Elsevier; London: 2006. pp. 531&#x2013;557.</Citation></Reference><Reference><Citation>McNay EC, Gold PE. Food for thought: fluctuations in brain extracellular glucose provide insight into the mechanisms of memory modulation. Behav. Cogn. Neurosci. Rev. 2002;1:264&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">17712984</ArticleId></ArticleIdList></Reference><Reference><Citation>Messier C. Glucose improvement of memory: a review. Eur. J. Pharmacol. 2004;490:33&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">15094072</ArticleId></ArticleIdList></Reference><Reference><Citation>Panatier A, Theodosis DT, Mothet JP, Touquet B, Pollegioni L, Poulain DA, Oliet SH. Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell. 2006;125:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713567</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. U S A. 1994;91:10625&#x2013;10629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45074</ArticleId><ArticleId IdType="pubmed">7938003</ArticleId></ArticleIdList></Reference><Reference><Citation>Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci. 2009;32:421&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">19615761</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierre K, Pellerin L. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J. Neurochem. 2005;94:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15953344</ArticleId></ArticleIdList></Reference><Reference><Citation>Rex A, Bert B, Fink H, Voigt JP. Stimulus-dependent changes of extracellular glucose in the rat hippocampus determined by in vivo microdialysis. Physiol. Behav. 2009;98:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">19660483</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinholm JE, Hamilton NB, Kessarism N, Richardson WD, Bergersen LH, Attwell D. Regulation of oligodendrocyte development and myelination by glucose and lactate. J. Neurosci. 2011;31:538&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044866</ArticleId><ArticleId IdType="pubmed">21228163</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouach N, Koulakoff A, Abudara V, Willecke K, Giaume C. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science. 2008;322:1551&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056987</ArticleId></ArticleIdList></Reference><Reference><Citation>Schurr A, Miller JJ, Payne RS, Rigor BM. An increase in lactate output by brain tissue serves to meet the energy needs of glutamate-activated neurons. J. Neurosci. 1999;19:34&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782362</ArticleId><ArticleId IdType="pubmed">9870935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotelo C, Palay SL. The fine structure of the lateral vestibular nucleus in the rat. I. Neurons and neuroglial cells. J. Cell Biol. 1968;36:151&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">19866716</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson RA. Physiologic coupling of glial glycogen metabolism to neuronal activity in brain. Can. J. Physiol. Pharmacol. 1992;70:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">1295664</ArticleId></ArticleIdList></Reference><Reference><Citation>Taubenfeld SM, Milekic MH, Monti B, Alberini CM. The consolidation of new but not reactivated memory requires hippocampal C/EBP&#x3b2;. Nat. Neurosci. 2001a;4:813&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">11477427</ArticleId></ArticleIdList></Reference><Reference><Citation>Taubenfeld SM, Wiig KA, Monti B, Dolan B, Pollonini G, Alberini CM. Fornix-dependent induction of hippocampal CCAAT enhancer-binding protein &#x3b2; and &#x3b4; co-localizes with phosphorylated cAMP response element-binding protein and accompanies long-term memory consolidation. J. Neurosci. 2001b;21:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762431</ArticleId><ArticleId IdType="pubmed">11150323</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsacopoulos M, Magistretti PJ. Metabolic coupling between glia and neurons. J. Neurosci. 1996;16:877&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578818</ArticleId><ArticleId IdType="pubmed">8558256</ArticleId></ArticleIdList></Reference><Reference><Citation>Urrila AS, Hakkarainen A, Heikkinen S, Vuori K, Stenberg D, H&#xe4;kkinen AM, Lundbom N, Porkka-Heiskanen T. Stimulus-induced brain lactate: effects of aging and prolonged wakefulness. J. Sleep Res. 2004;13:111&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">15175090</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazdarjanova A, Ramirez-Amaya V, Insel N, Plummer TK, Rosi S, Chowdhury S, Mikhael D, Worley PF, Guzowski JF, Barnes CA. Spatial exploration induces ARC, a plasticity-related immediate-early gene, only in calcium/calmodulin-dependent protein kinase II-positive principal excitatory and inhibitory neurons of the rat forebrain. J. Comp. Neurol. 2006;498:317&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">16871537</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilchez D, Ros S, Cifuentes D, Pujadas L, Vall&#xe8;s J, Garc&#xed;a-Fojeda B, CriadoGarc&#xed;a O, Fern&#xe1;ndez-S&#xe1;nchez E, Medra&#xf1;o-Fern&#xe1;ndez I, Dom&#xed;nguez J, et al. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat. Neurosci. 2007;10:1407&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pubmed">17952067</ArticleId></ArticleIdList></Reference><Reference><Citation>Villasana LE, Klann E, Tejada-Simon MV. Rapid isolation of synaptoneurosomes and postsynaptic densities from adult mouse hippocampus. J. Neurosci. Methods. 2006;158:30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2014514</ArticleId><ArticleId IdType="pubmed">16797717</ArticleId></ArticleIdList></Reference><Reference><Citation>Waagepetersen HS, Westergaard N, Schousboe A. The effects of isofagomine, a potent glycogen phosphorylase inhibitor, on glycogen metabolism in cultured mouse cortical astrocytes. Neurochem. Int. 2000;36:435&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">10733011</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AB, Sickmann HM, Brown A, Bouman SD, Ransom B, Schousboe A, Waagepetersen HS. Characterization of 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) as an inhibitor of brain glycogen shunt activity. J. Neurochem. 2008;105:1462&#x2013;1470.</Citation><ArticleIdList><ArticleId IdType="pubmed">18221367</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science. 2006;313:1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams C, Mehrian Shai R, Wu Y, Hsu YH, Sitzer T, Spann B, McCleary C, Mo Y, Miller CA. Transcriptome analysis of synaptoneurosomes identifies neuroplasticity genes overexpressed in incipient Alzheimer's disease. PLoS One. 2009;4:e4936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654156</ArticleId><ArticleId IdType="pubmed">19295912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Gong N, Wang W, Xu L, Xu TL. Bell-shaped D-serine actions on hippocampal long-term depression and spatial memory retrieval. Cereb. Cortex. 2008;18:2391&#x2013;2401.</Citation><ArticleIdList><ArticleId IdType="pubmed">18281302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21383152</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>22</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta.</ArticleTitle><Pagination><StartPage>5063</StartPage><EndPage>5068</EndPage><MedlinePgn>5063-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1015413108</ELocationID><Abstract><AbstractText>Increasing evidence indicates that cerebrovascular dysfunction plays a pathogenic role in Alzheimer's dementia (AD). Amyloid-&#x3b2; (A&#x3b2;), a peptide central to the pathogenesis of AD, has profound vascular effects mediated, for the most part, by reactive oxygen species produced by the enzyme NADPH oxidase. The mechanisms linking A&#x3b2; to NADPH oxidase-dependent vascular oxidative stress have not been identified, however. We report that the scavenger receptor CD36, a membrane glycoprotein that binds A&#x3b2;, is essential for the vascular oxidative stress and neurovascular dysfunction induced by A&#x3b2;1-40. Thus, topical application of A&#x3b2;1-40 onto the somatosensory cortex attenuates the increase in cerebral blood flow elicited by neural activity or by endothelium-dependent vasodilators in WT mice but not in CD36-null mice (CD36(0/0)). The cerebrovascular effects of infusion of A&#x3b2;1-40 into cerebral arteries are not observed in mice pretreated with CD36 blocking antibodies or in CD36(0/0) mice. Furthermore, CD36 deficiency prevents the neurovascular dysfunction observed in transgenic mice overexpressing the Swedish mutation of the amyloid precursor protein Tg2576 despite elevated levels of brain A&#x3b2;1-40. CD36 is also required for the vascular oxidative stress induced by exogenous A&#x3b2;1-40 or observed in Tg2576 mice. These observations establish CD36 as a key link between A&#x3b2;1-40 and the NADPH oxidase-dependent vascular oxidative stress underlying the neurovascular dysfunction and suggest that CD36 is a potential therapeutical target to counteract the cerebrovascular dysfunction associated with A&#x3b2;.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Laibaik</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neurobiology, Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pitstick</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Previti</LastName><ForeName>Mary Lou</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Van Nostrand</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sunghee</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Anrather</LastName><ForeName>Josef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>George A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Iadecola</LastName><ForeName>Costantino</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS41997</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS037853</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS55118</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS37853</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS055118</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS041997</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018955">CD36 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.3.-</RegistryNumber><NameOfSubstance UI="D019255">NADPH Oxidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018955" MajorTopicYN="N">CD36 Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019255" MajorTopicYN="N">NADPH Oxidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013003" MajorTopicYN="N">Somatosensory Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21383152</ArticleId><ArticleId IdType="pmc">PMC3064396</ArticleId><ArticleId IdType="doi">10.1073/pnas.1015413108</ArticleId><ArticleId IdType="pii">1015413108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010;120:287&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001188</ArticleId><ArticleId IdType="pubmed">20623294</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC. Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res Rev. 2010;9:218&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">20385255</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Bennett DA. Where vascular meets neurodegenerative disease. Stroke. 2010;41(Suppl):S144&#x2013;S146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967303</ArticleId><ArticleId IdType="pubmed">20876491</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Nun Study Healthy aging and dementia: findings from the Nun Study. Ann Intern Med. 2003;139:450&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12965975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskowitz MA, Lo EH, Iadecola C. The science of stroke: Mechanisms in search of treatments. Neuron. 2010;67:181&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957363</ArticleId><ArticleId IdType="pubmed">20670828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipolla MJ. The Cerebral Circulation. San Francisco: Morgan and Claypool; 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">21452434</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811062</ArticleId><ArticleId IdType="pubmed">19471024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson B, Koenigsknecht-Talboo J, Grommes C, Lee CY, Landreth G. Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem. 2006;281:20842&#x2013;20850.</Citation><ArticleIdList><ArticleId IdType="pubmed">16728400</ArticleId></ArticleIdList></Reference><Reference><Citation>Coraci IS, et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol. 2002;160:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867121</ArticleId><ArticleId IdType="pubmed">11786404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianca VD, Dusi S, Bianchini E, Dal Pr&#xe0; I, Rossi F. beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J Biol Chem. 1999;274:15493&#x2013;15499.</Citation><ArticleIdList><ArticleId IdType="pubmed">10336441</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama K, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res. 2004;95:1019&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pubmed">15499027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurol ME, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66:23&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401840</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk EJ, et al. Plasma beta amyloid and impaired CO2-induced cerebral vasomotor reactivity. Neurobiol Aging. 2007;28:707&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698128</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdier Y, Zar&#xe1;ndi M, Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: Binding sites and implications for Alzheimer's disease. J Pept Sci. 2004;10:229&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15160835</ArticleId></ArticleIdList></Reference><Reference><Citation>Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC. Scavenger receptors in neurobiology and neuropathology: Their role on microglia and other cells of the nervous system. Glia. 2002;40:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003;23:2665&#x2013;2674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742111</ArticleId><ArticleId IdType="pubmed">12684452</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Carlson GA, Iadecola C. Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab. 2000;20:1659&#x2013;1668.</Citation><ArticleIdList><ArticleId IdType="pubmed">11129782</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353377</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, et al. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci USA. 2008;105:1347&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234141</ArticleId><ArticleId IdType="pubmed">18202172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole GM, et al. NSAID and antioxidant prevention of Alzheimer's disease: Lessons from in vitro and animal models. Ann N Y Acad Sci. 2004;1035:68&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15681801</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21:8370&#x2013;8377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762797</ArticleId><ArticleId IdType="pubmed">11606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 1999;2:157&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe T, et al. Key role of CD36 in Toll-like receptor 2 signaling in cerebral ischemia. Stroke. 2010;41:898&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950279</ArticleId><ArticleId IdType="pubmed">20360550</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoebe K, et al. CD36 is a sensor of diacylglycerides. Nature. 2005;433:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">15690042</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CR, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11:155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809046</ArticleId><ArticleId IdType="pubmed">20037584</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafilou M, et al. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem. 2006;281:31002&#x2013;31011.</Citation><ArticleIdList><ArticleId IdType="pubmed">16880211</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar Abeta-stimulated microglial activation. J Neurosci. 2009;29:11982&#x2013;11992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="pubmed">19776284</ArticleId></ArticleIdList></Reference><Reference><Citation>Febbraio M, et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999;274:19055&#x2013;19062.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383407</ArticleId></ArticleIdList></Reference><Reference><Citation>Judkins CP, et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE&#x2212;/&#x2212; mice. Am J Physiol Heart Circ Physiol. 2010;298:H24&#x2013;H32.</Citation><ArticleIdList><ArticleId IdType="pubmed">19837950</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Anrather J, Girouard H, Zhou P, Iadecola C. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab. 2007;27:1908&#x2013;1918.</Citation><ArticleIdList><ArticleId IdType="pubmed">17429347</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. Retroviral delivery of homeobox D3 gene induces cerebral angiogenesis in mice. J Cereb Blood Flow Metab. 2004;24:1280&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pubmed">15545924</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21387370</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Apomorphine treatment in Alzheimer mice promoting amyloid-&#x3b2; degradation.</ArticleTitle><Pagination><StartPage>248</StartPage><EndPage>256</EndPage><MedlinePgn>248-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.22319</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Intracellular amyloid &#x3b2;-protein (A&#x3b2;) contributes to neurodegeneration in Alzheimer disease (AD). Apomorphine (APO) is a dopamine receptor agonist for Parkinson disease and also protects against oxidative stress. Efficacy of APO for an AD mouse model and effects of APO on cell cultures are studied.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The triple transgenic AD mouse model (3xTg-AD) has 2 familial AD-related gene mutations (APP(KM670/671NL) /PS1(M146V)) and a tau gene mutation (Tau(P301L)). Six-month-old 3xTg-AD mice were treated with subcutaneous injections of APO once a week for 1 month. Memory function was evaluated by Morris water maze before and after the treatment. Brain tissues were examined by immunohistochemical staining and Western blotting. Effects of APO on intracellular A&#x3b2; degradation, activity of A&#x3b2;-degrading enzymes, and protection against oxidative stress were studied in cultured SH-SY5Y cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After APO treatment, short-term memory function was dramatically improved. Significant decreases in the levels of intraneuronal A&#x3b2;, hyper-phosphorylated tau (p-tau), p53, and heme oxygenase-1 proteins were observed. Moreover, APO promoted degradation of intracellular A&#x3b2;, increased activity of proteasome and insulin-degrading enzyme, protected against H(2) O(2) toxicity, and decreased p53 protein levels in the cultured cells.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">3xTg-AD mice show intraneuronal A&#x3b2; accumulation and memory disturbances before extracellular A&#x3b2; deposition. Our data demonstrating improvement of memory function of 3xTg-AD mice with decreases in intraneuronal A&#x3b2; and p-tau levels by APO treatment strongly suggest that intraneuronal A&#x3b2; is an important therapeutic target and APO will be a novel drug for AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Himeno</LastName><ForeName>Eri</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohyagi</LastName><ForeName>Yasumasa</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Linqing</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Norimichi</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Katsue</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sakae</LastName><ForeName>Nobutaka</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Motomura</LastName><ForeName>Kyoko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Soejima</LastName><ForeName>Naoko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Yamasaki</LastName><ForeName>Ryo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tabira</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Kira</LastName><ForeName>Jun-ichi</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.56</RegistryNumber><NameOfSubstance UI="D007339">Insulysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2011 Feb;69(2):221-5. doi: 10.1002/ana.22359.</RefSource><PMID Version="1">21387363</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007339" MajorTopicYN="N">Insulysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21387370</ArticleId><ArticleId IdType="doi">10.1002/ana.22319</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21389984</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>472</Volume><Issue>7343</Issue><PubDate><Year>2011</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Caspase signalling controls microglia activation and neurotoxicity.</ArticleTitle><Pagination><StartPage>319</StartPage><EndPage>324</EndPage><MedlinePgn>319-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature09788</ELocationID><Abstract><AbstractText>Activation of microglia and inflammation-mediated neurotoxicity are suggested to play a decisive role in the pathogenesis of several neurodegenerative disorders. Activated microglia release pro-inflammatory factors that may be neurotoxic. Here we show that the orderly activation of caspase-8 and caspase-3/7, known executioners of apoptotic cell death, regulate microglia activation through a protein kinase C (PKC)-&#x3b4;-dependent pathway. We find that stimulation of microglia with various inflammogens activates caspase-8 and caspase-3/7 in microglia without triggering cell death in vitro and in vivo. Knockdown or chemical inhibition of each of these caspases hindered microglia activation and consequently reduced neurotoxicity. We observe that these caspases are activated in microglia in the ventral mesencephalon of Parkinson's disease (PD) and the frontal cortex of individuals with Alzheimer's disease (AD). Taken together, we show that caspase-8 and caspase-3/7 are involved in regulating microglia activation. We conclude that inhibition of these caspases could be neuroprotective by targeting the microglia rather than the neurons themselves.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burguillos</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet, 171 76, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deierborg</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kavanagh</LastName><ForeName>Edel</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Persson</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hajji</LastName><ForeName>Nabil</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Garcia-Quintanilla</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cano</LastName><ForeName>Josefina</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brundin</LastName><ForeName>Patrik</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Englund</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Venero</LastName><ForeName>Jose L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061945">Caspase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D051745">Protein Kinase C-delta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053179">Caspase 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053181">Caspase 8</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 May;12(5):246. doi: 10.1038/nrn3026.</RefSource><PMID Version="1">21448223</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053179" MajorTopicYN="N">Caspase 7</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053181" MajorTopicYN="N">Caspase 8</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061945" MajorTopicYN="N">Caspase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017072" MajorTopicYN="N">Neostriatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020258" MajorTopicYN="N">Neurotoxicity Syndromes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051745" MajorTopicYN="N">Protein Kinase C-delta</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21389984</ArticleId><ArticleId IdType="doi">10.1038/nature09788</ArticleId><ArticleId IdType="pii">nature09788</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trends Mol Med. 2007 Nov;13(11):460-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18029230</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 1992 Apr;31(4):616-21</Citation><ArticleIdList><ArticleId IdType="pubmed">1578513</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Apr 3;348(14):1365-75</Citation><ArticleIdList><ArticleId IdType="pubmed">12672865</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2008;14(33):3549-64</Citation><ArticleIdList><ArticleId IdType="pubmed">19075732</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Apr 14;281(15):10073-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16484229</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurodegeneration. 1996 Jun;5(2):137-43</Citation><ArticleIdList><ArticleId IdType="pubmed">8819134</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2009 Nov 4;29(44):13761-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19889988</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1986 Aug;6(8):2163-78</Citation><ArticleIdList><ArticleId IdType="pubmed">3018187</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7464-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8755496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2009 Apr 3;137(1):47-59</Citation><ArticleIdList><ArticleId IdType="pubmed">19345186</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Nov;10(11):1387-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2003 Nov;18(10):2731-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14656322</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2007 Jun;101(6):1567-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17437543</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 1999;22:219-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10202538</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1997 Aug 15;326 ( Pt 1):1-16</Citation><ArticleIdList><ArticleId IdType="pubmed">9337844</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1998 Jan 15;91(2):577-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9427712</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1994 May 1;179(5):1437-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8163930</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2001 Aug-Dec;24(1-3):169-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11831551</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1998 Apr;70(4):1584-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9580157</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Chem. 2003 Oct;10(19):1931-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12871095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 1999 Nov;6(11):1067-74</Citation><ArticleIdList><ArticleId IdType="pubmed">10578175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2007 Jan;8(1):57-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2001 Jun 8;276(23):19746-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11274209</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1999 Aug 20;10(12):2605-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10574377</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2008 Mar 7;132(5):818-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18329368</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2008 May;14(5):501-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 2004 Apr;24(7):2614-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15024053</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 May 15;174(10):6467-76</Citation><ArticleIdList><ArticleId IdType="pubmed">15879150</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1997 Mar 3;185(5):933-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9120399</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15619-24</Citation><ArticleIdList><ArticleId IdType="pubmed">14671317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1995 Feb 10;80(3):401-11</Citation><ArticleIdList><ArticleId IdType="pubmed">7859282</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 1998 Oct;5(10):847-57</Citation><ArticleIdList><ArticleId IdType="pubmed">10203688</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Physiol Biochem. 2007;20(6):947-56</Citation><ArticleIdList><ArticleId IdType="pubmed">17982277</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2008;14(26):2672-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19006850</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 1998 Dec 24;17(25):3237-45</Citation><ArticleIdList><ArticleId IdType="pubmed">9916986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Jul 2;274(27):19115-23</Citation><ArticleIdList><ArticleId IdType="pubmed">10383415</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2000 Jul 3;19(13):3325-36</Citation><ArticleIdList><ArticleId IdType="pubmed">10880445</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2003 Oct 29;358(1438):1669-77</Citation><ArticleIdList><ArticleId IdType="pubmed">14561325</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1995 Jul 6;376(6535):37-43</Citation><ArticleIdList><ArticleId IdType="pubmed">7596430</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15188-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12415117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2005 May;162(1-2):89-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15833363</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2008 May 29;5:23</Citation><ArticleIdList><ArticleId IdType="pubmed">18510752</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2002 Jan 3;21(1):65-77</Citation><ArticleIdList><ArticleId IdType="pubmed">11791177</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1992 Oct 15;149(8):2736-41</Citation><ArticleIdList><ArticleId IdType="pubmed">1383325</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Investig Drugs. 2002 Dec;3(12):1745-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12528311</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2006 Apr 21;1084(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16564033</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1999 Mar;5(3):298-302</Citation><ArticleIdList><ArticleId IdType="pubmed">10086385</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21391952</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Greater risk of Alzheimer's disease in older adults with insomnia.</ArticleTitle><Pagination><StartPage>559</StartPage><EndPage>562</EndPage><MedlinePgn>559-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1532-5415.2010.03288.x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Osorio</LastName><ForeName>Ricardo S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Pirraglia</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ag&#xfc;era-Ortiz</LastName><ForeName>Luis F</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>During</LastName><ForeName>Emmanuel H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Sacks</LastName><ForeName>Hayley</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ayappa</LastName><ForeName>Indu</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Walsleben</LastName><ForeName>Joyce</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mooney</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Asad</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Frangione</LastName><ForeName>Blas</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Mart&#xed;n</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR0096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007319" MajorTopicYN="N">Sleep Initiation and Maintenance Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest:</b> The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21391952</ArticleId><ArticleId IdType="mid">NIHMS378992</ArticleId><ArticleId IdType="pmc">PMC3378676</ArticleId><ArticleId IdType="doi">10.1111/j.1532-5415.2010.03288.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Espiritu JR. Aging-related sleep changes. Clin Geriatr Med. 2008;24:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035227</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo A, Lopez-Anton R, de-la-Camara C, et al. Non-cognitive psychopathological symptoms associated with incident mild cognitive impairment and dementia, Alzheimer&#x2019;s type. Neurotox Res. 2008;14:263&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">19073431</ArticleId></ArticleIdList></Reference><Reference><Citation>Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc. 2001;49:1185&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559377</ArticleId></ArticleIdList></Reference><Reference><Citation>Benito-Leon J, Bermejo-Pareja F, Vega S, et al. Total daily sleep duration and the risk of dementia: A prospective population-based study. Eur J Neurol. 2009;16:990&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">19473367</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley D, Monjan A, Masaki K, et al. Daytime sleepiness is associated with 3-year incident dementia and cognitive decline in older Japanese-American men. J Am Geriatr Soc. 2001;49:1628&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">11843995</ArticleId></ArticleIdList></Reference><Reference><Citation>Tworoger SS, Lee S, Schernhammer ES, et al. The association of self-reported sleep duration, difficulty sleeping, and snoring with cognitive function in older women. Alzheimer Dis Assoc Disord. 2006;20:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493235</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Naidoo N, Ferber M, Master M, et al. Aging impairs the unfolded protein response to sleep deprivation and leads to proapoptotic signaling. J Neurosci. 2008;28:6539&#x2013;6548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925257</ArticleId><ArticleId IdType="pubmed">18579727</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21403675</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites.</ArticleTitle><Pagination><StartPage>223</StartPage><EndPage>233</EndPage><MedlinePgn>223-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2011.24</ELocationID><Abstract><AbstractText>Two multicentre genome-wide association (GWA) studies provided substantial evidence, implicating the complement receptor 1 gene (CR1) in Alzheimer disease (AD) genetic etiology. CR1 encodes a large transmembrane receptor with a crucial role in the immune complement cascade. We performed a genetic follow-up of the GWA CR1 association in a Flanders-Belgian cohort (n=1883), and investigated the effect of single-nucleotide polymorphisms (SNPs) located in the CR1 locus on AD risk and cerebrospinal fluid (CSF) biomarker levels. We obtained significant association (P(adj)&lt;0.03; odds ratio (OR)=1.24 (95% confidence interval (CI): 1.02-1.51)) for one CR1 risk haplotype, and haplotype association was strongest in individuals carrying apolipoprotein E (APOE) &#x25b;4 alleles (P(adj)&lt;0.006; OR=1.50 (95% CI: 1.08-2.09)). Also, four SNPs correlated with increased CSF amyloid A&#x3b2;&#x2081;&#x208b;&#x2084;&#x2082; levels, suggesting a role for the CR1 protein in A&#x3b2; metabolism. Moreover, we quantified a low-copy repeat (LCR)-associated copy number variation (CNV) in CR1, producing different CR1 isoforms, CR1-F and CR1-S, and obtained significant association in carriers of CR1-S. We replicated the CR1 CNV association finding in a French cohort (n=2003) and calculated in the combined cohorts, an OR of 1.32; 95% CI: 1.10-1.59 (P=0.0025). Our data showed that the common AD risk association may well be explained by the presence of CR1-S increasing the number of C3b/C4b and cofactor activity sites and AD risk with 30% in CR1-S carriers. How precisely the different functional role of CR1-S in the immune complement cascade contributes to AD pathogenesis will need additional functional studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brouwers</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerpen, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Cauwenberghe</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>J-C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Bettens</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Le Bastard</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Montoya</LastName><ForeName>A Gil</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Peeters</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mattheijssens</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Deyn</LastName><ForeName>P P De</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Cruts</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011951">Receptors, Complement</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.45</RegistryNumber><NameOfSubstance UI="D017244">Complement Factor I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017244" MajorTopicYN="N">Complement Factor I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056915" MajorTopicYN="N">DNA Copy Number Variations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011951" MajorTopicYN="N">Receptors, Complement</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056916" MajorTopicYN="N">Segmental Duplications, Genomic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21403675</ArticleId><ArticleId IdType="pmc">PMC3265835</ArticleId><ArticleId IdType="doi">10.1038/mp.2011.24</ArticleId><ArticleId IdType="pii">mp201124</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Krych-Goldberg M, Atkinson JP. Structure-function relationships of complement receptor type 1. Immunol Rev. 2001;180:112&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11414353</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Das N. Complement receptor 1: disease associations and therapeutic implications. Mol Immunol. 2009;46:761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125513</ArticleId><ArticleId IdType="pubmed">19004497</ArticleId></ArticleIdList></Reference><Reference><Citation>Dykman TR, Cole JL, Iida K, Atkinson JP. Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci USA. 1983;80:1698&#x2013;1702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC393670</ArticleId><ArticleId IdType="pubmed">6572933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WW, Wilson JG, Fearon DT. Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest. 1983;72:685&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1129228</ArticleId><ArticleId IdType="pubmed">6223944</ArticleId></ArticleIdList></Reference><Reference><Citation>Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT. Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med. 1987;165:1095&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2188588</ArticleId><ArticleId IdType="pubmed">2951479</ArticleId></ArticleIdList></Reference><Reference><Citation>Klickstein LB, Bartow TJ, Miletic V, Rabson LD, Smith JA, Fearon DT. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med. 1988;168:1699&#x2013;1717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2189104</ArticleId><ArticleId IdType="pubmed">2972794</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WW, Farrell SA. Proposed structure of the F&#x2032; allotype of human CR1. Loss of a C3b binding site may be associated with altered function. J Immunol. 1991;146:656&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">1670949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WW, Cahill JM, Rosen MD, Kennedy CA, Bonaccio ET, Morris MJ, et al. Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J Exp Med. 1989;169:847&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2189269</ArticleId><ArticleId IdType="pubmed">2564414</ArticleId></ArticleIdList></Reference><Reference><Citation>McLure CA, Dawkins RL, Williamson JF, Davies RA, Berry J, Natalie LJ, et al. Amino acid patterns within short consensus repeats define conserved duplicons shared by genes of the RCA complex. J Mol Evol. 2004;59:143&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">15486690</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm. 2006;113:1685&#x2013;1695.</Citation><ArticleIdList><ArticleId IdType="pubmed">17036175</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, Klegeris A, McGeer PL. Inflammation, the complement system and the diseases of aging. Neurobiol Aging. 2005;26 (Suppl 1:94&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16198446</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van BC. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet. 2010;26:84&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20080314</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1992;89:10016&#x2013;10020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50268</ArticleId><ArticleId IdType="pubmed">1438191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med. 1998;188:431&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212467</ArticleId><ArticleId IdType="pubmed">9687521</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Bradt B, Rogers J, Cooper N. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J Neurochem. 1997;69:388&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, et al. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging. 2006;27:1733&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pubmed">16290270</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci. 2004;24:6457&#x2013;6465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729885</ArticleId><ArticleId IdType="pubmed">15269255</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ. Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. J Neurochem. 2008;106:2080&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574638</ArticleId><ArticleId IdType="pubmed">18624920</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, et al. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatry. 2003;74:1148&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738626</ArticleId><ArticleId IdType="pubmed">12876259</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Dermaut B, Marien P, Symons A, Vloeberghs E, Maertens K, et al. Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol Aging. 2006;27:285&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">16399213</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, van MH, Gil A, Engelborghs S, De Deyn PP, et al. Follow-up study of susceptibility loci for Alzheimer's disease and onset age identified by genome-wide association. J Alzheimers Dis. 2010;19:1169&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">20308783</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell. 2008;133:1149&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577842</ArticleId><ArticleId IdType="pubmed">18585350</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry. 2009;14:1004&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860783</ArticleId><ArticleId IdType="pubmed">19204726</ArticleId></ArticleIdList></Reference><Reference><Citation>The International HapMap Consortium The International HapMap Project. Nature. 2003;426:789&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685227</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Sleegers K, Engelborghs S, Bogaerts V, Serneels S, Kamali K, et al. Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. Brain. 2006;129:2984&#x2013;2991.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931535</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumps C, Van RN, Heyrman L, Goossens D, Del-Favero J, Noguera R, et al. Multiplex amplicon quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma. BMC Genomics. 2010;11:298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879279</ArticleId><ArticleId IdType="pubmed">20459859</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J-H, Blay S, McNeney B, Graham J.LDheatmap: an R function for graphical display of pairwise linkage disequilibria between single nucleaotide polymorphisms J Stat Soft 200616code snippet 3.</Citation></Reference><Reference><Citation>Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384917</ArticleId><ArticleId IdType="pubmed">11791212</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez JR, Subirana I, Escaramis G, Peraza S, Caceres A, Estivill X, et al. Accounting for uncertainty when assessing association between copy number and disease: a latent class model. BMC Bioinformatics. 2009;10:172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707368</ArticleId><ArticleId IdType="pubmed">19500389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA. 2002;99:10837&#x2013;10842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125059</ArticleId><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, De Vreese K, Van de CT, Vanderstichele H, Van Everbroeck B, Cras P, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging. 2008;29:1143&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">17428581</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera AH, Xiang L, Martin SG, Lewis J, Wilson JG. Analysis of complement receptor type 1 (CR1) expression on erythrocytes and of CR1 allelic markers in Caucasian and African American populations. Clin Immunol Immunopathol. 1998;87:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">9614933</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">20010915</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333&#x2013;6341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21411544</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-7197</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3beta in peripheral blood mononuclear cells.</ArticleTitle><Pagination><StartPage>1783</StartPage><EndPage>1788</EndPage><MedlinePgn>1783-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1210/jc.2010-2961</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our objective was to determine whether peripheral blood mononuclear cells express amyloid precursor protein (APP) and other mediators involved in the pathogenesis of Alzheimer's disease and whether their expression is suppressed by insulin.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">Ten obese type 2 diabetic patients were infused with insulin (2 U/h with 100 ml 5% dextrose/h) for 4 h. Patients were also infused with 5% dextrose/h or normal physiological saline for 4 h, respectively, on two other days as controls. Blood samples were obtained at 0, 2, 4, and 6 h.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Insulin infusion significantly suppressed the expression of APP, presenilin-1, presenilin-2, and glycogen synthase kinase-3&#x3b2; in peripheral blood mononuclear cells. Dextrose and saline infusions did not alter these indices. Insulin infusion also caused significant parallel reductions in nuclear factor-&#x3ba;B binding activity and plasma concentrations of serum amyloid A and intercellular adhesion molecule-1.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A low dose infusion of insulin suppresses APP, presenilin-1, presenilin-2, and glycogen synthase kinase-3&#x3b2;, key proteins involved in the pathogenesis of Alzheimer's disease, in parallel with exerting its other antiinflammatory effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dandona</LastName><ForeName>Paresh</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo and Kaleida Health, Buffalo, New York 14209, USA. pdandona@KaleidaHealth.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Islam</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ghanim</LastName><ForeName>Husam</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sia</LastName><ForeName>Chang Ling</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Dhindsa</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dandona</LastName><ForeName>Sonny</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Makdissi</LastName><ForeName>Antoine</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chaudhuri</LastName><ForeName>Ajay</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK069805</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK075877</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21411544</ArticleId><ArticleId IdType="pmc">PMC3100748</ArticleId><ArticleId IdType="doi">10.1210/jc.2010-2961</ArticleId><ArticleId IdType="pii">jc.2010-2961</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741&#x2013;766</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. 1999. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23&#x2013;A31</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez F, G&#xf3;mez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J. 2010. GSK3: A possible link between beta amyloid peptide and tau protein. Exp Neurol 223:322&#x2013;325</Citation><ArticleIdList><ArticleId IdType="pubmed">19782073</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. 2004. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61:661&#x2013;666</Citation><ArticleIdList><ArticleId IdType="pubmed">15148141</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. 1993. Cellular processing of &#x3b2;-amyloid precursor protein and the genesis of amyloid &#x3b2;-peptide. Cell 75:1039&#x2013;1042</Citation><ArticleIdList><ArticleId IdType="pubmed">8261505</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow VW, Mattson MP, Wong PC, Gleichmann M. 2010. An overview of APP processing enzymes and products. Neuromolecular Med 12:1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889200</ArticleId><ArticleId IdType="pubmed">20232515</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH. 2008. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615&#x2013;29619</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. 2008. A&#x3b2;-degrading enzymes in Alzheimer's disease. Brain Pathol 18:240&#x2013;252</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095507</ArticleId><ArticleId IdType="pubmed">18363935</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL. 2009. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A&#x3b2; oligomers. Proc Natl Acad Sci USA 106:1971&#x2013;1976</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2634809</ArticleId><ArticleId IdType="pubmed">19188609</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. 2001. Insulin inhibits intranuclear nuclear factor &#x3ba;B and stimulates I&#x3ba;B in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257&#x2013;3265</Citation><ArticleIdList><ArticleId IdType="pubmed">11443198</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Karlo JC, Kao SC, Landreth GE. 2001. &#x3b2;-Amyloid stimulation of microglia and monocytes results in TNF&#x3b1;-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21:1179&#x2013;1188</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762255</ArticleId><ArticleId IdType="pubmed">11160388</ArticleId></ArticleIdList></Reference><Reference><Citation>Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH, 2nd, Craft S. 2008. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-&#x3b2; in memory-impaired older adults. J Alzheimers Dis 13:323&#x2013;331</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804944</ArticleId><ArticleId IdType="pubmed">18430999</ArticleId></ArticleIdList></Reference><Reference><Citation>Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. 2005. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease: is this type 3 diabetes? J Alzheimers Dis 7:63&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pubmed">15750215</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandona P, Aljada A, Mohanty P, Ghanim H, Bandyopadhyay A, Chaudhuri A. 2003. Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 26:3310&#x2013;3314</Citation><ArticleIdList><ArticleId IdType="pubmed">14633819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanim H, Mohanty P, Deopurkar R, Sia CL, Korzeniewski K, Abuaysheh S, Chaudhuri A, Dandona P. 2008. Acute modulation of toll-like receptors by insulin. Diabetes Care 31:1827&#x2013;1831</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518353</ArticleId><ArticleId IdType="pubmed">18556339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanim H, Korzeniewski K, Sia CL, Abuaysheh S, Lohano T, Chaudhuri A, Dandona P. 2010. Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care 33:1103&#x2013;1108</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858184</ArticleId><ArticleId IdType="pubmed">20200310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondag CM, Combs CK. 2010. Adhesion of monocytes to type I collagen stimulates an APP-dependent proinflammatory signaling response and release of A&#x3b2;1&#x2013;40. J Neuroinflammation 7:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850892</ArticleId><ArticleId IdType="pubmed">20302643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri A, Janicke D, Wilson MF, Tripathy D, Garg R, Bandyopadhyay A, Calieri J, Hoffmeyer D, Syed T, Ghanim H, Aljada A, Dandona P. 2004. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 109:849&#x2013;854</Citation><ArticleIdList><ArticleId IdType="pubmed">14757687</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser L, Zuurbier CJ, Hoek FJ, Opmeer BC, de Jonge E, de Mol BA, van Wezel HB. 2005. Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normoglycaemic clamp: effects on inflammatory response during coronary artery surgery. Br J Anaesth 95:448&#x2013;457</Citation><ArticleIdList><ArticleId IdType="pubmed">16100235</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF. 2009. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 106:3907&#x2013;3912</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656178</ArticleId><ArticleId IdType="pubmed">19237574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. 2000. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85:2970&#x2013;2973</Citation><ArticleIdList><ArticleId IdType="pubmed">10946914</ArticleId></ArticleIdList></Reference><Reference><Citation>Saczynski JS, J&#xf3;nsd&#xf3;ttir MK, Garcia ME, Jonsson PV, Peila R, Eiriksdottir G, Olafsdottir E, Harris TB, Gudnason V, Launer LJ. 2008. Cognitive impairment: an increasingly important complication of type 2 diabetes. Am J Epidemiol 168:1132&#x2013;1139</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727243</ArticleId><ArticleId IdType="pubmed">18836152</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R. 2010. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and A&#x3b2; deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107:7036&#x2013;7041</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872449</ArticleId><ArticleId IdType="pubmed">20231468</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Patel N, Quadros A, Linan M, Bakshi P, Ait-Ghezala G, Mullan M. 2007. Inhibition of A&#x3b2; production by NF-&#x3ba;B inhibitors. Neurosci Lett 415:11&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pubmed">17223266</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondag CM, Combs CK. 2006. Amyloid precursor protein cross-linking stimulates &#x3b2; amyloid production and pro-inflammatory cytokine release in monocytic lineage cells. J Neurochem 97:449&#x2013;461</Citation><ArticleIdList><ArticleId IdType="pubmed">16539666</ArticleId></ArticleIdList></Reference><Reference><Citation>Susan AA, Colin KC. 2010. Amyloid precursor protein mediates monocyte adhesion in AD tissue and apoE&#x2212;/&#x2212; mice. Neurobiol Aging 31:1854&#x2013;1866</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2968738</ArticleId><ArticleId IdType="pubmed">19058878</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n AM, Schiapparelli L, Salazar-Colocho P, Cuadrado-Tejedor M, Escribano L, L&#xf3;pez de Maturana R, Del R&#xed;o J, P&#xe9;rez-Mediavilla A, Frechilla D. 2009. Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to A&#x3b2; levels. Neurobiol Dis 33:369&#x2013;378</Citation><ArticleIdList><ArticleId IdType="pubmed">19101630</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21411641</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis.</ArticleTitle><Pagination><StartPage>3981</StartPage><EndPage>3989</EndPage><MedlinePgn>3981-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3617-10.2011</ELocationID><Abstract><AbstractText>Injury and inflammation are potent regulators of adult neurogenesis. As the complement system forms a key immune pathway that may also exert critical functions in neural development and neurodegeneration, we asked whether complement receptors regulate neurogenesis. We discovered that complement receptor 2 (CR2), classically known as a coreceptor of the B-lymphocyte antigen receptor, is expressed in adult neural progenitor cells (NPCs) of the dentate gyrus. Two of its ligands, C3d and interferon-&#x3b1; (IFN-&#x3b1;), inhibited proliferation of wild-type NPCs but not NPCs derived from mice lacking Cr2 (Cr2(-/-)), indicating functional Cr2 expression. Young and old Cr2(-/-) mice exhibited prominent increases in basal neurogenesis compared with wild-type littermates, whereas intracerebral injection of C3d resulted in fewer proliferating neuroblasts in wild-type than in Cr2(-/-) mice. We conclude that Cr2 regulates hippocampal neurogenesis and propose that increased C3d and IFN-&#x3b1; production associated with brain injury or viral infections may inhibit neurogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moriyama</LastName><ForeName>Maiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuhara</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Britschgi</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yingbo</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Narasimhan</LastName><ForeName>Ramya</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Villeda</LastName><ForeName>Saul</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Hector</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Brigitte T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Holers</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG020603</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG27505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20603</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017464">Receptors, Complement 3d</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-45-0</RegistryNumber><NameOfSubstance UI="D015933">Complement C3d</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015933" MajorTopicYN="N">Complement C3d</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017464" MajorTopicYN="N">Receptors, Complement 3d</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21411641</ArticleId><ArticleId IdType="mid">NIHMS279933</ArticleId><ArticleId IdType="pmc">PMC3071463</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3617-10.2011</ArticleId><ArticleId IdType="pii">31/11/3981</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson MF, Aberg MA, Nilsson M, Eriksson PS. Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Brain Res Dev Brain Res. 2002;134:115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11947942</ArticleId></ArticleIdList></Reference><Reference><Citation>Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J Immunol. 2006;177:383&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">16785534</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer S, Patterson PH. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J Neurosci. 2006;26:12089&#x2013;12099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674883</ArticleId><ArticleId IdType="pubmed">17108182</ArticleId></ArticleIdList></Reference><Reference><Citation>Belteki G, Haigh J, Kabacs N, Haigh K, Sison K, Costantini F, Whitsett J, Quaggin SE, Nagy A. Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Res. 2005;33:e51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1069131</ArticleId><ArticleId IdType="pubmed">15784609</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckwalter MS, Yamane M, Coleman BS, Ormerod BK, Chin JT, Palmer T, Wyss-Coray T. Chronically increased transforming growth factor-beta1 strongly inhibits hippocampal neurogenesis in aged mice. Am J Pathol. 2006;169:154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698757</ArticleId><ArticleId IdType="pubmed">16816369</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll MC. The complement system in B cell regulation. Mol Immunol. 2004;41:141&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">15159059</ArticleId></ArticleIdList></Reference><Reference><Citation>Coxon A, Rieu P, Barkalow FJ, Askari S, Sharpe AH, von Andrian UH, Arnaout MA, Mayadas TN. A novel role for the b2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity. 1996;5:653&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986723</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ambrosio AL, Pinsky DJ, Connolly ES. The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol Med. 2001;7:367&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950048</ArticleId><ArticleId IdType="pubmed">11474130</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash PK, Mach SA, Moore AN. Enhanced neurogenesis in the rodent hippocampus following traumatic brain injury. J Neurosci Res. 2001;63:313&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11170181</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupret D, Revest JM, Koehl M, Ichas F, De Giorgi F, Costet P, Abrous DN, Piazza PV. Spatial relational memory requires hippocampal adult neurogenesis. PLoS One. 2008;3:e1959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396793</ArticleId><ArticleId IdType="pubmed">18509506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A. 2003;100:13632&#x2013;13637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263865</ArticleId><ArticleId IdType="pubmed">14581618</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci. 2004;24:6457&#x2013;6465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729885</ArticleId><ArticleId IdType="pubmed">15269255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fust G, Ujhelyi E, Hidvegi T, Paloczi K, Mihalik R, Hollan S, Nagy K, Kirschfink M. The complement system in HIV disease. Immunol Invest. 1991;20:231&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">1864641</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol. 2004;41:1089&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">15476920</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P, Chan P, Mauger C, Schouft MT, Singhrao S, Dierich MP, Morgan BP, Fontaine M. Identification and characterization of complement C3 receptors on human astrocytes. J Immunol. 1996;156:2247&#x2013;2255.</Citation><ArticleIdList><ArticleId IdType="pubmed">8690915</ArticleId></ArticleIdList></Reference><Reference><Citation>Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">15761120</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison MJ, Ravdin LD. Cognitive dysfunction in neuropsychiatric systemic lupus erythematosus. Curr Opin Rheumatol. 2002;14:510&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">12192246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2005;11:16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15686604</ArticleId></ArticleIdList></Reference><Reference><Citation>Holers VM. Complement. In: Rich RR, editor. Clinical immunology principles and practice. St. Louis: Mosby&#x2013;Year Book; 1996. pp. 363&#x2013;391.</Citation></Reference><Reference><Citation>Hsiao FC, Lin M, Tai A, Chen G, Huber BT. Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells. J Immunol. 2006;177:2056&#x2013;2060.</Citation><ArticleIdList><ArticleId IdType="pubmed">16887963</ArticleId></ArticleIdList></Reference><Reference><Citation>Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, Jacobsen SE, Lindvall O. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci. 2006;26:9703&#x2013;9712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674454</ArticleId><ArticleId IdType="pubmed">16988041</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson AC, Weis JH. Comparative functional evolution of human and mouse CR1 and CR2. J Immunol. 2008;181:2953&#x2013;2959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366432</ArticleId><ArticleId IdType="pubmed">18713965</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Minami M, Xie L, Sun Y, Mao XO, Wang Y, Simon RP, Greenberg DA. Ischemia-induced neurogenesis is preserved but reduced in the aged rodent brain. Aging Cell. 2004;3:373&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">15569354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N, Kudo K, Mabuchi T, Takemoto K, Fujimaki K, Wati H, Iguchi H, Tezuka H, Kanba S. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology. 2006;31:2619&#x2013;2626.</Citation><ArticleIdList><ArticleId IdType="pubmed">16823390</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1512523</ArticleId><ArticleId IdType="pubmed">15761122</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A. 2008;105:751&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206608</ArticleId><ArticleId IdType="pubmed">18178625</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">15186779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci. 1996;16:2027&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578509</ArticleId><ArticleId IdType="pubmed">8604047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fi&#xe9;vet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuner B, Gould E, Shors TJ. Is there a link between adult neurogenesis and learning? Hippocampus. 2006;16:216&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421862</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333&#x2013;6341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin DR, Yuryev A, Kalli KR, Fearon DT, Ahearn JM. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J Exp Med. 1991;174:1299&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119041</ArticleId><ArticleId IdType="pubmed">1660522</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina H, Brenner C, Jacobi S, Gorka J, Carel JC, Kinoshita T, Holers VM. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J Biol Chem. 1991;266:12173&#x2013;12179.</Citation><ArticleIdList><ArticleId IdType="pubmed">1712014</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina H, Kinoshita T, Webster CB, Holers VM. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2. J Immunol. 1994;153:789&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021513</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina H, Holers VM, Li B, Fang Y-F, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A. 1996;93:3357&#x2013;3361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39612</ArticleId><ArticleId IdType="pubmed">8622941</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med. 2002;8:955&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">12161748</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302:1760&#x2013;1765.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615545</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45:593&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">17868096</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology. 1995;45:947&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">7746412</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, Nilsson AK, Zwirner J, Wetsel RA, Gerard C, Pekny M, Pekna M. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J. 2006;25:1364&#x2013;1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422160</ArticleId><ArticleId IdType="pubmed">16498410</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds BA, Rietze RL. Neural stem cells and neurospheres&#x2014;re-evaluating the relationship. Nat Methods. 2005;2:333&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15846359</ArticleId></ArticleIdList></Reference><Reference><Citation>Rho MB, Wesselingh S, Glass JD, McArthur JC, Choi S, Griffin J, Tyor WR. A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun. 1995;9:366&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">8903853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rother E, Lang B, Coldewey R, Hartung K, Peter HH. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol. 1993;12:31&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">8467609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu A, Lambris J. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev. 2001;180:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11414361</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibel RS, Valentine AD, O'Brien S, Meyers CA. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci. 2004;16:185&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">15260370</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt KN, Ouyang W. Targeting interferon-alpha: a promising approach for systemic lupus erythematosus therapy. Lupus. 2004;13:348&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">15230291</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty AK, Rao MS, Hattiangady B, Zaman V, Shetty GA. Hippocampal neurotrophin levels after injury: relationship to the age of the hippocampus at the time of injury. J Neurosci Res. 2004;78:520&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">15468179</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimazaki T, Shingo T, Weiss S. The ciliary neurotrophic factor/leukemia inhibitory factor/gp130 receptor complex operates in the maintenance of mammalian forebrain neural stem cells. J Neurosci. 2001;21:7642&#x2013;7653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762896</ArticleId><ArticleId IdType="pubmed">11567054</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15771573</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolnay M, Tsokos GC. Complement receptor 2 in the regulation of the immune response. Clin Immunol Immunopathol. 1998;88:123&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9714689</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachs FP, Winner B, Couillard-Despres S, Schiller T, Aigner R, Winkler J, Bogdahn U, Aigner L. Transforming growth factor-beta1 is a negative modulator of adult neurogenesis. J Neuropathol Exp Neurol. 2006;65:358&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">16691117</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A. 2002;99:10837&#x2013;10842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125059</ArticleId><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagita Y, Kitagawa K, Ohtsuki T, Takasawa K, Miyata T, Okano H, Hori M, Matsumoto M. Neurogenesis by progenitor cells in the ischemic adult rat hippocampus. Stroke. 2001;32:1890&#x2013;1896.</Citation><ArticleIdList><ArticleId IdType="pubmed">11486122</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang CL, Zou Y, He W, Gage FH, Evans RM. A role for adult TLX-positive neural stem cells in learning and behaviour. Nature. 2008;451:1004&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">18235445</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132:645&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21427723</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>The acetylation of tau inhibits its function and promotes pathological tau aggregation.</ArticleTitle><Pagination><StartPage>252</StartPage><MedlinePgn>252</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms1255</ELocationID><Abstract><AbstractText>The microtubule associated protein tau promotes neuronal survival through binding and stabilization of MTs. Phosphorylation regulates tau-microtubule interactions and hyperphosphorylation contributes to the aberrant formation of insoluble tau aggregates in Alzheimer's disease (AD) and related tauopathies. However, other pathogenic post-translational tau modifications have not been well characterized. Here we demonstrate that tau acetylation inhibits tau function via impaired tau-microtubule interactions and promotes pathological tau aggregation. Mass spectrometry analysis identified specific lysine residues, including lysine 280 (K280) within the microtubule-binding motif as the major sites of tau acetylation. Immunohistochemical and biochemical studies of brains from tau transgenic mice and patients with AD and related tauopathies showed that acetylated tau pathology is specifically associated with insoluble, Thioflavin-positive tau aggregates. Thus, tau K280 acetylation in our studies was only detected in diseased tissue, suggesting it may have a role in pathological tau transformation. This study suggests that tau K280 acetylation is a potential target for drug discovery and biomarker development for AD and related tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Todd J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Hurtado</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Linda K</ForeName><Initials>LK</Initials></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Ian P</ForeName><Initials>IP</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C404785">tau 40 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>K3Z4F929H6</RegistryNumber><NameOfSubstance UI="D008239">Lysine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008867" MajorTopicYN="N">Microtomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing financial interests:</b> The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21427723</ArticleId><ArticleId IdType="mid">NIHMS299343</ArticleId><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="doi">10.1038/ncomms1255</ArticleId><ArticleId IdType="pii">ncomms1255</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee VM-Y, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry. 1992;31:10626&#x2013;10633.</Citation><ArticleIdList><ArticleId IdType="pubmed">1420178</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 1989;3:519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron. 1993;11:153&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">8393323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramblett GT, et al. Abnormal tau phosphorylation at Ser396 in Alzheimer&#x2019;s disease recapitulates development and contributes to reduced microtubule binding. Neuron. 1993;10:1089&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">8318230</ArticleId></ArticleIdList></Reference><Reference><Citation>Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992;3:1141&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC275678</ArticleId><ArticleId IdType="pubmed">1421571</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282:1914&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P, et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet. 1999;64:414&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377751</ArticleId><ArticleId IdType="pubmed">9973279</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan HM, La Thangue N. B p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001;114:2363&#x2013;2373.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559745</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun. 2007;358:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646256</ArticleId><ArticleId IdType="pubmed">17482143</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee VMY. Characterization of two VQIXXK motifs for tau fibrillization in vitro. Biochemistry. 2006;45:15692&#x2013;15701.</Citation><ArticleIdList><ArticleId IdType="pubmed">17176091</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 1996;383:550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez M, Valpuesta JM, Medina M, Montejo de Garcini E, Avila J. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. J Neurochem. 1996;67:1183&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752125</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39:11714&#x2013;11721.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995239</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem. 2001;276:48165&#x2013;48174.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010;5:253&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866163</ArticleId><ArticleId IdType="pubmed">20078221</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelsberg-Ragaglia V, et al. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol Biol Cell. 2000;11:4093&#x2013;4104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15059</ArticleId><ArticleId IdType="pubmed">11102510</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode BL, Feinstein SC. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol. 1994;124:769&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119949</ArticleId><ArticleId IdType="pubmed">8120098</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukrasch MD, et al. Sites of tau important for aggregation populate {beta}-structure and bind to microtubules and polyanions. J Biol Chem. 2005;280:24978&#x2013;24986.</Citation><ArticleIdList><ArticleId IdType="pubmed">15855160</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtado DE, et al. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol. 2010;177:1977&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947292</ArticleId><ArticleId IdType="pubmed">20802182</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary C, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">19608861</ArticleId></ArticleIdList></Reference><Reference><Citation>Creppe C, et al. Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulin. Cell. 2009;136:551&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">19185337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbert C, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417:455&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">12024216</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM-Y, Wang J, Trojanowski JQ. Purification of paired helical filament tau and normal tau from human brain tissue. Methods Enzymol. 1999;309:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507018</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21441921</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2;(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3&#x3b2;.</ArticleTitle><Pagination><StartPage>545</StartPage><EndPage>547</EndPage><MedlinePgn>545-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2785</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2;(1-42) (A&#x3b2;) is thought to be a major mediator of the cognitive deficits in Alzheimer's disease. The ability of A&#x3b2; to inhibit hippocampal long-term potentiation provides a cellular correlate of this action, but the underlying molecular mechanism is only partially understood. We found that a signaling pathway involving caspase-3, Akt1 and glycogen synthase kinase-3&#x3b2; is an important mediator of this effect in rats and mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Jihoon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, School of Clinical Sciences, Faculty of Medicine and Dentistry, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitcomb</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Kimberly Moore</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Kerrigan</LastName><ForeName>Talitha L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Shih-Ching</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Bru-Mercier</LastName><ForeName>Gilles</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Dickinson</LastName><ForeName>Bryony</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Scullion</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Collingridge</LastName><ForeName>Graham</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Kwangwook</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>089703</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BB/G003963/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C473711">Chir 99021</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051636">X-Linked Inhibitor of Apoptosis Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C514862">Akt1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605507">Gsk3b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605508">Gsk3b protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001703" MajorTopicYN="N">Biophysics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051636" MajorTopicYN="N">X-Linked Inhibitor of Apoptosis Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21441921</ArticleId><ArticleId IdType="doi">10.1038/nn.2785</ArticleId><ArticleId IdType="pii">nn.2785</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Biol Chem. 2006 Jul 21;281(29):20315-25</Citation><ArticleIdList><ArticleId IdType="pubmed">16714296</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 2007 Dec 15;408(3):297-315</Citation><ArticleIdList><ArticleId IdType="pubmed">17850214</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 May 22;423(6938):435-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12761548</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Mar 1;53(5):703-17</Citation><ArticleIdList><ArticleId IdType="pubmed">17329210</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2001 Jul 1;65(1):45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11433428</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2010 Jul;13(7):812-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2010 May 28;141(5):859-71</Citation><ArticleIdList><ArticleId IdType="pubmed">20510932</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Mar 31;24(13):3370-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2009 Jun 25;62(6):788-801</Citation><ArticleIdList><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Dec 24;279(52):54716-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15494420</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2008 Aug;14(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2002 Apr 4;416(6880):535-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Aug 5;430(7000):631-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2008 Mar;131(Pt 3):651-64</Citation><ArticleIdList><ArticleId IdType="pubmed">18292081</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Dec 7;52(5):831-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21451035</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>13</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid &#x3b2;-induced death in neurons involves glial and neuronal hemichannels.</ArticleTitle><Pagination><StartPage>4962</StartPage><EndPage>4977</EndPage><MedlinePgn>4962-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6417-10.2011</ELocationID><Abstract><AbstractText>The mechanisms involved in Alzheimer's disease are not completely understood and how glial cells contribute to this neurodegenerative disease remains to be elucidated. Because inflammatory treatments and products released from activated microglia increase glial hemichannel activity, we investigated whether amyloid-&#x3b2; peptide (A&#x3b2;) could regulate these channels in glial cells and affect neuronal viability. Microglia, astrocytes, or neuronal cultures as well as acute hippocampal slices made from GFAP-eGFP transgenic mice were treated with the active fragment of A&#x3b2;. Hemichannel activity was monitored by single-channel recordings and by time-lapse ethidium uptake, whereas neuronal death was assessed by Fluoro-Jade C staining. We report that low concentrations of A&#x3b2;(25-35) increased hemichannel activity in all three cell types and microglia initiate these effects triggered by A&#x3b2;. Finally, neuronal damage occurs by activation of neuronal hemichannels induced by ATP and glutamate released from A&#x3b2;(25-35)-activated glia. These responses were observed in the presence of external calcium and were differently inhibited by hemichannel blockers, whereas the A&#x3b2;(25-35)-induced neuronal damage was importantly reduced in acute slices made from Cx43 knock-out mice. Thus, A&#x3b2; leads to a cascade of hemichannel activation in which microglia promote the release of glutamate and ATP through glial (microglia and astrocytes) hemichannels that induces neuronal death by triggering hemichannels in neurons. Consequently, this work opens novel avenues for alternative treatments that target glial cells and neurons to maintain neuronal survival in the presence of A&#x3b2;.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orellana</LastName><ForeName>Juan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Departamento de Fisiolog&#xed;a, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago 6513677, Chile. jaorella@uc.cl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoji</LastName><ForeName>Kenji F</ForeName><Initials>KF</Initials></Author><Author ValidYN="Y"><LastName>Abudara</LastName><ForeName>Ver&#xf3;nica</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ezan</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Amigou</LastName><ForeName>Edwige</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>S&#xe1;ez</LastName><ForeName>Pablo J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jean X</ForeName><Initials>JX</Initials></Author><Author ValidYN="Y"><LastName>Naus</LastName><ForeName>Christian C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>S&#xe1;ez</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Giaume</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018031">Connexin 43</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074636">amyloid beta-protein (25-35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018031" MajorTopicYN="N">Connexin 43</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21451035</ArticleId><ArticleId IdType="pmc">PMC6622997</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6417-10.2011</ArticleId><ArticleId IdType="pii">31/13/4962</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord. 2000;14(Suppl 1):S47&#x2013;S53.</Citation><ArticleIdList><ArticleId IdType="pubmed">10850730</ArticleId></ArticleIdList></Reference><Reference><Citation>Allaman I, Gavillet M, B&#xe9;langer M, Laroche T, Viertl D, Lashuel HA, Magistretti PJ. Amyloid-&#x3b2; aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci. 2010;30:3326&#x2013;3338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634099</ArticleId><ArticleId IdType="pubmed">20203192</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Locovei S, Dahl G. Pannexin membrane channels are mechanosensitive conduits for ATP. FEBS Lett. 2004;572:65&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304325</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer M, Gimsa U, Ey&#xfc;poglu IY, Hailer NP, Nitsch R. Phagocytosis of neuronal or glial debris by microglial cells: upregulation of MHC class II expression and multinuclear giant cell formation in vitro. Glia. 2000;31:262&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">10941152</ArticleId></ArticleIdList></Reference><Reference><Citation>Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz NF, Ball KK, Dienel GA. Astrocytic gap junctional communication is reduced in amyloid-beta-treated cultured astrocytes, but not in Alzheimer's disease transgenic mice. ASN Neuro. 2010;2:pii:e00041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922840</ArticleId><ArticleId IdType="pubmed">20730033</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta G, Zhang P, Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol. 2008;22:453&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632601</ArticleId><ArticleId IdType="pubmed">18710400</ArticleId></ArticleIdList></Reference><Reference><Citation>Eugen&#xed;n EA, Bra&#xf1;es MC, Berman JW, S&#xe1;ez JC. TNF-&#x3b1; plus IFN-&#x3b3; induce connexin43 expression and formation of gap junctions between human monocytes/macrophages that enhance physiological responses. J Immunol. 2003;170:1320&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">12538692</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans WH, Leybaert L. Mimetic peptides as blockers of connexin channel-facilitated intercellular communication. Cell Commun Adhes. 2007;14:265&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">18392994</ArticleId></ArticleIdList></Reference><Reference><Citation>Genever PG, Skerry TM. Regulation of spontaneous glutamate release activity in osteoblastic cells and its role in differentiation and survival: evidence for intrinsic glutamatergic signaling in bone. FASEB J. 2001;15:1586&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pubmed">11427494</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz M, Bolz J. Differentiation of transmitter phenotypes in rat cerebral cortex. Eur J Neurosci. 1994;6:18&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">7907521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective &#x3b2;-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008;28:8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Grinspan JB, Abrams CK, Scherer SS. Pannexin1 is expressed by neurons and glia but does not form functional gap junctions. Glia. 2007;55:46&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">17009242</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias R, Locovei S, Roque A, Alberto AP, Dahl G, Spray DC, Scemes E. P2X7 receptor-Pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol. 2008;295:C752&#x2013;C760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544446</ArticleId><ArticleId IdType="pubmed">18596211</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias R, Dahl G, Qiu F, Spray DC, Scemes E. Pannexin 1: the molecular substrate of astrocyte &#x201c;hemichannels.&#x201d;. J Neurosci. 2009;29:7092&#x2013;7097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733788</ArticleId><ArticleId IdType="pubmed">19474335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci. 1999;893:113&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Kang N, Lovatt D, Torres A, Zhao Z, Lin J, Nedergaard M. Connexin 43 hemichannels are permeable to ATP. J Neurosci. 2008;28:4702&#x2013;4711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3638995</ArticleId><ArticleId IdType="pubmed">18448647</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;ster-Patzlaff C, Hosseini SM, Reuss B. Loss of connexin36 in rat hippocampus and cerebellar cortex in persistent Borna disease virus infection. J Chem Neuroanat. 2009;37:118&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">19038327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science. 2009;323:1211&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884172</ArticleId><ArticleId IdType="pubmed">19251629</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8:499&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">7905600</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Bolteus AJ, Balkin DM, Henschel O, Bordey A. GFAP-expressing cells in the postnatal subventricular zone display a unique glial phenotype intermediate between radial glia and astrocytes. Glia. 2006;54:394&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">16886203</ArticleId></ArticleIdList></Reference><Reference><Citation>Locovei S, Wang J, Dahl G. Activation of pannexin 1 channels by ATP through P2Y receptors and by cytoplasmic calcium. FEBS Lett. 2006;580:239&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364313</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25&#x2013;35] J Neuroimmunol. 1999;93:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10378868</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei X, Ezan P, Giaume C, Koulakoff A. Astroglial connexin immunoreactivity is specifically altered at beta-amyloid plaques in beta-amyloid precursor protein/presenilin1 mice. Neuroscience. 2010;171:92&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20813165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy JI, Li W, Hertzberg EL, Marotta CA. Elevated connexin43 immunoreactivity at sites of amyloid plaques in Alzheimer's disease. Brain Res. 1996;717:173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">8738268</ArticleId></ArticleIdList></Reference><Reference><Citation>Noraberg J, Kristensen BW, Zimmer J. Markers for neuronal degeneration in organotypic slice cultures. Brain Res Brain Res Protoc. 1999;3:278&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">9974143</ArticleId></ArticleIdList></Reference><Reference><Citation>Orellana JA, S&#xe1;ez PJ, Shoji KF, Schalper KA, Palacios-Prado N, Velarde V, Giaume C, Bennett MV, S&#xe1;ez JC. Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration. Antioxid Redox Signal. 2009;11:369&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713807</ArticleId><ArticleId IdType="pubmed">18816186</ArticleId></ArticleIdList></Reference><Reference><Citation>Orellana JA, Hern&#xe1;ndez DE, Ezan P, Velarde V, Bennett MV, Giaume C, S&#xe1;ez JC. Hypoxia in high glucose followed by reoxygenation in normal glucose reduces the viability of cortical astrocytes through increased permeability of connexin 43 hemichannels. Glia. 2010;58:329&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794960</ArticleId><ArticleId IdType="pubmed">19705457</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J. 2006;25:5071&#x2013;5082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1630421</ArticleId><ArticleId IdType="pubmed">17036048</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters O, Schipke CG, Philipps A, Haas B, Pannasch U, Wang LP, Benedetti B, Kingston AE, Kettenmann H. Astrocyte function is modified by Alzheimer's disease-like pathology in aged mice. J Alzheimers Dis. 2009;18:177&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">19584439</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25&#x2013;35 region to aggregation and neurotoxicity. J Neurochem. 1995a;64:253&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">7798921</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem. 1995b;270:23895&#x2013;23898.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592576</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume AG, de Sousa PA, Kulkarni S, Langille BL, Zhu D, Davies TC, Juneja SC, Kidder GM, Rossant J. Cardiac malformation in neonatal mice lacking connexin43. Science. 1995;267:1831&#x2013;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">7892609</ArticleId></ArticleIdList></Reference><Reference><Citation>Retamal MA, Froger N, Palacios-Prado N, Ezan P, S&#xe1;ez PJ, S&#xe1;ez JC, Giaume C. Cx43 hemichannels and gap junction channels in astrocytes are regulated oppositely by proinflammatory cytokines released from activated microglia. J Neurosci. 2007;27:13781&#x2013;13792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673621</ArticleId><ArticleId IdType="pubmed">18077690</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouach N, Koulakoff A, Abudara V, Willecke K, Giaume C. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science. 2008;322:1551&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056987</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez JC, Berthoud VM, Bra&#xf1;es MC, Mart&#xed;nez AD, Beyer EC. Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev. 2003;83:1359&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506308</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez JC, Retamal MA, Basilio D, Bukauskas FF, Bennett MV. Connexin-based gap junction hemichannels: gating mechanisms. Biochim Biophys Acta. 2005;1711:215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617572</ArticleId><ArticleId IdType="pubmed">15955306</ArticleId></ArticleIdList></Reference><Reference><Citation>Scemes E, Spray DC, Meda P. Connexins, pannexins, innexins: novel roles of &#x201c;hemi-channels.&#x201d;. Pflugers Arch. 2009;457:1207&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656403</ArticleId><ArticleId IdType="pubmed">18853183</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmuck G, Kahl R. The use of Fluoro-Jade in primary neuronal cell cultures. Arch Toxicol. 2009;83:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">18815771</ArticleId></ArticleIdList></Reference><Reference><Citation>Schock SC, Leblanc D, Hakim AM, Thompson CS. ATP release by way of connexin 36 hemichannels mediates ischemic tolerance in vitro. Biochem Biophys Res Commun. 2008;368:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">18211823</ArticleId></ArticleIdList></Reference><Reference><Citation>Shestopalov VI, Panchin Y. Pannexins and gap junction protein diversity. Cell Mol Life Sci. 2008;65:376&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11131650</ArticleId><ArticleId IdType="pubmed">17982731</ArticleId></ArticleIdList></Reference><Reference><Citation>Siller-Jackson AJ, Burra S, Gu S, Xia X, Bonewald LF, Sprague E, Jiang JX. Adaptation of connexin 43-hemichannel prostaglandin release to mechanical loading. J Biol Chem. 2008;283:26374&#x2013;26382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546557</ArticleId><ArticleId IdType="pubmed">18676366</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman W, Locovei S, Dahl G. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol. 2008;295:C761&#x2013;C767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544448</ArticleId><ArticleId IdType="pubmed">18596212</ArticleId></ArticleIdList></Reference><Reference><Citation>Stridh MH, Tranberg M, Weber SG, Blomstrand F, Sandberg M. Stimulated efflux of amino acids and glutathione from cultured hippocampal slices by omission of extracellular calcium: likely involvement of connexin hemichannels. J Biol Chem. 2008;283:10347&#x2013;10356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447665</ArticleId><ArticleId IdType="pubmed">18272524</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem. 2006;281:21362&#x2013;21368.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720574</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson RJ, Zhou N, MacVicar BA. Ischemia opens neuronal gap junction hemichannels. Science. 2006;312:924&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">16690868</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson RJ, Jackson MF, Olah ME, Rungta RL, Hines DJ, Beazely MA, MacDonald JF, MacVicar BA. Activation of pannexin-1 hemichannels augments aberrant bursting in the hippocampus. Science. 2008;322:1555&#x2013;1559.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Ma M, Locovei S, Keane RW, Dahl G. Modulation of membrane channel currents by gap junction protein mimetic peptides: size matters. Am J Physiol Cell Physiol. 2007;293:C1112&#x2013;C1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">17652431</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellershaus K, Degen J, Deuchars J, Theis M, Charollais A, Caille D, Gauthier B, Janssen-Bienhold U, Sonntag S, Herrera P, Meda P, Willecke K. A new conditional mouse mutant reveals specific expression and functions of connexin36 in neurons and pancreatic beta-cells. Exp Cell Res. 2008;314:997&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">18258229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye ZC, Wyeth MS, Baltan-Tekkok S, Ransom BR. Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J Neurosci. 2003;23:3588&#x2013;3596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742182</ArticleId><ArticleId IdType="pubmed">12736329</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21451522</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>472</Volume><Issue>7342</Issue><PubDate><Year>2011</Year><Month>Apr</Month><Day>14</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan.</ArticleTitle><Pagination><StartPage>226</StartPage><EndPage>229</EndPage><MedlinePgn>226-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature09873</ELocationID><Abstract><AbstractText>Genetic studies indicate that protein homeostasis is a major contributor to metazoan longevity. Collapse of protein homeostasis results in protein misfolding cascades and the accumulation of insoluble protein fibrils and aggregates, such as amyloids. A group of small molecules, traditionally used in histopathology to stain amyloid in tissues, bind protein fibrils and slow aggregation in vitro and in cell culture. We proposed that treating animals with such compounds would promote protein homeostasis in vivo and increase longevity. Here we show that exposure of adult Caenorhabditis elegans to the amyloid-binding dye Thioflavin T (ThT) resulted in a profoundly extended lifespan and slowed ageing. ThT also suppressed pathological features of mutant metastable proteins and human &#x3b2;-amyloid-associated toxicity. These beneficial effects of ThT depend on the protein homeostasis network regulator heat shock factor 1 (HSF-1), the stress resistance and longevity transcription factor SKN-1, molecular chaperones, autophagy and proteosomal functions. Our results demonstrate that pharmacological maintenance of the protein homeostatic network has a profound impact on ageing rates, prompting the development of novel therapeutic interventions against ageing and age-related diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alavez</LastName><ForeName>Silvestre</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, 8001 Redwood Blvd, Novato, California 94945, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vantipalli</LastName><ForeName>Maithili C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Zucker</LastName><ForeName>David J S</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Klang</LastName><ForeName>Ida M</ForeName><Initials>IM</Initials></Author><Author ValidYN="Y"><LastName>Lithgow</LastName><ForeName>Gordon J</ForeName><Initials>GJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RL1 ES016655</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022868</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG029631-01A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029631-01A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029631</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19AG0231222</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021069</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG21069</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG22868</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024917</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ES016655</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029742">Caenorhabditis elegans Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108831">daf-16 protein, C elegans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C474710">heat shock factor-1, C elegans</NameOfSubstance></Chemical><Chemical><RegistryNumber>148733-36-2</RegistryNumber><NameOfSubstance UI="C073702">skn-1 protein, C elegans</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>IT942ZTH98</RegistryNumber><NameOfSubstance UI="D003474">Curcumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Methods. 2011 May;8(5):376. doi: 10.1038/nmeth0511-376.</RefSource><PMID Version="1">21678622</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Rejuvenation Res. 2011 Jun;14(3):335-9. doi: 10.1089/rej.2011.1211.</RefSource><PMID Version="1">21751864</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029742" MajorTopicYN="N">Caenorhabditis elegans Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010243" MajorTopicYN="N">Paralysis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21451522</ArticleId><ArticleId IdType="mid">NIHMS445244</ArticleId><ArticleId IdType="pmc">PMC3610427</ArticleId><ArticleId IdType="doi">10.1038/nature09873</ArticleId><ArticleId IdType="pii">nature09873</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morimoto RI. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 2008;22:1427&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732416</ArticleId><ArticleId IdType="pubmed">18519635</ArticleId></ArticleIdList></Reference><Reference><Citation>Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008;319:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">18276881</ArticleId></ArticleIdList></Reference><Reference><Citation>Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 2006;67:27&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">16492146</ArticleId></ArticleIdList></Reference><Reference><Citation>Frid P, Anisimov SV, Popovic N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Brain Res. Rev. 2007;53:135&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell. 2005;120:449&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tullet JM, et al. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell. 2008;132:1025&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2367249</ArticleId><ArticleId IdType="pubmed">18358814</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JF, Morimoto RI. Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol. Biol. Cell. 2004;15:657&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC329286</ArticleId><ArticleId IdType="pubmed">14668486</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu AL, Murphy CT, Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science. 2003;300:1142&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">12750521</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313:1604&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902091</ArticleId></ArticleIdList></Reference><Reference><Citation>Groenning M. Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils&#x2014;current status. J. Chem. Biol. 2009;3:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2816742</ArticleId><ArticleId IdType="pubmed">19693614</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Rodr&#xed;guez C, et al. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer&#x2019;s disease. J. Am. Chem. Soc. 2009;131:1436&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">19133767</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer&#x2019;s disease amyloid &#x3b2;-peptide (1&#x2013;42) in a transgenic Caenorhabditis elegans model. Neurobiol. Aging. 2003;24:415&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">12600717</ArticleId></ArticleIdList></Reference><Reference><Citation>McColl G, et al. The Caenorhabditis elegans A&#x3b2;1&#x2013;42 model of Alzheimer&#x2019;s disease predominantly expresses A&#x3b2;3&#x2013;42. J. Biol. Chem. 2009;284:22697&#x2013;22702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755678</ArticleId><ArticleId IdType="pubmed">19574211</ArticleId></ArticleIdList></Reference><Reference><Citation>Temussi PA, Masino L, Pastore A. From Alzheimer to Huntington: why is a structural understanding so difficult? EMBO J. 2003;22:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140729</ArticleId><ArticleId IdType="pubmed">12554637</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science. 2006;311:1471&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469881</ArticleId></ArticleIdList></Reference><Reference><Citation>Zengel JM, Epstein HF. Identification of genetic elements associated with muscle structure in the nematode Caenorhabditis elegans. Cell Motil. 1980;1:73&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">7348600</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P, Brenner S. A selection for myosin heavy chain mutants in the nematode Caenorhabditis elegans. Proc. Natl Acad. Sci. USA. 1984;81:4470&#x2013;4474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC345612</ArticleId><ArticleId IdType="pubmed">6589606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Zvi A, Miller EA, Morimoto RI. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc. Natl Acad. Sci. USA. 2009;106:14914&#x2013;14919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736453</ArticleId><ArticleId IdType="pubmed">19706382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakowski B, Hekimi S. The genetics of caloric restriction in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA. 1998;95:13091&#x2013;13096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23719</ArticleId><ArticleId IdType="pubmed">9789046</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Thomas EL, Kapahi P. HIF-1 modulates dietary restriction-mediated lifespan extension via IRE-1 in Caenorhabditis elegans. PLoS Genet. 2009;5:e1000486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676694</ArticleId><ArticleId IdType="pubmed">19461873</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy CT, et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature. 2003;424:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">12845331</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker GA, Lithgow GJ. Lifespan extension in C. elegans by a molecular chaperone dependent upon insulin-like signals. Aging Cell. 2003;2:131&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">12882326</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Gao B, Lee SM, Bennett K, Fang D. RLE-1, an E3 ubiquitin ligase, regulates C. elegans aging by catalyzing DAF-16 polyubiquitination. Dev. Cell. 2007;12:235&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">17276341</ArticleId></ArticleIdList></Reference><Reference><Citation>McColl G, et al. Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J. Biol. Chem. 2008;283:350&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739662</ArticleId><ArticleId IdType="pubmed">17959600</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Thomas EL, Kapahi P. HIF-1 modulates dietary restriction-mediated lifespan extension via IRE-1 in Caenorhabditis elegans. PLoS Genet. 2009;5:e1000486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676694</ArticleId><ArticleId IdType="pubmed">19461873</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmons L, Court DL, Fire A. Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene. 2001;263:103&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">11223248</ArticleId></ArticleIdList></Reference><Reference><Citation>McColl G, et al. Insulin-like signaling determines survival during stress via posttranscriptional mechanisms in C. elegans. Cell Metab. 2010;12:260&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945254</ArticleId><ArticleId IdType="pubmed">20816092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21454603</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>286</Volume><Issue>21</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions.</ArticleTitle><Pagination><StartPage>18664</StartPage><EndPage>18672</EndPage><MedlinePgn>18664-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M111.231209</ELocationID><Abstract><AbstractText>The transactivation response element (TAR) DNA-binding protein-43 (TDP-43) is a nuclear protein that normally regulates transcription and splicing. Abnormal accumulation of insoluble inclusions containing TDP-43 has been recently reported in the affected tissues of amyotrophic lateral sclerosis (ALS) patients. Here, we show that intracellular aggregation of TDP-43 can be triggered by transduction of fibrillar aggregates prepared from in vitro functional TDP-43. Sarkosyl is found to be incapable of solubilizing those intracellularly seeded aggregates of TDP-43, which is consistent with the observation that TDP-43 inclusions in ALS patients are sarkosyl-insoluble. In addition, intracellular seeding in our cell models reproduces ubiquitination of TDP-43 aggregates, which is another prominent feature of TDP-43 inclusions in ALS patients. Although it has been so far difficult to initiate disease-associated changes of TDP-43 using cultured cell models, we propose that a seeding reaction is a key to construct a model to monitor TDP-43 pathologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory for Structural Neuropathology, RIKEN Brain Science Institute, Wako, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Kumi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Shoji</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nukina</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>632GS99618</RegistryNumber><NameOfSubstance UI="C025231">sarkosyl</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z711V88R5F</RegistryNumber><NameOfSubstance UI="D012521">Sarcosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045586" MajorTopicYN="N">Intranuclear Inclusion Bodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020218" MajorTopicYN="Y">Response Elements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012521" MajorTopicYN="N">Sarcosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21454603</ArticleId><ArticleId IdType="pmc">PMC3099683</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111.231209</ArticleId><ArticleId IdType="pii">S0021-9258(20)51124-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiti F., Dobson C. M. (2009) Nat. Chem. Biol. 5, 15&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">19088715</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler D. M., Koulov A. V., Alory-Jost C., Marks M. S., Balch W. E., Kelly J. W. (2006) PLoS Biol. 4, e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288039</ArticleId><ArticleId IdType="pubmed">16300414</ArticleId></ArticleIdList></Reference><Reference><Citation>Maji S. K., Perrin M. H., Sawaya M. R., Jessberger S., Vadodaria K., Rissman R. A., Singru P. S., Nilsson K. P., Simon R., Schubert D., Eisenberg D., Rivier J., Sawchenko P., Vale W., Riek R. (2009) Science 325, 328&#x2013;332</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865899</ArticleId><ArticleId IdType="pubmed">19541956</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F., Dobson C. M. (2006) Annu. Rev. Biochem. 75, 333&#x2013;366</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A., O'Connor T. (2010) Nat. Rev. Drug Discov. 9, 237&#x2013;248</Citation><ArticleIdList><ArticleId IdType="pubmed">20190788</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., Oda T. (2006) Biochem. Biophys. Res. Commun. 351, 602&#x2013;611</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D. M., Kwong L. K., Truax A. C., Micsenyi M. C., Chou T. T., Bruce J., Schuck T., Grossman M., Clark C. M., McCluskey L. F., Miller B. L., Masliah E., Mackenzie I. R., Feldman H., Feiden W., Kretzschmar H. A., Trojanowski J. Q., Lee V. M. (2006) Science 314, 130&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho M. A., Baloh R. H., Chakraverty S., Mayo K., Norton J. B., Levitch D., Hatanpaa K. J., White C. L., 3rd, Bigio E. H., Caselli R., Baker M., Al-Lozi M. T., Morris J. C., Pestronk A., Rademakers R., Goate A. M., Cairns N. J. (2008) Ann. Neurol. 63, 535&#x2013;538</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P. N., Dion P., Spiegelman D., McConkey B. J., Vande Velde C., Bouchard J. P., Lacomblez L., Pochigaeva K., Salachas F., Pradat P. F., Camu W., Meininger V., Dupre N., Rouleau G. A. (2008) Nat. Genet. 40, 572&#x2013;574</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I. P., Tripathi V. B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J. C., Williams K. L., Buratti E., Baralle F., de Belleroche J., Mitchell J. D., Leigh P. N., Al-Chalabi A., Miller C. C., Nicholson G., Shaw C. E. (2008) Science 319, 1668&#x2013;1672</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin V. M., Leverenz J. B., Bekris L. M., Bird T. D., Yuan W., Elman L. B., Clay D., Wood E. M., Chen-Plotkin A. S., Martinez-Lage M., Steinbart E., McCluskey L., Grossman M., Neumann M., Wu I. L., Yang W. S., Kalb R., Galasko D. R., Montine T. J., Trojanowski J. Q., Lee V. M., Schellenberg G. D., Yu C. E. (2008) Lancet Neurol 7, 409&#x2013;416</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T. G., Buratti E., Baralle F., Morita M., Nakano I., Oda T., Tsuchiya K., Akiyama H. (2008) Ann. Neurol 64, 60&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W. L., Dickson D. W. (2008) Acta Neuropathol. 116, 205&#x2013;213</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Arai T., Buratti E., Baralle F. E., Akiyama H., Hasegawa M. (2009) FEBS Lett. 583, 394&#x2013;400</Citation><ArticleIdList><ArticleId IdType="pubmed">19111550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Kametani F., Arai T., Akiyama H., Hasegawa M. (2009) Hum. Mol. Genet. 18, 3353&#x2013;3364</Citation><ArticleIdList><ArticleId IdType="pubmed">19515851</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B. S., Snead D., Lee J. J., McCaffery J. M., Shorter J., Gitler A. D. (2009) J. Biol. Chem. 284, 20329&#x2013;20339</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper J. D., Lansbury P. T., Jr. (1997) Annu. Rev. Biochem. 66, 385&#x2013;407</Citation><ArticleIdList><ArticleId IdType="pubmed">9242912</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk K. C., Song C., O'Brien P., Stieber A., Branch J. R., Brunden K. R., Trojanowski J. Q., Lee V. M. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 20051&#x2013;20056</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785290</ArticleId><ArticleId IdType="pubmed">19892735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong I., Lohman T. M. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 5428&#x2013;5432</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46733</ArticleId><ArticleId IdType="pubmed">8516284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo P. H., Doudeva L. G., Wang Y. T., Shen C. K., Yuan H. S. (2009) Nucleic Acids Res. 37, 1799&#x2013;1808</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665213</ArticleId><ArticleId IdType="pubmed">19174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Baralle F. E. (2001) J. Biol. Chem. 276, 36337&#x2013;36343</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., 3rd (1999) Methods Enzymol. 309, 274&#x2013;284</Citation><ArticleIdList><ArticleId IdType="pubmed">10507030</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Kaneko K., Yamanaka K., Nukina N. (2010) J. Biol. Chem. 285, 22221&#x2013;22231</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903422</ArticleId><ArticleId IdType="pubmed">20404329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerman A., Liu H. N., Croul S., Bilbao J., Rogaeva E., Zinman L., Robertson J., Chakrabartty A. (2010) Acta Neuropathol. 119, 335&#x2013;344</Citation><ArticleIdList><ArticleId IdType="pubmed">20111867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik C. M., Novak M., Th&#xf8;gersen H. C., Edwards P. C., Runswick M. J., Jakes R., Walker J. E., Milstein C., Roth M., Klug A. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 4506&#x2013;4510</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280459</ArticleId><ArticleId IdType="pubmed">3132715</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D., Capell A., Carlson A. M., Shankaran S. S., Rodde R., Neumann M., Kremmer E., Matsuwaki T., Yamanouchi K., Nishihara M., Haass C. (2009) J. Neurochem. 110, 1082&#x2013;1094</Citation><ArticleIdList><ArticleId IdType="pubmed">19522733</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L. M., Kwong L. K., Chen-Plotkin A., Winton M. J., Unger T. L., Xu Y., Neumann M., Trojanowski J. Q., Lee V. M. (2009) J. Biol. Chem. 284, 8516&#x2013;8524</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton M. J., Igaz L. M., Wong M. M., Kwong L. K., Trojanowski J. Q., Lee V. M. (2008) J. Biol. Chem. 283, 13302&#x2013;13309</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. J., Xu Y. F., Dickey C. A., Buratti E., Baralle F., Bailey R., Pickering-Brown S., Dickson D., Petrucelli L. (2007) J. Neurosci. 27, 10530&#x2013;10534</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L. M., Kwong L. K., Xu Y., Truax A. C., Uryu K., Neumann M., Clark C. M., Elman L. B., Miller B. L., Grossman M., McCluskey L. F., Trojanowski J. Q., Lee V. M. (2008) Am. J. Pathol 173, 182&#x2013;194</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. J., Xu Y. F., Cook C., Gendron T. F., Roettges P., Link C. D., Lin W. L., Tong J., Castanedes-Casey M., Ash P., Gass J., Rangachari V., Buratti E., Baralle F., Golde T. E., Dickson D. W., Petrucelli L. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 7607&#x2013;7612</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L. M., Kwong L. K., Lee E. B., Chen-Plotkin A., Swanson E., Unger T., Malunda J., Xu Y., Winton M. J., Trojanowski J. Q., Lee V. M. (2011) J. Clin. Invest. 121, 726&#x2013;738</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I., Bell S., Cairns N. J., Miller T. M., Baloh R. H. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 18809&#x2013;18814</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H., Kleinberger G., Janssens J., Pereson S., Joris G., Cuijt I., Smits V., Ceuterick-de Groote C., Van Broeckhoven C., Kumar-Singh S. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 3858&#x2013;3863</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A., Rajendran L. (2009) Neuron 64, 783&#x2013;790</Citation><ArticleIdList><ArticleId IdType="pubmed">20064386</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P., Melki R., Kopito R. (2010) Nat. Rev. Mol. Cell Biol. 11, 301&#x2013;307</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892479</ArticleId><ArticleId IdType="pubmed">20308987</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21454607</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>286</Volume><Issue>21</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport.</ArticleTitle><Pagination><StartPage>18845</StartPage><EndPage>18855</EndPage><MedlinePgn>18845-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M111.231118</ELocationID><Abstract><AbstractText>Carboxyl-terminal fragments (CTFs) of TDP-43 aggregate to form the diagnostic signature inclusions of frontotemporal lobar degeneration and amyotrophic lateral sclerosis, but the biological significance of these CTFs and how they are generated remain enigmatic. To address these issues, we engineered mammalian cells with an inducible tobacco etch virus (TEV) protease that cleaves TDP-43 containing a TEV cleavage site. Regions of TDP-43 flanking the second RNA recognition motif (RRM2) are efficiently cleaved by TEV, whereas sites within this domain are more resistant to cleavage. CTFs containing RRM2 generated from de novo cleavage of nuclear TDP-43 are transported to the cytoplasm and efficiently cleared, indicating that cleavage alone is not sufficient to initiate CTF aggregation. However, CTFs rapidly aggregated into stable cytoplasmic inclusions following de novo cleavage when dynein-mediated microtubule transport was disrupted, RNA was depleted, or natively misfolded CTFs were introduced into these cells. Our data support a "two-hit" mechanism of CTF aggregation dependent on TDP-43 cleavage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pesiridis</LastName><ForeName>G Scott</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathy</LastName><ForeName>Kalyan</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tanik</LastName><ForeName>Sel&#xe7;uk</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.2</RegistryNumber><NameOfSubstance UI="D004398">Dyneins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004398" MajorTopicYN="N">Dyneins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21454607</ArticleId><ArticleId IdType="pmc">PMC3099701</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111.231118</ArticleId><ArticleId IdType="pii">S0021-9258(20)51142-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M., Sampathu D. M., Kwong L. K., Truax A. C., Micsenyi M. C., Chou T. T., Bruce J., Schuck T., Grossman M., Clark C. M., McCluskey L. F., Miller B. L., Masliah E., Mackenzie I. R., Feldman H., Feiden W., Kretzschmar H. A., Trojanowski J. Q., Lee V. M.-Y. (2006) Science 314, 130&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Cleveland D. W. (2009) Cell 136, 1001&#x2013;1004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesiridis G. S., Lee V. M.-Y., Trojanowski J. Q. (2009) Hum. Mol. Genet. 18, R156&#x2013;R162</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758707</ArticleId><ArticleId IdType="pubmed">19808791</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory R. I., Yan K. P., Amuthan G., Chendrimada T., Doratotaj B., Cooch N., Shiekhattar R. (2004) Nature 432, 235&#x2013;240</Citation><ArticleIdList><ArticleId IdType="pubmed">15531877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou S. H., Wu F., Harrich D., Garc&#xed;a-Mart&#xed;nez L. F., Gaynor R. B. (1995) J. Virol. 69, 3584&#x2013;3596</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhyankar M. M., Urekar C., Reddi P. P. (2007) J. Biol. Chem. 282, 36143&#x2013;36154</Citation><ArticleIdList><ArticleId IdType="pubmed">17932037</ArticleId></ArticleIdList></Reference><Reference><Citation>Burd C. G., Matunis E. L., Dreyfuss G. (1991) Mol. Cell. Biol. 11, 3419&#x2013;3424</Citation><ArticleIdList><ArticleId IdType="pmc">PMC361068</ArticleId><ArticleId IdType="pubmed">1675426</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Baralle F. E. (2001) J. Biol. Chem. 276, 36337&#x2013;36343</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Brindisi A., Giombi M., Tisminetzky S., Ayala Y. M., Baralle F. E. (2005) J. Biol. Chem. 280, 37572&#x2013;37584</Citation><ArticleIdList><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ambrogio A., Buratti E., Stuani C., Guarnaccia C., Romano M., Ayala Y. M., Baralle F. E. (2009) Nucleic Acids Res. 37, 4116&#x2013;4126</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709582</ArticleId><ArticleId IdType="pubmed">19429692</ArticleId></ArticleIdList></Reference><Reference><Citation>Pi&#xf1;ol-Roma S. (1997) Semin. Cell Dev. Biol. 8, 57&#x2013;63</Citation><ArticleIdList><ArticleId IdType="pubmed">15001106</ArticleId></ArticleIdList></Reference><Reference><Citation>Pi&#xf1;ol-Roma S., Dreyfuss G. (1992) Nature 355, 730&#x2013;732</Citation><ArticleIdList><ArticleId IdType="pubmed">1371331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y. M., Zago P., D'Ambrogio A., Xu Y. F., Petrucelli L., Buratti E., Baralle F. E. (2008) J. Cell Sci. 121, 3778&#x2013;3785</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton M. J., Igaz L. M., Wong M. M., Kwong L. K., Trojanowski J. Q., Lee V. M.-Y. (2008) J. Biol. Chem. 283, 13302&#x2013;13309</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L. M., Kwong L. K., Chen-Plotkin A., Winton M. J., Unger T. L., Xu Y., Neumann M., Trojanowski J. Q., Lee V. M.-Y. (2009) J. Biol. Chem. 284, 8516&#x2013;8524</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D., Capell A., Carlson A. M., Shankaran S. S., Rodde R., Neumann M., Kremmer E., Matsuwaki T., Yamanouchi K., Nishihara M., Haass C. (2009) J. Neurochem. 110, 1082&#x2013;1094</Citation><ArticleIdList><ArticleId IdType="pubmed">19522733</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Kametani F., Arai T., Akiyama H., Hasegawa M. (2009) Hum. Mol. Genet. 18, 3353&#x2013;3364</Citation><ArticleIdList><ArticleId IdType="pubmed">19515851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. J., Xu Y. F., Cook C., Gendron T. F., Roettges P., Link C. D., Lin W. L., Tong J., Castanedes-Casey M., Ash P., Gass J., Rangachari V., Buratti E., Baralle F., Golde T. E., Dickson D. W., Petrucelli L. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 7607&#x2013;7612</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A. K., Lin R. Y., Hsieh E. Z., Tu P. H., Chen R. P., Liao T. Y., Chen W., Wang C. H., Huang J. J. (2010) J. Am. Chem. Soc. 132, 1186&#x2013;1187</Citation><ArticleIdList><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B. S., Snead D., Lee J. J., McCaffery J. M., Shorter J., Gitler A. D. (2009) J. Biol. Chem. 284, 20329&#x2013;20339</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Ray P., Rao E. J., Shi C., Guo W., Chen X., Woodruff E. A., 3rd, Fushimi K., Wu J. Y. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 3169&#x2013;3174</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840283</ArticleId><ArticleId IdType="pubmed">20133767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Ferris J., Gao F. B. (2009) Mol. Brain 2, 30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762964</ArticleId><ArticleId IdType="pubmed">19781077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauli A., Althoff F., Oliveira R. A., Heidmann S., Schuldiner O., Lehner C. F., Dickson B. J., Nasmyth K. (2008) Dev. Cell 14, 239&#x2013;251</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2258333</ArticleId><ArticleId IdType="pubmed">18267092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kredel S., Oswald F., Nienhaus K., Deuschle K., R&#xf6;cker C., Wolff M., Heilker R., Nienhaus G. U., Wiedenmann J. (2009) PLoS One 4, e4391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633614</ArticleId><ArticleId IdType="pubmed">19194514</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L. M., Kwong L. K., Xu Y., Truax A. C., Uryu K., Neumann M., Clark C. M., Elman L. B., Miller B. L., Grossman M., McCluskey L. F., Trojanowski J. Q., Lee V. M.-Y. (2008) Am. J. Pathol. 173, 182&#x2013;194</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Kwong L. K., Lee E. B., Kremmer E., Flatley A., Xu Y., Forman M. S., Troost D., Kretzschmar H. A., Trojanowski J. Q., Lee V. M.-Y. (2009) Acta Neuropathol. 117, 137&#x2013;149</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansens A., Braakman I. (2003) Methods Mol. Biol. 232, 133&#x2013;145</Citation><ArticleIdList><ArticleId IdType="pubmed">12840546</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhapparova O. N., Burakov A. V., Nadezhdina E. S. (2007) Biochemistry 72, 1233&#x2013;1240</Citation><ArticleIdList><ArticleId IdType="pubmed">18205606</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasanth K. V., Sacco-Bubulya P. A., Prasanth S. G., Spector D. L. (2003) Mol. Biol. Cell 14, 1043&#x2013;1057</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151578</ArticleId><ArticleId IdType="pubmed">12631722</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasanth K. V., Prasanth S. G., Xuan Z., Hearn S., Freier S. M., Bennett C. F., Zhang M. Q., Spector D. L. (2005) Cell 123, 249&#x2013;263</Citation><ArticleIdList><ArticleId IdType="pubmed">16239143</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo P. H., Doudeva L. G., Wang Y. T., Shen C. K., Yuan H. S. (2009) Nucleic Acids Res. 37, 1799&#x2013;1808</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665213</ArticleId><ArticleId IdType="pubmed">19174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K. R., Stone K. L., LoPresti M. B., Merrill B. M., Planck S. R. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 5666&#x2013;5670</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390612</ArticleId><ArticleId IdType="pubmed">2994041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner W. M. (1975) J. Cell Biol. 64, 421&#x2013;430</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2109498</ArticleId><ArticleId IdType="pubmed">46868</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. J., Gendron T. F., Xu Y. F., Ko L. W., Yen S. H., Petrucelli L. (2010) Mol. Neurodegener. 5, 33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941488</ArticleId><ArticleId IdType="pubmed">20804554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T. G., Buratti E., Baralle F., Morita M., Nakano I., Oda T., Tsuchiya K., Akiyama H. (2008) Ann. Neurol. 64, 60&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Mili S., Shu H. J., Zhao Y., Pi&#xf1;ol-Roma S. (2001) Mol. Cell. Biol. 21, 7307&#x2013;7319</Citation><ArticleIdList><ArticleId IdType="pmc">PMC99905</ArticleId><ArticleId IdType="pubmed">11585913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S. C., Albuquerque C. P., Han J. S., Lagier-Tourenne C., Tokunaga S., Zhou H., Cleveland D. W. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 13318&#x2013;13323</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922163</ArticleId><ArticleId IdType="pubmed">20624952</ArticleId></ArticleIdList></Reference><Reference><Citation>Corth&#xe9;sy-Theulaz I., Pauloin A., Pfeffer S. R. (1992) J. Cell Biol. 118, 1333&#x2013;1345</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289611</ArticleId><ArticleId IdType="pubmed">1387874</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B., Tu P., Abtahian F., Trojanowski J. Q., Lee V. M.-Y. (1997) J. Cell Biol. 139, 1307&#x2013;1315</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140205</ArticleId><ArticleId IdType="pubmed">9382875</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Annaert W. (2010) Annu. Rev. Cell Dev. Biol. 26, 235&#x2013;260</Citation><ArticleIdList><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S. H., Shanware N. P., Bowler M. J., Tibbetts R. S. (2010) J. Biol. Chem. 285, 34097&#x2013;34105</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962508</ArticleId><ArticleId IdType="pubmed">20720006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton C. F., Cenik C., Kucukural A., Dammer E. B., Cenik B., Han Y., Dewey C. M., Roth F. P., Herz J., Peng J., Moore M. J., Yu G. (2011) J. Biol. Chem. 286, 1204&#x2013;1215</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020728</ArticleId><ArticleId IdType="pubmed">21051541</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A. L., Zupunski V., Troakes C., Kathe C., Fratta P., Howell M., Gallo J. M., Hortob&#xe1;gyi T., Shaw C. E., Rogelj B. (2010) Brain 133, 1763&#x2013;1771</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21460841</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>436</StartPage><EndPage>441</EndPage><MedlinePgn>436-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.801</ELocationID><Abstract><AbstractText>The Alzheimer Disease Genetics Consortium (ADGC) performed a genome-wide association study of late-onset Alzheimer disease using a three-stage design consisting of a discovery stage (stage 1) and two replication stages (stages 2 and 3). Both joint analysis and meta-analysis approaches were used. We obtained genome-wide significant results at MS4A4A (rs4938933; stages 1 and 2, meta-analysis P (P(M)) = 1.7 &#xd7; 10(-9), joint analysis P (P(J)) = 1.7 &#xd7; 10(-9); stages 1, 2 and 3, P(M) = 8.2 &#xd7; 10(-12)), CD2AP (rs9349407; stages 1, 2 and 3, P(M) = 8.6 &#xd7; 10(-9)), EPHA1 (rs11767557; stages 1, 2 and 3, P(M) = 6.0 &#xd7; 10(-10)) and CD33 (rs3865444; stages 1, 2 and 3, P(M) = 1.6 &#xd7; 10(-9)). We also replicated previous associations at CR1 (rs6701713; P(M) = 4.6 &#xd7; 10(-10), P(J) = 5.2 &#xd7; 10(-11)), CLU (rs1532278; P(M) = 8.3 &#xd7; 10(-8), P(J) = 1.9 &#xd7; 10(-8)), BIN1 (rs7561528; P(M) = 4.0 &#xd7; 10(-14), P(J) = 5.2 &#xd7; 10(-14)) and PICALM (rs561655; P(M) = 7.0 &#xd7; 10(-11), P(J) = 1.0 &#xd7; 10(-10)), but not at EXOC3L2, to late-onset Alzheimer's disease susceptibility.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri Narayan</ForeName><Initials>BN</Initials></Author><Author ValidYN="Y"><LastName>Buros</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gallins</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Jarvik</LastName><ForeName>Gail P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>Michael M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Demirci</LastName><ForeName>F Yesim</ForeName><Initials>FY</Initials></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Bowen</LastName><ForeName>James D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Chris S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Carney</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Corneveaux</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cotman</LastName><ForeName>Carl W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dick</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>William G</ForeName><Initials>WG</Initials></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Ganguli</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Gilman</LastName><ForeName>Sid</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Giordani</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Mack</LastName><ForeName>Wendy J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Martiniuk</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>McCormick</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials></Author><Author ValidYN="Y"><LastName>McCurry</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>McDavid</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Joshua W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Perl</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Rajbhandary</LastName><ForeName>Ruchita A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Shelanski</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Slifer</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Sonnen</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Author><Author ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Dombroski</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG008671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA137788</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG006375</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031278</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG019085</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG02213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR029893</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016575</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023801</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025741</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH080295</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_G1000735</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RC2 AG036535</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG08051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089703</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA132378</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 AG06781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA129769</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG30146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016582</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MO1RR00096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS059873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1RR02777</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015214">Antigens, Differentiation, Myelomonocytic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C114545">CD2-associated protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C571163">CD33 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063268">Sialic Acid Binding Ig-like Lectin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D036082">Receptor, EphA1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015214" MajorTopicYN="N">Antigens, Differentiation, Myelomonocytic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005810" MajorTopicYN="N">Multigene Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036082" MajorTopicYN="N">Receptor, EphA1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063268" MajorTopicYN="N">Sialic Acid Binding Ig-like Lectin 3</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21460841</ArticleId><ArticleId IdType="mid">NIHMS287699</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pii">ng.801</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41 1088-U61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41 1094-U68.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population - Prevalence estimates using the 2000 census. Arch. Neurol. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer's Association, Alzheimer's Disease Facts and Figures. Washington, D.C.: 2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">19426951</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev EI, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376:775&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269:973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Gene Dose of Apolipoprotein-E Type-4 Allele and the Risk of Alzheimer's Disease in Late Onset Families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, et al. Heritability for Alzheimer's disease: The study of dementia in Swedish twins. Journals of Gerontology Series A - Biological Sciences and Medical Sciences. 1997;52:M117&#x2013;M125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9060980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Nature Genetics. 2011 (in press)</Citation></Reference><Reference><Citation>Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38:209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JP, Rosenberg PS, Goedert JJ, O&#x2019;Brien TR. Commentary: meta-analysis of individual participants' data in genetic epidemiology. Am J Epidemiol. 2002;156:204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83:623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon 4 carriers. Neuron. 2007;54:713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet. 2009;41:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 2008;65:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Beecham GW, Martin ER, Gallins PJ, Powell EH, Konidari I, Whitehead PL, Cai G, Haroutunian V, Scott WK, Vance JM, Slifer MA, Gwirtsman HE, Gilbert JR, Haines JL, Buxbaum JD, Pericak-Vance MA. Dementia Revealed: Novel Chromosome 6 Locus for Late-Onset Alzheimer Disease Provides Genetic Evidence for Folate-Pathway Abnormalities. Plos Genetics. 2010;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944795</ArticleId><ArticleId IdType="pubmed">20885792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, et al. Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Arch Neurol. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health. 1998;88:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1508384</ArticleId><ArticleId IdType="pubmed">9584027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku CS, Loy EY, Pawitan Y, Chia KS. The pursuit of genome-wide association studies: where are we now? J Hum Genet. 2010;55:195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">20300123</ArticleId></ArticleIdList></Reference><Reference><Citation>Florez JC. Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab. 2008;93:4633&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626447</ArticleId><ArticleId IdType="pubmed">18782870</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: A tool set for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>McPeek MS, Sun L. Statistical tests for detection of misspecified relationships by use of genome-screen data. Am J Hum Genet. 2000;66:1076&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288143</ArticleId><ArticleId IdType="pubmed">10712219</ArticleId></ArticleIdList></Reference><Reference><Citation>Abecasis GR, Cherny SS, Cookson WO, Cardon LR. GRR: graphical representation of relationship errors. Bioinformatics. 2001;17:742&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524377</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Abecasis GR. Rapid haplotype reconstruction and missing genotype inference. American Journal of Human Genetics. 2006;S79:2290.</Citation></Reference><Reference><Citation>Wittwer CT, et al. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques. 1997;22:176&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994665</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadian A, et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem. 2000;280:103&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human of human apolipoprotien E by gene amplification and cleavage with HhaI. J. Liped Res. 1990;31:545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai E, Riley J, Purvis I, Roses A. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics. 1998;54:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">9806827</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am. J. Hum. Genet. 2000;67:170&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1287075</ArticleId><ArticleId IdType="pubmed">10827107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK, Stephens M, Donnelly PJ. Inference of population structure using multilocus genotype data. Genetics. 2000;155:945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461096</ArticleId><ArticleId IdType="pubmed">10835412</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 2006;38:904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey VJ. GEE: Generalized Estimation Equation Solver. 4.13&#x2013;15. edn. 2010</Citation></Reference><Reference><Citation>Chen MH, Yang Q. GWAF: an R package for genome-wide association analyses with family data. Bioinformatics. 2010;26:580&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852219</ArticleId><ArticleId IdType="pubmed">20040588</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, V., Austria. 2009 ISBN 3-900051-07-0, URL  http://www.R-project.org.</Citation></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Abecasis GR, Wigginton JE. Handling marker-marker linkage disequilibrium: Pedigree analysis with clustered markers. Am. J. Hum. Genet. 2005;77:754&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271385</ArticleId><ArticleId IdType="pubmed">16252236</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21467285</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>305</Volume><Issue>13</Issue><PubDate><Year>2011</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Plasma clusterin and the risk of Alzheimer disease.</ArticleTitle><Pagination><StartPage>1322</StartPage><EndPage>1326</EndPage><MedlinePgn>1322-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2011.381</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Variants in the clusterin gene are associated with the risk of Alzheimer disease (AD) and clusterin levels have been found to be increased in brain and cerebrospinal fluid of patients with AD. Plasma clusterin was reported to be associated with brain atrophy, baseline disease severity, and rapid clinical progression in patients with AD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the potential of plasma clusterin as a biomarker of the presence, severity, and risk of AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A case-cohort study nested within the Rotterdam Study, a prospective population-based cohort study conducted in Rotterdam, The Netherlands. Plasma levels of clusterin were measured at baseline (1997-1999) in 60 individuals with prevalent AD, a random subcohort of 926 participants, and an additional 156 participants diagnosed with AD during follow-up until January 1, 2007 (mean [SD], 7.2 [2.3] years).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Prevalent AD, severity of AD measured by the Mini-Mental State Examination (MMSE) score, and the risk of developing AD during follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The likelihood of prevalent AD increased with increasing plasma levels of clusterin (odds ratio [OR] per SD increase of plasma clusterin level, 1.63; 95% confidence interval [CI], 1.21-2.20; adjusted for age, sex, education level, apolipoprotein E status, diabetes, smoking, coronary heart disease, and hypertension). Among patients with AD, higher clusterin levels were associated with more severe disease (adjusted difference in MMSE score per SD increase in clusterin levels, -1.36; 95% CI, -2.70 to -0.02; P = .047). Plasma clusterin levels were not related to the risk of incident AD during total follow-up (adjusted HR, 1.00; 95% CI, 0.85-1.17; P for trend = .77) or within 3 years of baseline (adjusted HR, 1.09; 95% CI, 0.84-1.42; P for trend = .65).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Plasma clusterin levels were significantly associated with baseline prevalence and severity of AD, but not with incidence of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schrijvers</LastName><ForeName>Elisabeth M C</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koudstaal</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Breteler</LastName><ForeName>Monique M B</ForeName><Initials>MM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2011 Nov;68(11):1459-60. doi: 10.1001/archneurol.2011.1000.</RefSource><PMID Version="1">22084130</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21467285</ArticleId><ArticleId IdType="doi">10.1001/jama.2011.381</ArticleId><ArticleId IdType="pii">305/13/1322</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21472771</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Acid &#x3b2;-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter &#x3b1;-synuclein processing.</ArticleTitle><Pagination><StartPage>940</StartPage><EndPage>953</EndPage><MedlinePgn>940-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.22400</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Heterozygous mutations in the GBA1 gene elevate the risk of Parkinson disease and dementia with Lewy bodies; both disorders are characterized by misprocessing of &#x3b1;-synuclein (SNCA). A loss in lysosomal acid-&#x3b2;-glucosidase enzyme (GCase) activity due to biallelic GBA1 mutations underlies Gaucher disease. We explored mechanisms for the gene's association with increased synucleinopathy risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed the effects of wild-type (WT) and several GBA mutants on SNCA in cellular and in vivo models using biochemical and immunohistochemical protocols.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed that overexpression of all GBA mutants examined (N370S, L444P, D409H, D409V, E235A, and E340A) significantly raised human SNCA levels to 121 to 248% of vector control (p &lt; 0.029) in neural MES23.5 and PC12 cells, but without altering GCase activity. Overexpression of WT GBA in neural and HEK293-SNCA cells increased GCase activity, as expected (ie, to 167% in MES-SNCA, 128% in PC12-SNCA, and 233% in HEK293-SNCA; p &lt; 0.002), but had mixed effects on SNCA. Nevertheless, in HEK293-SNCA cells high GCase activity was associated with SNCA reduction by &#x2264;32% (p = 0.009). Inhibition of cellular GCase activity (to 8-20% of WT; p &lt; 0.0017) did not detectably alter SNCA levels. Mutant GBA-induced SNCA accumulation could be pharmacologically reversed in D409V-expressing PC12-SNCA cells by rapamycin, an autophagy-inducer (&#x2264;40%; 10&#x3bc;M; p &lt; 0.02). Isofagomine, a GBA chaperone, showed a related trend. In mice expressing two D409Vgba knockin alleles without signs of Gaucher disease (residual GCase activity, &#x2265;20%), we recorded an age-dependent rise of endogenous Snca in hippocampal membranes (125% vs WT at 52 weeks; p = 0.019). In young Gaucher disease mice (V394Lgba+/+//prosaposin[ps]-null//ps-transgene), which demonstrate neurological dysfunction after age 10 weeks (GCase activity, &#x2264;10%), we recorded no significant change in endogenous Snca levels at 12 weeks of age. However, enhanced neuronal ubiquitin signals and axonal spheroid formation were already present. The latter changes were similar to those seen in three week-old cathepsin D-deficient mice.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our results demonstrate that GBA mutants promote SNCA accumulation in a dose- and time-dependent manner, thereby identifying a biochemical link between GBA1 mutation carrier status and increased synucleinopathy risk. In cell culture models, this gain of toxic function effect can be mitigated by rapamycin. Loss in GCase activity did not immediately raise SNCA concentrations, but first led to neuronal ubiquitinopathy and axonal spheroids, a phenotype shared with other lysosomal storage disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sardi</LastName><ForeName>S Pablo</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Juliana</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>You-Hai</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Julianna J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Kolodziej</LastName><ForeName>Piotr</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Ilana</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Saftig</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Woulfe</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rochet</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Glicksman</LastName><ForeName>Marcie A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Seng H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Grabowski</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Shihabuddin</LastName><ForeName>Lamya S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Schlossmacher</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.45</RegistryNumber><NameOfSubstance UI="D005962">Glucosylceramidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.5</RegistryNumber><NameOfSubstance UI="D002402">Cathepsin D</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002402" MajorTopicYN="N">Cathepsin D</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005776" MajorTopicYN="N">Gaucher Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005962" MajorTopicYN="N">Glucosylceramidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21472771</ArticleId><ArticleId IdType="doi">10.1002/ana.22400</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21482915</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Lack of evidence for the efficacy of memantine in mild Alzheimer disease.</ArticleTitle><Pagination><StartPage>991</StartPage><EndPage>998</EndPage><MedlinePgn>991-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.69</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD). Memantine is indicated in the United States and Europe for moderate to severe AD, which is diagnosed if a patient has a Mini-Mental State Examination (MMSE) score of less than 15 or less than 20, respectively. Yet memantine is very frequently prescribed for mild AD and mild cognitive impairment, and a manufacturer-sponsored meta-analysis claimed its efficacy in mild AD.</AbstractText><AbstractText Label="DATA SOURCES, STUDY SELECTION, AND DATA EXTRACTION" NlmCategory="METHODS">Manufacturer-sponsored meta-analyses, registries, presentations, and publications were systematically searched for randomized placebo-controlled, parallel-group clinical trials of memantine in patients with mild to moderate AD. The trials' characteristics and outcomes were extracted by one reviewer and checked by another. Meta-analyses were performed as inverse variance-weighted averages of mean differences using fixed-effects models. Summary results for patients with mild AD were obtained by contrasting the summary results for patients with mild or moderate AD with the summary results for the subset of patients with moderate AD.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Three trials were identified that included 431 patients with mild AD (ie, with MMSE scores of 20-23) and 697 patients with moderate AD (ie, with MMSE scores of 10-19). There were no significant differences between memantine and placebo on any outcome for patients with mild AD, either within any trial or when data were combined: mean differences (95% confidence intervals [CIs]) on the Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog), the Clinician's Interview-Based Impression of Change plus caregiver's input (CIBIC-plus), the Alzheimer Disease Cooperative Study-activities of daily living (ADCS-ADL) scale, and the Neuropsychiatric Inventory (NPI) were -0.17 (95% CI, -1.60 to 1.26), -0.09 (95% CI, -0.30 to 0.12), 0.62 (95% CI, -1.64 to 2.71), and 0.09 (95% CI, -2.11 to 2.29), respectively. For patients with moderate AD, there were small differences on the ADAS-cog and the CIBIC-plus, -1.33 (95% CI, -2.28 to -0.38) and -0.16 (95% CI, -0.32 to 0.00), respectively, but no differences on the ADCS-ADL scale (-0.57 [95% CI, -1.75 to 0.60]) or the NPI (0.25 [95% CI, -1.48 to 1.99]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite its frequent off-label use, evidence is lacking for a benefit of memantine in mild AD, and there is meager evidence for its efficacy in moderate AD. Prospective trials are needed to further assess the potential for efficacy of memantine either alone or added to cholinesterase inhibitors in mild and moderate AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA. lschneid@usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Higgins</LastName><ForeName>Julian P T</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>McShane</LastName><ForeName>Rupert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105285807</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21482915</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.69</ArticleId><ArticleId IdType="pii">archneurol.2011.69</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21487023</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>13</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43.</ArticleTitle><Pagination><StartPage>2510</StartPage><EndPage>2523</EndPage><MedlinePgn>2510-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddr150</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disorder characterized by the loss of motor neurons. Fused in sarcoma/translated in liposarcoma (FUS/TLS) and TAR DNA-binding protein (TDP)-43 are DNA/RNA-binding proteins found to be mutated in sporadic and familial forms of ALS. Ectopic expression of human ALS-causing FUS/TLS mutations in Drosophila caused an accumulation of ubiquitinated proteins, neurodegeneration, larval-crawling defect and early lethality. Mutant FUS/TLS localized to both the cytoplasm and nucleus, whereas wild-type FUS/TLS localized only to the nucleus, suggesting that the cytoplasmic localization of FUS/TLS is required for toxicity. Furthermore, we found that deletion of the nuclear export signal strongly suppressed toxicity, suggesting that cytoplasmic localization is necessary for neurodegeneration. Interestingly, we observed that FUS/TLS genetically interacts with TDP-43 in a mutation-dependent fashion to cause neurodegeneration in vivo. In summary, we demonstrate that ALS-associated mutations in FUS/TLS cause adult-onset neurodegeneration via a gain-of-toxicity mechanism that involves redistribution of the protein from the nucleus to the cytoplasm and is likely to involve an interaction with TDP-43.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lanson</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maltare</LastName><ForeName>Astha</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji Han</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Lloyd</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Udai Bhan</ForeName><Initials>UB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 NS062890</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS050274</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007381">Intermediate Filament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577484">NES protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064231">Nestin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="Y">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005123" MajorTopicYN="N">Eye</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007381" MajorTopicYN="N">Intermediate Filament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042541" MajorTopicYN="N">Intracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064231" MajorTopicYN="N">Nestin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21487023</ArticleId><ArticleId IdType="pmc">PMC4288133</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddr150</ArticleId><ArticleId IdType="pii">ddr150</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kabashi E., Valdmanis P.N., Dion P., Spielgelman D., McConkey B.J., Vande Velde C., Bouchard J.P., Lacomblez L., Pochigaeva K., Salachas F., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortob&#xe1;gyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Cleveland D.W. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136:1001&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson M.K., Stahlberg A., Arvidsson Y., Olofsson A., Semb H., Stenman G., Nilsson O., Aman P. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol. 2008;9:37&#x2013;54. doi: 10.1186/1471-2121-9-37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2121-9-37</ArticleId><ArticleId IdType="pmc">PMC2478660</ArticleId><ArticleId IdType="pubmed">18620564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinszner H., Sok J., Immanuel D., Yin Y., Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell. Sci. 1997;110:1741&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">9264461</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D., Rodde R., Edbauer D., Bentmann E., Fischer I., Hruscha A., Than M.E., Mackenzie I.R., Capell A., Schmid B., Neumann M., Haass C. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010;29:2841&#x2013;2857. doi: 10.1038/emboj.2010.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.143</ArticleId><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T., van der Zee J., Sleegers K., Engelborghs S., Vandenberghe R., Gijselinck I., Van den Broeck M., Mattheijssens M., Peeters K., De Deyn P.P., et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology. 2010;74:366&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">20124201</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.X., Zhai H., Bigio E.H., Yan J., Fecto F., Ajroud K., Mishra M., Ajroud-Driss S., Heller S., Sufit R., et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann. Neurol. 2010;67:739&#x2013;748. doi: 10.1001/archneurol.2010.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.101</ArticleId><ArticleId IdType="pmc">PMC4376270</ArticleId><ArticleId IdType="pubmed">20517935</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Chitta R.K., High A.A., Taylor J.P. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J. Proteome Res. 2010;9:1104&#x2013;1120. doi: 10.1021/pr901076y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr901076y</ArticleId><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton C.F., Cenik C., Kucukural A., Dammer E.B., Cenik B., Han Y.H., Dewey C.M., Roth F.P., Herz J., Peng J., et al. Identification of neuronal RNA targets of TDP-43-containing Ribonucleoprotein complexes. J. Biol. Chem. 2011;286:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020728</ArticleId><ArticleId IdType="pubmed">21051541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Polymenidou M., Cleveland D.W. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010;19:R46&#x2013;R64. doi: 10.1093/hmg/ddq137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq137</ArticleId><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand A.H., Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">8223268</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447:859&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568747</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterwalder T., Yoon K.S., White B.H., Keshishian H. A conditional tissue-specific transgene expression system using inducible GAL4. Proc. Natl Acad. Sci. USA. 2001;98:12596&#x2013;12601. doi: 10.1073/pnas.221303298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.221303298</ArticleId><ArticleId IdType="pmc">PMC60099</ArticleId><ArticleId IdType="pubmed">11675495</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd P.K., Oh S.Y., Krans A., Pandey U.B., Di Prospero N.A., Min K.T., Taylor J.P., Paulson H.L. Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet. 2010;6:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000359</ArticleId><ArticleId IdType="pubmed">21170301</ArticleId></ArticleIdList></Reference><Reference><Citation>Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature. 2000;404:394&#x2013;398. doi: 10.1038/35006074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35006074</ArticleId><ArticleId IdType="pubmed">10746727</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther D.C., Kinghorn K.J., Miranda E., Page R., Curry J.A., Duthie F.A., Gubb D.C., Lomas D.A. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience. 2005;132:123&#x2013;135. doi: 10.1016/j.neuroscience.2004.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2004.12.025</ArticleId><ArticleId IdType="pubmed">15780472</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Wairkar Y.P., Collins C.A., DiAntonio A. Highwire function at the Drosophila neuromuscular junction: spatial, structural, and temporal requirements. J. Neurosci. 2005;25:9557&#x2013;9566. doi: 10.1523/JNEUROSCI.2532-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2532-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725727</ArticleId><ArticleId IdType="pubmed">16237161</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel L., Fr&#xe9;bourg T., Campion D., Lecourtois M. Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies. Neurobiol. Dis. 2011;41:398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">20951205</ArticleId></ArticleIdList></Reference><Reference><Citation>Batlevi Y., Martin D.N., Pandey U.B., Simon C.R., Powers C.M., Taylor J.P., Baehrecke E.H. Dynein light chain 1 is required for autophagy, protein clearance, and cell death in Drosophila. Proc. Natl Acad. Sci. USA. 2010;107:742&#x2013;747. doi: 10.1073/pnas.0907967107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0907967107</ArticleId><ArticleId IdType="pmc">PMC2818958</ArticleId><ArticleId IdType="pubmed">20080745</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi T., Hokonohara T., Yamasaki R., Miura S., Kikuchi H., Iwaki A., Tashiro H., Furuya H., Nagara Y., Ohyagi Y., et al. Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol. 2010;119:355&#x2013;364. doi: 10.1007/s00401-009-0621-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0621-1</ArticleId><ArticleId IdType="pubmed">19967541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.C., Albuquerque C.P., Han J.S., Lagier-Tourenne C., Tokunaga S., Zhou H., Cleveland D.W. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc. Natl Acad. Sci., USA. 2010;107:13318&#x2013;13323. doi: 10.1073/pnas.1008227107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008227107</ArticleId><ArticleId IdType="pmc">PMC2922163</ArticleId><ArticleId IdType="pubmed">20624952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritson G.P., Custer S.K., Freibaum B.D., Guinto J.B., Geffel D., Moore J., Tang W., Winton M.J., Neumann M., Trojanowski J.Q., et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J. Neurosci. 2010;30:7729&#x2013;7739. doi: 10.1523/JNEUROSCI.5894-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5894-09.2010</ArticleId><ArticleId IdType="pmc">PMC2890254</ArticleId><ArticleId IdType="pubmed">20519548</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil V.V., Valdmanis P.N., Dion P.A., Daoud H., Kabashi E., Noreau A., Gauthier J. Hince P., Desjarlais A., et al. S2D team. Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology. 2009;73:1176&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3462471</ArticleId><ArticleId IdType="pubmed">19741216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K., Van Broeckhoven C. Motor-neuron disease: Rogue gene in the family. Nature. 2009;458:415&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">19325616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofola O., Kerr F., Rogers I., Killick R., Augustin H., Gandy C., Allen M.J., Hardy J., Lovestone S., Partridge L. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet. 2010;6:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932684</ArticleId><ArticleId IdType="pubmed">20824130</ArticleId></ArticleIdList></Reference><Reference><Citation>Latouche M., Lasbleiz C., Martin E., Monnier V., Debeir T., Mouatt-Prigent A., Muriel M.P., Morel L., Ruberg M., Brice A., et al. A conditional pan-neuronal Drosophila model of spinocerebellar ataxia 7 with a reversible adult phenotype suitable for identifying modifier genes. J. Neurosci. 2007;27:2483&#x2013;2492. doi: 10.1523/JNEUROSCI.5453-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5453-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672519</ArticleId><ArticleId IdType="pubmed">17344386</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh J.L., Pallos J., Thompson L.M. Fly models of Huntington's disease. Hum. Mol. Genet. 2003;12:R187&#x2013;R193.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925571</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Ray P., Rao E.J., Shi C., Guo W., Chen X., Woodruff E.A., 3rd, Fushimi K., Wu J.Y. A Drosophila model for TDP-43 proteinopathy. Proc. Natl Acad. Sci. USA. 2010;107:3169&#x2013;3174. doi: 10.1073/pnas.0913602107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0913602107</ArticleId><ArticleId IdType="pmc">PMC2840283</ArticleId><ArticleId IdType="pubmed">20133767</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudher A., Shepherd D., Newman T.A., Mildren P., Jukes J.P., Squire A., Mears A., Drummond J.A., Berg S., MacKay D., et al. GSK-3 beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry. 2004;9:522&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">14993907</ArticleId></ArticleIdList></Reference><Reference><Citation>Chee F.C., Mudher A., Cuttle M.F., Newman T.A., MacKay D., Lovestone S., Shepherd D. Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol. Dis. 2005;20:918&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023860</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson K.A., Kim S.H., Wassarman D.A., Tibbetts R.S. Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS) J. Biol. Chem. 2010;285:11068&#x2013;11072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856981</ArticleId><ArticleId IdType="pubmed">20154090</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams S.J., Crook R.J., Deture M., Randle S.J., Innes A.E., Yu X.Z., Lin W.L., Dugger B.N., McBride M., Hutton M., et al. Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. Am. J. Pathol. 2009;175:1598&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751556</ArticleId><ArticleId IdType="pubmed">19717642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd T.E., Taylor J.P. Flightless flies: Drosophila models of neuromuscular disease. Ann. N. Y. Acad. Sci. 2010;1184:E1&#x2013;E20. doi: 10.1111/j.1749-6632.2010.05432.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2010.05432.x</ArticleId><ArticleId IdType="pmc">PMC3062507</ArticleId><ArticleId IdType="pubmed">20329357</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepper A.S., Beerman R.W., Bhogal B., Jongens T.A. Argonaute2 suppresses Drosophila fragile X expression preventing neurogenesis and oogenesis defects. PLoS One. 2009;4:1&#x2013;9. doi: 10.1371/journal.pone.0005361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005361</ArticleId><ArticleId IdType="pmc">PMC2770736</ArticleId><ArticleId IdType="pubmed">19888420</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H.C., Dimlich D.N., Yokokura T., Mukherjee A., Kankel M.W., Sen A., Sridhar V., Fulga T.A., Hart A.C., Van Vactor D., Artavanis-Tsakonas S. Modeling spinal muscular atrophy in Drosophila. PLoS One. 2008;3:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527655</ArticleId><ArticleId IdType="pubmed">18791638</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardena S., Goldstein L.S. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron. 2001;32:389&#x2013;401. doi: 10.1016/S0896-6273(01)00496-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00496-2</ArticleId><ArticleId IdType="pubmed">11709151</ArticleId></ArticleIdList></Reference><Reference><Citation>Chee F., Mudher A., Newman T.A., Cuttle M., Lovestone S., Shepherd D. Overexpression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Biochem. Soc. Trans. 2006;34:88&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16417489</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ramahi I., P&#xe9;rez A.M., Lim J., Zhang M., Sorensen R., de Haro M., Branco J., Pulst S.M., Zoghbi H.Y., Botas J. dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. PLoS Genet. 2007;3:2551&#x2013;2564. doi: 10.1371/journal.pgen.0030234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.0030234</ArticleId><ArticleId IdType="pmc">PMC2323314</ArticleId><ArticleId IdType="pubmed">18166084</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos K.J., Grierson A.J., Ackerley S., Miller C.C. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 2008;31:151&#x2013;173. doi: 10.1146/annurev.neuro.31.061307.090711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.31.061307.090711</ArticleId><ArticleId IdType="pubmed">18558852</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan J.E., Goldstein L.S. The genetics of axonal transport and axonal transport disorders. PLoS Genet. 2006;2:1275&#x2013;1284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1584265</ArticleId><ArticleId IdType="pubmed">17009871</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone T.L., Gunawardena S., McCleary D., Reis G.F., Goldstein L.S. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. Hum. Mol. Genet. 2010;19:4399&#x2013;4408. doi: 10.1093/hmg/ddq363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq363</ArticleId><ArticleId IdType="pmc">PMC2957317</ArticleId><ArticleId IdType="pubmed">20817925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D., Seki M., Tsunoda Y., Uchiyama H., Suzuki N. Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Ann. Neurol. 2011;69:152&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">21280085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.H., Shanware N.P., Bowler M.J., Tibbetts R.S. Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. J. Biol. Chem. 2010;28:34097&#x2013;34105. doi: 10.1074/jbc.M110.154831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.154831</ArticleId><ArticleId IdType="pmc">PMC2962508</ArticleId><ArticleId IdType="pubmed">20720006</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiesel F.C., Voigt A., Weber S.S., Van den Haute C., Waldenmaier A., G&#xf6;rner K., Walter M., Anderson M.L., Kern J.V., Rasse T.M., et al. Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J. 2010;29:209&#x2013;221. doi: 10.1038/emboj.2009.324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.324</ArticleId><ArticleId IdType="pmc">PMC2808372</ArticleId><ArticleId IdType="pubmed">19910924</ArticleId></ArticleIdList></Reference><Reference><Citation>Du G., Liu X., Chen X., Song M., Yan Y., Jiao R., Wang C.C. Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation. Mol. Biol. Cell. 2010;21:2128&#x2013;2137. doi: 10.1091/mbc.E10-03-0200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E10-03-0200</ArticleId><ArticleId IdType="pmc">PMC2893978</ArticleId><ArticleId IdType="pubmed">20444973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.Y., Koga H., Kawaguchi Y., Tang W., Wong E., Gao Y.S., Pandey U.B., Kaushik S., Tresse E., Lu J., et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010;29:969&#x2013;980. doi: 10.1038/emboj.2009.405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.405</ArticleId><ArticleId IdType="pmc">PMC2837169</ArticleId><ArticleId IdType="pubmed">20075865</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey U.B., Batlevi Y., Baehrecke E.H., Taylor J.P. HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration. Autophagy. 2007;3:643&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">17912024</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Allemand E., Gattoni R., Bourbon H.M., Stevenin J., C&#xe1;ceres J.F., Soret J., Tazi J. Distinctive features of Drosophila alternative splicing factor RS domain: implication for specific phosphorylation, shuttling, and splicing activation. Mol. Cell. Biol. 2001;4:1345&#x2013;1359. doi: 10.1128/MCB.21.4.1345-1359.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.21.4.1345-1359.2001</ArticleId><ArticleId IdType="pmc">PMC99587</ArticleId><ArticleId IdType="pubmed">11158320</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory R.I., Yan K.P., Amuthan G., Chendrimada T., Doratotaj B., Cooch N., Shiekhattar R. The microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432:235&#x2013;240. doi: 10.1038/nature03120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03120</ArticleId><ArticleId IdType="pubmed">15531877</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R., Taylor J.P. Dissection and Imaging of Active Zones in the Drosophila Neuromuscular Junction. J. Vis. Exp. 2011 doi: 10.3791/2676. . Aailable at: http://www.jove.com/details.stp?id=2676.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2676</ArticleId><ArticleId IdType="pmc">PMC3169289</ArticleId><ArticleId IdType="pubmed">21559003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21490216</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>15</Issue><PubDate><Year>2011</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system.</ArticleTitle><Pagination><StartPage>5744</StartPage><EndPage>5754</EndPage><MedlinePgn>5744-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6810-10.2011</ELocationID><Abstract><AbstractText>&#x3b2;-Site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is an aspartyl protease best known for its role in generating the amyloid-&#x3b2; peptides that are present in plaques of Alzheimer's disease. BACE1 has been an attractive target for drug development. In cultured embryonic neurons, BACE1-cleaved N-terminal APP is further processed to generate a fragment that can trigger axonal degeneration, suggesting a vital role for BACE1 in axonal health. In addition, BACE1 cleaves neuregulin 1 type III, a protein critical for myelination of peripheral axons by Schwann cells during development. Here, we asked whether axonal degeneration or axonal regeneration in adult nerves might be affected by inhibition or elimination of BACE1. We report that BACE1 knock-out and wild-type nerves degenerated at a similar rate after axotomy and to a similar extent in the experimental neuropathies produced by administration of paclitaxel and acrylamide. These data indicate N-APP is not the sole culprit in axonal degeneration in adult nerves. Unexpectedly, however, we observed that BACE1 knock-out mice had markedly enhanced clearance of axonal and myelin debris from degenerated fibers, accelerated axonal regeneration, and earlier reinnervation of neuromuscular junctions, compared with littermate controls. These observations were reproduced in part by pharmacological inhibition of BACE1. These data suggest BACE1 inhibition as a therapeutic approach to accelerate regeneration and recovery after peripheral nerve damage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farah</LastName><ForeName>Mohamed H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Departments of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Bao Han</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>Paul N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Ferraris</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tsukamoto</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Thien</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Slusher</LastName><ForeName>Barbara S</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>John W</ForeName><Initials>JW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 AG025658</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS047308</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041269</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025005</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C070614">neurobiotin</NameOfSubstance></Chemical><Chemical><RegistryNumber>20R035KLCI</RegistryNumber><NameOfSubstance UI="D020106">Acrylamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>6SO6U10H04</RegistryNumber><NameOfSubstance UI="D001710">Biotin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020106" MajorTopicYN="N">Acrylamide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001710" MajorTopicYN="N">Biotin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005727" MajorTopicYN="N">Ganglia, Spinal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015918" MajorTopicYN="N">Infusion Pumps, Implantable</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017933" MajorTopicYN="N">Peripheral Nervous System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014855" MajorTopicYN="N">Wallerian Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21490216</ArticleId><ArticleId IdType="mid">NIHMS288123</ArticleId><ArticleId IdType="pmc">PMC3302726</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6810-10.2011</ArticleId><ArticleId IdType="pii">31/15/5744</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S, Kimura J. Trophic effect of &#x3b2;-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun. 1991;181:265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">1958195</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrette B, H&#xe9;bert MA, Filali M, Lafortune K, Valli&#xe8;res N, Gowing G, Julien JP, Lacroix S. Requirement of myeloid cells for axon regeneration. J Neurosci. 2008;28:9363&#x2013;9376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671109</ArticleId><ArticleId IdType="pubmed">18799670</ArticleId></ArticleIdList></Reference><Reference><Citation>Beirowski B, Berek L, Adalbert R, Wagner D, Grumme DS, Addicks K, Ribchester RR, Coleman MP. Quantitative and qualitative analysis of Wallerian degeneration using restricted axonal labelling in YFP-H mice. J Neurosci Methods. 2004;134:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102500</ArticleId></ArticleIdList></Reference><Reference><Citation>Beirowski B, Adalbert R, Wagner D, Grumme DS, Addicks K, Ribchester RR, Coleman MP. The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. BMC Neurosci. 2005;6:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549193</ArticleId><ArticleId IdType="pubmed">15686598</ArticleId></ArticleIdList></Reference><Reference><Citation>Boivin A, Pineau I, Barrette B, Filali M, Valli&#xe8;res N, Rivest S, Lacroix S. Toll-like receptor signaling is critical for Wallerian degeneration and functional recovery after peripheral nerve injury. J Neurosci. 2007;27:12565&#x2013;12576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673340</ArticleId><ArticleId IdType="pubmed">18003835</ArticleId></ArticleIdList></Reference><Reference><Citation>Brushart TM. Motor axons preferentially reinnervate motor pathways. J Neurosci. 1993;13:2730&#x2013;2738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576505</ArticleId><ArticleId IdType="pubmed">8501535</ArticleId></ArticleIdList></Reference><Reference><Citation>Brushart TM, Gerber J, Kessens P, Chen YG, Royall RM. Contributions of pathway and neuron to preferential motor reinnervation. J Neurosci. 1998;18:8674&#x2013;8681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793544</ArticleId><ArticleId IdType="pubmed">9786974</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZL, Yu WM, Strickland S. Peripheral regeneration. Annu Rev Neurosci. 2007;30:209&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341159</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Beta-secretase inhibition for the treatment of Alzheimer's disease&#x2014;promise and challenge. Trends Pharmacol Sci. 2004;25:92&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ert&#xfc;rk A, Hellal F, Enes J, Bradke F. Disorganized microtubules underlie the formation of retraction bulbs and the failure of axonal regeneration. J Neurosci. 2007;27:9169&#x2013;9180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672197</ArticleId><ArticleId IdType="pubmed">17715353</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah MH. Cumulative labeling of embryonic mouse neural retina with bromodeoxyuridine supplied by an osmotic minipump. J Neurosci Methods. 2004;134:169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003383</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah MH, Easter SS., Jr Cell birth and death in the mouse retinal ganglion cell layer. J Comp Neurol. 2005;489:120&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15977166</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci. 2003;4:703&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">12951563</ArticleId></ArticleIdList></Reference><Reference><Citation>George R, Griffin JW. Delayed macrophage responses and myelin clearance during Wallerian degeneration in the central nervous system: the dorsal radiculotomy model. Exp Neurol. 1994;129:225&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">7957737</ArticleId></ArticleIdList></Reference><Reference><Citation>Geremia NM, Pettersson LM, Hasmatali JC, Hryciw T, Danielsen N, Schreyer DJ, Verge VM. Endogenous BDNF regulates induction of intrinsic neuronal growth programs in injured sensory neurons. Exp Neurol. 2010;223:128&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">19646438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon T, Chan KM, Sulaiman OA, Udina E, Amirjani N, Brushart TM. Accelerating axon growth to overcome limitations in functional recovery after peripheral nerve injury. Neurosurgery. 2009;5(4 Suppl):A132&#x2013;A144.</Citation><ArticleIdList><ArticleId IdType="pubmed">19927058</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JW, Pan B, Polley MA, Hoffman PN, Farah MH. Measuring nerve regeneration in the mouse. Exp Neurol. 2010;223:60&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20080088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammarlund M, Nix P, Hauth L, Jorgensen EM, Bastiani M. Axon regeneration requires a conserved MAP kinase pathway. Science. 2009;323:802&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2729122</ArticleId><ArticleId IdType="pubmed">19164707</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;ke A. Mechanisms of disease: what factors limit the success of peripheral nerve regeneration in humans? Nat Clin Pract Neurol. 2006;2:448&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">16932603</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109:1144&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob JM, McQuarrie IG. Acceleration of axonal outgrowth in rat sciatic nerve at one week after axotomy. J Neurobiol. 1993;24:356&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">8492112</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquin MF, Hu JW, Sessle BJ, Renehan WE, Waite PM. Intra-axonal Neurobiotin injection rapidly stains the long-range projections of identified trigeminal primary afferents in vivo: comparisons with HRP and PHA-L. J Neurosci Methods. 1992;45:71&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">1283434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y. Alzheimer's &#x3b2;-secretase, &#x3b2;-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci U S A. 2001;98:13554&#x2013;13559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61079</ArticleId><ArticleId IdType="pubmed">11698669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanners HN, Grafstein B. Effect of a conditioning lesion on regeneration of goldfish optic axons: ultrastructural evidence of enhanced outgrowth and pinocytosis. Brain Res. 1980;196:547&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">7190457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapper SR, Bolam JP. The anterograde and retrograde transport of Neurobiotin in the central nervous system of the rat: comparison with biocytin. J Neurosci Methods. 1991;39:163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">1724681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, De Strooper B, Seed B. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem. 2003;278:48713&#x2013;48719.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>Link TM, Park U, Vonakis BM, Raben DM, Soloski MJ, Caterina MJ. TRPV2 has a pivotal role in macrophage particle binding and phagocytosis. Nat Immunol. 2010;11:232&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840267</ArticleId><ArticleId IdType="pubmed">20118928</ArticleId></ArticleIdList></Reference><Reference><Citation>Malamas MS, Erdei J, Gunawan I, Turner J, Hu Y, Wagner E, Fan K, Chopra R, Olland A, Bard J, Jacobsen S, Magolda RL, Pangalos M, Robichaud AJ. Design and synthesis of 5,5&#x2032;-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. J Med Chem. 2010;53:1146&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pubmed">19968289</ArticleId></ArticleIdList></Reference><Reference><Citation>McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 1997;100(11 Suppl):S97&#x2013;S103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9413410</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuarrie IG. The effect of a conditioning lesion on the regeneration of motor axons. Brain Res. 1978;152:597&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">80247</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuarrie IG. Effect of conditioning lesion on axonal sprout formation at nodes of Ranvier. J Comp Neurol. 1985;231:239&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">2578490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mears S, Schachner M, Brushart TM. Antibodies to myelin-associated glycoprotein accelerate preferential motor reinnervation. J Peripher Nerv Syst. 2003;8:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">12795713</ArticleId></ArticleIdList></Reference><Reference><Citation>Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. Axonal neuregulin-1 regulates myelin sheath thickness. Science. 2004;304:700&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T, Mehta NR, Conant K, Kim KJ, Jones M, Calabresi PA, Melli G, Hoke A, Schnaar RL, Ming GL, Song H, Keswani SC, Griffin JW. Axonal protective effects of the myelin-associated glycoprotein. J Neurosci. 2009;29:630&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774126</ArticleId><ArticleId IdType="pubmed">19158290</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Zheng H, Van der Ploeg LH, Koo EH. The &#x3b2;-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci. 1997;17:9407&#x2013;9414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573428</ArticleId><ArticleId IdType="pubmed">9390996</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH, Colonna M, Panina-Bordignon P. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol. 2007;37:1290&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">17407101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramon y Cajal S. Degeneration and regeneration of the nervous system. In: Mays R, editor. London: Oxford UP; 1928.</Citation></Reference><Reference><Citation>R&#xf6;ytta M, Raine CS. Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ. J Neurocytol. 1985;14:157&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">2861255</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;ytt&#xe4; M, Raine CS. Tool-induced neuropathy: chronic effects of local injection. J Neurocytol. 1986;15:483&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">2427662</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A. 2008;105:5585&#x2013;5590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;fer M, Fruttiger M, Montag D, Schachner M, Martini R. Disruption of the gene for the myelin-associated glycoprotein improves axonal regrowth along myelin in C57BL/Wlds mice. Neuron. 1996;16:1107&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">8663987</ArticleId></ArticleIdList></Reference><Reference><Citation>Seijffers R, Mills CD, Woolf CJ. ATF3 increases the intrinsic growth state of DRG neurons to enhance peripheral nerve regeneration. J Neurosci. 2007;27:7911&#x2013;7920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672733</ArticleId><ArticleId IdType="pubmed">17652582</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim S, Ming GL. Roles of channels and receptors in the growth cone during PNS axonal regeneration. Exp Neurol. 2010;223:38&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849920</ArticleId><ArticleId IdType="pubmed">19833126</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestri R. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Med Res Rev. 2009;29:295&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">18651582</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, Lai MT, Crouthamel MC, Xu M, Tugusheva K, Lineberger JE, Pietrak BL, Espeseth AS, Shi XP, Chen-Dodson E, Holloway MK, Munshi S, Simon AJ, Kuo L, et al. Structure-based design of potent and selective cell permeable inhibitors of human beta-secretase (BACE-1) J Med Chem. 2004;47:6447&#x2013;6450.</Citation><ArticleIdList><ArticleId IdType="pubmed">15588077</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll G, Griffin JW, Li CY, Trapp BD. Wallerian degeneration in the peripheral nervous system: participation of both Schwann cells and macrophages in myelin degradation. J Neurocytol. 1989;18:671&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">2614485</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. 2007;4:e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851623</ArticleId><ArticleId IdType="pubmed">17425404</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M. Oxidative stress activates a positive feedback between the &#x3b3;- and &#x3b2;-secretase cleavages of the &#x3b2;-amyloid precursor protein. J Neurochem. 2008;104:683&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2220052</ArticleId><ArticleId IdType="pubmed">18005001</ArticleId></ArticleIdList></Reference><Reference><Citation>Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X, Esper RM, Loeb JA, Shrager P, Chao MV, Falls DL, Role L, Salzer JL. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron. 2005;47:681&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2387056</ArticleId><ArticleId IdType="pubmed">16129398</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177:3520&#x2013;3524.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas ME, Barres BA. Why is Wallerian degeneration in the CNS so slow? Annu Rev Neurosci. 2007;30:153&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">17506644</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas ME, Watanabe J, Singh SJ, Robinson WH, Barres BA. Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury. Proc Natl Acad Sci U S A. 2010;107:11993&#x2013;11998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900702</ArticleId><ArticleId IdType="pubmed">20547838</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vohra BP, Sasaki Y, Miller BR, Chang J, DiAntonio A, Milbrandt J. Amyloid precursor protein cleavage-dependent and -independent axonal degeneration programs share a common nicotinamide mononucleotide adenylyltransferase 1-sensitive pathway. J Neurosci. 2010;30:13729&#x2013;13738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3104322</ArticleId><ArticleId IdType="pubmed">20943913</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller AV. Nouvelles recherches sur la regeneration des fibres nerveuses. CR Acad Sci (Paris) 1852;34:675&#x2013;679.</Citation></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, Chen HY, Price DL, Van der Ploeg LH, Sisodia SS. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 1997;387:288&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153393</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodard-Grice AV, McBrayer AC, Wakefield JK, Zhuo Y, Bellis SL. Proteolytic shedding of ST6Gal-I by BACE1 regulates the glycosylation and function of alpha4beta1 integrins. J Biol Chem. 2008;283:26364&#x2013;26373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546544</ArticleId><ArticleId IdType="pubmed">18650447</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo S, van Niekerk EA, Merianda TT, Twiss JL. Dynamics of axonal mRNA transport and implications for peripheral nerve regeneration. Exp Neurol. 2010;223:19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849851</ArticleId><ArticleId IdType="pubmed">19699200</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev. 2008;3:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442059</ArticleId><ArticleId IdType="pubmed">18573216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, Xu H, Zhang YW. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem. 2007;282:10873&#x2013;10880.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303576</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21514247</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>257</StartPage><EndPage>262</EndPage><MedlinePgn>257-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2011.03.004</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Criteria for the clinical diagnosis of Alzheimer's disease (AD) were established in 1984. A broad consensus now exists that these criteria should be revised to incorporate state-of-the-art scientific knowledge.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The National Institute on Aging (NIA) and the Alzheimer's Association sponsored a series of advisory round table meetings in 2009 whose purpose was to establish a process for revising diagnostic and research criteria for AD. The recommendation from these advisory meetings was that three separate work groups should be formed with each assigned the task of formulating diagnostic criteria for one phase of the disease: the dementia phase; the symptomatic, pre-dementia phase; and the asymptomatic, preclinical phase of AD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two notable differences from the AD criteria published in 1984 are incorporation of biomarkers of the underlying disease state and formalization of different stages of disease in the diagnostic criteria. There was a broad consensus within all three workgroups that much additional work is needed to validate the application of biomarkers for diagnostic purposes. In the revised NIA-Alzheimer's Association criteria, a semantic and conceptual distinction is made between AD pathophysiological processes and clinically observable syndromes that result, whereas this distinction was blurred in the 1984 criteria.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The new criteria for AD are presented in three documents. The core clinical criteria of the recommendations regarding AD dementia and MCI due to AD are intended to guide diagnosis in the clinical setting. However, the recommendations of the preclinical AD workgroup are intended purely for research purposes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 The Alzheimer's Association. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN, USA. jack.clifford@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>McKhann</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Thies</LastName><ForeName>Bill</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Phelps</LastName><ForeName>Creighton H</ForeName><Initials>CH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015975" MajorTopicYN="N">Consensus Development Conferences, NIH as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006287" MajorTopicYN="N">Health Planning Guidelines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054561" MajorTopicYN="N">National Institute on Aging (U.S.)</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21514247</ArticleId><ArticleId IdType="mid">NIHMS284298</ArticleId><ArticleId IdType="pmc">PMC3096735</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2011.03.004</ArticleId><ArticleId IdType="pii">S1552-5260(11)00100-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DG, et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58(4):376&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218633</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62(11):1087&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45(3):358&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Alladi S, et al. Focal cortical presentations of Alzheimer&#x2019;s disease. Brain. 2007;130(Pt 10):2636&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898010</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64(4):388&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648510</ArticleId><ArticleId IdType="pubmed">18991338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang-Wai DF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63(7):1168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477533</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS. Diagnosis of Alzheimer&#x2019;s disease. Arch Neurol. 1985;42(11):1097&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. The neuropathological diagnosis of Alzheimer&#x2019;s disease: clinical-pathological studies. Neurobiol Aging. 1997;18(4 Suppl):S27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330982</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006;63(1):38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63(5):665&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682536</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, et al. Revising the definition of Alzheimer&#x2019;s disease: a new lexicon. Lancet Neurol. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, et al. Research criteria for the diagnosis of Alzheimer&#x2019;s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarfield AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med. 2003;163(18):2219&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">14557220</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson L. Clinical picture of frontal lobe degeneration of non-Alzheimer type. Dementia. 1993;4(3&#x2013;4):143&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8401782</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D. Non Alzheimer&#x2019;s disease forms of cerebral atrophy. J Neurol Neurosurg Psychiatry. 1990;53(11):929&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC488269</ArticleId><ArticleId IdType="pubmed">2283521</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol. 1982;11(6):592&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7114808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomo-Tempini ML, Hillis AE, Weintraub S. Recommendations for the classification of primary progressive aphasia and its variants. Neurology. 2011 In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis. 2009;18(3):713&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, et al. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330(6012):1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol. 1994;53(5):429&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann Neurol. 1997;41(1):17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61(3):378&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, et al. Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131(Pt 3):665&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461(7266):916&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x2019;s disease: implications for sequence of pathological events in Alzheimer&#x2019;s disease. Brain. 2009;132(Pt 5):1355&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, et al. Biomarkers for Alzheimer&#x2019;s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592748</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21522131</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP.</ArticleTitle><Pagination><StartPage>2266</StartPage><EndPage>2280</EndPage><MedlinePgn>2266-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/emboj.2011.119</ELocationID><Abstract><AbstractText>Despite its key role in Alzheimer pathogenesis, the physiological function(s) of the amyloid precursor protein (APP) and its proteolytic fragments are still poorly understood. Previously, we generated APPs&#x3b1; knock-in (KI) mice expressing solely the secreted ectodomain APPs&#x3b1;. Here, we generated double mutants (APPs&#x3b1;-DM) by crossing APPs&#x3b1;-KI mice onto an APLP2-deficient background and show that APPs&#x3b1; rescues the postnatal lethality of the majority of APP/APLP2 double knockout mice. Surviving APPs&#x3b1;-DM mice exhibited impaired neuromuscular transmission, with reductions in quantal content, readily releasable pool, and ability to sustain vesicle release that resulted in muscular weakness. We show that these defects may be due to loss of an APP/Mint2/Munc18 complex. Moreover, APPs&#x3b1;-DM muscle showed fragmented post-synaptic specializations, suggesting impaired postnatal synaptic maturation and/or maintenance. Despite normal CNS morphology and unaltered basal synaptic transmission, young APPs&#x3b1;-DM mice already showed pronounced hippocampal dysfunction, impaired spatial learning and a deficit in LTP that could be rescued by GABA(A) receptor inhibition. Collectively, our data show that APLP2 and APP are synergistically required to mediate neuromuscular transmission, spatial learning and synaptic plasticity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weyer</LastName><ForeName>Sascha W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klevanski</LastName><ForeName>Maja</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Delekate</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Voikar</LastName><ForeName>Vootele</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Aydin</LastName><ForeName>Dorothee</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hick</LastName><ForeName>Meike</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Filippov</LastName><ForeName>Mikhail</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Drost</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Schaller</LastName><ForeName>Kristin L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Saar</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vogt</LastName><ForeName>Miriam A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Gass</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Samanta</LastName><ForeName>Ayan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>J&#xe4;schke</LastName><ForeName>Andres</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Korte</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wolfer</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Caldwell</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrike C</ForeName><Initials>UC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492952">Aplp2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>EMBO J. 2011 Jun 1;30(11):2306</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21522131</ArticleId><ArticleId IdType="pmc">PMC3117640</ArticleId><ArticleId IdType="doi">10.1038/emboj.2011.119</ArticleId><ArticleId IdType="pii">emboj2011119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anliker B, M&#xfc;ller U (2006) The functions of mammalian amyloid precursor protein and related amyloid precursor-like proteins. Neurodegener Dis 3: 239&#x2013;246</Citation><ArticleIdList><ArticleId IdType="pubmed">17047363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashley J, Packard M, Ataman B, Budnik V (2005) Fasciclin II signals new synapse formation through amyloid precursor protein and the scaffolding protein dX11/Mint. J Neurosci 25: 5943&#x2013;5955</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724788</ArticleId><ArticleId IdType="pubmed">15976083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmans BA, Shariati SA, Habets RL, Verstreken P, Schoonjans L, M&#xfc;ller U, Dotti CG, De Strooper B (2010) Neurons generated from APP/APLP1/APLP2 triple knockout embryonic stem cells behave normally in vitro and in vivo: lack of evidence for a cell autonomous role of the amyloid precursor protein in neuronal differentiation. Stem Cells 28: 399&#x2013;406</Citation><ArticleIdList><ArticleId IdType="pubmed">20049903</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC (2001) A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293: 115&#x2013;120</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Colacicco G, Voikar V, Vannoni E, Lipp H-P, Wolfer DP (2009) Cognitive functions of hippocampus lesioned mice assessed in the IntelliCage. Neuroscience Meeting Planner Society for Neuroscience, 2009 Program No 47819 2009</Citation></Reference><Reference><Citation>Copanaki E, Chang S, Vlachos A, Tschape JA, Muller UC, Kogel D, Deller T (2010) sAPPalpha antagonizes dendritic degeneration and neuron death triggered by proteasomal stress. Mol Cell Neurosci 44: 386&#x2013;393</Citation><ArticleIdList><ArticleId IdType="pubmed">20472066</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RM, Croucher A, Rawlins JN (2002) Hippocampal cytotoxic lesion effects on species-typical behaviours in mice. Behav Brain Res 132: 203&#x2013;213</Citation><ArticleIdList><ArticleId IdType="pubmed">11997150</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RM, Rawlins JN (2006) T-maze alternation in the rodent. Nat Protoc 1: 7&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">17406205</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, Beyreuther K (2004) The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem 279: 18146&#x2013;18156</Citation><ArticleIdList><ArticleId IdType="pubmed">14970212</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmqvist D, Quastel DM (1965) A quantitative study of end-plate potentials in isolated human muscle. J Physiol 178: 505&#x2013;529</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1357310</ArticleId><ArticleId IdType="pubmed">5827910</ArticleId></ArticleIdList></Reference><Reference><Citation>Endres K, Postina R, Schroeder A, Mueller U, Fahrenholz F (2005) Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. FEBS J 272: 5808&#x2013;5820</Citation><ArticleIdList><ArticleId IdType="pubmed">16279945</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazeli MS, Breen K, Errington ML, Bliss TV (1994) Increase in extracellular NCAM and amyloid precursor protein following induction of long-term potentiation in the dentate gyrus of anaesthetized rats. Neurosci Lett 169: 77&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pubmed">8047297</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzjohn SM, Morton RA, Kuenzi F, Davies CH, Seabrook GR, Collingridge GL (2000) Similar levels of long-term potentiation in amyloid precursor protein -null and wild-type mice in the CA1 region of picrotoxin treated slices. Neurosci Lett 288: 9&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">10869803</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MA, Ho MS, Smyth N, Sanes JR (2008) A synaptic nidogen: developmental regulation and role of nidogen-2 at the neuromuscular junction. Neural Dev 3: 24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2567315</ArticleId><ArticleId IdType="pubmed">18817539</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MA, Sanes JR, Borza DB, Eswarakumar VP, Fassler R, Hudson BG, John SW, Ninomiya Y, Pedchenko V, Pfaff SL, Rheault MN, Sado Y, Segal Y, Werle MJ, Umemori H (2007) Distinct target-derived signals organize formation, maturation, and maintenance of motor nerve terminals. Cell 129: 179&#x2013;193</Citation><ArticleIdList><ArticleId IdType="pubmed">17418794</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, Mattson MP (1998) Secreted amyloid precursor protein alpha selectively suppresses N-methyl-D-aspartate currents in hippocampal neurons: involvement of cyclic GMP. Neuroscience 83: 429&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pubmed">9460751</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, Fox M, Mattson MP (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 67: 1882&#x2013;1896</Citation><ArticleIdList><ArticleId IdType="pubmed">8863493</ArticleId></ArticleIdList></Reference><Reference><Citation>Gakhar-Koppole N, Hundeshagen P, Mandl C, Weyer SW, Allinquant B, Muller U, Ciccolini F (2008) Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway. Eur J Neurosci 28: 871&#x2013;882</Citation><ArticleIdList><ArticleId IdType="pubmed">18717733</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez M, Ruggiero FP, Chang Q, Shi YJ, Rich MM, Kraner S, Balice-Gordon RJ (1999) Disruption of Trkb-mediated signaling induces disassembly of postsynaptic receptor clusters at neuromuscular junctions. Neuron 24: 567&#x2013;583</Citation><ArticleIdList><ArticleId IdType="pubmed">10595510</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T, von Kretzschmar H, von Koch C, Sisodia S, Tremml P, Lipp HP, Wolfer DP, M&#xfc;ller U (2000) Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 20: 7951&#x2013;7963</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig R, Lomo T (1985) Firing patterns of motor units in normal rats. Nature 314: 164&#x2013;166</Citation><ArticleIdList><ArticleId IdType="pubmed">3974720</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, M&#xfc;ller U (2004) Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J 23: 4106&#x2013;4115</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsh R (1970) Lack of variability or perseveration: describing the effect of hippocampal ablation. Physiol Behav 5: 1249&#x2013;1254</Citation><ArticleIdList><ArticleId IdType="pubmed">5524507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho A, Morishita W, Hammer RE, Malenka RC, Sudhof TC (2003) A role for Mints in transmitter release: Mint 1 knockout mice exhibit impaired GABAergic synaptic transmission. Proc Natl Acad Sci USA 100: 1409&#x2013;1414</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298786</ArticleId><ArticleId IdType="pubmed">12547917</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornsten A, Lieberthal J, Fadia S, Malins R, Ha L, Xu X, Daigle I, Markowitz M, O'Connor G, Plasterk R, Li C (2007) APL-1, a Caenorhabditis elegans protein related to the human beta-amyloid precursor protein, is essential for viability. Proc Natl Acad Sci USA 104: 1971&#x2013;1976</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794273</ArticleId><ArticleId IdType="pubmed">17267616</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerppola TK (2008) Bimolecular fluorescence complementation (BiFC) analysis as a probe of protein interactions in living cells. Annu Rev Biophys 37: 465&#x2013;487</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829326</ArticleId><ArticleId IdType="pubmed">18573091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J, Anderson JE (1999) Dystrophin is required for organizing large acetylcholine receptor aggregates. Brain Res 839: 298&#x2013;304</Citation><ArticleIdList><ArticleId IdType="pubmed">10519053</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL (1995) Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer&#x2032;s disease. Nat Med 1: 829&#x2013;832</Citation><ArticleIdList><ArticleId IdType="pubmed">7585189</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Sudhof TC, Zheng H (2010) Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci USA 107: 17362&#x2013;17367</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951422</ArticleId><ArticleId IdType="pubmed">20855613</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills J, Reiner PB (1999) Mitogen-activated protein kinase is involved in N-methyl-D-aspartate receptor regulation of amyloid precursor protein cleavage. Neuroscience 94: 1333&#x2013;1338</Citation><ArticleIdList><ArticleId IdType="pubmed">10625071</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457: 981&#x2013;989</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Neher E, Sakaba T (2008) Multiple roles of calcium ions in the regulation of neurotransmitter release. Neuron 59: 861&#x2013;872</Citation><ArticleIdList><ArticleId IdType="pubmed">18817727</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Rossner S, Albrecht C, Mayhaus M, Enderich J, Schliebs R, Wegner M, Arendt T, von der Kammer H (1998) Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter. J Physiol Paris 92: 257&#x2013;264</Citation><ArticleIdList><ArticleId IdType="pubmed">9789819</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258: 304&#x2013;307</Citation><ArticleIdList><ArticleId IdType="pubmed">1411529</ArticleId></ArticleIdList></Reference><Reference><Citation>Olton DS, Walker JA, Gage FH (1978) Hippocampal connections and spatial discrimination. Brain Res 139: 295&#x2013;308</Citation><ArticleIdList><ArticleId IdType="pubmed">624061</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Zheng H, Van der Ploeg LH, Koo EH (1997) The beta-amyloid precursor protein of Alzheimer&#x2032;s disease enhances neuron viability and modulates neuronal polarity. J Neurosci 17: 9407&#x2013;9414</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573428</ArticleId><ArticleId IdType="pubmed">9390996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, Herms J, Buchholz C, Eckman CB, Korte M, Wolfer DP, M&#xfc;ller UC (2007) The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci 27: 7817&#x2013;7826</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672885</ArticleId><ArticleId IdType="pubmed">17634375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizo J, Rosenmund C (2008) Synaptic vesicle fusion. Nat Struct Mol Biol 15: 665&#x2013;674</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519048</ArticleId><ArticleId IdType="pubmed">18618940</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts WW, Dember WN, Brodwick M (1962) Alternation and exploration in rats with hippocampal lesions. J Comp Physiol Psychol 55: 695&#x2013;700</Citation><ArticleIdList><ArticleId IdType="pubmed">13974341</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogelj B, Mitchell JC, Miller CC, McLoughlin DM (2006) The X11/Mint family of adaptor proteins. Brain Res Rev 52: 305&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pubmed">16764936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi-Arnaud C, Fagioli S, Ammassari-Teule M (1991) Spatial learning in two inbred strains of mice: genotype-dependent effect of amygdaloid and hippocampal lesions. Behav Brain Res 45: 9&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pubmed">1764209</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanes JR, Lichtman JW (1999) Development of the vertebrate neuromuscular junction. Annu Rev Neurosci 22: 389&#x2013;442</Citation><ArticleIdList><ArticleId IdType="pubmed">10202544</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook GR, Smith DW, Bowery BJ, Easter A, Reynolds T, Fitzjohn SM, Morton RA, Zheng H, Dawson GR, Sirinathsinghji DJ, Davies CH, Collingridge GL, Hill RG (1999) Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 38: 349&#x2013;359</Citation><ArticleIdList><ArticleId IdType="pubmed">10219973</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbach JP, Muller U, Leist M, Li ZW, Nicotera P, Aguzzi A (1998) Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice. Cell Death Differ 5: 858&#x2013;866</Citation><ArticleIdList><ArticleId IdType="pubmed">10203685</ArticleId></ArticleIdList></Reference><Reference><Citation>Szodorai A, Kuan YH, Hunzelmann S, Engel U, Sakane A, Sasaki T, Takai Y, Kirsch J, M&#xfc;ller U, Beyreuther K, Brady S, Morfini G, Kins S (2009) APP anterograde transport requires Rab3A GTPase activity for assembly of the transport vesicle. J Neurosci 29: 14534&#x2013;14544</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849269</ArticleId><ArticleId IdType="pubmed">19923287</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor CJ, Ireland DR, Ballagh I, Bourne K, Marechal NM, Turner PR, Bilkey DK, Tate WP, Abraham WC (2008) Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol Dis 31: 250&#x2013;260</Citation><ArticleIdList><ArticleId IdType="pubmed">18585048</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Minogue AM, Sala Frigerio C, Fadeeva JV, Wasco W, Selkoe DJ (2007) The APP family of proteins: similarities and differences. Biochem Soc Trans 35: 416&#x2013;420</Citation><ArticleIdList><ArticleId IdType="pubmed">17371289</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez B, Lee KF, Gan WB, Zheng H (2005) Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci 25: 1219&#x2013;1225</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725967</ArticleId><ArticleId IdType="pubmed">15689559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang B, Yang L, Guo Q, Aithmitti N, Songyang Z, Zheng H (2009) Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J Neurosci 29: 10788&#x2013;10801</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757256</ArticleId><ArticleId IdType="pubmed">19726636</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood SJ, Slater CR (1997) The contribution of postsynaptic folds to the safety factor for neuromuscular transmission in rat fast- and slow-twitch muscles. J Physiol 500(Part 1): 165&#x2013;176</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1159367</ArticleId><ArticleId IdType="pubmed">9097941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Xiong WC, Mei L (2010) To build a synapse: signaling pathways in neuromuscular junction assembly. Development 137: 1017&#x2013;1033</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2835321</ArticleId><ArticleId IdType="pubmed">20215342</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Gong YD, Gong K, Jiang WL, Kwon E, Wang P, Zheng H, Zhang XF, Gan WB, Zhao NM (2005) Reduced synaptic vesicle density and active zone size in mice lacking amyloid precursor protein (APP) and APP-like protein 2. Neurosci Lett 384: 66&#x2013;71</Citation><ArticleIdList><ArticleId IdType="pubmed">15919150</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao LL, Liu XY, Jin JY, Tao BB, Chen YJ, Yu YC, Bian WH, Yu J, Huang J, Wang YG (2011) Expression and ultrastructural localization of Mint2 in the spinal cord of rats. Mol Biol Rep 38: 667&#x2013;673</Citation><ArticleIdList><ArticleId IdType="pubmed">20369384</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ (2008) Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev 3: 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442059</ArticleId><ArticleId IdType="pubmed">18573216</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21543591</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>18</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors.</ArticleTitle><Pagination><StartPage>6627</StartPage><EndPage>6638</EndPage><MedlinePgn>6627-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0203-11.2011</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD), dementia severity correlates strongly with decreased synapse density in hippocampus and cortex. Numerous studies report that hippocampal long-term potentiation (LTP) can be inhibited by soluble oligomers of amyloid &#x3b2;-protein (A&#x3b2;), but the synaptic elements that mediate this effect remain unclear. We examined field EPSPs and whole-cell recordings in wild-type mouse hippocampal slices. Soluble A&#x3b2; oligomers from three distinct sources (cultured cells, AD cortex, or synthetic peptide) inhibited LTP, and this was prevented by the selective NR2B inhibitors ifenprodil and Ro 25-6981. Soluble A&#x3b2; enhanced NR2B-mediated NMDA currents and extrasynaptic responses; these effects were mimicked by the glutamate reuptake inhibitor dl-threo-&#x3b2;-benzyloxyaspartic acid. Downstream, an A&#x3b2;-mediated rise in p38 mitogen-activated protein kinase (MAPK) activation was followed by downregulation of cAMP response element-binding protein, and LTP impairment was prevented by inhibitors of p38 MAPK or calpain. Thus, soluble A&#x3b2; oligomers at low nanomolar levels present in AD brain increase activation of extrasynaptic NR2B-containing receptors, thereby impairing synaptic plasticity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaomin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Ming</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Koeglsperger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Shepardson</LastName><ForeName>Nina E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Ganesh M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>R8OE3P6O5S</RegistryNumber><NameOfSubstance UI="C010739">ifenprodil</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21543591</ArticleId><ArticleId IdType="mid">NIHMS293332</ArticleId><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0203-11.2011</ArticleId><ArticleId IdType="pii">31/18/6627</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berberich S, Jensen V, Hvalby &#xd8;, Seeburg PH, K&#xf6;hr G. The role of NMDAR subtypes and charge transfer during hippocampal LTP induction. Neuropharmacology. 2007;52:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16901514</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter-Hyland EP, Woodward JJ, Chandler LJ. Chronic ethanol induces synaptic but not extrasynaptic targeting of NMDA receptors. J Neurosci. 2004;24:7859&#x2013;7868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729936</ArticleId><ArticleId IdType="pubmed">15356198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem. 2002;77:354&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">11991763</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ. ERK1/2 activation mediates A&#x3b2; oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem. 2006;281:20315&#x2013;20325.</Citation><ArticleIdList><ArticleId IdType="pubmed">16714296</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewachter I, Filipkowski RK, Priller C, Ris L, Neyton J, Croes S, Terwel D, Gysemans M, Devijver H, Borghgraef P, Godaux E, Kaczmarek L, Herms J, Van Leuven F. Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. Neurobiol Aging. 2009;30:241&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">17673336</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci. 2001;21:4125&#x2013;4133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762764</ArticleId><ArticleId IdType="pubmed">11404397</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues A, Almeida S, da Cruz e Silva EF, Oliveira CR, Rego AC. Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-d-aspartate receptor subunits. Neurochem Int. 2007;50:872&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">17403555</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C, Gill MB, Tronson NC, Guedea AL, Guzm&#xe1;n YF, Huh KH, Corcoran KA, Swanson GT, Radulovic J. Hippocampal NMDA receptor subunits differentially regulate fear memory formation and neuronal signal propagation. Hippocampus. 2010;20:1072&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891656</ArticleId><ArticleId IdType="pubmed">19806658</ArticleId></ArticleIdList></Reference><Reference><Citation>Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD. Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience. 2009;158:1446&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">11953750</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkany T, Abrah&#xe1;m I, Timmerman W, Laskay G, T&#xf3;th B, Sasv&#xe1;ri M, K&#xf3;nya C, Sebens JB, Korf J, Nyakas C, Zar&#xe1;ndi M, So&#xf3;s K, Penke B, Luiten PG. &#x3b2;-Amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci. 2000;12:2735&#x2013;2745.</Citation><ArticleIdList><ArticleId IdType="pubmed">10971616</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem. 1999;72:2053&#x2013;2058.</Citation><ArticleIdList><ArticleId IdType="pubmed">10217284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies A&#x3b2;-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu NW, Smith IM, Walsh DM, Rowan MJ. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain. 2008;131:2414&#x2013;2424.</Citation><ArticleIdList><ArticleId IdType="pubmed">18678563</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu NW, Klyubin I, Anwyl R, Rowan MJ. GluN2B subunit-containing NMDA receptor antagonists prevent A&#x3b2;-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci U S A. 2009;106:20504&#x2013;20509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787128</ArticleId><ArticleId IdType="pubmed">19918059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, Medina I. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol. 2006;572:789&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779993</ArticleId><ArticleId IdType="pubmed">16513670</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumi Y, Tokuda K, Zorumski CF. Long-term potentiation inhibition by low-level N-methyl-d-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase. Hippocampus. 2008;18:258&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">18000819</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Katagiri H, Tanaka K, Manabe T. Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction. Eur J Neurosci. 2001;14:547&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">11553304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly BL, Ferreira A. beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-d-aspartate receptors in hippocampal neurons. J Biol Chem. 2006;281:28079&#x2013;28089.</Citation><ArticleIdList><ArticleId IdType="pubmed">16864575</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid &#x3b2; protein immunotherapy neutralizes A&#x3b2; oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Wang Q, Reed MN, Irving EA, Upton N, Hofmeister J, Cleary JP, Anwyl R, Rowan MJ. Protection against A&#x3b2;-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol Aging. 2011;32:614&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">19446369</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM. A&#x3b2; oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci. 2007;27:7648&#x2013;7653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672892</ArticleId><ArticleId IdType="pubmed">17634359</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M, Mishina M. Molecular diversity of the NMDA receptor channel. Nature. 1992;358:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">1377365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski M, Craig AM, Wang YT. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci. 2007;27:2846&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672582</ArticleId><ArticleId IdType="pubmed">17360906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Man H, Ju W, Trimble WS, MacDonald JF, Wang YT. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron. 2001;29:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks N, Berg MJ. Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders. Neurochem Int. 2008;52:184&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">17719698</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey PV, Johnson BE, Moult PR, Auberson YP, Brown MW, Molnar E, Collingridge GL, Bashir ZI. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci. 2004;24:7821&#x2013;7828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729941</ArticleId><ArticleId IdType="pubmed">15356193</ArticleId></ArticleIdList></Reference><Reference><Citation>Matos M, Augusto E, Oliveira CR, Agostinho P. Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience. 2008;156:898&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">18790019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer ML, Vyklicky L, Jr, Clements J. Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine. Nature. 1989;338:425&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">2538755</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of A&#x3b2; amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 2010;65:178&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">20152125</ArticleId></ArticleIdList></Reference><Reference><Citation>Min MY, Rusakov DA, Kullmann DM. Activation of AMPA, kainate, and metabotropic receptors at hippocampal mossy fiber synapses: role of glutamate diffusion. Neuron. 1998;21:561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">9768842</ArticleId></ArticleIdList></Reference><Reference><Citation>Moln&#xe1;r Z, So&#xf3;s K, Lengyel I, Penke B, Szegedi V, Budai D. Enhancement of NMDA responses by beta-amyloid peptides in the hippocampus in vivo. Neuroreport. 2004;15:1649&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">15232300</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulholland PJ, Luong NT, Woodward JJ, Chandler LJ. Brain-derived neurotrophic factor activation of extracellular signal-regulated kinase is autonomous from the dominant extrasynaptic NMDA receptor extracellular signal-regulated kinase shutoff pathway. Neuroscience. 2008;151:419&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390783</ArticleId><ArticleId IdType="pubmed">18055129</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2009;15:1407&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789858</ArticleId><ArticleId IdType="pubmed">19915593</ArticleId></ArticleIdList></Reference><Reference><Citation>Okubo Y, Sekiya H, Namiki S, Sakamoto H, Iinuma S, Yamasaki M, Watanabe M, Hirose K, Iino M. Imaging extrasynaptic glutamate dynamics in the brain. Proc Natl Acad Sci U S A. 2010;107:6526&#x2013;6531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851965</ArticleId><ArticleId IdType="pubmed">20308566</ArticleId></ArticleIdList></Reference><Reference><Citation>Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, Chen JX, Schmidt AM, Arancio O, Yan SD, Domenici L. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci. 2008;28:3521&#x2013;3530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670592</ArticleId><ArticleId IdType="pubmed">18367618</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Shea SD, Smith IM, McCabe OM, Cronin MM, Walsh DM, O'Connor WT. Intracerebroventricular administration of amyloid &#x3b2;-protein oligomers selectively increases dorsal hippocampal dialysate glutamate levels in the awake rat. Sensors. 2008;8:7428&#x2013;7437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787453</ArticleId><ArticleId IdType="pubmed">27873937</ArticleId></ArticleIdList></Reference><Reference><Citation>Overstreet LS, Pasternak JF, Colley PA, Slater NT, Trommer BL. Metabotropic glutamate receptor mediated long-term depression in developing hippocampus. Neuropharmacology. 1997;36:831&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225311</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadia S, Hardingham GE. The dichotomy of NMDA receptor signaling. Neuroscientist. 2007;13:572&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830536</ArticleId><ArticleId IdType="pubmed">18000068</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadia S, Stevenson P, Hardingham NR, Bading H, Hardingham GE. Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci. 2005;25:4279&#x2013;4287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725111</ArticleId><ArticleId IdType="pubmed">15858054</ArticleId></ArticleIdList></Reference><Reference><Citation>Paschen W. Glutamate excitotoxicity in transient global cerebral ischemia. Acta Neurobiol Exp (Wars) 1996;56:313&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">8787192</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomara N, Singh R, Deptula D, Chou JC, Schwartz MB, LeWitt PA. Glutamate and other CSF amino acids in Alzheimer's disease. Am J Psychiatry. 1992;149:251&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734749</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond CR, Ireland DR, Abraham WC. NMDA receptor regulation by amyloid-&#x3b2; does not account for its inhibition of LTP in rat hippocampus. Brain Res. 2003;968:263&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">12663096</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nicke R, Mikhaylova M, R&#xf6;nicke S, Meinhardt J, Schr&#xf6;der UH, F&#xe4;ndrich M, Reiser G, Kreutz MR, Reymann KG. Early neuronal dysfunction by amyloid beta oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol Aging. 2010 doi: 10.1016/j.neurobiolaging.2010.01.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.01.01</ArticleId><ArticleId IdType="pubmed">20133015</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A. 1993;90:2628&#x2013;2632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46148</ArticleId><ArticleId IdType="pubmed">8464868</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The cell biology of &#x3b2;-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8:447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Soluble amyloid &#x3b2;-protein dimers isolated directly from Alzheimer disease patients potently impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinor JD, Du S, Venneti S, Blitzblau RC, Leszkiewicz DN, Rosenberg PA, Aizenman E. NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro. J Neurosci. 2000;20:8831&#x2013;8837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773069</ArticleId><ArticleId IdType="pubmed">11102491</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondag CM, Dhawan G, Combs CK. Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation. 2009;6:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632990</ArticleId><ArticleId IdType="pubmed">19123954</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanika RI, Pivovarova NB, Brantner CA, Watts CA, Winters CA, Andrews SB. Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc Natl Acad Sci U S A. 2009;106:9854&#x2013;9859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2701040</ArticleId><ArticleId IdType="pubmed">19482936</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A, Liu M, Nguyen XV, Bing G. p38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp Neurol. 2003;183:394&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">14552880</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid &#x3b2;-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Mehta T, Selkoe DJ. Soluble A&#x3b2; inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007;282:33305&#x2013;33312.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855343</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaslin A, Puyal J, Borsello T, Clarke PG. Excitotoxicity-related endocytosis in cortical neurons. J Neurochem. 2007;102:789&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">17437546</ArticleId></ArticleIdList></Reference><Reference><Citation>von Engelhardt J, Coserea I, Pawlak V, Fuchs EC, K&#xf6;hr G, Seeburg PH, Monyer H. Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology. 2007;53:10&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17570444</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, Hartley DM, Selkoe DJ. Certain inhibitors of synthetic amyloid &#x3b2;-peptide (A&#x3b2;) fibrillogenesis block oligomerization of natural A&#x3b2; and thereby rescue long-term potentiation. J Neurosci. 2005;25:2455&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725159</ArticleId><ArticleId IdType="pubmed">15758153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of &#x3b2; amyloid (1&#x2013;42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002;924:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid &#x3b2;-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004;24:3370&#x2013;3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730034</ArticleId><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Lynch DR. N-methyl-d-aspartate receptor subtype mediated bidirectional control of p38 mitogen-activated protein kinase. J Biol Chem. 2005;280:29322&#x2013;29333.</Citation><ArticleIdList><ArticleId IdType="pubmed">15967799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Anwyl R, Rowan MJ. beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport. 1995;6:2409&#x2013;2413.</Citation><ArticleIdList><ArticleId IdType="pubmed">8747164</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30:11246&#x2013;11250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932667</ArticleId><ArticleId IdType="pubmed">20720132</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Kurup P, Zhang Y, Goebel-Goody SM, Wu PH, Hawasli AH, Baum ML, Bibb JA, Lombroso PJ. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci. 2009;29:9330&#x2013;9343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737362</ArticleId><ArticleId IdType="pubmed">19625523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D, Watson JB, Xie CW. Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol. 2004;92:2853&#x2013;2858.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, Baudry M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J Neurosci. 2006;26:2956&#x2013;2963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673978</ArticleId><ArticleId IdType="pubmed">16540573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21543615</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>18</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>BACE1 activity is modulated by cell-associated sphingosine-1-phosphate.</ArticleTitle><Pagination><StartPage>6850</StartPage><EndPage>6857</EndPage><MedlinePgn>6850-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6467-10.2011</ELocationID><Abstract><AbstractText>Sphingosine kinase (SphK) 1 and 2 phosphorylate sphingosine to generate sphingosine-1-phosphate (S1P), a pluripotent lipophilic mediator implicated in a variety of cellular events. Here we show that the activity of &#x3b2;-site APP cleaving enzyme-1 (BACE1), the rate-limiting enzyme for amyloid-&#x3b2; peptide (A&#x3b2;) production, is modulated by S1P in mouse neurons. Treatment by SphK inhibitor, RNA interference knockdown of SphK, or overexpression of S1P degrading enzymes decreased BACE1 activity, which reduced A&#x3b2; production. S1P specifically bound to full-length BACE1 and increased its proteolytic activity, suggesting that cellular S1P directly modulates BACE1 activity. Notably, the relative activity of SphK2 was upregulated in the brains of patients with Alzheimer's disease. The unique modulatory effect of cellular S1P on BACE1 activity is a novel potential therapeutic target for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takasugi</LastName><ForeName>Nobumasa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuropathology and Neuroscience, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Tomoki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kunimichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Osawa</LastName><ForeName>Satoko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Isshiki</LastName><ForeName>Hayato</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hori</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Shimada</LastName><ForeName>Naoaki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Higo</LastName><ForeName>Takuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yokoshima</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fukuyama</LastName><ForeName>Tohru</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Taisuke</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008246">Lysophospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>26993-30-6</RegistryNumber><NameOfSubstance UI="C060506">sphingosine 1-phosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>NGZ37HRE42</RegistryNumber><NameOfSubstance UI="D013110">Sphingosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008246" MajorTopicYN="N">Lysophospholipids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013110" MajorTopicYN="N">Sphingosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21543615</ArticleId><ArticleId IdType="mid">NIHMS713228</ArticleId><ArticleId IdType="pmc">PMC4534000</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6467-10.2011</ArticleId><ArticleId IdType="pii">31/18/6850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP. BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem. 2010;112:1045&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819564</ArticleId><ArticleId IdType="pubmed">19968762</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab. 2007;18:300&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">17904858</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, Maceyka M, Jiang H, Luo C, Kordula T, Milstien S, Spiegel S. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465:1084&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946785</ArticleId><ArticleId IdType="pubmed">20577214</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Lee EB, Moberg PJ, Stutzbach L, Kazi H, Han LY, Lee VM, Trojanowski JQ. Olfactory epithelium amyloid-&#x3b2; and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol. 2010;67:462&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864948</ArticleId><ArticleId IdType="pubmed">20437581</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondeau N, Lai Y, Tyndall S, Popolo M, Topalkara K, Pru JK, Zhang L, Kim H, Liao JK, Ding K, Waeber C. Distribution of sphingosine kinase activity and mRNA in rodent brain. J Neurochem. 2007;103:509&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639651</ArticleId><ArticleId IdType="pubmed">17623044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of A&#x3b2; peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow VW, Savonenko AV, Melnikova T, Kim H, Price DL, Li T, Wong PC. Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci Transl Med. 2010;2:13ra1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852193</ArticleId><ArticleId IdType="pubmed">20371462</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet. 2010;19:R12&#x2013;R20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875049</ArticleId><ArticleId IdType="pubmed">20413653</ArticleId></ArticleIdList></Reference><Reference><Citation>Darios F, Wasser C, Shakirzyanova A, Giniatullin A, Goodman K, Munoz-Bravo JL, Raingo J, Jorgacevski J, Kreft M, Zorec R, Rosa JM, Gandia L, Guti&#xe9;rrez LM, Binz T, Giniatullin R, Kavalali ET, Davletov B. Sphingosine facilitates SNARE complex assembly and activates synaptic vesicle exocytosis. Neuron. 2009;62:683&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2697323</ArticleId><ArticleId IdType="pubmed">19524527</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879045</ArticleId><ArticleId IdType="pubmed">20139999</ArticleId></ArticleIdList></Reference><Reference><Citation>Don AS, Martinez-Lamenca C, Webb WR, Proia RL, Roberts E, Rosen H. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues. J Biol Chem. 2007;282:15833&#x2013;15842.</Citation><ArticleIdList><ArticleId IdType="pubmed">17400555</ArticleId></ArticleIdList></Reference><Reference><Citation>French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003;63:5962&#x2013;5969.</Citation><ArticleIdList><ArticleId IdType="pubmed">14522923</ArticleId></ArticleIdList></Reference><Reference><Citation>French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006;318:596&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632640</ArticleId></ArticleIdList></Reference><Reference><Citation>French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010;333:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846016</ArticleId><ArticleId IdType="pubmed">20061445</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido TC, Iwatsubo T. Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid &#x3b2; peptides ending at A&#x3b2;40 and A&#x3b2;42. Neuroreport. 1999;10:2965&#x2013;2969.</Citation><ArticleIdList><ArticleId IdType="pubmed">10549806</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. &#x3b2;-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59:1381&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M. A noncompetitive BACE1 inhibitor TAK-070 ameliorates A&#x3b2; pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010;30:11157&#x2013;11166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633483</ArticleId><ArticleId IdType="pubmed">20720123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hait NC, Bellamy A, Milstien S, Kordula T, Spiegel S. Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J Biol Chem. 2007;282:12058&#x2013;12065.</Citation><ArticleIdList><ArticleId IdType="pubmed">17311928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, Spiegel S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325:1254&#x2013;1257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850596</ArticleId><ArticleId IdType="pubmed">19729656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Wakabayashi T, Watanabe A, Kowa H, Hosoda R, Nakamura A, Kanazawa I, Arai T, Takio K, Mann DM, Iwatsubo T. CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J. 2002;21:1524&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125364</ArticleId><ArticleId IdType="pubmed">11927537</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Lu Y, Qahwash I, Hu XY, Chang A, Yan R. Reticulon family members modulate BACE1 activity and amyloid-&#x3b2; peptide generation. Nat Med. 2004;10:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hempen B, Brion JP. Reduction of acetylated &#x3b1;-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol. 1996;55:964&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">8800092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hori Y, Hashimoto T, Wakutani Y, Urakami K, Nakashima K, Condron MM, Tsubuki S, Saido TC, Teplow DB, Iwatsubo T. The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate A&#x3b2; fibril formation without increasing protofibril formation. J Biol Chem. 2007;282:4916&#x2013;4923.</Citation><ArticleIdList><ArticleId IdType="pubmed">17170111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG, Yan R. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci. 2010;30:8819&#x2013;8829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902368</ArticleId><ArticleId IdType="pubmed">20592204</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A&#x3b2;42(43) and A&#x3b2;40 in senile plaques with end-specific A&#x3b2; monoclonals: evidence that an initially deposited species is A&#x3b2;42(43) Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem. 2005;280:36815&#x2013;36823.</Citation><ArticleIdList><ArticleId IdType="pubmed">16115865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kan T, Tominari Y, Morohashi Y, Natsugari H, Tomita T, Iwatsubo T, Fukuyama T. Solid-phase synthesis of photoaffinity probes: highly efficient incorporation of biotin-tag and cross-linking groups. Chem Commun (Camb) 2003:2244&#x2013;2245.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima N, Yoon SJ, Itoh K, Nakayama K. Tyrosine kinase activity of epidermal growth factor receptor is regulated by GM3 binding through carbohydrate to carbohydrate interactions. J Biol Chem. 2009;284:6147&#x2013;6155.</Citation><ArticleIdList><ArticleId IdType="pubmed">19124464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kihara A, Ikeda M, Kariya Y, Lee EY, Lee YM, Igarashi Y. Sphingosine-1-phosphate lyase is involved in the differentiation of F9 embryonal carcinoma cells to primitive endoderm. J Biol Chem. 2003;278:14578&#x2013;14585.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Schroeter EH, Weintraub H, Nye JS. Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc Natl Acad Sci U S A. 1996;93:1683&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40002</ArticleId><ArticleId IdType="pubmed">8643690</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y. Amyloid &#x3b2; peptide load is correlated with increased &#x3b2;-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2004;101:3632&#x2013;3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, Sankala H, Payne SG, Bektas M, Ishii I, Chun J, Milstien S, Spiegel S. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem. 2003;278:40330&#x2013;40336.</Citation><ArticleIdList><ArticleId IdType="pubmed">12835323</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R. Mice deficient in BACE1, the Alzheimer's &#x3b2;-secretase, have normal phenotype and abolished &#x3b2;-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill AH, Jr, Milstien S, Spiegel S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005;280:37118&#x2013;37129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16118219</ArticleId></ArticleIdList></Reference><Reference><Citation>McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem. 2007;282:26326&#x2013;26334.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616527</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005;25:11113&#x2013;11121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1316977</ArticleId><ArticleId IdType="pubmed">16314531</ArticleId></ArticleIdList></Reference><Reference><Citation>Murayama KS, Kametani F, Saito S, Kume H, Akiyama H, Araki W. Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid &#x3b2;-protein. Eur J Neurosci. 2006;24:1237&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16965550</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutoh T, Tokuda A, Miyadai T, Hamaguchi M, Fujiki N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc Natl Acad Sci U S A. 1995;92:5087&#x2013;5091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41853</ArticleId><ArticleId IdType="pubmed">7539142</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivera A, Urtz N, Mizugishi K, Yamashita Y, Gilfillan AM, Furumoto Y, Gu H, Proia RL, Baumruker T, Rivera J. IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses. J Biol Chem. 2006;281:2515&#x2013;2525.</Citation><ArticleIdList><ArticleId IdType="pubmed">16316995</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10:489&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">20555359</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, Schwille P, Schulz JB, Schroeder C, Simons M, Jennings G, Kn&#xf6;lker HJ, Simons K. Efficient inhibition of the Alzheimer's disease &#x3b2;-secretase by membrane targeting. Science. 2008;320:520&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">18436784</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss U, Oskouian B, Zhou J, Gupta V, Sooriyakumaran P, Kelly S, Wang E, Merrill AH, Jr, Saba JD. Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. J Biol Chem. 2004;279:1281&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570870</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A. 2008;105:5585&#x2013;5590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005;309:1735&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pubmed">16151014</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel S, Milstien S. Functions of the multifaceted family of sphingosine kinases and some close relatives. J Biol Chem. 2007;282:2125&#x2013;2129.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135245</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumioka A, Yan D, Tomita S. TARP phosphorylation regulates synaptic AMPA receptors through lipid bilayers. Neuron. 2010;66:755&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887694</ArticleId><ArticleId IdType="pubmed">20547132</ArticleId></ArticleIdList></Reference><Reference><Citation>Takabe K, Paugh SW, Milstien S, Spiegel S. &#x201c;Inside-out&#x201d; signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60:181&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695666</ArticleId><ArticleId IdType="pubmed">18552276</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T. The role of presenilin cofactors in the &#x3b3;-secretase complex. Nature. 2003;422:438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen M, Yang SH, Zhong Z, Shen Y, Simpkins JW, Tanzi RE. Depletion of GGA3 stabilizes BACE and enhances &#x3b2;-secretase activity. Neuron. 2007;54:721&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009;9:661&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">19402777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, Capell A, Walter J, Gr&#xfc;nberg J, Haass C, Iwatsubo T, Obata K. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid &#x3b2; protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci U S A. 1997;94:2025&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20036</ArticleId><ArticleId IdType="pubmed">9050898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, Takikawa R, Koyama A, Morohashi Y, Takasugi N, Saido TC, Maruyama K, Iwatsubo T. C terminus of presenilin is required for overproduction of amyloidogenic A&#x3b2;42 through stabilization and endoproteolysis of presenilin. J Neurosci. 1999;19:10627&#x2013;10634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6784929</ArticleId><ArticleId IdType="pubmed">10594046</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29:12787&#x2013;12794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer's disease &#x3b2;-amyloid production. Biochim Biophys Acta. 2010;1801:860&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886169</ArticleId><ArticleId IdType="pubmed">20303415</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW. Increased &#x3b2;-secretase activity and expression in rats following transient cerebral ischemia. Brain Res. 2004;1009:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15120577</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the &#x3b2;-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T. A&#x3b2; immunotherapy: intracerebral sequestration of A&#x3b2; by an anti-A&#x3b2; monoclonal antibody 266 with high affinity to soluble A&#x3b2;. J Neurosci. 2009;29:11393&#x2013;11398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665926</ArticleId><ArticleId IdType="pubmed">19741145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y. Elevated &#x3b2;-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003;9:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto T, Furuhata M, Kamiya S, Hisada M, Miyaji H, Magami Y, Yamamoto K, Fujiwara H, Mizuguchi J. Positive modulation of IL-12 signaling by sphingosine kinase 2 associating with the IL-12 receptor beta 1 cytoplasmic region. J Immunol. 2003;171:1352&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemann B, Kinzel B, M&#xfc;ller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, Billich A. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood. 2006;107:1454&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">16223773</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21555601</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Risk factors and preventive interventions for Alzheimer disease: state of the science.</ArticleTitle><Pagination><StartPage>1185</StartPage><EndPage>1190</EndPage><MedlinePgn>1185-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.100</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Numerous studies have investigated risk factors for Alzheimer disease (AD). However, at a recent National Institutes of Health State-of-the-Science Conference, an independent panel found insufficient evidence to support the association of any modifiable factor with risk of cognitive decline or AD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present key findings for selected factors and AD risk that led the panel to their conclusion.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">An evidence report was commissioned by the Agency for Healthcare Research and Quality. It included English-language publications in MEDLINE and the Cochrane Database of Systematic Reviews from 1984 through October 27, 2009. Expert presentations and public discussions were considered.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Study inclusion criteria for the evidence report were participants aged 50 years and older from general populations in developed countries; minimum sample sizes of 300 for cohort studies and 50 for randomized controlled trials; at least 2 years between exposure and outcome assessment; and use of well-accepted diagnostic criteria for AD.</AbstractText><AbstractText Label="DATA EXTRACTION" NlmCategory="METHODS">Included studies were evaluated for eligibility and data were abstracted. Quality of overall evidence for each factor was summarized as low, moderate, or high.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Diabetes mellitus, hyperlipidemia in midlife, and current tobacco use were associated with increased risk of AD, and Mediterranean-type diet, folic acid intake, low or moderate alcohol intake, cognitive activities, and physical activity were associated with decreased risk. The quality of evidence was low for all of these associations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Currently, insufficient evidence exists to draw firm conclusions on the association of any modifiable factors with risk of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daviglus</LastName><ForeName>Martha L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. daviglus@northwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plassman</LastName><ForeName>Brenda L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Pirzada</LastName><ForeName>Amber</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Carl C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Bowen</LastName><ForeName>Phyllis E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Connolly</LastName><ForeName>E Sander</ForeName><Initials>ES</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Dunbar-Jacob</LastName><ForeName>Jacqueline M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Granieri</LastName><ForeName>Evelyn C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>McGarry</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Dinesh</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Trevisan</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>John W</ForeName><Initials>JW</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006937" MajorTopicYN="N">Hypercholesterolemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21555601</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.100</ArticleId><ArticleId IdType="pii">archneurol.2011.100</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21555604</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Effect of APOE &#x3b5;4 status on intrinsic network connectivity in cognitively normal elderly subjects.</ArticleTitle><Pagination><StartPage>1131</StartPage><EndPage>1136</EndPage><MedlinePgn>1131-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.108</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine default mode and salience network functional connectivity as a function of APOE &#x3b5;4 status in a group of cognitively normal age-, sex-, and education-matched older adults.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Case-control study.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Fifty-six cognitively normal APOE &#x3b5;4 carriers and 56 age-, sex- and education-matched cognitively normal APOE &#x3b5;4 noncarriers.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Alterations in in-phase default mode and salience network connectivity in APOE &#x3b5;4 carriers compared with APOE &#x3b5;4 noncarriers ranging from 63 to 91 years of age.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A posterior cingulate seed revealed decreased in-phase connectivity in regions of the posterior default mode network that included the left inferior parietal lobe, left middle temporal gyrus, and bilateral anterior temporal lobes in the &#x3b5;4 carriers relative to APOE &#x3b5;4 noncarriers. An anterior cingulate seed showed greater in-phase connectivity in the salience network including the cingulate gyrus, medial prefrontal cortex, bilateral insular cortex, striatum, and thalamus in APOE &#x3b5;4 carriers vs noncarriers. There were no groupwise differences in brain anatomy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The observation of functional alterations in default mode and salience network connectivity in the absence of structural changes between APOE &#x3b5;4 carriers and noncarriers suggests that alterations in connectivity may have the potential to serve as an early biomarker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Machulda</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA. machulda.mary@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Avula</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Przybelski</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Brad F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG32306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2011 Sep;68(9):1107-8. doi: 10.1001/archneurol.2011.202.</RefSource><PMID Version="1">21911693</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21555604</ArticleId><ArticleId IdType="mid">NIHMS390304</ArticleId><ArticleId IdType="pmc">PMC3392960</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.108</ArticleId><ArticleId IdType="pii">archneurol.2011.108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrews-Hanna J, Snyder A, Vincent J, et al. Disruption of large-scale brain systems in advanced aging. Neuron. 2007;56:924&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709284</ArticleId><ArticleId IdType="pubmed">18054866</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen M, Mullin K, Blacker D, Tanzi R. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature Genetics. 2008;29:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010;67:308&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886799</ArticleId><ArticleId IdType="pubmed">20373342</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KR, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686&#x2013;12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009;106:7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher A, Sherzai A, Taylor C, Langbaum J, Chen K, Buxton R. Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. NeuroImage. 2009;47:1678&#x2013;1690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722694</ArticleId><ArticleId IdType="pubmed">19539034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline Y, Morris J, Snyder A, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF AB42. The Journal of Neuroscience. 2010;30:17035&#x2013;17040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023180</ArticleId><ArticleId IdType="pubmed">21159973</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox M, Snyder A, Vincent J, Corbetta M, Van Essen D, Raichle M. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proceedings of the National Academy of Sciences USA. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley W, Crawford R, Zhou J, Miller B, Greicius M. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Greicius M, Gennatas E, et al. Divergent network connectivity changes in behavioral variant frontotemporal dementia and Alzheimer's disease. Brain. 2010;133:1352&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912696</ArticleId><ArticleId IdType="pubmed">20410145</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts R, Geda Y, Knopman D, et al. The Mayo Clinic Study of Aging: Design, sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30:58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao-Gan Y, Yu-Feng Z. DPARSF: a MATLAB toolbox for &#x201c;pipeline&#x201d; data analysis of resting-state fMRI. Frontiers in Systems Neuroscience. 2010;4:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889691</ArticleId><ArticleId IdType="pubmed">20577591</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun VD, Adali T, Pearlson GD, Pekar JJ. A method for making group inferences from functional MRI data using independent component analysis. Hum Brain Mapp. 2001;14:140&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871952</ArticleId><ArticleId IdType="pubmed">11559959</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissenbacher A, Kasess C, Gerstl F, Lanzenberger R, Moser E, Windischberger C. Correlations and anti-correlations in resting-state functional connectivity MRI: a quantitative comparison of preprocessing strategies. NeuroImage. 2009;47:1408&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pubmed">19442749</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox M, Zhang D, Snyder A, Raichle M. The global signal and observed anticorrelated resting state brain networks. Journal of Neurophysiology. 2009;101:3270&#x2013;3283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694109</ArticleId><ArticleId IdType="pubmed">19339462</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C, Glover G. Effects of model-based physiological noise correction on default mode network anti-correlations and correlations. NeuroImage. 2009;47:1448&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995588</ArticleId><ArticleId IdType="pubmed">19446646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaglia M, Dombrowski S, Drazba J, Vasanji A, Bokesch P, Janigro D. Regional variation in brain capillary density and vascular response to ischemia. Brain Research. 2001;910:81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">11489257</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith S, Fox P, Miller K, et al. Correspondence of the brain's functional architecture during activation and rest. Proceedings of the National Academy of Sciences USA. 2009;106:13040&#x2013;13045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722273</ArticleId><ArticleId IdType="pubmed">19620724</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007;27:2349&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680293</ArticleId><ArticleId IdType="pubmed">17329432</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry--the methods. NeuroImage. 2000;11:805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Unified segmentation. NeuroImage. 2005;26:839&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol. 1991;48:725&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">1859300</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle M, MacLeod A, Snyder A, Powers W, Gusnard D, Shulman G. A default mode of brain function. Proceedings of the National Academy of Sciences USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon V, Adleman N, White C, Glover G, Reiss A. Error-related brain activation during a go/nogo response inhibition task. Human Brain Mapping. 2001;12:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6872006</ArticleId><ArticleId IdType="pubmed">11170305</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinblad J, Hirsch J, Ferrera V. A neural representation of categorization uncertainty in the human brain. Neuron. 2006;49:757&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504950</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyron R, Laurent B, CGarcia-Larrea L. Functional imaging of brain responses to pain. A review and meta-analysis. Clinical Neurophysiology. 2000;30:263&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">11126640</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeza R, Nyberg L. Imaging cognition II: An empirical review of 275 PET and fMRI studies. J Cogn Neurosci. 2000;12:1&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769304</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridharan D, Levitin D, Menon V. A critical role for the right fronto-insular cortex in switching betweem the central-executive and default-mode networks. Proceedings of the National Academy of Sciences USA. 2008;105:12569&#x2013;12574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527952</ArticleId><ArticleId IdType="pubmed">18723676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Houston W, Jak A, et al. Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiology of Agin. 2007;28:238&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1705815</ArticleId><ArticleId IdType="pubmed">16434125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart H, Saykin A, Rabin L, et al. Increased barin activation during working memory in cognitively intact adults with the APOE e4 allele. American Journal of Psychiatry. 2006;163:1603&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16946187</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Houston W, Jak A, et al. Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiology of Aging. 2007;28:238&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1705815</ArticleId><ArticleId IdType="pubmed">16434125</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Bondi M. Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. Alzheimer's and Dementia. 2008;4:251&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631975</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21555638</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Mild cognitive impairment, dementia, and their subtypes in oldest old women.</ArticleTitle><Pagination><StartPage>631</StartPage><EndPage>636</EndPage><MedlinePgn>631-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.82</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The population of oldest old is increasing, but the prevalence of cognitive impairment is not well characterized in this group.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the prevalence of mild cognitive impairment (MCI), dementia, and their subtypes in oldest old women and to examine whether some groups of oldest old women were more likely to have cognitive impairment.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Women Cognitive Impairment Study of Exceptional Aging.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 1299 oldest old (&#x2265;85 years) women.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">All the women completed a neuropsychological test battery. Those who screened positive for possible cognitive impairment (n&#xa0;=&#xa0;634) were further assessed for a diagnosis of dementia, MCI, or normal cognition. The remaining women (n&#xa0;=&#xa0;665) were considered cognitively normal. Dementia and MCI subtypes were determined using standard criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The women had a mean age of 88.2 years, and 27.0% were 90 years or older; 231 women (17.8%) were diagnosed as having dementia and 301 (23.2%) as having MCI, for a combined cognitive impairment prevalence of 41.0%. Clinical features consistent with Alzheimer disease and mixed dementia were most common, each accounting for 40% of dementia cases. Amnestic multiple domain and nonamnestic single domain were the most common MCI types, accounting for 33.9% and 28.9% of cases, respectively. Cognitive impairment was more frequent in women 90 years or older compared with those 85 to 89 years (dementia, 28.2% vs 13.9%, P&#xa0;&lt;&#xa0;.001; MCI, 24.5% vs 22.7%, P&#xa0;=&#xa0;.02) and was more common in women with less education, a history of stroke, and prevalent depression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this large sample of oldest old women, 41.0% had clinically adjudicated cognitive impairment. Subtypes of dementia and MCI were similar to those in younger populations. Women in the fastest growing demographic, the oldest old, should be screened for cognitive disorders, especially high-risk groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California at San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA. kristine.yaffe@ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Lui</LastName><ForeName>Li-Yung</ForeName><Initials>LY</Initials></Author><Author ValidYN="Y"><LastName>Spira</LastName><ForeName>Adam P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Racine</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ensrud</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AR035583</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05394</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1K01AG033195</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2 R01 AG027574-22A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG 031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 R01AG026720-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR035582</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR35584</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2 R01 AG005394-22A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05407</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR35582</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026720</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR035584</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>K24 AG031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG005407</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027576-22</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR35583</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG005394</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG033195</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21555638</ArticleId><ArticleId IdType="mid">NIHMS296062</ArticleId><ArticleId IdType="pmc">PMC3108074</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.82</ArticleId><ArticleId IdType="pii">68/5/631</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moore A. Older people. We can work it out. Health Serv J. 2007 Jan 11;117(6038):24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">17319526</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998 Sep;51(3):728&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748017</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J. 1994 Mar 15;150(6):899&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1486712</ArticleId><ArticleId IdType="pubmed">8131123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas CH. The oldest old and the 90+ Study. Alzheimers Dement. 2008 Jan;4(1) Suppl 1:S56&#x2013;S59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3373258</ArticleId><ArticleId IdType="pubmed">18632002</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve B, McCormick J, Smith G, et al. Mild cognitive impairment in the oldest old. Neurology. 2003 February 11;60(3):477&#x2013;480. 2003.</Citation><ArticleIdList><ArticleId IdType="pubmed">12578930</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioggiosi PP, Berardi D, Ferrari B, Quartesan R, De Ronchi D. Occurrence of cognitive impairment after age 90: MCI and other broadly used concepts. Brain Research Bulletin. 2006;68(4):227&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">16377428</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines abstracted from the American Academy of Neurology's Dementia Guidelines for Early Detection, Diagnosis, and Management of Dementia. J Am Geriatr Soc. 2003 Jun;51(6):869&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">12757578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravaglia G, Forti P, Maioli F, et al. Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors. Dement Geriatr Cogn Disord. 2006;21(1):51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">16276110</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 Aug 13;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Decarli C. Vascular factors in dementia: an overview. J Neurol Sci. 2004 Nov 15;226(1&#x2013;2):19&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537513</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994 March 1;151(3):390&#x2013;396. 1994.</Citation><ArticleIdList><ArticleId IdType="pubmed">8109647</ArticleId></ArticleIdList></Reference><Reference><Citation>White L, Katzman R, Losonczy K, et al. Association of education with incidence of cognitive impairment in three established populations for epidemiologic studies of the elderly. J Clin Epidemiol. 1994 Apr;47(4):363&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">7730861</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings SR, Nevitt MC, Browner WS, et al. Risk Factors for Hip Fracture in White Women. New England Journal of Medicine. 1995;332(12):767&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">7862179</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Cauley J, Sands L, Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol. 1997 Sep;54(9):1110&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9311354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyness JM, Noel TK, Cox C, King DA, Conwell Y, Caine ED. Screening for depression in elderly primary care patients. A comparison of the Center for Epidemiologic Studies-Depression Scale and the Geriatric Depression Scale. Arch Intern Med. 1997 Feb 24;157(4):449&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">9046897</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med. 1989 Nov;19(4):1015&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">2594878</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Battery: Theory and Clinical Interpretation. Tuscon, AZ: Neuropsychology Press; 1985.</Citation></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987 Aug;48(8):314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test - Second Edition (CVLT-II) San Antonio, TX: Psychological Corporation; 2000.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale-III. San Antonio: The Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms and Commentary. New York: Oxford University Press; 1991.</Citation></Reference><Reference><Citation>Espeland MA, Rapp SR, Robertson J, et al. Benchmarks for designing two-stage studies using modified mini-mental state examinations: experience from the Women's Health Initiative Memory Study. Clin Trials. 2006;3(2):99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">16773952</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001 Dec;58(12):1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006 Apr 15;367(9518):1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrada MM, Brookmeyer R, Berlau D, Paganini-Hill A, Kawas CH. Prevalence of dementia after age 90: results from the 90+ study. Neurology. 2008 Jul 29;71(5):337&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">18596243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(11) Suppl 5:S4&#x2013;S9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854354</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedel-Heller SG, Busse A, Aurich C, Matschinger H, Angermeyer MC. Prevalence of dementia according to DSM-III-R and ICD-10: results of the Leipzig Longitudinal Study of the Aged (LEILA75+) Part 1. Br J Psychiatry. 2001 Sep;179:250&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">11532803</ArticleId></ArticleIdList></Reference><Reference><Citation>von Strauss E, Viitanen M, De Ronchi D, Winblad B, Fratiglioni L. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol. 1999 May;56(5):587&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">10328254</ArticleId></ArticleIdList></Reference><Reference><Citation>Heeren TJ, Lagaay AM, Hijmans W, Rooymans HG. Prevalence of dementia in the 'oldest old' of a Dutch community. J Am Geriatr Soc. 1991 Aug;39(8):755&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">2071805</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp SR, Legault C, Henderson VW, et al. Subtypes of Mild Cognitive Impairment in Older Postmenopausal Women: The Women's Health Initiative Memory Study. Alzheimer Disease &amp; Associated Disorders. Epub 2010 May 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929315</ArticleId><ArticleId IdType="pubmed">20473134</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord. 2006;22(4):312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">16940725</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: Long-term course of four clinical subtypes. Neurology. 2006 December 26;67(12):2176&#x2013;2185. 2006.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190940</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton LE, Yaffe K. Promising Strategies for the Prevention of Dementia. Arch Neurol. 2009;66(10):1210&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762111</ArticleId><ArticleId IdType="pubmed">19822776</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlau DJ, Corrada MM, Head E, Kawas CH. APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 2009 Mar 3;72(9):829&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667799</ArticleId><ArticleId IdType="pubmed">19255410</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillenbaum GG, Burchett BM, Lee JH, Blazer DG. Mortality and apolipoprotein E in African-American, and White Elders: An attempted replication. American Journal of Medical Genetics Part A. 2003;119A(2):141&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">12749052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21593310</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>20</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease brain-derived amyloid-&#x3b2;-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein.</ArticleTitle><Pagination><StartPage>7259</StartPage><EndPage>7263</EndPage><MedlinePgn>7259-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6500-10.2011</ELocationID><Abstract><AbstractText>Synthetic amyloid-&#x3b2; protein (A&#x3b2;) oligomers bind with high affinity to cellular prion protein (PrP(C)), but the role of this interaction in mediating the disruption of synaptic plasticity by such soluble A&#x3b2; in vitro is controversial. Here we report that intracerebroventricular injection of A&#x3b2;-containing aqueous extracts of Alzheimer's disease (AD) brain robustly inhibits long-term potentiation (LTP) without significantly affecting baseline excitatory synaptic transmission in the rat hippocampus in vivo. Moreover, the disruption of LTP was abrogated by immunodepletion of A&#x3b2;. Importantly, intracerebroventricular administration of antigen-binding antibody fragment D13, directed to a putative A&#x3b2;-binding site on PrP(C), prevented the inhibition of LTP by AD brain-derived A&#x3b2;. In contrast, R1, a Fab directed to the C terminus of PrP(C), a region not implicated in binding of A&#x3b2;, did not significantly affect the A&#x3b2;-mediated inhibition of LTP. These data support the pathophysiological significance of SDS-stable A&#x3b2; dimer and the role of PrP(C) in mediating synaptic plasticity disruption by soluble A&#x3b2;.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klyubin</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mc Donald</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Mably</LastName><ForeName>Alexandra J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Rowan</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018621">PrPC Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="N">Neural Inhibition</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018621" MajorTopicYN="N">PrPC Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21593310</ArticleId><ArticleId IdType="pmc">PMC6622598</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6500-10.2011</ArticleId><ArticleId IdType="pii">31/20/7259</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A. 2010;107:2295&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836680</ArticleId><ArticleId IdType="pubmed">20133875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi X, Gall CM, Zhou J, Lynch G. Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience. 2002;112:827&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">12088742</ArticleId></ArticleIdList></Reference><Reference><Citation>Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med. 2010;2:306&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962809</ArticleId><ArticleId IdType="pubmed">20665634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role of N-terminal residues. J Biol Chem. 2010;285:26377&#x2013;26383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924066</ArticleId><ArticleId IdType="pubmed">20576610</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM, Wisniewski T. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse. BMC Neurosci. 2010;11:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964735</ArticleId><ArticleId IdType="pubmed">20946660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen WK, Suh YH, Anwyl R, Rowan MJ. Block of LTP in rat hippocampus in vivo by &#x3b2;-amyloid precursor protein fragments. Neuroreport. 1997;8:3213&#x2013;3217.</Citation><ArticleIdList><ArticleId IdType="pubmed">9351645</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R., Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Delint-Ramirez I, Fern&#xe1;ndez E, Bay&#xe9;s A, Kicsi E, Komiyama NH, Grant SG. In vivo composition of NMDA receptor signaling complexes differs between membrane subdomains and is modulated by PSD-95 and PSD-93. J Neurosci. 2010;30:8162&#x2013;8170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912510</ArticleId><ArticleId IdType="pubmed">20554866</ArticleId></ArticleIdList></Reference><Reference><Citation>Francesconi A, Kumari R, Zukin RS. Regulation of group I metabotropic glutamate receptor trafficking and signaling by the caveolar/lipid raft pathway. J Neurosci. 2009;29:3590&#x2013;3602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734995</ArticleId><ArticleId IdType="pubmed">19295163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laur&#xe9;n J, Gimbel ZA, Strittmatter SM. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010;30:6367&#x2013;6374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323924</ArticleId><ArticleId IdType="pubmed">20445063</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuffrida ML, Caraci F, De Bona P, Pappalardo G, Nicoletti F, Rizzarelli E, Copani A. The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. Rev Neurosci. 2010;21:83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20614800</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, K&#xe4;lin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci. 2009;12:1361&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, Kinney G, Joyce JG. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry. 2006;45:15157&#x2013;15167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17176037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellett KA, Hooper NM. Prion protein and Alzheimer disease. Prion. 2009;3:190&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807690</ArticleId><ArticleId IdType="pubmed">19887909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Nguyen LN, Nabavi S, Malinow R. The prion protein as a receptor for amyloid-beta. Nature. 2010;466:E3&#x2013;E4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057871</ArticleId><ArticleId IdType="pubmed">20703260</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008;28:4231&#x2013;4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685151</ArticleId><ArticleId IdType="pubmed">18417702</ArticleId></ArticleIdList></Reference><Reference><Citation>Laur&#xe9;n J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain. 2010;133:1328&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859152</ArticleId><ArticleId IdType="pubmed">20403962</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of A beta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Leznik E, F&#xe0; M, Staniszewski A, Palmeri A, Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008;28:14537&#x2013;14545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010;66:739&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111138</ArticleId><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener. 2009;4:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788538</ArticleId><ArticleId IdType="pubmed">19930651</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow AD, Kinsella MG, Parks E, Sekiguchi RT, Miller JD, Kimata K, Wight TN. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Arch Biochem Biophys. 1995;320:84&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">7793988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. Beta-Amyloid(1&#x2013;42) binds to alpha7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology. J Biol Chem. 2000;275:5626&#x2013;5632.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol. 1999;158:328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson RA, Peretz D, Pinilla C, Ball H, Bastidas RB, Rozenshteyn R, Houghten RA, Prusiner SB, Burton DR. Mapping the prion protein using recombinant antibodies. J Virol. 1998;72:9413&#x2013;9418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110372</ArticleId><ArticleId IdType="pubmed">9765500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright S, Malinin NL, Powell KA, Yednock T, Rydel RE, Griswold-Prenner I. Alpha2beta1 and alphaVbeta1 integrin signaling pathways mediate amyloid-beta-induced neurotoxicity. Neurobiol Aging. 2007;28:226&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">16448724</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci. 2002;22(RC221)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757630</ArticleId><ArticleId IdType="pubmed">12006603</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, Gilchrest BA. Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J Clin Invest. 1997;100:2333&#x2013;2340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508430</ArticleId><ArticleId IdType="pubmed">9410912</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis. 2009;16:833&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726270</ArticleId><ArticleId IdType="pubmed">19387116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampagni M, Evangelisti E, Cascella R, Liguri G, Becatti M, Pensalfini A, Uberti D, Cenini G, Memo M, Bagnoli S, Nacmias B, Sorbi S, Cecchi C. Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. J Mol Med. 2010;88:597&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">20217034</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21613622</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2011</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>84</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A therapeutic antibody targeting BACE1 inhibits amyloid-&#x3b2; production in vivo.</ArticleTitle><Pagination><StartPage>84ra43</StartPage><MedlinePgn>84ra43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3002254</ELocationID><Abstract><AbstractText>Reducing production of amyloid-&#x3b2; (A&#x3b2;) peptide by direct inhibition of the enzymes that process amyloid precursor protein (APP) is a central therapeutic strategy for treating Alzheimer's disease. However, small-molecule inhibitors of the &#x3b2;-secretase (BACE1) and &#x3b3;-secretase APP processing enzymes have shown a lack of target selectivity and poor penetrance of the blood-brain barrier (BBB). Here, we have developed a high-affinity, phage-derived human antibody that targets BACE1 (anti-BACE1) and is anti-amyloidogenic. Anti-BACE1 reduces endogenous BACE1 activity and A&#x3b2; production in human cell lines expressing APP and in cultured primary neurons. Anti-BACE1 is highly selective and does not inhibit the related enzymes BACE2 or cathepsin D. Competitive binding assays and x-ray crystallography indicate that anti-BACE1 binds noncompetitively to an exosite on BACE1 and not to the catalytic site. Systemic dosing of mice and nonhuman primates with anti-BACE1 resulted in sustained reductions in peripheral A&#x3b2; peptide concentrations. Anti-BACE1 also reduces central nervous system A&#x3b2; concentrations in mouse and monkey, consistent with a measurable uptake of antibody across the BBB. Thus, BACE1 can be targeted in a highly selective manner through passive immunization with anti-BACE1, providing a potential approach for treating Alzheimer's disease. Nevertheless, therapeutic success with anti-BACE1 will depend on improving antibody uptake into the brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Atwal</LastName><ForeName>Jasvinder K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Neurodegeneration Labs, Department of Neuroscience, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yongmei</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mortensen</LastName><ForeName>Deborah L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Meilandt</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yichin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Heise</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Hoyte</LastName><ForeName>Kwame</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Luk</LastName><ForeName>Wilman</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Kun</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rouge</LastName><ForeName>Lionel</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yingnan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lazarus</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Weiru</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tessier-Lavigne</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019151">Peptide Library</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2011 Jun 21;7(7):359. doi: 10.1038/nrneurol.2011.95.</RefSource><PMID Version="1">21691336</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019151" MajorTopicYN="N">Peptide Library</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21613622</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3002254</ArticleId><ArticleId IdType="pii">3/84/84ra43</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21632484</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>305</Volume><Issue>21</Issue><PubDate><Year>2011</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses.</ArticleTitle><Pagination><StartPage>2200</StartPage><EndPage>2210</EndPage><MedlinePgn>2200-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2011.713</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Many biomarkers are proposed in highly cited studies as determinants of disease risk, prognosis, or response to treatment, but few eventually transform clinical practice.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether the magnitude of the effect sizes of biomarkers proposed in highly cited studies is accurate or overestimated.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">We searched ISI Web of Science and MEDLINE until December 2010.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">We included biomarker studies that had a relative risk presented in their abstract. Eligible articles were those that had received more than 400 citations in the ISI Web of Science and that had been published in any of 24 highly cited biomedical journals. We also searched MEDLINE for subsequent meta-analyses on the same associations (same biomarker and same outcome).</AbstractText><AbstractText Label="DATA EXTRACTION" NlmCategory="METHODS">In the highly cited studies, data extraction was focused on the disease/outcome, biomarker under study, and first reported relative risk in the abstract. From each meta-analysis, we extracted the overall relative risk and the relative risk in the largest study. Data extraction was performed independently by 2 investigators.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We evaluated 35 highly cited associations. For 30 of the 35 (86%), the highly cited studies had a stronger effect estimate than the largest study; for 3 the largest study was also the highly cited study; and only twice was the effect size estimate stronger in the largest than in the highly cited study. For 29 of the 35 (83%) highly cited studies, the corresponding meta-analysis found a smaller effect estimate. Only 15 of the associations were nominally statistically significant based on the largest studies, and of those only 7 had a relative risk point estimate greater than 1.37.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Highly cited biomarker studies often report larger effect estimates for postulated associations than are reported in subsequent meta-analyses evaluating the same associations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ioannidis</LastName><ForeName>John P A</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. jioannid@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panagiotou</LastName><ForeName>Orestis A</ForeName><Initials>OA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2011 Jun 1;305(21):2229-30. doi: 10.1001/jama.2011.729.</RefSource><PMID Version="1">21632488</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015987" MajorTopicYN="N">Effect Modifier, Epidemiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="Y">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="Y">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="Y">Sample Size</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21632484</ArticleId><ArticleId IdType="doi">10.1001/jama.2011.713</ArticleId><ArticleId IdType="pii">305/21/2200</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21636279</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-0445</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>Current biology : CB</Title><ISOAbbreviation>Curr Biol</ISOAbbreviation></Journal><ArticleTitle>The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.</ArticleTitle><Pagination><StartPage>961</StartPage><EndPage>966</EndPage><MedlinePgn>961-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cub.2011.04.028</ELocationID><Abstract><AbstractText>Neuroactive metabolites of the kynurenine pathway (KP) of tryptophan degradation have been implicated in the pathophysiology of neurodegenerative disorders, including Huntington's disease (HD) [1]. A central hallmark of HD is neurodegeneration caused by a polyglutamine expansion in the huntingtin (htt) protein [2]. Here we exploit a transgenic Drosophila melanogaster model of HD to interrogate the therapeutic potential of KP manipulation. We observe that genetic and pharmacological inhibition of kynurenine 3-monooxygenase (KMO) increases levels of the neuroprotective metabolite kynurenic acid (KYNA) relative to the neurotoxic metabolite 3-hydroxykynurenine (3-HK) and ameliorates neurodegeneration. We also find that genetic inhibition of tryptophan 2,3-dioxygenase (TDO), the first and rate-limiting step in the pathway, leads to a similar neuroprotective shift toward KYNA synthesis. Importantly, we demonstrate that the feeding of KYNA and 3-HK to HD model flies directly modulates neurodegeneration, underscoring the causative nature of these metabolites. This study provides the first genetic evidence that inhibition of KMO and TDO activity protects against neurodegenerative disease in an animal model, indicating that strategies targeted&#xa0;at&#xa0;two key points within the KP may have therapeutic relevance in HD, and possibly other neurodegenerative disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Campesan</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Genetics, University of Leicester, Leicester LE1 7RH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Edward W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Breda</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sathyasaikumar</LastName><ForeName>Korrapati V</ForeName><Initials>KV</Initials></Author><Author ValidYN="Y"><LastName>Muchowski</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Schwarcz</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kyriacou</LastName><ForeName>Charalambos P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Giorgini</LastName><ForeName>Flaviano</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS057715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Biol</MedlineTA><NlmUniqueID>9107782</NlmUniqueID><ISSNLinking>0960-9822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>27723548JL</RegistryNumber><NameOfSubstance UI="C005045">3-hydroxykynurenine</NameOfSubstance></Chemical><Chemical><RegistryNumber>343-65-7</RegistryNumber><NameOfSubstance UI="D007737">Kynurenine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.11.11</RegistryNumber><NameOfSubstance UI="D014366">Tryptophan Oxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.9</RegistryNumber><NameOfSubstance UI="D050601">Kynurenine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>H030S2S85J</RegistryNumber><NameOfSubstance UI="D007736">Kynurenic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2011 Jul 26;7(8):417. doi: 10.1038/nrneurol.2011.102.</RefSource><PMID Version="1">21788979</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2011 Aug 01;10(8):576. doi: 10.1038/nrd3521.</RefSource><PMID Version="1">21804592</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007736" MajorTopicYN="N">Kynurenic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007737" MajorTopicYN="N">Kynurenine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050601" MajorTopicYN="N">Kynurenine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014366" MajorTopicYN="N">Tryptophan Oxygenase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21636279</ArticleId><ArticleId IdType="mid">NIHMS550938</ArticleId><ArticleId IdType="pmc">PMC3929356</ArticleId><ArticleId IdType="doi">10.1016/j.cub.2011.04.028</ArticleId><ArticleId IdType="pii">S0960-9822(11)00467-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington&#x2019;s disease. CNS Neurol. Disord. Drug Targets. 2010;9:791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">20942784</ArticleId></ArticleIdList></Reference><Reference><Citation>The Huntington&#x2019;s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington&#x2019;s disease chromosomes. Cell. 1993;72:971&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Iwahashi H, Sugata R, Kido R. Formation of hydroxanthommatin-derived radical in the oxidation of 3-hydroxykynurenine. Arch. Biochem. Biophys. 1992;294:616&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">1314547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraku Y, Inoue S, Oikawa S, Yamamoto K, Tada S, Nishino K, Kawanishi S. Metal-mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites. Carcinogenesis. 1995;16:349&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">7859368</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 1981;72:411&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">6268428</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz R, Whetsell WO, Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">6849138</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;csei L, Beal MF. Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats. Brain Res. Bull. 1990;25:623&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">2271966</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 1984;48:273&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">6237279</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteri M, Moroni F. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 2001;13:2141&#x2013;2147.</Citation><ArticleIdList><ArticleId IdType="pubmed">11422455</ArticleId></ArticleIdList></Reference><Reference><Citation>Goda K, Hamane Y, Kishimoto R, Ogishi Y. Radical scavenging properties of tryptophan metabolites. Estimation of their radical reactivity. Adv. Exp. Med. Biol. 1999;467:397&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">10721081</ArticleId></ArticleIdList></Reference><Reference><Citation>Linzen B. Tryptophan-ommochrome pathway in insects. Adv. Insect Physiol. 1974;10:117&#x2013;246.</Citation></Reference><Reference><Citation>Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol. 2004;4:12&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15018833</ArticleId></ArticleIdList></Reference><Reference><Citation>Tearle R. Tissue specific effects of ommochrome pathway mutations in Drosophila melanogaster. Genet. Res. 1991;57:257&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">1909678</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JE. Ocular phototoxicity. J. Photochem. Photobiol. B. 2001;64:136&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744400</ArticleId></ArticleIdList></Reference><Reference><Citation>Savvateeva E, Popov A, Kamyshev N, Bragina J, Heisenberg M, Senitz D, Kornhuber J, Riederer P. Age-dependent memory loss, synaptic pathology and altered brain plasticity in the Drosophila mutant cardinal accumulating 3-hydroxykynurenine. J. Neural Transm. 2000;107:581&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">11072753</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxenkrug GF. The extended life span of Drosophila melanogaster eye-color (white and vermilion) mutants with impaired formation of kynurenine. J. Neural Transm. 2010;117:23&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013506</ArticleId><ArticleId IdType="pubmed">19941150</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti P, Reddy PH, Tagle DA, Schwarcz R. Early kynurenergic impairment in Huntington&#x2019;s disease and in a transgenic animal model. Neurosci. Lett. 2000;283:233&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">10754231</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001;413:739&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">11607033</ArticleId></ArticleIdList></Reference><Reference><Citation>Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J. Neurochem. 2009;109:316&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3666345</ArticleId><ArticleId IdType="pubmed">19226371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwilling D, Huang S-Y, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu H-Q, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011;145 in press. Published online June 2, 2011. 10.1016/j.cell.2011.05.020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3118409</ArticleId><ArticleId IdType="pubmed">21640374</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;ver S, Cesura AM, Huguenin P, Kettler R, Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem. 1997;40:4378&#x2013;4385.</Citation><ArticleIdList><ArticleId IdType="pubmed">9435907</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi S, Ogawa H. Effect of tryptophan metabolites on fluorescent granules in the Malpighian tubules of eye color mutants of Drosophila melanogaster. Zoolog. Sci. 1996;13:97&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">8688814</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xe1;dori D, Nyiri G, Sz&#xf6;nyi A, Szatm&#xe1;ri I, F&#xfc;l&#xf6;p F, Toldi J, Freund TF, V&#xe9;csei L, Kliv&#xe9;nyi P. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington&#x2019;s disease. J. Neural Transm. 2010 in press. Published online December 31, 2011. 10.1007/s00702-010-0573-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21194001</ArticleId></ArticleIdList></Reference><Reference><Citation>Howells AJ, Summers KM, Ryall RL. Developmental patterns of 3-hydroxykynurenine accumulation in white and various other eye color mutants of Drosophila melanogaster. Biochem. Genet. 1977;15:1049&#x2013;1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">414739</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 2005;37:526&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449881</ArticleId><ArticleId IdType="pubmed">15806102</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgini F, M&#xf6;ller T, Kwan W, Zwilling D, Wacker JL, Hong S, Tsai LC, Cheah CS, Schwarcz R, Guidetti P, Muchowski PJ. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J. Biol. Chem. 2008;283:7390&#x2013;7400.</Citation><ArticleIdList><ArticleId IdType="pubmed">18079112</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkondon M, Pereira ER, Eisenberg HM, Kajii Y, Schwarcz R, Albuquerque EX. Age dependency of inhibition of {alpha}7 nicotinic receptors and tonically active NMDA receptors by endogenously produced kynurenic acid in the brain. J. Pharmacol. Exp. Ther. 2011 in press. Published online January 26, 2011. 10.1124/jpet.110.177386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101010</ArticleId><ArticleId IdType="pubmed">21270133</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Chiang AS. NMDA receptors in Drosophila. In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton, FL: CRC Press; 2009. pp. 213&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">21204418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansdell SJ, Millar NS. Molecular characterization of Dalpha6 and Dalpha7 nicotinic acetylcholine receptor subunits from Drosophila: formation of a high-affinity alpha-bungarotoxin binding site revealed by expression of subunit chimeras. J. Neurochem. 2004;90:479&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">15228604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Tabrizi SJ. Huntington&#x2019;s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">21163446</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero E, Cha GH, Verstreken P, Ly CV, Hughes RE, Bellen HJ, Botas J. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron. 2008;57:27&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2277511</ArticleId><ArticleId IdType="pubmed">18184562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafice SA, Chauhan N, Efimov I, Basran J, Raven EL. Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase. Biochem. Soc. Trans. 2009;37:408&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">19290871</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21640374</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.</ArticleTitle><Pagination><StartPage>863</StartPage><EndPage>874</EndPage><MedlinePgn>863-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2011.05.020</ELocationID><Abstract><AbstractText>Metabolites in the kynurenine pathway, generated by tryptophan degradation, are thought to play an important role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases. In these disorders, glutamate receptor-mediated excitotoxicity and free radical formation have been correlated with decreased levels of the neuroprotective metabolite kynurenic acid. Here, we describe the synthesis and characterization of JM6, a small-molecule prodrug inhibitor of kynurenine 3-monooxygenase (KMO). Chronic oral administration of JM6 inhibits KMO in the blood, increasing kynurenic acid levels and reducing extracellular glutamate in the brain. In a transgenic mouse model of Alzheimer's disease, JM6 prevents spatial memory deficits, anxiety-related behavior, and synaptic loss. JM6 also extends life span, prevents synaptic loss, and decreases microglial activation in a mouse model of Huntington's disease. These findings support a critical link between tryptophan metabolism in the blood and neurodegeneration, and they provide a foundation for treatment of neurodegenerative diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zwilling</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shao-Yi</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Sathyasaikumar</LastName><ForeName>Korrapati V</ForeName><Initials>KV</Initials></Author><Author ValidYN="Y"><LastName>Notarangelo</LastName><ForeName>Francesca M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Guidetti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hui-Qiu</ForeName><Initials>HQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Truong</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Andrews-Zwilling</LastName><ForeName>Yaisa</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Eric W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Louie</LastName><ForeName>Jamie Y</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Patrick</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Adame</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Giorgini</LastName><ForeName>Flaviano</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Moussaoui</LastName><ForeName>Saliha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Laue</LastName><ForeName>Grit</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rassoulpour</LastName><ForeName>Arash</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Flik</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yadong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Muchowski</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Schwarcz</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Muchowski</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS057715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS057715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR18928-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C560311">2-(3,4-dimethoxybenzenesulfonylamino)-4-(3-nitrophenyl)-5-(piperidin-1-yl)methylthiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110196">Ro 61-8048</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.9</RegistryNumber><NameOfSubstance UI="D050601">Kynurenine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>H030S2S85J</RegistryNumber><NameOfSubstance UI="D007736">Kynurenic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2011 Jun 10;145(6):813-4. doi: 10.1016/j.cell.2011.05.031.</RefSource><PMID Version="1">21663784</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2011 Jul 26;7(8):417. doi: 10.1038/nrneurol.2011.102.</RefSource><PMID Version="1">21788979</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2011 Aug 01;10(8):576. doi: 10.1038/nrd3521.</RefSource><PMID Version="1">21804592</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007736" MajorTopicYN="N">Kynurenic Acid</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050601" MajorTopicYN="N">Kynurenine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21640374</ArticleId><ArticleId IdType="mid">NIHMS300418</ArticleId><ArticleId IdType="pmc">PMC3118409</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2011.05.020</ArticleId><ArticleId IdType="pii">S0092-8674(11)00581-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andin&#xe9; P, Lehmann A, Ellren K, Wennberg E, Kjellmer I, Nielsen T, Hagberg H. The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neurosci Lett. 1988;90:208&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">3412643</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF, Matson WR, Storey E, Milbury P, Ryan EA, Ogawa T, Bird ED. Kynurenic acid concentrations are reduced in Huntington&#x2019;s disease cerebral cortex. J Neurol Sci. 1992;108:80&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">1385624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med. 2008;205:1869&#x2013;1877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525598</ArticleId><ArticleId IdType="pubmed">18625748</ArticleId></ArticleIdList></Reference><Reference><Citation>Boegman RJ, el-Defrawy SR, Jhamandas K, Beninger RJ, Ludwin SK. Quinolinic acid neurotoxicity in the nucleus basalis antagonized by kynurenic acid. Neurobiol Aging. 1985;6:331&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">2935745</ArticleId></ArticleIdList></Reference><Reference><Citation>Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, Kyriacou CP, Giorgini F. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington&#x2019;s disease. Curr Biol. 2011 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929356</ArticleId><ArticleId IdType="pubmed">21636279</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteri M, Moroni F. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci. 2001;13:2141&#x2013;2147.</Citation><ArticleIdList><ArticleId IdType="pubmed">11422455</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo-Mora P, Mendez-Cuesta LA, Perez-De La Cruz V, Fortoul-van Der Goes TI, Santamaria A. Protective effect of systemic L-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25&#x2013;35) in rat hippocampus. Behav Brain Res. 2010;210:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">20219555</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington&#x2019;s disease. J Neurosci. 2003;23:961&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741903</ArticleId><ArticleId IdType="pubmed">12574425</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puolivali J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CJ, Mackay GM, Smythe GA, Bustamante S, Stone TW, Phillips RS. Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect Immun. 2005;73:5249&#x2013;5251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201246</ArticleId><ArticleId IdType="pubmed">16041050</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzi A, Carpenedo R, Moroni F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J Cereb Blood Flow Metab. 1999;19:771&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">10413032</ArticleId></ArticleIdList></Reference><Reference><Citation>DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277:1990&#x2013;1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302293</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2009;29:8805&#x2013;8815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753494</ArticleId><ArticleId IdType="pubmed">19587288</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckstein JA, Ammerman GM, Reveles JM, Ackermann BL. Simultaneous profiling of multiple neurochemical pathways from a single cerebrospinal fluid sample using GC/MS/MS with electron capture detection. J Mass Spectr. 2008;43:782&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">18286669</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer&#x2019;s disease. Neurosci Lett. 1991;129:318&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">1745413</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett. 1984;48:273&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">6237279</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">1827495</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet. 2005;37:526&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449881</ArticleId><ArticleId IdType="pubmed">15806102</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregoire L, Rassoulpour A, Guidetti P, Samadi P, Bedard PJ, Izzo E, Schwarcz R, Di Paolo T. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res. 2008;186:161&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17868931</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J. Neurochem. 2007;102:103&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">17442055</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R. Elevated brain 3- hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis. 2006;23:190&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697652</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington&#x2019;s disease. Neurobiol Dis. 2004;17:455&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571981</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in Alzheimer&#x2019;s disease patients. Adv Med Sci. 2010;55:204&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">20639188</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E, Mucke L. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer&#x2019;s disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci. 2010;30:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064502</ArticleId><ArticleId IdType="pubmed">20053918</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992a;115(Pt 5):1249&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pubmed">1422788</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyes MP, Saito K, Markey SP. Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J. 1992b;283(Pt 3):633&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1130930</ArticleId><ArticleId IdType="pubmed">1534219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21:7463&#x2013;7473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762893</ArticleId><ArticleId IdType="pubmed">11567036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP. Environmental enrichment slows disease progression in R6/2 Huntington&#x2019;s disease mice. Ann Neurol. 2002;51:235&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835380</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 1989;52:1319&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">2538568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates GP. Impaired glutamate uptake in the R6 Huntington&#x2019;s disease transgenic mice. Neurobiol Dis. 2001;8:807&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592850</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">8898202</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer&#x2019;s disease. Ann Neurol. 1996;40:759&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">8957017</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Terry RD, DeTeresa RM, Hansen LA. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett. 1989;103:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">2505201</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, Kennedy RT, Rebec GV. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington&#x2019;s disease phenotype in the R6/2 mouse. Neuroscience. 2008;153:329&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2424273</ArticleId><ArticleId IdType="pubmed">18353560</ArticleId></ArticleIdList></Reference><Reference><Citation>Misztal M, Skangiel-Kramska J, Niewiadomska G, Danysz W. Subchronic intraventricular infusion of quinolinic acid produces working memory impairment--a model of progressive excitotoxicity. Neuropharmacology. 1996;35:449&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">8793907</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni F, Cozzi A, Carpendo R, Cipriani G, Veneroni O, Izzo E. Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus. Neuropharmacology. 2005;48:788&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829251</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni F, Cozzi A, Peruginelli F, Carpenedo R, Pellegrini-Giampietro DE. Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. Adv Exp Med Biol. 1999;467:199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">10721057</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozaki K, Beal MF. Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab. 1992;12:400&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">1569135</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuda S, Nishiyama N, Saito H, Katsuki H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci (USA) 1996;93:12553&#x2013;12558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38030</ArticleId><ArticleId IdType="pubmed">8901620</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellicciari R, Rizzo R, Costantino G, Marinozzi M, Amori L, Guidetti P, Wu H-Q, Schwarcz R. Modulators of the kynurenine pathway of tryptophan metabolism. Synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem. 2006;1:528&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16892388</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res Bull. 1982;247:184&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">6215086</ArticleId></ArticleIdList></Reference><Reference><Citation>Rassoulpour A, Wu H-Q, Ferr&#xe9; S, Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem. 2005;93:762&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">15836634</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers J, Stone TW, Barrett MP, Bradley B, Kennedy PG. Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis. Brain. 2009;132:1259&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677800</ArticleId><ArticleId IdType="pubmed">19339256</ArticleId></ArticleIdList></Reference><Reference><Citation>Romani L, Zelante T, De Luca A, Fallarino F, Puccetti P. IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. J Immunol. 2008;180:5157&#x2013;5162.</Citation><ArticleIdList><ArticleId IdType="pubmed">18390695</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;ver S, Cesura AM, Huguenin P, Kettler R, Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem. 1997;40:4378&#x2013;4385.</Citation><ArticleIdList><ArticleId IdType="pubmed">9435907</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington&#x2019;s disease. Exp Neurol. 2006;197:31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">16099455</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997;90:549&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">9267034</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz R, Whetsell WO, Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">6849138</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Adaya D, Perez-De La Cruz V, Villeda-Hernandez J, Carrillo-Mora P, Gonzalez-Herrera IG, Garcia E, Colin-Barenque L, Pedraza-Chaverri J, Santamaria A. Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy. Neurotoxicol Terat. 2010 Oct 7; [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">20933078</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons DA, Casale M, Alcon B, Pham N, Narayan N, Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington&#x2019;s disease. Glia. 2007;55:1074&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551926</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, Darlington LG. Tryptophan metabolism and oxidative stress in patients with Huntington&#x2019;s disease. J Neurochem. 2005;93:611&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">15836620</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacker JL, Huang SY, Steele AD, Aron R, Lotz GP, Nguyen Q, Giorgini F, Roberson ED, Lindquist S, Masliah E, et al. Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington&#x2019;s disease. J Neurosci. 2009;29:9104&#x2013;9114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739279</ArticleId><ArticleId IdType="pubmed">19605647</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006;281:22021&#x2013;22028.</Citation><ArticleIdList><ArticleId IdType="pubmed">16754668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Amer J Pathol. 2007;170:680&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851864</ArticleId><ArticleId IdType="pubmed">17255335</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21654636</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><PubDate><Year>2011</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Interaction between prion protein and toxic amyloid &#x3b2; assemblies can be therapeutically targeted at multiple sites.</ArticleTitle><Pagination><StartPage>336</StartPage><MedlinePgn>336</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms1341</ELocationID><Abstract><AbstractText>A role for PrP in the toxic effect of oligomeric forms of A&#x3b2;, implicated in Alzheimer's disease (AD), has been suggested but remains controversial. Here we show that PrP is required for the plasticity-impairing effects of ex vivo material from human AD brain and that standardized A&#x3b2;-derived diffusible ligand (ADDL) preparations disrupt hippocampal synaptic plasticity in a PrP-dependent manner. We screened a panel of anti-PrP antibodies for their ability to disrupt the ADDL-PrP interaction. Antibodies directed to the principal PrP/A&#x3b2;-binding site and to PrP helix-1, were able to block A&#x3b2; binding to PrP suggesting that the toxic A&#x3b2; species are of relatively high molecular mass and/or may bind multiple PrP molecules. Two representative and extensively characterized monoclonal antibodies directed to these regions, ICSM-35 and ICSM-18, were shown to block the A&#x3b2;-mediated disruption of synaptic plasticity validating these antibodies as candidate therapeutics for AD either individually or in combination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freir</LastName><ForeName>Darragh B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin 4, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicoll</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Klyubin</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Panico</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mc Donald</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Risse</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Asante</LastName><ForeName>Emmanuel A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Farrow</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Sessions</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Saibil</LastName><ForeName>Helen R</ForeName><Initials>HR</Initials></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Anthony R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Rowan</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U123192748</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160656</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>070776</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>079605</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160653</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002850" MajorTopicYN="N">Chromatography, Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="Y">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014461" MajorTopicYN="N">Ultracentrifugation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>J.C. is a director of, and J.C. and A.R.C. are consultants to and shareholders of D-Gen Limited, an academic spin-out company in the field of prion diagnosis, decontamination and therapeutics. D.M.W. is a consultant, shareholder and member of the scientific advisory board of Senexis plc. The remaining authors have no competing financial interest to declare</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21654636</ArticleId><ArticleId IdType="pmc">PMC3156817</ArticleId><ArticleId IdType="doi">10.1038/ncomms1341</ArticleId><ArticleId IdType="pii">ncomms1341</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walsh D. M. &amp; Selkoe D. J. A beta oligomers&#x2014;a decade of discovery. J. Neurochem. 101, 1172&#x2013;1184 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen W. K., Suh Y. H., Anwyl R. &amp; Rowan M. J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8, 3213&#x2013;3217 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9351645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert M. P. et al.. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448&#x2013;6453 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H. W. et al.. Soluble oligomers of beta amyloid (1&#x2013;42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133&#x2013;140 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I. et al.. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci. 19, 2839&#x2013;2846 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15147317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J., Gimbel D. A., Nygaard H. B., Gilbert J. W. &amp; Strittmatter S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128&#x2013;1132 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C. et al.. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc. Natl Acad. Sci. USA 107, 2295&#x2013;2300 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836680</ArticleId><ArticleId IdType="pubmed">20133875</ArticleId></ArticleIdList></Reference><Reference><Citation>Calella A. M. et al.. Prion protein and abeta-related synaptic toxicity impairment. EMBO Mol. Med. 2, 306&#x2013;314 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962809</ArticleId><ArticleId IdType="pubmed">20665634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S. G., Yadav S. P. &amp; Surewicz W. K. Interaction between human prion protein and amyloid-beta (A beta) oligomers: role of N-terminal residues. J. Biol. Chem. 285, 26377&#x2013;26383 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924066</ArticleId><ArticleId IdType="pubmed">20576610</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimbel D. A. et al.. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 30, 6367&#x2013;6374 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323924</ArticleId><ArticleId IdType="pubmed">20445063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E. et al.. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci. 11, 130 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964735</ArticleId><ArticleId IdType="pubmed">20946660</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll A. J. &amp; Collinge J. Preventing prion pathogenicity by targeting the cellular prion protein. Infect. Disord. Drug Targets 9, 48&#x2013;57 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19200015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallucci G. et al.. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. 21, 202&#x2013;210 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125833</ArticleId><ArticleId IdType="pubmed">11823413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallucci G. et al.. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302, 871&#x2013;874 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14593181</ArticleId></ArticleIdList></Reference><Reference><Citation>White A. R. et al.. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80&#x2013;83 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12621436</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonyuk S. V. et al.. Crystal structure of human prion protein bound to a therapeutic antibody. Proc. Natl Acad. Sci. USA 106, 2554&#x2013;2558 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637903</ArticleId><ArticleId IdType="pubmed">19204296</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll A. J. et al.. Pharmacological chaperone for the structured domain of human prion protein. Proc. Natl Acad. Sci. USA 107, 17610&#x2013;17615 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955083</ArticleId><ArticleId IdType="pubmed">20876144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels H. W., Nguyen L. N., Nabavi S. &amp; Malinow R. The prion protein as a receptor for amyloid-beta. Nature 466, E3&#x2013;E4 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057871</ArticleId><ArticleId IdType="pubmed">20703260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepler R. W. et al.. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45, 15157&#x2013;15167 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17176037</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., Lomakin A., Benedek G. B., Condron M. M. &amp; Teplow D. B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364&#x2013;22372 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9268388</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M. et al.. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837&#x2013;842 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M. &amp; Walsh D. M. Alzheimer's disease: synaptic dysfunction and Abeta. Mol. Neurodegener. 4, 48 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788538</ArticleId><ArticleId IdType="pubmed">19930651</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B. et al.. Amyloid-beta protein dimers rapidly form stable synaptotoxic protofibrils. J. Neurosci. 30, 14411&#x2013;14419 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987723</ArticleId><ArticleId IdType="pubmed">20980598</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson G. S. et al.. Location and properties of metal-binding sites on the human prion protein. Proc. Natl Acad. Sci. USA 98, 8531&#x2013;8535 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37470</ArticleId><ArticleId IdType="pubmed">11438695</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood C. S. et al.. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta 1&#x2013;42. J. Neurochem. 75, 1219&#x2013;1233 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10936205</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson, R. M. C., Elliot, D., Elliot, W. H. &amp; Jones, K. M. (eds). Data for Biochemical Research 399&#x2013;415 (Clarendon Press, Oxford, 1989).</Citation></Reference><Reference><Citation>Khalili-Shirazi A. et al.. Beta-PrP form of human prion protein stimulates production of monoclonal antibodies to epitope 91&#x2013;110 that recognise native PrP(Sc). Biochim. Biophys. Acta 1774, 1438&#x2013;1450 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17936697</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M. et al.. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739&#x2013;754 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111138</ArticleId><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M. et al.. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47&#x2013;52 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker H. et al.. N-Methyl-d-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-beta peptide oligomers. J. Neurochem. 115, 1520&#x2013;1529 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20950339</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravani H. et al.. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J. Cell Biol. 181, 551&#x2013;565 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2364707</ArticleId><ArticleId IdType="pubmed">18443219</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuck P., Perugini M. A., Gonzales N. R., Howlett G. J. &amp; Schubert D. Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys. J. 82, 1096&#x2013;1111 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1301916</ArticleId><ArticleId IdType="pubmed">11806949</ArticleId></ArticleIdList></Reference><Reference><Citation>Laue T. M., Shah B. D., Ridgeway T. M. &amp; Pelletier S. L. in Analytical Ultracentrifugation in Biochemistry and Polymer Science (eds Harding, S. E. et al..) 90&#x2013;125 (Royal Society of Chemistry, 1992).</Citation></Reference><Reference><Citation>McDonald J. M. et al.. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133, 1328&#x2013;1341 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859152</ArticleId><ArticleId IdType="pubmed">20403962</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueler H. et al.. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577&#x2013;582 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1373228</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson G. S. et al. Multiple folding pathways for heterologously expressed human prion protein. Biochim. Biophys. Acta 1431, 1&#x2013;13 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10209273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahn R., von Schroetter C. &amp; Wuthrich K. Human prion proteins expressed in Escherichia coli and purified by high-affinity column refolding. FEBS Lett. 417, 400&#x2013;404 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9409760</ArticleId></ArticleIdList></Reference><Reference><Citation>Soini E. &amp; Kojola H. Time-resolved fluorometer for lanthanide chelates&#x2014;a new generation of non-isotopic immunoassays. Clin. Chem. 29, 65&#x2013;68 (1983).</Citation><ArticleIdList><ArticleId IdType="pubmed">6336682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21670398</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment.</ArticleTitle><Pagination><StartPage>743</StartPage><EndPage>752</EndPage><MedlinePgn>743-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.125</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the effects of a 4-week high-saturated fat/high-glycemic index (HIGH) diet with a low-saturated fat/low-glycemic index (LOW) diet on insulin and lipid metabolism, cerebrospinal fluid (CSF) markers of Alzheimer disease, and cognition for healthy adults and adults with amnestic mild cognitive impairment (aMCI).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Randomized controlled trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Veterans Affairs Medical Center clinical research unit.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Forty-nine older adults (20 healthy adults with a mean [SD] age of 69.3 [7.4] years and 29 adults with aMCI with a mean [SD] age of 67.6 [6.8] years).</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Participants received the HIGH diet (fat, 45% [saturated fat, &gt; 25%]; carbohydrates, 35%-40% [glycemic index, &gt; 70]; and protein, 15%-20%) or the LOW diet (fat, 25%; [saturated fat, &lt; 7%]; carbohydrates, 55%-60% [glycemic index, &lt; 55]; and protein, 15%-20%) for 4 weeks. Cognitive tests, an oral glucose tolerance test, and lumbar puncture were conducted at baseline and during the fourth week of the diet.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The CSF concentrations of &#x3b2;-amyloid (A&#x3b2;42 and A&#x3b2;40), tau protein, insulin, F2-isoprostanes, and apolipoprotein E, plasma lipids and insulin, and measures of cognition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For the aMCI group, the LOW diet increased CSF A&#x3b2;42 concentrations, contrary to the pathologic pattern of lowered CSF A&#x3b2;42 typically observed in Alzheimer disease. The LOW diet had the opposite effect for healthy adults, ie, decreasing CSF A&#x3b2;42, whereas the HIGH diet increased CSF A&#x3b2;42. The CSF apolipoprotein E concentration was increased by the LOW diet and decreased by the HIGH diet for both groups. For the aMCI group, the CSF insulin concentration increased with the LOW diet, but the HIGH diet lowered the CSF insulin concentration for healthy adults. The HIGH diet increased and the LOW diet decreased plasma lipids, insulin, and CSF F2-isoprostane concentrations. Delayed visual memory improved for both groups after completion of 4 weeks of the LOW diet.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that diet may be a powerful environmental factor that modulates Alzheimer disease risk through its effects on central nervous system concentrations of A&#x3b2;42, lipoproteins, oxidative stress, and insulin.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bayer-Carter</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Pattie S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>VanFossen</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Laura D</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>G Stennis</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Bonner</LastName><ForeName>Laura M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Callaghan</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Brooke K</ForeName><Initials>BK</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Plymate</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Postupna</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Charles W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lampe</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AG000258</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32 AG-000258</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG010880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG-10880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG-05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK017047</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004040">Dietary Carbohydrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004042">Dietary Fats, Unsaturated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004040" MajorTopicYN="N">Dietary Carbohydrates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004042" MajorTopicYN="N">Dietary Fats, Unsaturated</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005526" MajorTopicYN="N">Food, Formulated</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21670398</ArticleId><ArticleId IdType="mid">NIHMS266838</ArticleId><ArticleId IdType="pmc">PMC3175115</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.125</ArticleId><ArticleId IdType="pii">68/6/743</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev. 2010;68(suppl 2):S74&#x2013;S87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058404</ArticleId><ArticleId IdType="pubmed">21091952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science. 2003;299(5608):853&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">12574618</ArticleId></ArticleIdList></Reference><Reference><Citation>Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr. 2010;91(3):502&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824150</ArticleId><ArticleId IdType="pubmed">20089734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Olendzki BC, Hafner AR, et al. Low-carbohydrate and high-fat intake among adult patients with poorly controlled type 2 diabetes mellitus. Nutrition. 2006;22(11&#x2013;12):1129&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2039705</ArticleId><ArticleId IdType="pubmed">17027229</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunnane SC, Plourde M, Pifferi F, B&#xe9;gin M, F&#xe9;art C, Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res. 2009;48(5):239&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">19362576</ArticleId></ArticleIdList></Reference><Reference><Citation>Solfrizzi V, Frisardi V, Capurso C, et al. Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms. Ageing Res Rev. 2010;9(2):184&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">19643207</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F, Frisardi V, Capurso C, et al. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis. 2010;21(3):691&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">20571214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanoski SE, Davidson TL. Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. Physiol Behav. 2011;103(1):59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056912</ArticleId><ArticleId IdType="pubmed">21167850</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund-Levi Y, Eriksdotter-J&#xf6;nhagen M, Cederholm T, et al. &#x3c9;-3 Fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD Study: a randomized double-blind trial. Arch Neurol. 2006;63(10):1402&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030655</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xe9;art C, Samieri C, Rondeau V, et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia [published correction appears in JAMA. 2009;302(22):2436] JAMA. 2009;302(6):638&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850376</ArticleId><ArticleId IdType="pubmed">19671905</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch Neurol. 2010;67(6):699&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3029147</ArticleId><ArticleId IdType="pubmed">20385883</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol. 2009;66(2):216&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2653223</ArticleId><ArticleId IdType="pubmed">19204158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu FB, van Dam RM, Liu S. Diet and risk of type II diabetes: the role of types of fat and carbohydrate. Diabetologia. 2001;44(7):805&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">11508264</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder JE, Richardson JC, Virley DJ. Dietary manipulation and caloric restriction in the development of mouse models relevant to neurological diseases. Biochim Biophys Acta. 2010;1802(10):840&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472058</ArticleId></ArticleIdList></Reference><Reference><Citation>Takechi R, Galloway S, Pallebage-Gamarallage MMS, Lam V, Mamo JCL. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res. 2010;49(2):159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">19896503</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, et al. International Psychogeriatric Association Expert Conference on Mild Cognitive Impairment. Mild cognitive impairment. Lancet. 2006;367(9518):1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates &#x3b2;-amyloid in early AD [published correction appears in Neurology. 2008;71(11):866] Neurology. 2008;70(6):440&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">17942819</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Benedict FG. A Biometric Study of Basal Metabolism in Man. Carnegie Institution of Washington; Washington, DC: 1919.</Citation></Reference><Reference><Citation>Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr. 1990;51(2):241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">2305711</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolever TMS, Yang M, Zeng XY, Atkinson F, Brand-Miller JC. Food glycemic index, as given in glycemic index tables, is a significant determinant of glycemic responses elicited by composite breakfast meals. Am J Clin Nutr. 2006;83(6):1306&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">16762941</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol. 2010;67(1):71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056436</ArticleId><ArticleId IdType="pubmed">20065132</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedict RH. Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis. J Int Neuropsychol Soc. 2005;11(6):727&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">16248908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Abbasi F, Reaven GM. Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care. 2004;27(8):1998&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277430</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging. 1996;17(1):123&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">8786794</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol. 2005;62(10):1539&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pubmed">16216936</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and &#x3b2;-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">3899825</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">4337382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PD, Pirttil&#xe4; T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid &#x3b2; proteins 1&#x2013;40 and 1&#x2013;42 in Alzheimer disease. Arch Neurol. 2000;57(1):100&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298(7):776&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">17699011</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins IJ, Berger T, Sharman MJ, Verdile G, Fuller SJ, Martins RN. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem. 2009;111(6):1275&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">20050287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118(2):671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Breitner JC, Lovell MA, Markesbery WR, Quinn JF, Montine TJ. Free radical&#x2013;mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med. 2008;45(3):219&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2459222</ArticleId><ArticleId IdType="pubmed">18482592</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-&#x3b2; (A&#x3b2;) equilibrium in a mouse model of Alzheimer's disease. J Neurochem. 2002;81(2):229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21(2):372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Herukka S-K, Minkeviciene R, van Groen T, Tanila H. Longitudinal observation on CSF A&#x3b2;42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol Dis. 2004;17(3):516&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571987</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid &#x3b2;-amyloid 42 in adults with normal cognition. Arch Neurol. 2006;63(7):936&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">16831961</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji M, Kanai M, Matsubara E, et al. The levels of cerebrospinal fluid A&#x3b2;40 and A&#x3b2;42(43) are regulated age-dependently. Neurobiol Aging. 2001;22(2):209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182470</ArticleId></ArticleIdList></Reference><Reference><Citation>Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol. 2010;67(2):217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">20142530</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino SA, Stern Y, Sokolov E, et al. Plasma &#xdf;-amyloid and cognitive decline. Arch Neurol. 2010;67(12):1485&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3006003</ArticleId><ArticleId IdType="pubmed">20697031</ArticleId></ArticleIdList></Reference><Reference><Citation>Englund H, Anner&#xe9;n G, Gustafsson J, et al. Increase in &#x3b2;-amyloid levels in cerebrospinal fluid of children with Down syndrome. Dement Geriatr Cogn Disord. 2007;24(5):369&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">17914261</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Soininen H, Pirttil&#xe4; T. CSF tau and A&#x3b2;42 levels in patients with Down's syndrome. Neurology. 2001;56(7):979&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">11294944</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y-M, Emmerling MR, Bisgaier CL, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain A&#x3b2; 1&#x2013;42 levels. Biochem Biophys Res Commun. 1998;252(3):711&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">9837771</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61(2):199&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874399</ArticleId></ArticleIdList></Reference><Reference><Citation>Shobab LA, Hsiung G-YR, Feldman HH. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005;4(12):841&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">16297842</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Moreno C, Dorfman SE, Lichtenstein AH, Mart&#xed;n A. Dietary fat type affects vitamins C and E and biomarkers of oxidative status in peripheral and brain tissues of golden Syrian hamsters. J Nutr. 2004;134(3):655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">14988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratic&#xf2; D, Clark CM, Liun F, Rokach J, Lee VY-M, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59(6):972&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">12056933</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Peskind ER, Quinn JF, et al. Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med. 2011;13(1):37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000441</ArticleId><ArticleId IdType="pubmed">20632131</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Brickell K, et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol. 2009;66(3):315&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2766529</ArticleId><ArticleId IdType="pubmed">19139294</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CYD, Mandrekar S, et al. ApoE promotes the proteolytic degradation of A&#x3b2;. Neuron. 2008;58(5):681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005;8(3):247&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">16340083</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D., Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998;50(1):164&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443474</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol. 2009;66(3):300&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717716</ArticleId><ArticleId IdType="pubmed">19273747</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides. 1997;18(9):1423&#x2013;1429.</Citation><ArticleIdList><ArticleId IdType="pubmed">9392846</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes. 2000;49(9):1525&#x2013;1533.</Citation><ArticleIdList><ArticleId IdType="pubmed">10969837</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke JG, Taghibiglou C, Liu L, et al. A biochemical and functional characterization of diet-induced brain insulin resistance. J Neurochem. 2005;93(6):1568&#x2013;1578.</Citation><ArticleIdList><ArticleId IdType="pubmed">15935073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Teter B, Morihara T, et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci. 2004;24(49):11120&#x2013;11126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730264</ArticleId><ArticleId IdType="pubmed">15590928</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Vieira MNN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A&#x3b2; oligomers. Proc Natl Acad Sci U S A. 2009;106(6):1971&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2634809</ArticleId><ArticleId IdType="pubmed">19188609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21677644</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>475</Volume><Issue>7354</Issue><PubDate><Year>2011</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation.</ArticleTitle><Pagination><StartPage>96</StartPage><EndPage>100</EndPage><MedlinePgn>96-100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature10154</ELocationID><Abstract><AbstractText>Many globular and natively disordered proteins can convert into amyloid fibrils. These fibrils are associated with numerous pathologies as well as with normal cellular functions, and frequently form during protein denaturation. Inhibitors of pathological amyloid fibril formation could be useful in the development of therapeutics, provided that the inhibitors were specific enough to avoid interfering with normal processes. Here we show that computer-aided, structure-based design can yield highly specific peptide inhibitors of amyloid formation. Using known atomic structures of segments of amyloid fibrils as templates, we have designed and characterized an all-D-amino-acid inhibitor of the fibril formation of the tau protein associated with Alzheimer's disease, and a non-natural L-amino-acid inhibitor of an amyloid fibril that enhances sexual transmission of human immunodeficiency virus. Our results indicate that peptides from structure-based designs can disrupt the fibril formation of full-length proteins, including those, such as tau protein, that lack fully ordered native structures. Because the inhibiting peptides have been designed on structures of dual-&#x3b2;-sheet 'steric zippers', the successful inhibition of amyloid fibril formation strengthens the hypothesis that amyloid spines contain steric zippers.</AbstractText><CopyrightInformation>&#xa9;2011 Macmillan Publishers Limited. All rights reserved</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sievers</LastName><ForeName>Stuart A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry, Howard Hughes Medical Institute, UCLA, Box 951970, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karanicolas</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Howard W</ForeName><Initials>HW</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Anni</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zirafi</LastName><ForeName>Onofrio</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>OMIM</DataBankName><AccessionNumberList><AccessionNumber>3PPD</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029430</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>25104-18-1</RegistryNumber><NameOfSubstance UI="D011107">Polylysine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017076" MajorTopicYN="N">Computer-Aided Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006860" MajorTopicYN="N">Hydrogen Bonding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011107" MajorTopicYN="N">Polylysine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21677644</ArticleId><ArticleId IdType="mid">NIHMS591364</ArticleId><ArticleId IdType="pmc">PMC4073670</ArticleId><ArticleId IdType="doi">10.1038/nature10154</ArticleId><ArticleId IdType="pii">nature10154</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Westermark P, et al. A primer of amyloid nomenclature. Amyloid. 2007;14:179&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">17701465</ArticleId></ArticleIdList></Reference><Reference><Citation>Maji SK, et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science (New York, NY) 2009;325:328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865899</ArticleId><ArticleId IdType="pubmed">19541956</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler DM, Koulov AV, Balch WE, Kelly JW. Functional amyloid--from bacteria to humans. Trends Biochem Sci. 2007;32:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412596</ArticleId></ArticleIdList></Reference><Reference><Citation>Astbury WT, Dickinson S. The X-ray interpretation of denaturation and the structure of the seed globulins. The Biochemical Journal. 1935;29:2351&#x2013;2360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1266766</ArticleId><ArticleId IdType="pubmed">16745914</ArticleId></ArticleIdList></Reference><Reference><Citation>Calamai M, Chiti F, Dobson CM. Amyloid fibril formation can proceed from different conformations of a partially unfolded protein. Biophysical Journal. 2005;89:4201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1366985</ArticleId><ArticleId IdType="pubmed">16169975</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjernberg LO, et al. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996;271:8545&#x2013;8548.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621479</ArticleId></ArticleIdList></Reference><Reference><Citation>Findeis MA. Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem. 2002;2:417&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">11966464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciarretta KL, Gordon DJ, Meredith SC. Peptide-based inhibitors of amyloid assembly. Methods Enzymol. 2006;413:273&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046402</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer&#x2019;s amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996;226:672&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">8831674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ. N-Methylated Peptide Inhibitors of Amyloid Aggregation and Toxicity. Optimization of the Inhibitor Structure. Biochemistry. 2006;45:9906&#x2013;9918.</Citation><ArticleIdList><ArticleId IdType="pubmed">16893191</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, et al. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry. 2006;45:5503&#x2013;5516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593882</ArticleId><ArticleId IdType="pubmed">16634632</ArticleId></ArticleIdList></Reference><Reference><Citation>Larbig G, Pickhardt M, Lloyd DG, Schmidt B, Mandelkow E. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Curr Alzheimer Res. 2007;4:315&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesehan K, et al. Selection of D-amino-acid peptides that bind to Alzheimer&#x2019;s disease amyloid peptide abeta1&#x2013;42 by mirror image phage display. Chembiochem. 2003;4:748&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">12898626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R, et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature. 2005;435:773&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479801</ArticleId><ArticleId IdType="pubmed">15944695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltzius JJ, et al. Molecular mechanisms for protein-encoded inheritance. Nat Struct Mol Biol. 2009;16:973&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640378</ArticleId><ArticleId IdType="pubmed">19684598</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Goux WJ, et al. The formation of straight and twisted filaments from short tau peptides. J Biol Chem. 2004;279:26868&#x2013;26875.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100221</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 2000;97:5129&#x2013;5134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldschmidt L, Teng PK, Riek R, Eisenberg D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci U S A. 2010;107:3487&#x2013;3492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840437</ArticleId><ArticleId IdType="pubmed">20133726</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MJ, et al. The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci U S A. 2006;103:4074&#x2013;4078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449648</ArticleId><ArticleId IdType="pubmed">16537487</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nch J, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell. 2007;131:1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083097</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedhoff P, von Bergen M, Mandelkow EM, Davies P, Mandelkow E. A nucleated assembly mechanism of Alzheimer paired helical filaments. Proc Natl Acad Sci U S A. 1998;95:15712&#x2013;15717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28109</ArticleId><ArticleId IdType="pubmed">9861035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol. 1992;118:573&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289542</ArticleId><ArticleId IdType="pubmed">1639844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlman B, et al. Design of a novel globular protein fold with atomic-level accuracy. Science. 2003;302:1364&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pubmed">14631033</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Krause G, Reif B. Structure and orientation of peptide inhibitors bound to beta-amyloid fibrils. J Mol Biol. 2005;354:760&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271725</ArticleId></ArticleIdList></Reference><Reference><Citation>Roan NR, et al. The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol. 2009;83:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2612336</ArticleId><ArticleId IdType="pubmed">18945786</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrassi HM, Klabunde T, Sacchettini J, Kelly JW. Structure-Based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors. J Am Chem Soc. 2000;122:2178&#x2013;2192.</Citation></Reference><Reference><Citation>Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem. 1994;269:24290&#x2013;24297.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortemme T, et al. Computational redesign of protein-protein interaction specificity. Nat Struct Mol Biol. 2004;11:371&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034550</ArticleId></ArticleIdList></Reference><Reference><Citation>The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994;50:760&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence MC, Colman PM. Shape complementarity at protein/protein interfaces. J Mol Biol. 1993;234:946&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">8263940</ArticleId></ArticleIdList></Reference><Reference><Citation>Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 1990;185:60&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">2199796</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. Embo J. 1992;11:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Biernat J, Mandelkow E. Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro. Methods Mol Biol. 2005;299:35&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980594</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedhoff P, Schneider A, Mandelkow EM, Mandelkow E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry. 1998;37:10223&#x2013;10230.</Citation><ArticleIdList><ArticleId IdType="pubmed">9665729</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez M, Valpuesta JM, Medina M, Montejo de Garcini E, Avila J. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. J Neurochem. 1996;67:1183&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752125</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweers O, Mandelkow EM, Biernat J, Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci U S A. 1995;92:8463&#x2013;8467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41177</ArticleId><ArticleId IdType="pubmed">7667312</ArticleId></ArticleIdList></Reference><Reference><Citation>Team, R. D. C. R Foundation for Statistical Computing. 2008. R: A Language and Environment for Statistical Computing.</Citation></Reference><Reference><Citation>Rojas Quijano FA, Morrow D, Wise BM, Brancia FL, Goux WJ. Prediction of nucleating sequences from amyloidogenic propensities of tau-related peptides. Biochemistry. 2006;45:4638&#x2013;4652.</Citation><ArticleIdList><ArticleId IdType="pubmed">16584199</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris AM, Watzky MA, Agar JN, Finke RG. Fitting neurological protein aggregation kinetic data via a 2-step, minimal/&#x201c;Ockham&#x2019;s razor&#x201d; model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth. Biochemistry. 2008;47:2413&#x2013;2427.</Citation><ArticleIdList><ArticleId IdType="pubmed">18247636</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt K, Segond von Banchet G, Heppelmann B. Labelling of peptides with 1.4-nm gold particles to demonstrate their binding sites in the rat spinal cord. J Neurosci Methods. 1999;87:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">11230816</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, Wesson M, Yamashita M. Interpretation of Protein Folding and Binding with Atomic Solvation Parameters. Chemica Scripta. 1989;29A:217&#x2013;221.</Citation></Reference><Reference><Citation>McCoy AJ, et al. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53:240&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126&#x2013;2132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLano WL. DeLano Scientific; San Carlos, CA, USA: 2002.</Citation></Reference><Reference><Citation>Papkalla A, Munch J, Otto C, Kirchhoff F. Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism. J Virol. 2002;76:8455&#x2013;8459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155138</ArticleId><ArticleId IdType="pubmed">12134048</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998;72:2855&#x2013;2864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109730</ArticleId><ArticleId IdType="pubmed">9525605</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21685912</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.</ArticleTitle><Pagination><StartPage>699</StartPage><EndPage>705</EndPage><MedlinePgn>699-705</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.859</ELocationID><Abstract><AbstractText>Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most common of which is Alzheimer's disease. Environmental causes of tauopathies include repetitive head trauma associated with some sports. To identify common genetic variation contributing to risk for tauopathies, we carried out a genome-wide association study of 1,114 individuals with PSP (cases) and 3,247 controls (stage 1) followed by a second stage in which we genotyped 1,051 cases and 3,560 controls for the stage 1 SNPs that yielded P &#x2264; 10(-3). We found significant previously unidentified signals (P &lt; 5 &#xd7; 10(-8)) associated with PSP risk at STX6, EIF2AK3 and MOBP. We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression. The genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface, for the endoplasmic reticulum unfolded protein response and for a myelin structural component.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H&#xf6;glinger</LastName><ForeName>G&#xfc;nter U</ForeName><Initials>GU</Initials><AffiliationInfo><Affiliation>Department of Neurology, Philipps-Universit&#xe4;t, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melhem</LastName><ForeName>Nadine M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Sleiman</LastName><ForeName>Patrick M A</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Klei</LastName><ForeName>Lambertus</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>de Silva</LastName><ForeName>Rohan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Riley</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew K</ForeName><Initials>ZK</Initials></Author><Author ValidYN="Y"><LastName>Uitti</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Vandrovcova</LastName><ForeName>Jana</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hurtig</LastName><ForeName>Howard I</ForeName><Initials>HI</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Rachel G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Maetzler</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Goldwurm</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tolosa</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Pau</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><CollectiveName>PSP Genetics Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Mi Ryung</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Dillman</LastName><ForeName>Allissa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>van der Brug</LastName><ForeName>Marcel P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chang-En</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Golbe</LastName><ForeName>Lawrence I</ForeName><Initials>LI</Initials></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>Bernie</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH077930</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG 11762</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0502157</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701441</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01HG004608</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>1RC2NS070276</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS057567</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01HG004438</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG004438</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0501560</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R37 MH057881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS72187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH077930</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NS057567</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG004603</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG17216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH057881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900652</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0501560(76517)</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R37 AG011762</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GTB07001</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 NS070276</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH057881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01HG004603</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 HG004608</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0600676</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0700943</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002877" MajorTopicYN="N">Chromosomes, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="Y">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alonso</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonini</LastName><ForeName>Angelo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apfelbacher</LastName><ForeName>Manuela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avila</LastName><ForeName>Jesus</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beecher</LastName><ForeName>Sherry</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bogdanovic</LastName><ForeName>Nenad</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boon</LastName><ForeName>Agnita J W</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordelon</LastName><ForeName>Yvette</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budka</LastName><ForeName>Herbert</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canesi</LastName><ForeName>Margherita</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiu</LastName><ForeName>Wang Zheng</ForeName><Initials>WZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cilia</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colosimo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a de Yebenes</LastName><ForeName>Justo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donker Kaat</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durr</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fabbrini</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finch</LastName><ForeName>NiCole A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flook</LastName><ForeName>Robyn</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaig</LastName><ForeName>Carles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geller</LastName><ForeName>Evan T</ForeName><Initials>ET</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Deborah A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hazrati</LastName><ForeName>Lili-Naz</ForeName><Initials>LN</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xf6;llerhage</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juncos</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kretzschmar</LastName><ForeName>Hans A</ForeName><Initials>HA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyons</LastName><ForeName>Kelly E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mariani</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massey</LastName><ForeName>Luke A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLean</LastName><ForeName>Catriona A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meucci</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mollenhauer</LastName><ForeName>Brit</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xf6;ller</LastName><ForeName>Jens C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Huw R</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Sullivan</LastName><ForeName>Sean S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oertel</LastName><ForeName>Wolfgang H</ForeName><Initials>WH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ottaviani</LastName><ForeName>Donatella</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pezzoli</LastName><ForeName>Gianni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pickering-Brown</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabano</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajput</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reich</LastName><ForeName>Stephen G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Respondek</LastName><ForeName>Gesine</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roeber</LastName><ForeName>Sigrun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>Owen A</ForeName><Initials>OA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sacilotto</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seppi</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silveira-Moriyama</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Srulijes</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stamelou</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Standaert</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tesei</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tourtellotte</LastName><ForeName>Wallace W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trenkwalder</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wenning</LastName><ForeName>Gregor K</ForeName><Initials>GK</Initials></Investigator><Investigator ValidYN="Y"><LastName>White</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winter</LastName><ForeName>Pia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zarow</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zecchinelli</LastName><ForeName>Anna L</ForeName><Initials>AL</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21685912</ArticleId><ArticleId IdType="mid">NIHMS297077</ArticleId><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="doi">10.1038/ng.859</ArticleId><ArticleId IdType="pii">ng.859</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hoppitt T, et al. A Systematic Review of the Incidence and Prevalence of Long-Term Neurological Conditions in the UK. Neuroepidemiology. 2011;36:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997442</ArticleId><ArticleId IdType="pubmed">21088431</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I. Update on progressive supranuclear palsy. Curr Neurol Neurosci Rep. 2004;4:296&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Rademakers R, Hutton ML. Progressive supranuclear palsy: Pathology and genetics. Brain Pathology. 2007;17:74&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095545</ArticleId><ArticleId IdType="pubmed">17493041</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamelou M, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010;133:1578&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472654</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, et al. TDP-43 Proteinopathy and Motor Neuron Disease in Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol. 2010;69:918&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951281</ArticleId><ArticleId IdType="pubmed">20720505</ArticleId></ArticleIdList></Reference><Reference><Citation>Golbe LI, et al. Follow-up study of risk factors in progressive supranuclear palsy. Neurology. 1996;47:148&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710069</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H, et al. A common inversion under selection in Europeans. Nat. Genet. 2005;37:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">15654335</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 1999;8:711&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072441</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. 5'-Upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiol Dis. 2009;33:164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">19022385</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56:1702&#x2013;1706.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundar PD, et al. Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Hum. Molec. Genet. 2007;16:295&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17185385</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Sanchez J, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41:1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787725</ArticleId><ArticleId IdType="pubmed">19915575</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanock SJ, et al. Replicating genotype-phenotype associations. Nature. 2007;447:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">17554299</ArticleId></ArticleIdList></Reference><Reference><Citation>Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 2006;38:209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415888</ArticleId></ArticleIdList></Reference><Reference><Citation>Zody MC, et al. Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet. 2008;40:1076&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684794</ArticleId><ArticleId IdType="pubmed">19165922</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian C, et al. Analysis and application of European genetic substructure using 300 K SNP information. PLoS Genet. 2008;4:e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211544</ArticleId><ArticleId IdType="pubmed">18208329</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology. 1996;47:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710059</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki Y, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Movement Disorders. 2004;19:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14978673</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy DL, et al. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol. 2010;130:520&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672059</ArticleId><ArticleId IdType="pubmed">19710684</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum. Mol. Genet. 2005;14:3281&#x2013;3292.</Citation><ArticleIdList><ArticleId IdType="pubmed">16195395</ArticleId></ArticleIdList></Reference><Reference><Citation>Caffrey TM, Joachim C, Paracchini S, Esiri MM, WadeMartins R. Haplotype-specific expression of exon 10 at the human MAPT locus. Human Molecular Genetics. 2006;15:3529&#x2013;3537.</Citation><ArticleIdList><ArticleId IdType="pubmed">17085483</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol. Dis. 2007;25:561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">17174556</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41 1088-U61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696507</ArticleId><ArticleId IdType="pubmed">21292315</ArticleId></ArticleIdList></Reference><Reference><Citation>Unterberger U, et al. Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo. Journal of Neuropathology and Experimental Neurology. 2006;65:348&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16691116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans JJM, et al. The Unfolded Protein Response Is Activated in Pretangle Neurons in Alzheimer's Disease Hippocampus. Amer J Pathol. 2009;174:1241&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671357</ArticleId><ArticleId IdType="pubmed">19264902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans JJ, et al. Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun. 2007;354:707&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17254549</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn R, Scheller RH. SNAREs--engines for membrane fusion. Nat Rev Mol Cell Biol. 2006;7:631&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">16912714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendler F, Tooze S. Syntaxin 6: the promiscuous behaviour of a SNARE protein. Traffic. 2001;2:606&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">11555414</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague P, McCallion AS, Davies RW, Griffiths IR. Myelin-associated oligodendrocytic basic protein: a family of abundant CNS myelin proteins in search of a function. Dev Neurosci. 2006;28:479&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">17028425</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheper W, Hoozemans JJM. Endoplasmic Reticulum Protein Quality Control in Neurodegenerative Disease: The Good, the Bad and the Therapy. Curr Medicinal Chem. 2009;16:615&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">19199926</ArticleId></ArticleIdList></Reference><Reference><Citation>Paschen W, Mengesdorf T. Cellular abnormalities linked to endoplasmic reticulum dysfunction in cerebrovascular disease - therapeutic potential. Pharmacology &amp; Therapeutics. 2005;108:362&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16140387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Devlin B, Ringquist S, Trucco M, Roeder K. Screen and clean: a tool for identifying interactions in genome-wide association studies. Genet Epidemiol. 2010;34:275&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2915560</ArticleId><ArticleId IdType="pubmed">20088021</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauw JJ, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy) Neurology. 1994;44:2015&#x2013;2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969952</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. Journal of Neuropathology and Experimental Neurology. 2002;61:935&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">12430710</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AB, Luca D, Klei L, Devlin B, Roeder K. Discovering genetic ancestry using spectral graph theory. Genet Epidemiol. 2010;34:51&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4610359</ArticleId><ArticleId IdType="pubmed">19455578</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossett A, et al. Using ancestry matching to combine family-based and unrelated samples for genome-wide association studies. Stat Med. 2010;29:2932&#x2013;2945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4629477</ArticleId><ArticleId IdType="pubmed">20862653</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian C, Plenge RM, Ransom M, Lee A, Villoslada P. Analysis and application of European genetic substructure using 300K SNP information. PLoS Genet. 2008;4:e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211544</ArticleId><ArticleId IdType="pubmed">18208329</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 2006;38:904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca D, et al. On the use of general control samples for genome-wide association studies: genetic matching highlights causal variants. Am. J. Hum. Genet. 2008 (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427172</ArticleId><ArticleId IdType="pubmed">18252225</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs JR, et al. Abundant quantitative trait Loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010;6:e1000952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869317</ArticleId><ArticleId IdType="pubmed">20485568</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: A tool set for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21700581</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>02</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Early detection of Alzheimer disease: &#xb9;&#xb9;C-PiB PET in twins discordant for cognitive impairment.</ArticleTitle><Pagination><StartPage>453</StartPage><EndPage>460</EndPage><MedlinePgn>453-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e318225118e</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to investigate whether cognitively preserved monozygotic or dizygotic cotwins of persons with Alzheimer disease (AD) exhibit increased brain amyloid accumulation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a cross-sectional carbon-11 labeled 2-(4'-methylaminophenyl)-6-hydroxybenzothiazole ((11)C)-Pittsburgh compound B (PiB) PET study on 9 monozygotic and 8 dizygotic twin pairs discordant for cognitive impairment as well as on 9 healthy elderly control subjects. (11)C-PiB uptake was analyzed with Statistical Parametric Mapping and with region of interest analysis with the region-to-cerebellum ratio as a measure of tracer uptake.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cognitively preserved monozygotic cotwins of cognitively impaired probands had increased cortical (11)C-PiB uptake (117%-121% of control mean) in their temporal and parietal cortices and the posterior cingulate. Cognitively preserved dizygotic subjects did not differ from the controls. Further, the cognitively preserved monozygotic subjects showed similar (11)C-PiB uptake patterns as their cognitively impaired cotwins. The cognitively impaired subjects (monozygotic and dizygotic individuals combined) showed typical Alzheimer-like patterns of (11)C-PiB uptake.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Genetic factors appear to influence the development of Alzheimer-like &#x3b2;-amyloid plaque pathology. The dissociation between cognitive impairment and brain &#x3b2;-amyloidosis in monozygotic twins implies that there may be important environmental/acquired factors that modulate the relationship between brain amyloidosis and neurodegeneration. AD may be detectable in high-risk individuals in its presymptomatic stage with (11)C-PiB PET, but clinical follow-up will be needed to confirm this.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scheinin</LastName><ForeName>N M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Turku PET Centre, University of Turku, Turku, Finland. noora.scheinin@utu.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aalto</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kaprio</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Koskenvuo</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>R&#xe4;ih&#xe4;</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Rokka</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hinkka-Yli-Salom&#xe4;ki</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>J O</ForeName><Initials>JO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="Y">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="Y">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004200" MajorTopicYN="N">Diseases in Twins</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21700581</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318225118e</ArticleId><ArticleId IdType="pii">WNL.0b013e318225118e</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21705906</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-5487</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Epidemiology (Cambridge, Mass.)</Title><ISOAbbreviation>Epidemiology</ISOAbbreviation></Journal><ArticleTitle>The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>646</StartPage><EndPage>659</EndPage><MedlinePgn>646-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/EDE.0b013e31822708b5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Many epidemiologic studies have considered the association between blood pressure (BP) and Alzheimer disease, yet the relationship remains poorly understood.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In parallel with work on the AlzRisk online database (www.alzrisk.org), we conducted a systematic review to identify all epidemiologic studies meeting prespecified criteria reporting on the association between hypertension, systolic BP, or diastolic BP and incident Alzheimer disease. When possible, we computed summary measures using random-effects models and explored potential heterogeneity related to age at BP assessment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighteen studies reporting on 19 populations met the eligibility criteria. We computed summary relative risks (RR(&#x3a3;)) for 3 measures of BP: hypertension (RR(&#x3a3;) = 0.97 [95% confidence interval = 0.80-1.16]); a 10-mm Hg increase in systolic BP (RR(&#x3a3;) = 0.95 [0.91-1.00]); and a 10-mm Hg increase in diastolic BP (RR(&#x3a3;) = 0.94 [0.85-1.04]). We were unable to compute summary estimates for the association between categories of systolic or diastolic BP and Alzheimer disease; however, there did not appear to be a consistent pattern across studies. After stratifying on age at BP assessment, we found a suggestion of an inverse association between late-life hypertension and Alzheimer disease and a suggestion of an adverse association between midlife diastolic hypertension and Alzheimer disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Based on existing epidemiologic research, we cannot determine whether there is a causal association between BP and Alzheimer disease. Selection bias and reverse causation may account for the suggested inverse association between late-life hypertension on Alzheimer disease, but, given the expected direction of these biases, they are less likely to account for the suggestion that midlife hypertension increases risk. We advocate continuing systematic review; the AlzRisk database entry on this topic (www.alzrisk.org), which was completed in parallel with this work, will be updated as new studies are published.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Power</LastName><ForeName>Melinda C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard School of Public Health, Boston, MA 02215, USA. mcpower@hsph.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weuve</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gagne</LastName><ForeName>Joshua J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>McQueen</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Viswanathan</LastName><ForeName>Anand</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 AG038233</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD060726</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 ES007069</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epidemiology</MedlineTA><NlmUniqueID>9009644</NlmUniqueID><ISSNLinking>1044-3983</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Epidemiology. 2012 Jan;23(1):176-7; author reply 177-8. doi: 10.1097/EDE.0b013e31823b679c.</RefSource><PMID Version="1">22157315</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21705906</ArticleId><ArticleId IdType="mid">NIHMS457951</ArticleId><ArticleId IdType="pmc">PMC3640480</ArticleId><ArticleId IdType="doi">10.1097/EDE.0b013e31822708b5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stampfer MJ. Cardiovascular disease and Alzheimer&#x2019;s disease: common links. J Intern Med. 2006;260(3):211&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">16918818</ArticleId></ArticleIdList></Reference><Reference><Citation>Breteler MM. Vascular risk factors for Alzheimer&#x2019;s disease: an epidemiologic perspective. Neurobiol Aging. 2000;21(2):153&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc. 2002;50(8):1431&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165002</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Cerebral white matter lesions and the risk of dementia. Arch Neurol. 2004;61(10):1531&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477506</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MM. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain. 2005;128(Pt 9):2034&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15947059</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Ruiz C, Wang J, Ksiezak-Reding H, Ho L, Qian X, Humala N, Thomas S, Martinez-Martin P, Pasinetti GM. Role of Hypertension in Aggravating Abeta Neuropathology of AD Type and Tau-Mediated Motor Impairment. Cardiovasc Psychiatry Neurol. 2009;2009:107286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775676</ArticleId><ArticleId IdType="pubmed">19936102</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer&#x2019;s disease. Lancet. 1999;354(9182):919&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10489957</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62(7):1148&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15079015</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">8609748</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, von Strauss E, Winblad B, Fratiglioni L. Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen project. Stroke. 2004;35(8):1810&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15232128</ArticleId></ArticleIdList></Reference><Reference><Citation>Purnell C, Gao S, Callahan CM, Hendrie HC. Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord. 2009;23(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3689425</ArticleId><ArticleId IdType="pubmed">18703981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res Rev. 2009;8(2):61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">19063999</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. Am J Epidemiol. 1992;135(9):1019&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">1595688</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033691</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G, Shea B, O&#x2019;Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Health Research Institute; 2009.</Citation></Reference><Reference><Citation>Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">13655060</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794848</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo-Pareja F, Benito-Leon J, Louis ED, Trincado R, Carro E, Villarejo A, de la Camara AG. Risk of Incident Dementia in Drug-Untreated Arterial Hypertension: A Population-Based Study. Journal of Alzheimers Disease. 22(3):949&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">20858957</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CJ, Yip PK, Wu SC, Lu CS, Liou CW, Liu HC, Liu CK, Chu CH, Hwang CS, Sung SF, Hsu YD, Chen CC, Liu SI, Yan SH, Fong CS, Chang SF, You SL, Chen CJ. Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan. Am J Geriatr Psychiatry. 2007;15(9):762&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">17623813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, Tschanz JT, Norton MC, Pieper CF, Munger RG, Breitner JC, Welsh-Bohmer KA. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord. 2006;20(2):93&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160362</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Rhew IC, Shofer JB, Kukull WA, Breitner JC, Peskind E, Bowen JD, McCormick W, Teri L, Crane PK, Larson EB. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J Am Geriatr Soc. 2007;55(8):1161&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17661953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I. Risk factors for Alzheimer&#x2019;s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156(5):445&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196314</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol. 2001;58(10):1640&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11594923</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord. 2007;24(3):185&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268640</ArticleId><ArticleId IdType="pubmed">17641531</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunniyi A, Hall KS, Gureje O, Baiyewu O, Gao S, Unverzagt FW, Smith-Gamble V, Evans RE, Dickens J, Musick BS, Hendrie HC. Risk factors for incident Alzheimer&#x2019;s disease in African Americans and Yoruba. Metab Brain Dis. 2006;21(2&#x2013;3):235&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199593</ArticleId><ArticleId IdType="pubmed">16850256</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, Portet F, Dartigues JF, Alperovitch A, Barberger-Gateau P. Metabolic syndrome and risk for incident Alzheimer&#x2019;s disease or vascular dementia: the Three-City Study. Diabetes Care. 2009;32(1):169&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2606808</ArticleId><ArticleId IdType="pubmed">18945929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruitenberg A, Skoog I, Ott A, Aevarsson O, Witteman JC, Lernfelt B, van Harskamp F, Hofman A, Breteler MM. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord. 2001;12(1):33&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11125239</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah RC, Wilson RS, Bienias JL, Arvanitakis Z, Evans DA, Bennett DA. Relation of blood pressure to risk of incident Alzheimer&#x2019;s disease and change in global cognitive function in older persons. Neuroepidemiology. 2006;26(1):30&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254451</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyas SL, Manfreda J, Strain LA, Montgomery PR. Risk factors for Alzheimer&#x2019;s disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol. 2001;30(3):590&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11416089</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology. 2003;61(12):1667&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">14694027</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med. 2006;166(9):1003&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682574</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu QM, Qiao J, Han JF, Yang JB, Guo F, Luo GG, Yang H, Cao HM, Ju XC, Wu CB. The incidence of dementia among elderly people in Xi&#x2019; an, China. Zhonghua Liu Xing Bing Xue Za Zhi. 2005;26(7):529&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">16335007</ArticleId></ArticleIdList></Reference><Reference><Citation>Forti P, Pisacane N, Rietti E, Lucicesare A, Olivelli V, Mariani E, Mecocci P, Ravaglia G. Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc. 58(3):487&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">20398117</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125(Pt 4):765&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912110</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan A, Chabriat H. Cerebral microhemorrhage. Stroke. 2006;37(2):550&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16397165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazui S, Levi CR, Jones EF, Quang L, Calafiore P, Donnan GA. Risk factors for lacunar stroke: a case-control transesophageal echocardiographic study. Neurology. 2000;54(6):1385&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746618</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH, Scheltens P, Jonker C, Launer LJ. Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology. 1998;51(1):319&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674838</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth WT, Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol. 1998;55(9):1217&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740116</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhakaran S, Wright CB, Yoshita M, Delapaz R, Brown T, DeCarli C, Sacco RL. Prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study. Neurology. 2008;70(6):425&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714050</ArticleId><ArticleId IdType="pubmed">17898325</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2002;33(1):21&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11779883</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Niessen WJ, Hofman A, Krestin GP, Breteler MM. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology. 2008;70(14):1208&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">18378884</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging. 2000;21(1):57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009;72(20):1720&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683736</ArticleId><ArticleId IdType="pubmed">19228583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC., 3rd Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci. 1995;131(2):162&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7595642</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. 2003;34(2):335&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12574528</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Yang SH, Stubley L, Day AL, Simpkins JW. Hypoperfusion induces overexpression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model. Brain Res. 2000;853(1):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10627301</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Mao XO, Eshoo MW, Nagayama T, Minami M, Simon RP, Greenberg DA. Microarray analysis of hippocampal gene expression in global cerebral ischemia. Ann Neurol. 2001;50(1):93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11456315</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihashi T, Inao S, Kajita Y, Kawai T, Sugimoto T, Niwa M, Kabeya R, Hata N, Hayashi S, Yoshida J. Expression and distribution of beta amyloid precursor protein and beta amyloid peptide in reactive astrocytes after transient middle cerebral artery occlusion. Acta Neurochir (Wien) 2001;143(3):287&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11460917</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E, Ihara Y, Kawashima S. Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus. J Biol Chem. 1994;269(21):15253&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8195161</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Yow HY, Preston SD, Mazanti I, Nicoll JA. Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2002;977:162&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480747</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol. 2002;283(1):H315&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12063304</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A. 2000;97(17):9735&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16934</ArticleId><ArticleId IdType="pubmed">10944232</ArticleId></ArticleIdList></Reference><Reference><Citation>den Heijer T, Launer LJ, Prins ND, van Dijk EJ, Vermeer SE, Hofman A, Koudstaal PJ, Breteler MM. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology. 2005;64(2):263&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668423</ArticleId></ArticleIdList></Reference><Reference><Citation>Firbank MJ, Wiseman RM, Burton EJ, Saxby BK, O&#x2019;Brien JT, Ford GA. Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure. J Neurol. 2007;254(6):713&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17446997</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Andreasson LA, Landahl S, Lernfelt B. A population-based study on blood pressure and brain atrophy in 85-year-olds. Hypertension. 1998;32(3):404&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouvent E, Viswanathan A, Chabriat H. Cerebral atrophy in cerebrovascular disorders. J Neuroimaging. 2010;20(3):213&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19344366</ArticleId></ArticleIdList></Reference><Reference><Citation>Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension. 2004;44(1):29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15159381</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan A, Gray F, Bousser MG, Baudrimont M, Chabriat H. Cortical neuronal apoptosis in CADASIL. Stroke. 2006;37(11):2690&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SR, Hernan MA. Fallibility in estimating direct effects. Int J Epidemiol. 2002;31(1):163&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914314</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology. 1992;3(2):143&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">1576220</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology. 2003;14(3):300&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15308962</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernan MA, Alonso A, Logroscino G. Cigarette smoking and dementia: potential selection bias in the elderly. Epidemiology. 2008;19(3):448&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18414087</ArticleId></ArticleIdList></Reference><Reference><Citation>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12748199</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura K, Daviglus ML, Dyer AR, Liu K, Garside DB, Stamler J, Greenland P. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med. 2001;161(12):1501&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11427097</ArticleId></ArticleIdList></Reference><Reference><Citation>Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, O&#x2019;Leary DH, Bryan RN, Anderson M, Lumley T. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med. 2001;161(9):1183&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11343441</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493255</ArticleId></ArticleIdList></Reference><Reference><Citation>Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12759325</ArticleId></ArticleIdList></Reference><Reference><Citation>Euser SM, Schram MT, Hofman A, Westendorp RG, Breteler MM. Measuring cognitive function with age: the influence of selection by health and survival. Epidemiology. 2008;19(3):440&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18414086</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassuk SS, Wypij D, Berkman LF. Cognitive impairment and mortality in the community-dwelling elderly. Am J Epidemiol. 2000;151(7):676&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">10752795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST. Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol. 2005;62(5):779&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883266</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. J Clin Epidemiol. 2005;58(1):13&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649666</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews FE, Chatfield M, Freeman C, McCracken C, Brayne C. Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation. BMC Public Health. 2004;4:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419705</ArticleId><ArticleId IdType="pubmed">15113437</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16(5):343&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">18448847</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabriat H, Pappata S, Ostergaard L, Clark CA, Pachot-Clouard M, Vahedi K, Jobert A, Le Bihan D, Bousser MG. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke. 2000;31(8):1904&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10926955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao LL, Buckley ST, Kornak J, Schuff N, Madison C, Yaffe K, Miller BL, Kramer JH, Weiner MW. ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis Assoc Disord. 2010;24(1):19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865220</ArticleId><ArticleId IdType="pubmed">20220321</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayed N, Davila J, Oliveros A, Jr, Medrano J, Castillo J. Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment. Neurol Res. 2010;32(2):157&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">20158954</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson AL, Himali JJ, Beiser AS, Au R, Massaro JM, Seshadri S, Gona P, Salton CJ, DeCarli C, O&#x2019;Donnell CJ, Benjamin EJ, Wolf PA, Manning WJ. Cardiac index is associated with brain aging: the Framingham Heart Study. Circulation. 2010;122(7):690&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929763</ArticleId><ArticleId IdType="pubmed">20679552</ArticleId></ArticleIdList></Reference><Reference><Citation>Luckhaus C, Cohnen M, Fluss MO, Janner M, Grass-Kapanke B, Teipel SJ, Grothe M, Hampel H, Peters O, Kornhuber J, Maier W, Supprian T, Gaebel W, Modder U, Wittsack HJ. The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer&#x2019;s dementia. Psychiatry Res. 2010;183(1):44&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20541374</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappata S, Varrone A, Vicidomini C, Milan G, De Falco C, Sansone V, Iavarone A, Comerci M, Lore E, Panico MR, Quarantelli M, Postiglione A, Salvatore M. SPECT imaging of GABA(A)/benzodiazepine receptors and cerebral perfusion in mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2010;37(6):1156&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">20306034</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington M, Weuve J, Blacker D. The AlzRisk Database Alzheimer Research Forum. Physical Activity.</Citation></Reference><Reference><Citation>Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer&#x2019;s disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19358976</ArticleId></ArticleIdList></Reference><Reference><Citation>Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag. 2008;4(2):363&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2496986</ArticleId><ArticleId IdType="pubmed">18561512</ArticleId></ArticleIdList></Reference><Reference><Citation>Weuve J, McQueen M, Blacker D. The AlzRisk Database Alzheimer Research Forum. Diabetes.</Citation></Reference><Reference><Citation>Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcomittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure. Hypertension. 2005;45:142&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">15611362</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering TG. Blood pressure variability and ambulatory monitoring. Curr Opin Nephrol Hypertens. 1993;2(3):380&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7922198</ArticleId></ArticleIdList></Reference><Reference><Citation>James GD, Pickering TG, Yee LS, Harshfield GA, Riva S, Laragh JH. The reproducibility of average ambulatory, home, and clinic pressures. Hypertension. 1988;11:545&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">3384470</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders : DSM-IV. 1998;xxvii:886.</Citation></Reference><Reference><Citation>Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN) Stroke. 1996;27(1):30&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8553399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L. Cerebral blood flow in dementia. Arch Neurol. 1975;32(9):632&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1164215</ArticleId></ArticleIdList></Reference><Reference><Citation>Barone FC, Rosenbaum DM, Zhou J, Crystal H. Vascular cognitive impairment: dementia biology and translational animal models. Curr Opin Investig Drugs. 2009;10(7):624&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">19579168</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988&#x2013;2000. JAMA. 2003;290(2):199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12851274</ArticleId></ArticleIdList></Reference><Reference><Citation>Antikainen RL, Moltchanov VA, Chukwuma C, Sr, Kuulasmaa KA, Marques-Vidal PM, Sans S, Wilhelmsen L, Tuomilehto JO. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil. 2006;13(1):13&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">16449860</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26(1):60&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7607734</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology. 2009;72(4):368&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677504</ArticleId><ArticleId IdType="pubmed">19171835</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21709248</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>28</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice.</ArticleTitle><Pagination><StartPage>11686</StartPage><EndPage>11691</EndPage><MedlinePgn>11686-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1103098108</ELocationID><Abstract><AbstractText>Both normal aging and dementia are associated with dysregulation of the biological clock, which contributes to disrupted circadian organization of physiology and behavior. Diminished circadian organization in conjunction with the loss of cholinergic input to the cortex likely contributes to impaired cognition and behavior. One especially notable and relatively common circadian disturbance among the aged is "sundowning syndrome," which is characterized by exacerbated anxiety, agitation, locomotor activity, and delirium during the hours before bedtime. Sundowning has been reported in both dementia patients and cognitively intact elderly individuals living in institutions; however, little is known about temporal patterns in anxiety and agitation, and the neurobiological basis of these rhythms remains unspecified. In the present study, we explored the diurnal pattern of anxiety-like behavior in aged and amyloid precursor protein (APP) transgenic mice. We then attempted to treat the observed behavioral disturbances in the aged mice using chronic nightly melatonin treatment. Finally, we tested the hypothesis that time-of-day differences in acetylcholinesterase and choline acetyltransferase expression and general neuronal activation (i.e., c-Fos expression) coincide with the behavioral symptoms. Our results show a temporal pattern of anxiety-like behavior that emerges in elderly mice. This behavioral pattern coincides with elevated locomotor activity relative to adult mice near the end of the dark phase, and with time-dependent changes in basal forebrain acetylcholinesterase expression. Transgenic APP mice show a similar behavioral phenomenon that is not observed among age-matched wild-type mice. These results may have useful applications to the study and treatment of age- and dementia-related circadian behavioral disturbances, namely, sundowning syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bedrosian</LastName><ForeName>Tracy A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Institute for Behavioral Medicine Research, Ohio State University Medical Center, Columbus, OH 43210, USA. tracy.bedrosian@osumc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herring</LastName><ForeName>Kamillya L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Weil</LastName><ForeName>Zachary M</ForeName><Initials>ZM</Initials></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Randy J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016760">Proto-Oncogene Proteins c-fos</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>W980KJ009P</RegistryNumber><NameOfSubstance UI="D003345">Corticosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020532" MajorTopicYN="N">Basal Nucleus of Meynert</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021081" MajorTopicYN="N">Chronobiology Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003345" MajorTopicYN="N">Corticosterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="N">Melatonin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016760" MajorTopicYN="N">Proto-Oncogene Proteins c-fos</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21709248</ArticleId><ArticleId IdType="pmc">PMC3136261</ArticleId><ArticleId IdType="doi">10.1073/pnas.1103098108</ArticleId><ArticleId IdType="pii">1103098108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 2007;8:623&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">17383938</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Someren EJ. Van Someren EJ Circadian and sleep disturbances in the elderly. Exp Gerontol. 2000;35:1229&#x2013;1237.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113604</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley DJ, et al. Sleep complaints among elderly persons: An epidemiologic study of three communities. Sleep. 1995;18:425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">7481413</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan MJ. Aging of the mammalian circadian timing system: Changes in the central pacemaker and its regulation by photic and nonphotic signals. Neuroembryology and Aging. 2007;4(1-2):85&#x2013;101.</Citation></Reference><Reference><Citation>Klaffke S, Staedt J. Sundowning and circadian rhythm disorders in dementia. Acta Neurol Belg. 2006;106(4):168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">17323834</ArticleId></ArticleIdList></Reference><Reference><Citation>Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm. 2006;113:1625&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pubmed">17039298</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollak CP, Perlick D. Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol. 1991;4:204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789908</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollak CP, Perlick D, Linsner JP, Wenston J, Hsieh F. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health. 1990;15(2):123&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">2355110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Eastwood C, Gahir M, Wilcock G. A follow up study of depression in the carers of dementia sufferers. BMJ. 1996;312:947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2350802</ArticleId><ArticleId IdType="pubmed">8616308</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachman D, Rabins P. &#x201c;Sundowning&#x201d; and other temporally associated agitation states in dementia patients. Annu Rev Med. 2006;57:499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">16409163</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans LK. Sundown syndrome in institutionalized elderly. J Am Geriatr Soc. 1987;35(2):101&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">3805551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim P, Louis C, Muralee S, Tampi R. Sundowning syndrome in the older patient. Clinical Geriatrics. 2005;13(4):32&#x2013;36.</Citation></Reference><Reference><Citation>Gallagher-Thompson D, Brooks JO, 3rd, Bliwise D, Leader J, Yesavage JA. The relations among caregiver stress, &#x201c;sundowning&#x201d; symptoms, and cognitive decline in Alzheimer's disease. J Am Geriatr Soc. 1992;40:807&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">1634724</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterniczuk R, Dyck RH, Laferla FM, Antle MC. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: Part 1. Circadian changes. Brain Res. 2010;1348:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">20471965</ArticleId></ArticleIdList></Reference><Reference><Citation>Vloeberghs E, et al. Altered circadian locomotor activity in APP23 mice: A model for BPSD disturbances. Eur J Neurosci. 2004;20:2757&#x2013;2766.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548219</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia&#x2014;A preliminary study. Arch Gerontol Geriatr. 2000;31(1):65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">10989165</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274(5284):99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron D. Studies in senile nocturnal delirium. Psychiatr Q. 1941;15(1):47&#x2013;53.</Citation></Reference><Reference><Citation>Exum ME, Phelps BJ, Nabers KE, Osborne JG. Sundown syndrome: Is it reflected in the use of PRN medications for nursing home residents? Gerontologist. 1993;33:756&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">8314102</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Temporal patterns of agitation in dementia. Am J Geriatr Psychiatry. 2007;15:395&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463190</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgio LD, Scilley K, Hardin JM, Hsu C. Temporal patterns of disruptive vocalization in elderly nursing home residents. Int J Geriatr Psychiatry. 2001;16:378&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11333425</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahlberg R, Kunz D, Sutej I, K&#xfc;hl KP, Hellweg R. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: An open-label pilot study using actigraphy. J Clin Psychopharmacol. 2004;24:456&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">15232344</ArticleId></ArticleIdList></Reference><Reference><Citation>Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A. Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry. 2001;158:704&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancoli-Israel S, et al. Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep. 1997;20(1):18&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130329</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper DG, et al. Disturbance of endogenous circadian rhythm in aging and Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:359&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">15879584</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentinuzzi VS, Scarbrough K, Takahashi JS, Turek FW. Effects of aging on the circadian rhythm of wheel-running activity in C57BL/6 mice. Am J Physiol. 1997;273:R1957&#x2013;R1964.</Citation><ArticleIdList><ArticleId IdType="pubmed">9435649</ArticleId></ArticleIdList></Reference><Reference><Citation>Satlin A, Volicer L, Stopa EG, Harper D. Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease. Neurobiol Aging. 1995;16:765&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532109</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliwise DL, Carroll JS, Lee KA, Nekich JC, Dement WC. Sleep and &#x201c;sundowning&#x201d; in nursing home patients with dementia. Psychiatry Res. 1993;48:277&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">8272449</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, et al. Does sundowning occur in residents of an Alzheimer's unit? Int J Geriatr Psychiatry. 1989;4:293&#x2013;298.</Citation></Reference><Reference><Citation>Harper DG, et al. Dementia severity and Lewy bodies affect circadian rhythms in Alzheimer disease. Neurobiol Aging. 2004;25:771&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">15165702</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene DJ, Swaab DF. Melatonin rhythmicity: Effect of age and Alzheimer's disease. Exp Gerontol. 2003;38:199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res. 2005;38(3):145&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">15725334</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusco LI, M&#xe1;rquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett. 2000;21(1):39&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11455329</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry. 2010;25:1201&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">21086534</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol Aging. 2007;28:1239&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">16837102</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers RJ, Cole JC. Effects of scopolamine and its quaternary analogue in the murine elevated plus-maze test of anxiety. Behav Pharmacol. 1995;6:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224337</ArticleId></ArticleIdList></Reference><Reference><Citation>Smythe JW, Murphy D, Bhatnagar S, Timothy C, Costall B. Muscarinic antagonists are anxiogenic in rats tested in the black-white box. Pharmacol Biochem Behav. 1996;54(1):57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8728539</ArticleId></ArticleIdList></Reference><Reference><Citation>Brioni JD, O'Neill AB, Kim DJ, Decker MW. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol. 1993;238(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8405072</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine EE, Cheeta S, File SE. Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behav Pharmacol. 1999;10:691&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">10780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Szyndler J, et al. The anxiolytic-like effect of nicotine undergoes rapid tolerance in a model of contextual fear conditioning in rats. Pharmacol Biochem Behav. 2001;69:511&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">11509211</ArticleId></ArticleIdList></Reference><Reference><Citation>Sienkiewicz-Jarosz H, et al. The effects of physostigmine and cholinergic receptor ligands on novelty-induced neophobia. J Neural Transm. 2000;107:1403&#x2013;1412.</Citation><ArticleIdList><ArticleId IdType="pubmed">11458993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenk GL. The nucleus basalis magnocellularis cholinergic system: One hundred years of progress. Neurobiol Learn Mem. 1997;67(2):85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075237</ArticleId></ArticleIdList></Reference><Reference><Citation>Losier BJ, Semba K. Dual projections of single cholinergic and aminergic brainstem neurons to the thalamus and basal forebrain in the rat. Brain Res. 1993;604(1-2):41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7681346</ArticleId></ArticleIdList></Reference><Reference><Citation>Greve M, O'Connor D. A survey of Australian and New Zealand old age psychiatrists&#x2019; preferred medications to treat behavioral and psychological symptoms of dementia (BPSD) Int Psychogeriatr. 2005;17(2):195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">16050430</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan MJ, Grear KE, Hoskins MA. Aging and SB-269970-A, a selective 5-HT7 receptor antagonist, attenuate circadian phase advances induced by microinjections of serotonergic drugs in the hamster dorsal raphe nucleus. Brain Res. 2004;1008(1):40&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">15081380</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan MJ, Hensler JG. Aging alters in a region-specific manner serotonin transporter sites and 5-HT(1A) receptor-G protein interactions in hamster brain. Neuropharmacology. 2002;43(1):36&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12213257</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan MJ, Short J, Wheeler DL. Comparison of the effects of aging on 5-HT7 and 5-HT1A receptors in discrete regions of the circadian timing system in hamsters. Brain Res. 1999;829(1-2):39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">10350528</ArticleId></ArticleIdList></Reference><Reference><Citation>Skjerve A, Nygaard HA. Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil. Int J Geriatr Psychiatry. 2000;15:1147&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">11180473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring S, et al. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci. 2007;27:7817&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672885</ArticleId><ArticleId IdType="pubmed">17634375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustay NR, et al. Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease. Brain Res. 2010;1311:136&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">19944081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiebert SM, Green SA, Yellon SM. Daily timed melatonin feedings mimic effects of short days on testis regression and cortisol in circulation in Siberian hamsters. Gen Comp Endocrinol. 2006;146:211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">16386252</ArticleId></ArticleIdList></Reference><Reference><Citation>Broussard JI, Karelina K, Sarter M, Givens B. Cholinergic optimization of cue-evoked parietal activity during challenged attentional performance. Eur J Neurosci. 2009;29:1711&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030246</ArticleId><ArticleId IdType="pubmed">19419433</ArticleId></ArticleIdList></Reference><Reference><Citation>Trainor BC, Finy MS, Nelson RJ. Paternal aggression in a biparental mouse: Parallels with maternal aggression. Horm Behav. 2008;53:200&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2218985</ArticleId><ArticleId IdType="pubmed">17991466</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21712440</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>29</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>11848</StartPage><EndPage>11853</EndPage><MedlinePgn>11848-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1102664108</ELocationID><Abstract><AbstractText>The proteolytic processing of human amyloid precursor protein (APP) into shorter aggregating amyloid &#x3b2; (A&#x3b2;)-peptides, e.g., A&#x3b2;1-42, is considered a critical step in the pathogenesis of Alzheimer's disease (AD). Although APP is a well-known membrane glycoprotein carrying both N- and O-glycans, nothing is known about the occurrence of released APP/A&#x3b2; glycopeptides in cerebrospinal fluid (CSF). We used the 6E10 antibody and immunopurified A&#x3b2; peptides and glycopeptides from CSF samples and then liquid chromatography-tandem mass spectrometry for structural analysis using collision-induced dissociation and electron capture dissociation. In addition to 33 unglycosylated APP/A&#x3b2; peptides, we identified 37 APP/A&#x3b2; glycopeptides with sialylated core 1 like O-glycans attached to Thr(-39, -21, -20, and -13), in a series of APP/A&#x3b2;X-15 glycopeptides, where X was -63, -57, -52, and -45, in relation to Asp1 of the A&#x3b2; sequence. Unexpectedly, we also identified a series of 27 glycopeptides, the A&#x3b2;1-X series, where X was 20 (DAEFRHDSGYEVHHQKLVFF), 19, 18, 17, 16, and 15, which were all uniquely glycosylated on Tyr10. The Tyr10 linked O-glycans were (Neu5Ac)(1-2)Hex(Neu5Ac)HexNAc-O- structures with the disialylated terminals occasionally O-acetylated or lactonized, indicating a terminal Neu5Ac&#x3b1;2,8Neu5Ac linkage. We could not detect any glycosylation of the A&#x3b2;1-38/40/42 isoforms. We observed an increase of up to 2.5 times of Tyr10 glycosylated A&#x3b2; peptides in CSF in six AD patients compared to seven non-AD patients. APP/A&#x3b2; sialylated O-glycans, including that of a Tyr residue, the first in a mammalian protein, may modulate APP processing, inhibiting the amyloidogenic pathway associated with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Halim</LastName><ForeName>Adnan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinkmalm</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>R&#xfc;etschi</LastName><ForeName>Ulla</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Westman-Brinkmalm</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>G&#xf6;ran</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Jonas</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>2ZD004190S</RegistryNumber><NameOfSubstance UI="D013912">Threonine</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013912" MajorTopicYN="N">Threonine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21712440</ArticleId><ArticleId IdType="pmc">PMC3141957</ArticleId><ArticleId IdType="doi">10.1073/pnas.1102664108</ArticleId><ArticleId IdType="pii">1102664108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sato Y, et al. Study of the sugar chains of recombinant human amyloid precursor protein produced by Chinese hamster ovary cells. Biochim Biophys Acta. 1999;1472:344&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">10572956</ArticleId></ArticleIdList></Reference><Reference><Citation>Perdivara I, et al. Elucidation of O-glycosylation structures of the beta-amyloid precursor protein by liquid chromatography-mass spectrometry using electron transfer dissociation and collision induced dissociation. J Proteome Res. 2009;8:631&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743936</ArticleId><ArticleId IdType="pubmed">19093876</ArticleId></ArticleIdList></Reference><Reference><Citation>Akasaka-Manya K, et al. Increased bisecting and core-fucosylated N-glycans on mutant human amyloid precursor proteins. Glycoconjugate J. 2008;25:775&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">18521746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn K, et al. Activation and intrinsic {&#x3b3;}-secretase activity of presenilin 1. Proc Natl Acad Sci USA. 2010;107:21435&#x2013;21440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003001</ArticleId><ArticleId IdType="pubmed">21115843</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Vassar R, Golde T. The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879045</ArticleId><ArticleId IdType="pubmed">20139999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA. 1992;89:6075&#x2013;6079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49440</ArticleId><ArticleId IdType="pubmed">1631093</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe5;hlsson P, Spitalnik SL. The role of glycosylation in synthesis and secretion of beta-amyloid precursor protein by Chinese hamster ovary cells. Arch Biochem Biophys. 1996;331:177&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, et al. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 2006;5:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;slund J, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA. 1994;91:8378&#x2013;8382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44609</ArticleId><ArticleId IdType="pubmed">8078890</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986;83:4913&#x2013;4917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. The secretases of Alzheimer&#x2019;s disease. Curr Top Dev Biol. 2003;54:233&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12696752</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol. 2010;120:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568930</ArticleId><ArticleId IdType="pubmed">20419305</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med. 2000;6:143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655101</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998;273:32730&#x2013;32738.</Citation><ArticleIdList><ArticleId IdType="pubmed">9830016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280:37644&#x2013;37650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409196</ArticleId><ArticleId IdType="pubmed">16154999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, et al. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Gram Schjoldager KT-B, et al. O-glycosylation modulates proprotein convertase activation of angiopoietin-like protein 3&#x2014;possible role of polypeptide GalNAc-transferase-2 in regulation of concentrations of plasma lipids. J Biol Chem. 2010;285:36293&#x2013;36303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978557</ArticleId><ArticleId IdType="pubmed">20837471</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenov AG, et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem. 2009;55:489&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">19168558</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6:4433&#x2013;4439.</Citation><ArticleIdList><ArticleId IdType="pubmed">17927230</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res. 2006;5:1010&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">16602710</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther. 2010;2:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876785</ArticleId><ArticleId IdType="pubmed">20350302</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook JJ, et al. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci. 2010;30:6743&#x2013;6750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913973</ArticleId><ArticleId IdType="pubmed">20463236</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis. 2009;6:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">19229112</ArticleId></ArticleIdList></Reference><Reference><Citation>Riboni L, et al. Natural occurrence of ganglioside lactones. Isolation and characterization of GD1b inner ester from adult human brain. J Biol Chem. 1986;261:8514&#x2013;8519.</Citation><ArticleIdList><ArticleId IdType="pubmed">3722160</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirgorodskaya E, Roepstorff P, Zubarev RA. Localization of O-glycosylation sites in peptides by electron capture dissociation in a Fourier transform mass spectrometer. Anal Chem. 1999;71:4431&#x2013;4436.</Citation><ArticleIdList><ArticleId IdType="pubmed">10546526</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson J, et al. Enrichment of glycopeptides for glycan structure and attachment site identification. Nat Methods. 2009;6:809&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">19838169</ArticleId></ArticleIdList></Reference><Reference><Citation>Smythe C, Caudwell FB, Ferguson M, Cohen P. Isolation and structural analysis of a peptide containing the novel tyrosyl-glucose linkage in glycogenin. EMBO J. 1988;7:2681&#x2013;2686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC457056</ArticleId><ArticleId IdType="pubmed">3181138</ArticleId></ArticleIdList></Reference><Reference><Citation>Aon MA, Curtino JA. Protein-bound glycogen is linked to tyrosine residues. Biochem J. 1985;229:269&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1145177</ArticleId><ArticleId IdType="pubmed">2412547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarschler K, et al. Protein tyrosine O-glycosylation&#x2014;a rather unexplored prokaryotic glycosylation system. Glycobiology. 2010;20:787&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397588</ArticleId><ArticleId IdType="pubmed">20200052</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabak LA. The role of mucin-type O-glycans in eukaryotic development. Semin Cell Dev Biol. 2010;21:616&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902666</ArticleId><ArticleId IdType="pubmed">20144722</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda M, Lauffenburger M, Sasaki H, Rogers ME, Dell A. Structures of novel sialylated O-linked oligosaccharides isolated from human erythrocyte glycophorins. J Biol Chem. 1987;262:11952&#x2013;11957.</Citation><ArticleIdList><ArticleId IdType="pubmed">3624241</ArticleId></ArticleIdList></Reference><Reference><Citation>Canis K, et al. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemostasis. 2010;8:137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19874459</ArticleId></ArticleIdList></Reference><Reference><Citation>Molander-Melin M, et al. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem. 2005;92:171&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">15606906</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrier L, et al. Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer&#x2019;s disease. Neurobiol Aging. 2007;28:1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">17007963</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnaar RL. Brain gangliosides in axon-myelin stability and axon regeneration. FEBS Lett. 2010;584:1741&#x2013;1747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856809</ArticleId><ArticleId IdType="pubmed">19822144</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue S, Iwasaki M. Isolation of a novel glycoprotein from the eggs of rainbow trout: Occurrence of disialosyl groups on all carbohydrate chains. Biochem Biophy Res Commun. 1978;83:1018&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">708420</ArticleId></ArticleIdList></Reference><Reference><Citation>Finne J. Occurrence of unique polysialosyl carbohydrate units in glycoproteins of developing brain. J Biol Chem. 1982;257:11966&#x2013;11970.</Citation><ArticleIdList><ArticleId IdType="pubmed">7118922</ArticleId></ArticleIdList></Reference><Reference><Citation>Galuska SP, et al. Synaptic cell adhesion molecule SynCAM 1 is a target for polysialylation in postnatal mouse brain. Proc Natl Acad Sci USA. 2010;107:10250&#x2013;10255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890427</ArticleId><ArticleId IdType="pubmed">20479255</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, Angata K, Nakayama J, Fukuda M. Polysialic acid and mucin type O-glycans on the neural cell adhesion molecule differentially regulate myoblast fusion. J Biol Chem. 2003;278:49459&#x2013;49468.</Citation><ArticleIdList><ArticleId IdType="pubmed">13679364</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;hlenhoff M, Oltmann-Norden I, Weinhold B, Hildebrandt H, Gerardy-Schahn R. Brain development needs sugar: The role of polysialic acid in controlling NCAM functions. Biol Chem. 2009;390:567&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">19426138</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 2006;78:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117838</ArticleId><ArticleId IdType="pubmed">17098843</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. Cell. 2000;100:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693756</ArticleId></ArticleIdList></Reference><Reference><Citation>May P, Bock HH, Nimpf J, Herz J. Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase. J Biol Chem. 2003;278:37386&#x2013;37392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12871934</ArticleId></ArticleIdList></Reference><Reference><Citation>Maryon EB, Molloy SA, Kaplan JH. O-linked glycosylation at threonine 27 protects the copper transporter hCTR1 from proteolytic cleavage in mammalian cells. J Biol Chem. 2007;282:20376&#x2013;20387.</Citation><ArticleIdList><ArticleId IdType="pubmed">17525160</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32:1090&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21715678</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>89</Issue><PubDate><Year>2011</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance.</ArticleTitle><Pagination><StartPage>89ra57</StartPage><MedlinePgn>89ra57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3002156</ELocationID><Abstract><AbstractText>The apolipoprotein E (APOE) &#x3b5;4 allele is the strongest genetic risk factor for late-onset, sporadic Alzheimer's disease (AD). The APOE &#x3b5;4 allele markedly increases AD risk and decreases age of onset, likely through its strong effect on the accumulation of amyloid-&#x3b2; (A&#x3b2;) peptide. In contrast, the APOE &#x3b5;2 allele appears to decrease AD risk. Most rare, early-onset forms of familial AD are caused by autosomal dominant mutations that often lead to overproduction of A&#x3b2;(42) peptide. However, the mechanism by which APOE alleles differentially modulate A&#x3b2; accumulation in sporadic, late-onset AD is less clear. In a cohort of cognitively normal individuals, we report that reliable molecular and neuroimaging biomarkers of cerebral A&#x3b2; deposition vary in an apoE isoform-dependent manner. We hypothesized that human apoE isoforms differentially affect A&#x3b2; clearance or synthesis in vivo, resulting in an apoE isoform-dependent pattern of A&#x3b2; accumulation later in life. Performing in vivo microdialysis in a mouse model of A&#x3b2;-amyloidosis expressing human apoE isoforms (PDAPP/TRE), we find that the concentration and clearance of soluble A&#x3b2; in the brain interstitial fluid depends on the isoform of apoE expressed. This pattern parallels the extent of A&#x3b2; deposition observed in aged PDAPP/TRE mice. ApoE isoform-dependent differences in soluble A&#x3b2; metabolism are observed not only in aged but also in young PDAPP/TRE mice well before the onset of A&#x3b2; deposition in amyloid plaques in the brain. Additionally, amyloidogenic processing of amyloid precursor protein and A&#x3b2; synthesis, as assessed by in vivo stable isotopic labeling kinetics, do not vary according to apoE isoform in young PDAPP/TRE mice. Our results suggest that APOE alleles contribute to AD risk by differentially regulating clearance of A&#x3b2; from the brain, suggesting that A&#x3b2; clearance pathways may be useful therapeutic targets for AD prevention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castellano</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungsu</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>DeMattos</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce W</ForeName><Initials>BW</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi G</ForeName><Initials>KG</Initials></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30NS069329-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034004</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG034004</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS069329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23-AG03094601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS069329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG030946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG035083</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK56341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21715678</ArticleId><ArticleId IdType="mid">NIHMS329176</ArticleId><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3002156</ArticleId><ArticleId IdType="pii">3/89/89ra57</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr., Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer&#x2019;s disease and other neurological disorders. Lancet Neurol. 2011;10:241&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132088</ArticleId><ArticleId IdType="pubmed">21349439</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 2004;62:1977&#x2013;1983.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184600</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis. 2002;9:305&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul SM. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2005;102:1211&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544620</ArticleId><ArticleId IdType="pubmed">15657137</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci. 2005;25:2803&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, Hansen JC, Sullivan PM, Paul SM. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci. 2009;29:6771&#x2013;6779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665579</ArticleId><ArticleId IdType="pubmed">19474305</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O&#x2019;Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094&#x2013;2103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12709467</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Jr., Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60:1696&#x2013;1702.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676043</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, Tapiola T, Pirttila T, Rinne J, Jaaskelainen JE, Soininen H, Rinne JO. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65:1304&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695050</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706&#x2013;10714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009;64:632&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Cirrito JR, Parsadanian M, May PC, O&#x2019;Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Menacherry S, Hubert W, Justice JB., Jr. In vivo calibration of microdialysis probes for exogenous compounds. Anal Chem. 1992;64:577&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">1580357</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronne-Engstrom E, Cesarini KG, Enblad P, Hesselager G, Marklund N, Nilsson P, Salci K, Persson L, Hillered L. Intracerebral microdialysis in neurointensive care: the use of urea as an endogenous reference compound. J Neurosurg. 2001;94:397&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11235942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillered L, Vespa PM, Hovda DA. Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J Neurotrauma. 2005;22:3&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665601</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwetye KE, Cirrito JR, Esparza TJ, Donald C. L. Mac, Holtzman DM, Brody DL. Traumatic brain injury reduces soluble extracellular amyloid-beta in mice: a methodologically novel combined microdialysis-controlled cortical impact study. Neurobiol Dis. 2010;40:555&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955836</ArticleId><ArticleId IdType="pubmed">20682338</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM. Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer&#x2019;s Disease Diagnosis and Prognosis. PLoS One. 2011;6:e18850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079734</ArticleId><ArticleId IdType="pubmed">21526197</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Biere AL, Ostaszewski B, Zhao H, Gillespie S, Younkin SG, Selkoe DJ. Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. Neurobiol Dis. 1995;2:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">9174001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM. Alzheimer&#x2019;s disease: Moving towards a vaccine. Nature. 2008;454:418&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">18650906</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer&#x2019;s disease. Annu Rev Med. 1996;47:387&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">8712790</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB, Jr., Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372:92&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer&#x2019;s fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Poirier J. ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation. Neuroreport. 1998;9:3321&#x2013;3323.</Citation><ArticleIdList><ArticleId IdType="pubmed">9831470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood SJ, Chan W, Wetzel R. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry. 1996;35:12623&#x2013;12628.</Citation><ArticleIdList><ArticleId IdType="pubmed">8823200</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994;269:23403&#x2013;23406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8089103</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem. 1997;68:721&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9003062</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleshkov S, Abraham CR, Zannis VI. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer&#x2019;s disease. Biochemistry. 1997;36:10571&#x2013;10580.</Citation><ArticleIdList><ArticleId IdType="pubmed">9265639</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer&#x2019;s amyloid beta peptides. Biochem J. 2000;348(Pt 2):359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221074</ArticleId><ArticleId IdType="pubmed">10816430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV. Transport pathways for clearance of human Alzheimer&#x2019;s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853021</ArticleId><ArticleId IdType="pubmed">17077814</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2006;103:18787&#x2013;18792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1654132</ArticleId><ArticleId IdType="pubmed">17116874</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Aumont N, Dea D, Lussier-Cacan S, Davignon J, Poirier J. Beta-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons. J Neurochem. 1998;70:1458&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">9523562</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE, Martins RN. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience. 1999;90:1217&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">10338292</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Korwek KM, Trotter JH, Ladu MJ, Sullivan PM, Weeber EJ. ApoE isoform-dependent changes in hippocampal synaptic function. Mol Neurodegener. 2009;4:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695436</ArticleId><ArticleId IdType="pubmed">19725929</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Demattos RB, McCormick LM, O&#x2019;Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem. 2005;280:25754&#x2013;25759.</Citation><ArticleIdList><ArticleId IdType="pubmed">15888448</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, Xu L, Aschmies S, Kirksey Y, Hu Y, Wagner E, Parratt A, Xu J, Li Z, Zaleska MM, Jacobsen JS, Pangalos MN, Reinhart PH. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008;28:11445&#x2013;11453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671315</ArticleId><ArticleId IdType="pubmed">18987181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatters DM, Voss JC, Budamagunta MS, Newhouse YN, Weisgraber KH. Insight on the molecular envelope of lipid-bound apolipoprotein E from electron paramagnetic resonance spectroscopy. J Mol Biol. 2009;386:261&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665048</ArticleId><ArticleId IdType="pubmed">19124026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased Clearance of CNS {beta}-Amyloid in Alzheimer&#x2019;s Disease. Science. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21730160</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>29</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.</ArticleTitle><Pagination><StartPage>12101</StartPage><EndPage>12106</EndPage><MedlinePgn>12101-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1108197108</ELocationID><Abstract><AbstractText>Emerging genetic and clinical evidence suggests a link between Gaucher disease and the synucleinopathies Parkinson disease and dementia with Lewy bodies. Here, we provide evidence that a mouse model of Gaucher disease (Gba1(D409V/D409V)) exhibits characteristics of synucleinopathies, including progressive accumulation of proteinase K-resistant &#x3b1;-synuclein/ubiquitin aggregates in hippocampal neurons and a coincident memory deficit. Analysis of homozygous (Gba1(D409V/D409V)) and heterozygous (Gba1(D409V/+) and Gba1(+/-)) Gaucher mice indicated that these pathologies are a result of the combination of a loss of glucocerebrosidase activity and a toxic gain-of-function resulting from expression of the mutant enzyme. Importantly, adeno-associated virus-mediated expression of exogenous glucocerebrosidase injected into the hippocampus of Gba1(D409V/D409V) mice ameliorated both the histopathological and memory aberrations. The data support the contention that mutations in GBA1 can cause Parkinson disease-like &#x3b1;-synuclein pathology, and that rescuing brain glucocerebrosidase activity might represent a therapeutic strategy for GBA1-associated synucleinopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sardi</LastName><ForeName>S Pablo</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Genzyme Corporation, Framingham, MA 01701, USA. pablo.sardi@genzyme.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kinnecom</LastName><ForeName>Cathrine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tamsett</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lingyun</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Stanek</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Passini</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Grabowski</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Schlossmacher</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Sidman</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Seng H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Shihabuddin</LastName><ForeName>Lamya S</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.45</RegistryNumber><NameOfSubstance UI="D005962">Glucosylceramidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.64</RegistryNumber><NameOfSubstance UI="D019286">Endopeptidase K</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019286" MajorTopicYN="N">Endopeptidase K</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005776" MajorTopicYN="N">Gaucher Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005962" MajorTopicYN="N">Glucosylceramidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: S.P.S., J.C., C.K., T.J.T., L.L., L.M.S., M.A.P., S.H.C. and L.S.S. are employees of Genzyme Corporation. M.G.S., S.H.C and L.S.S. have been listed as co-inventors of an application to the US Patent Office on the &#x201c;Treatment of synucleinopathies.&#x201d;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21730160</ArticleId><ArticleId IdType="pmc">PMC3141921</ArticleId><ArticleId IdType="doi">10.1073/pnas.1108197108</ArticleId><ArticleId IdType="pii">1108197108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brady RO, Kanfer JN, Bradley RM, Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest. 1966;45:1112&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC292783</ArticleId><ArticleId IdType="pubmed">5338605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E. Gaucher disease: Complexity in a &#x201c;simple&#x201d; disorder. Mol Genet Metab. 2004;83:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464415</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox TM. Gaucher's disease&#x2014;An exemplary monogenic disorder. QJM. 2001;94:399&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493715</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008;372:1263&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pubmed">19094956</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: The first 5 years. Blood Rev. 1998;12:115&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">9661800</ArticleId></ArticleIdList></Reference><Reference><Citation>Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972&#x2013;1977.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525722</ArticleId></ArticleIdList></Reference><Reference><Citation>Goker-Alpan O, et al. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol. 2008;65:1353&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629407</ArticleId><ArticleId IdType="pubmed">18852351</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LN, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology. 2007;69:1270&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624967</ArticleId><ArticleId IdType="pubmed">17875915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mata IF, et al. Glucocerebrosidase gene mutations: A risk factor for Lewy body disorders. Arch Neurol. 2008;65:379&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826203</ArticleId><ArticleId IdType="pubmed">18332251</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LN, et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol. 2009;66:578&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758782</ArticleId><ArticleId IdType="pubmed">19433657</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann J, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132:1783&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702833</ArticleId><ArticleId IdType="pubmed">19286695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361:1651&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856322</ArticleId><ArticleId IdType="pubmed">19846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010;10:190&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529411</ArticleId><ArticleId IdType="pubmed">20425034</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med. 2004;10(7) Suppl:S58&#x2013;S62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272270</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayebi N, et al. Gaucher disease with parkinsonian manifestations: Does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab. 2003;79:104&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">12809640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong K, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82:192&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234332</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka K, et al. Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism Relat Disord. 2011;17:55&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721925</ArticleId><ArticleId IdType="pubmed">20971030</ArticleId></ArticleIdList></Reference><Reference><Citation>Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in &#x3b1;-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 2010;120:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3352317</ArticleId><ArticleId IdType="pubmed">20838799</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YH, et al. Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab. 2011;102:436&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059359</ArticleId><ArticleId IdType="pubmed">21257328</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen V, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol. 2011;69:940&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pubmed">21472771</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldin E. Gaucher disease and Parkinsonism, a molecular link theory. Mol Genet Metab. 2010;101:307&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991511</ArticleId><ArticleId IdType="pubmed">20801700</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlossmacher MG, Cullen V, M&#xfc;thing J. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2005;352:728&#x2013;731. author reply 728&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">15719451</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning-Bo&#x11f; AB, Sch&#xfc;le B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and Parkinsonism. Neurotoxicology. 2009;30:1127&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">19576930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ron I, Rapaport D, Horowitz M. Interaction between parkin and mutant glucocerebrosidase variants: A possible link between Parkinson disease and Gaucher disease. Hum Mol Genet. 2010;19:3771&#x2013;3781.</Citation><ArticleIdList><ArticleId IdType="pubmed">20643691</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest. 2002;110:1429&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151810</ArticleId><ArticleId IdType="pubmed">12438441</ArticleId></ArticleIdList></Reference><Reference><Citation>Shults CW. Lewy bodies. Proc Natl Acad Sci USA. 2006;103:1661&#x2013;1668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413649</ArticleId><ArticleId IdType="pubmed">16449387</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YH, Quinn B, Witte D, Grabowski GA. Viable mouse models of acid beta-glucosidase deficiency: The defect in Gaucher disease. Am J Pathol. 2003;163:2093&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892407</ArticleId><ArticleId IdType="pubmed">14578207</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem. 1982;39:709&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">7097276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson O, Grabowski GA, Ludman MD, Desnick RJ, Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. Clin Genet. 1985;27:443&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">3924448</ArticleId></ArticleIdList></Reference><Reference><Citation>Enquist IB, et al. Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci USA. 2007;104:17483&#x2013;17488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077282</ArticleId><ArticleId IdType="pubmed">17954912</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Salazar MA, et al. Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease. Exp Neurol. 2010;225:436&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">20673762</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: Clinical and pathological implications. Arch Neurol. 2001;58:186&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176955</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlossmacher M. &#x3b1;&#x2013;Synuclein and synucleinopathies. In: Rossor MN, Growdon JH, editors. The Dementias 2. Vol 30. Oxford: Butterworth Heinemann, Inc.; 2007. pp. 186&#x2013;215.</Citation></Reference><Reference><Citation>Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol. 2009;8:382&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">19296921</ArticleId></ArticleIdList></Reference><Reference><Citation>Goker-Alpan O, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006;67:908&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">16790605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd-Evans E, et al. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem. 2003;278:23594&#x2013;23599.</Citation><ArticleIdList><ArticleId IdType="pubmed">12709427</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan-Or Z, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008;70:2277&#x2013;2283.</Citation><ArticleIdList><ArticleId IdType="pubmed">18434642</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols WC, et al. Parkinson Study Group-PROGENI Investigators Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;72:310&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677501</ArticleId><ArticleId IdType="pubmed">18987351</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21734277</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>27</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.</ArticleTitle><Pagination><StartPage>9858</StartPage><EndPage>9868</EndPage><MedlinePgn>9858-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0560-11.2011</ELocationID><Abstract><AbstractText>Aggregated filamentous forms of hyperphosphorylated tau (a microtubule-associated protein) represent pathological hallmarks of Alzheimer's disease (AD) and other tauopathies. While axonal transport dysfunction is thought to represent a primary pathogenic factor in AD and other neurodegenerative diseases, the direct molecular link between pathogenic forms of tau and deficits in axonal transport remain unclear. Recently, we demonstrated that filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Here, we demonstrate that amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway in axoplasms isolated from squid giant axons. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Importantly, immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity, an early marker of pathological tau. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT. Results from these studies reveal a novel role for tau in modulating axonal phosphotransferases and provide a molecular basis for a toxic gain-of-function associated with pathogenic forms of tau.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kanaan</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morfini</LastName><ForeName>Gerardo A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>LaPointe</LastName><ForeName>Nichole E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Pigino</LastName><ForeName>Gustavo F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Kristina R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yuyu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Andreadis</LastName><ForeName>Athena</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>Scott T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>Lester I</ForeName><Initials>LI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 NS023868</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS41170</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS023320</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009466</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG020506</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041170</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS23868</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09466</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG020506-07</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS23320</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS023868</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS066942</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010759">Phosphorus Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016755">Proto-Oncogene Proteins c-jun</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017476">Receptors, Neuropeptide Y</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>55F8T1GN3X</RegistryNumber><NameOfSubstance UI="C109491">neuropeptide Y4 receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D010770">Phosphotransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049832" MajorTopicYN="N">Decapodiformes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010759" MajorTopicYN="N">Phosphorus Isotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010770" MajorTopicYN="N">Phosphotransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016755" MajorTopicYN="N">Proto-Oncogene Proteins c-jun</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017476" MajorTopicYN="N">Receptors, Neuropeptide Y</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21734277</ArticleId><ArticleId IdType="mid">NIHMS384599</ArticleId><ArticleId IdType="pmc">PMC3391724</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0560-11.2011</ArticleId><ArticleId IdType="pii">31/27/9858</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med. 1996;2:783&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">8673924</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreadis A. Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim Biophys Acta. 2005;1739:91&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615629</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Davies P, Mandelkow E. Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry. 2004;43:1694&#x2013;1703.</Citation><ArticleIdList><ArticleId IdType="pubmed">14769047</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry RW, Sweet AP, Clark FA, Lagalwar S, Lapin BR, Wang T, Topgi S, Guillozet-Bongaarts AL, Cochran EJ, Bigio EH, Binder LI. Tau epitope display in progressive supranuclear palsy and corticobasal degeneration. J Neurocytol. 2004;33:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475684</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Mandelkow EM, Schr&#xf6;ter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M, Mandelkow E. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 1992;11:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E, Braak H, Mandelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 1994;87:554&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">7522386</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Richards BW, Leopold PL. Assay of vesicle motility in squid axoplasm. Methods Cell Biol. 1993;39:191&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504159</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmel G, Mager EM, Binder LI, Kuret J. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem. 1996;271:32789&#x2013;32795.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955115</ArticleId></ArticleIdList></Reference><Reference><Citation>Dessi F, Colle MA, Hauw JJ, Duyckaerts C. Accumulation of SNAP-25 immunoreactive material in axons of Alzheimer's disease. Neuroreport. 1997;8:3685&#x2013;3689.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427351</ArticleId></ArticleIdList></Reference><Reference><Citation>Drubin DG, Feinstein SC, Shooter EM, Kirschner MW. Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors. J Cell Biol. 1985;101:1799&#x2013;1807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113947</ArticleId><ArticleId IdType="pubmed">2997236</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol. 1998;143:777&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148132</ArticleId><ArticleId IdType="pubmed">9813097</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussi&#xe8;re T, Bouras C, K&#xf6;vari E, Perl DP, Morrison JH, Gold G, Hof PR. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60:1495&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084&#x2013;6089.</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Morishima-Kawashima M, Takio K, Suzuki M, Titani K, Ihara Y. Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J Biol Chem. 1992;267:17047&#x2013;17054.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512244</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Saido TC, Suhara T. Animal models of tauopathies. Neuropathology. 2006;26:491&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">17080730</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci. 2004;24:7895&#x2013;7902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729917</ArticleId><ArticleId IdType="pubmed">15356202</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S, von Bergen M, Brutlach H, Steinhoff HJ, Mandelkow E. Global hairpin folding of tau in solution. Biochemistry. 2006;45:2283&#x2013;2293.</Citation><ArticleIdList><ArticleId IdType="pubmed">16475817</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Mandelkow EM, Mandelkow E. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J Biol Chem. 2008;283:32066&#x2013;32076.</Citation><ArticleIdList><ArticleId IdType="pubmed">18725412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaan NM, Kordower JH, Collier TJ. Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol. 2007;502:683&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">17436290</ArticleId></ArticleIdList></Reference><Reference><Citation>King ME, Ahuja V, Binder LI, Kuret J. Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. Biochemistry. 1999;38:14851&#x2013;14859.</Citation><ArticleIdList><ArticleId IdType="pubmed">10555967</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (&#x3c4;) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A. 1986;83:4044&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozikowski AP, Gaisina IN, Yuan H, Petukhov PA, Blond SY, Fedolak A, Caldarone B, McGonigle P. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-3beta therapies for bipolar disorders. J Am Chem Soc. 2007;129:8328&#x2013;8332.</Citation><ArticleIdList><ArticleId IdType="pubmed">17552518</ArticleId></ArticleIdList></Reference><Reference><Citation>LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res. 2009;87:440&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739042</ArticleId><ArticleId IdType="pubmed">18798283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, Do LH, Andreadis A, Van Hoesen G, Ksiezak-Reding H. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci. 2004;24:2304&#x2013;2312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730442</ArticleId><ArticleId IdType="pubmed">14999081</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao H, Li Y, Brautigan DL, Gundersen GG. Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau. J Biol Chem. 1998;273:21901&#x2013;21908.</Citation><ArticleIdList><ArticleId IdType="pubmed">9705329</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo MH, Tse SW, Memmott J, Andreadis A. Novel isoforms of tau that lack the microtubule-binding domain. J Neurochem. 2004;90:340&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">15228591</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E, von Bergen M, Biernat J, Mandelkow EM. Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol. 2007;17:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095506</ArticleId><ArticleId IdType="pubmed">17493042</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Pigino G, Beffert U, Busciglio J, Brady ST. Fast axonal transport misregulation and Alzheimer's disease. Neuromolecular Med. 2002a;2:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">12428805</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 2002b;21:281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125832</ArticleId><ArticleId IdType="pubmed">11823421</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, DeBoer S, Beffert U, Brady ST. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J. 2004;23:2235&#x2013;2245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419914</ArticleId><ArticleId IdType="pubmed">15152189</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Pigino G, Mizuno N, Kikkawa M, Brady ST. Tau binding to microtubules does not directly affect microtubule-based vesicle motility. J Neurosci Res. 2007;85:2620&#x2013;2630.</Citation><ArticleIdList><ArticleId IdType="pubmed">17265463</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH, Jr, Brown H, Tiwari A, Hayward L, Edgar J, Nave KA, Garberrn J, Atagi Y, Song Y, Pigino G, Brady ST. Axonal transport defects in neurodegenerative diseases. J Neurosci. 2009;29:12776&#x2013;12786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801051</ArticleId><ArticleId IdType="pubmed">19828789</ArticleId></ArticleIdList></Reference><Reference><Citation>Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol. 1999;58:188&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">10029101</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes JF, Reynolds MR, Horowitz PM, Fu Y, Guillozet-Bongaarts AL, Berry R, Binder LI. A possible link between astrocyte activation and tau nitration in Alzheimer's disease. Neurobiol Dis. 2008;31:198&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2766349</ArticleId><ArticleId IdType="pubmed">18562203</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Lecourtois M, Thomas-Anterion C, Le Ber I, Brice A, Frebourg T, Hannequin D, Campion D. Partial deletion of the MAPT gene: a novel mechanism of FTDP-17. Hum Mutat. 2009;30:E591&#x2013;E602.</Citation><ArticleIdList><ArticleId IdType="pubmed">19263483</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S, Zhang B, Lee VM, Trojanowski JQ. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. 2005;109:5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15645263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai K, Piao YS, Kikugawa K, Ohara S, Hasegawa M, Takano H, Fukase M, Nishizawa M, Kakita A, Takahashi H. Corticobasal degeneration with focal, massive tau accumulation in the subcortical white matter astrocytes. Acta Neuropathol. 2006;112:341&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">16804710</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging. 1990;11:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">2325814</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweers O, Sch&#xf6;nbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem. 1994;269:24290&#x2013;24297.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929085</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz A, Kojima H, Oiwa K, Mandelkow EM, Song YH, Mandelkow E. Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J. 2002;21:4896&#x2013;4905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126299</ArticleId><ArticleId IdType="pubmed">12234929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta S, Horowitz PM, Karsten SL, Jackson GR, Geschwind DH, Fu Y, Berry RW, Binder LI. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry. 2006;45:15111&#x2013;15119.</Citation><ArticleIdList><ArticleId IdType="pubmed">17154549</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci. 2002;59:1668&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11337454</ArticleId><ArticleId IdType="pubmed">12475178</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiarli AM, Jennings R, Shi J, Bailey K, Davidson Y, Tian J, Bigio EH, Ghetti B, Murrell JR, Delisle MB, Mirra S, Crain B, Zolo P, Arima K, Iseki E, Murayama S, Kretzschmar H, Neumann M, Lippa C, Halliday G, et al. Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. Neuropathol Appl Neurobiol. 2006;32:374&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866983</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Qureshi HY, Cafferty PW, Sobue K, Agarwal-Mawal A, Neufield KD, Paudel HK. Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. J Biol Chem. 2002;277:11933&#x2013;11940.</Citation><ArticleIdList><ArticleId IdType="pubmed">11812770</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Weidenheim KM, Dickson DW, Ksiezak-Reding H. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2002;61:33&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">11829342</ArticleId></ArticleIdList></Reference><Reference><Citation>Vershinin M, Carter BC, Razafsky DS, King SJ, Gross SP. Multiple-motor based transport and its regulation by Tau. Proc Natl Acad Sci U S A. 2007;104:87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1765483</ArticleId><ArticleId IdType="pubmed">17190808</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L. Tau reduction prevents Abeta-induced defects in axonal transport. Science. 2010;330:198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JG, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau) Proc Natl Acad Sci U S A. 1986;83:4040&#x2013;4043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323661</ArticleId><ArticleId IdType="pubmed">2424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci. 2008;28:1682&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814454</ArticleId><ArticleId IdType="pubmed">18272688</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21734300</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>27</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>&#x3b1;-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.</ArticleTitle><Pagination><StartPage>10076</StartPage><EndPage>10087</EndPage><MedlinePgn>10076-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0618-11.2011</ELocationID><Abstract><AbstractText>Abnormally accumulated &#x3b1;-synuclein (&#x3b1;-syn) is a pathological hallmark of Lewy body-related disorders such as Parkinson's disease (PD) and dementia with Lewy body disease (DLB). However, it is not well understood whether and how abnormal accumulation of &#x3b1;-syn leads to cognitive impairment or dementia in PD and DLB. Furthermore, it is not known whether targeted removal of &#x3b1;-syn pathology can reverse cognitive decline. Here, we found that the distribution of &#x3b1;-syn pathology in an inducible &#x3b1;-syn transgenic mouse model recapitulates that in human DLB. Abnormal accumulation of &#x3b1;-syn in the limbic system, particularly in the hippocampus, correlated with memory impairment and led to structural synaptic deficits. Furthermore, when &#x3b1;-syn expression was suppressed, we observed partial clearing of pre-existing &#x3b1;-syn pathology and reversal of structural synaptic defects, resulting in an improvement in memory function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Youngshin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kehm</LastName><ForeName>Victoria M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Soper</LastName><ForeName>James H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chi</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>47165-04-8</RegistryNumber><NameOfSubstance UI="C007293">DAPI</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.17</RegistryNumber><NameOfSubstance UI="D054732">Calcium-Calmodulin-Dependent Protein Kinase Type 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2011 Aug 1;26(9):1618. doi: 10.1002/mds.23902.</RefSource><PMID Version="1">21938768</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054732" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinase Type 2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003214" MajorTopicYN="N">Conditioning, Classical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003463" MajorTopicYN="N">Cues</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21734300</ArticleId><ArticleId IdType="mid">NIHMS309843</ArticleId><ArticleId IdType="pmc">PMC3144489</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0618-11.2011</ArticleId><ArticleId IdType="pii">31/27/10076</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aarsland D, Beyer MK, Kurz MW. Dementia in Parkinson's disease. Curr Opin Neurol. 2008;21:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">18989112</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VMY, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858234</ArticleId><ArticleId IdType="pubmed">9546347</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, S&#xfc;dhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235365</ArticleId><ArticleId IdType="pubmed">20798282</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005;8:657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834418</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci. 2009;29:3365&#x2013;3373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693917</ArticleId><ArticleId IdType="pubmed">19295143</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S. &#x3b1;-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science. 2006;313:324&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol. 2002a;52:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210791</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 2002b;104:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12070658</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. &#x3b1;-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Reitb&#xf6;ck P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, Ghetti B, Della Corte L, Spano P, Tofaris GK, Goedert M, Spillantini MG. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain. 2010;133:2032&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892942</ArticleId><ArticleId IdType="pubmed">20534649</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann Gross R, Siderowf A, Hurtig HI. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies: a spectrum of disease. Neurosignals. 2008;16:24&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097157</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Tortosa E, Newell K, Irizarry MC, Sanders JL, Hyman BT. Alpha-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol. 2000;99:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">10787032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson JC, Lippa CF. Lewy body dementia. Int Rev Neurobiol. 2009;84:215&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">19501720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeuchi T, Kakita A, Shiga A, Kasuga K, Kaneko H, Tan CF, Idezuka J, Wakabayashi K, Onodera O, Iwatsubo T, Nishizawa M, Takahashi H, Ishikawa A. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol. 2008;65:514&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">18413475</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2:e355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm. 2004;111:1219&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pubmed">15480835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W, Fuss B, Mallon B, Macklin WB, Fujiwara H, Hasegawa M, Iwatsubo T, Kretzschmar HA, Haass C. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 2002;3:583&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084143</ArticleId><ArticleId IdType="pubmed">12034752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JJ, Fanselow MS. Modality-specific retrograde-amnesia of fear. Science. 1992;256:675&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">1585183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol. 2004;187:279&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15144854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27:1405&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673583</ArticleId><ArticleId IdType="pubmed">17287515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwahara T, Koyama A, Koyama S, Yoshina S, Ren CH, Kato T, Mitani S, Iwatsubo T. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Hum Mol Genet. 2008;17:2997&#x2013;3009.</Citation><ArticleIdList><ArticleId IdType="pubmed">18617532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are ubiquitinated&#x2014;a light and electron-microscopic immunocytochemical study. Acta Neuropathol. 1988;75:345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">3364159</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, Savalle M, Nemani V, Chaudhry FA, Edwards RH, Stefanis L, Sulzer D. &#x3b1;-Synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci. 2006;26:11915&#x2013;11922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674868</ArticleId><ArticleId IdType="pubmed">17108165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennox G, Lowe J, Morrell K, Landon M, Mayer RJ. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry. 1989;52:67&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1032659</ArticleId><ArticleId IdType="pubmed">2540286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Y, Kehm VM, Li C, Trojanowski JQ, Lee VM. Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. Exp Neurol. 2010;221:86&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812632</ArticleId><ArticleId IdType="pubmed">19833127</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S, Nicoll JA. Comparison of modified Bielschowsky silver impregnation and antiubiquitin immunostaining of cortical and nigral Lewy bodies. Neuropathol Appl Neurobiol. 1992;18:585&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">1283205</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274:1678&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, et al. Diagnosis and management of dementia with Lewy bodies&#x2014;third report of the DLB Consortium. Neurology. 2005;65:1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikolaenko I, Pletnikova O, Kawas CH, O'Brien R, Resnick SM, Crain B, Troncoso JC. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA) J Neuropathol Exp Neurol. 2005;64:156&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751230</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119527</ArticleId><ArticleId IdType="pubmed">20152114</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von H&#xf6;rsten S, Schmidt T, Boy J, Kuhn M, Nguyen HP, Teismann P, Schulz JB, Neumann M, Pichler BJ, Reischl G, Holzmann C, Schmitt I, Bornemann A, Kuhn W, Zimmermann F, Servadio A, et al. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci. 2008;28:2471&#x2013;2484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671187</ArticleId><ArticleId IdType="pubmed">18322092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohara K, Takauchi S, Kokai M, Morimura Y, Nakajima T, Morita Y. Familial dementia with Lewy bodies (DLB) Clin Neuropathol. 1999;18:232&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">10505432</ArticleId></ArticleIdList></Reference><Reference><Citation>Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT, Jr, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem. 2008;283:16895&#x2013;16905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2423264</ArticleId><ArticleId IdType="pubmed">18343814</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropath Exp Neurol. 2003;62:363&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">12722828</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. San Diego: Academic; 2011.</Citation></Reference><Reference><Citation>Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VM. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol. 2003;163:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868149</ArticleId><ArticleId IdType="pubmed">12819014</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41:1303&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">19915576</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci. 2010;30:8083&#x2013;8095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901533</ArticleId><ArticleId IdType="pubmed">20554859</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidel K, Sch&#xf6;ls L, Nuber S, Petrasch-Parwez E, Gierga K, Wszolek Z, Dickson D, Gai WP, Bornemann A, Riess O, Rami A, Den Dunnen WF, Deller T, R&#xfc;b U, Kr&#xfc;ger R. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol. 2010;67:684&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">20437567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kr&#xfc;ger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41:1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787725</ArticleId><ArticleId IdType="pubmed">19915575</ArticleId></ArticleIdList></Reference><Reference><Citation>Soper JH, Roy S, Stieber A, Lee E, Wilson RB, Trojanowski JQ, Burd CG, Lee VM. &#x3b1;-Synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol Biol Cell. 2008;19:1093&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2262993</ArticleId><ArticleId IdType="pubmed">18172022</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol. 2001;49:313&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261505</ArticleId></ArticleIdList></Reference><Reference><Citation>Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, Hay JC. &#x3b1;-Synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell. 2010;21:1850&#x2013;1863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877643</ArticleId><ArticleId IdType="pubmed">20392839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay P, Meiner Z, Galou M, Heinrich C, Petromilli C, Lisse T, Cayetano J, Torchia M, Mobley W, Bujard H, DeArmond SJ, Prusiner SB. Doxycycline control of prion protein transgene expression modulates prion disease in mice. Proc Natl Acad Sci U S A. 1998;95:12580&#x2013;12585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22873</ArticleId><ArticleId IdType="pubmed">9770528</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ham TJ, Thijssen KL, Breitling R, Hofstra RM, Plasterk RH, Nollen EA. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet. 2008;4:e100027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265412</ArticleId><ArticleId IdType="pubmed">18369446</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol. 2008;67:402&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930078</ArticleId><ArticleId IdType="pubmed">18451726</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34:561&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267179</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Veasey SC, Wood MA, Leng LZ, Kaminski C, Leight S, Abel T, Lee VM, Trojanowski JQ. Impaired rapid eye movement sleep in the Tg2576 APP murine model of Alzheimer's disease with injury to pedunculopontine cholinergic neurons. Am J Pathol. 2005;167:1361&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603771</ArticleId><ArticleId IdType="pubmed">16251420</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21738487</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1553-7404</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>PLoS genetics</Title><ISOAbbreviation>PLoS Genet</ISOAbbreviation></Journal><ArticleTitle>Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease.</ArticleTitle><Pagination><StartPage>e1002141</StartPage><MedlinePgn>e1002141</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002141</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgen.1002141</ELocationID><Abstract><AbstractText>Although the causes of Parkinson's disease (PD) are thought to be primarily environmental, recent studies suggest that a number of genes influence susceptibility. Using targeted case recruitment and online survey instruments, we conducted the largest case-control genome-wide association study (GWAS) of PD based on a single collection of individuals to date (3,426 cases and 29,624 controls). We discovered two novel, genome-wide significant associations with PD-rs6812193 near SCARB2 (p = 7.6 &#xd7; 10(-10), OR = 0.84) and rs11868035 near SREBF1/RAI1 (p = 5.6 &#xd7; 10(-8), OR = 0.85)-both replicated in an independent cohort. We also replicated 20 previously discovered genetic associations (including LRRK2, GBA, SNCA, MAPT, GAK, and the HLA region), providing support for our novel study design. Relying on a recently proposed method based on genome-wide sharing estimates between distantly related individuals, we estimated the heritability of PD to be at least 0.27. Finally, using sparse regression techniques, we constructed predictive models that account for 6%-7% of the total variance in liability and that suggest the presence of true associations just beyond genome-wide significance, as confirmed through both internal and external cross-validation. These results indicate a substantial, but by no means total, contribution of genetics underlying susceptibility to both early-onset and late-onset PD, suggesting that, despite the novel associations discovered here and elsewhere, the majority of the genetic component for Parkinson's disease remains to be discovered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Chuong B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>23andMe, Mountain View, California, United States of America. cdo@23andme.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tung</LastName><ForeName>Joyce Y</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Dorfman</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kiefer</LastName><ForeName>Amy K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Drabant</LastName><ForeName>Emily M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Francke</LastName><ForeName>Uta</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Mountain</LastName><ForeName>Joanna L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Samuel M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Tanner</LastName><ForeName>Caroline M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Langston</LastName><ForeName>J William</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Wojcicki</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Genet</MedlineTA><NlmUniqueID>101239074</NlmUniqueID><ISSNLinking>1553-7390</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease.</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040941" MajorTopicYN="N">Heredity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="Y">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>CBD, JYT, ED, AKK, EMD, UF, JLM, AW, and NE are or have been employed by 23andMe and own stock options in the company. 23andMe CEO AW has provided general guidance, including guidance related to the company's research undertakings and direction. PLoS co-founder Michael B. Eisen is a member of the 23andMe Scientific Advisory Board.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21738487</ArticleId><ArticleId IdType="pmc">PMC3121750</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1002141</ArticleId><ArticleId IdType="pii">PGENETICS-D-11-00444</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, et al. Hereditary earlyonset Parkinson's disease caused by mutations in PINK1. Science. 2004;304:1158&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A, Heimbach A, Grndemann J, Stiller B, Hampshire D, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">16964263</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology. 2007;68:1557&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485642</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999;281:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">9929087</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45:577&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. No evidence for heritability of Parkinson disease in Swedish twins. Neurology. 2004;63:305&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277625</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7:306&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">16543934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sveinbj&#xf6;rnsdottir S, Hicks AA, Jonsson T, P&#xe9;tursson H, Gu&#x11f;mundsson G, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med. 2000;343:1765&#x2013;1770.</Citation><ArticleIdList><ArticleId IdType="pubmed">11114315</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124:593&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627511</ArticleId><ArticleId IdType="pubmed">18985386</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41:1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787725</ArticleId><ArticleId IdType="pubmed">19915575</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74:97&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853717</ArticleId><ArticleId IdType="pubmed">20070850</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet. 2010;42:781&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930111</ArticleId><ArticleId IdType="pubmed">20711177</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer CC, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5&#x2032; of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet. 2011;20:345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3005904</ArticleId><ArticleId IdType="pubmed">21044948</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41:1303&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">19915576</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad M, Lesage S, Saint-Pierre A, Corvol JC, Zelenika D, et al. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet. 2011;20:615&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">21084426</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696507</ArticleId><ArticleId IdType="pubmed">21292315</ArticleId></ArticleIdList></Reference><Reference><Citation>International Parkinson Disease Genomics Consortium. 2011. Tbd. TBD.</Citation></Reference><Reference><Citation>Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008;7:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832754</ArticleId><ArticleId IdType="pubmed">18539534</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361:1651&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856322</ArticleId><ArticleId IdType="pubmed">19846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;72:310&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677501</ArticleId><ArticleId IdType="pubmed">18987351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill C, Roehr J, McQueen M, Bagade S, Kavvoura F, et al.   The PDGene database, Alzheimer research forum. Available at:  pdgene.org. Accessed Nov. 18, 2010.</Citation></Reference><Reference><Citation>Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA. 2009;106:9362&#x2013;9367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687147</ArticleId><ArticleId IdType="pubmed">19474294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A Tool for Genome-wide Complex Trait Analysis. Am J Hum Genet. 2011;88:76&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014363</ArticleId><ArticleId IdType="pubmed">21167468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. Am J Hum Genet In press</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059431</ArticleId><ArticleId IdType="pubmed">21376301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray NR, Yang J, Goddard ME, Visscher PM. The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genet. 2010;6:e1000864. doi: 10.1371/journal.pgen.1000864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000864</ArticleId><ArticleId IdType="pmc">PMC2829056</ArticleId><ArticleId IdType="pubmed">20195508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooperberg C, LeBlanc M, Obenchain V. Risk prediction using genome-wide association studies. Genet Epidemiol. 2010;34:643&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964405</ArticleId><ArticleId IdType="pubmed">20842684</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912837</ArticleId><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkovic SF, Dibbens LM, Oshlack A, Silver JD, Katerelos M, et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet. 2008;82:673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427287</ArticleId><ArticleId IdType="pubmed">18308289</ArticleId></ArticleIdList></Reference><Reference><Citation>Reczek D, Schwake M, Schroder J, Hughes H, Blanz J, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell. 2007;131:770&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">18022370</ArticleId></ArticleIdList></Reference><Reference><Citation>Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972&#x2013;1977.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525722</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9150132</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghibiglou C, Martin HG, Lai TW, Cho T, Prasad S, et al. Role of NMDA receptordependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nat Med. 2009;15:1399&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">19966780</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, et al. SREBP-1, a basic-helix-loophelix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell. 1993;75:187&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">8402897</ArticleId></ArticleIdList></Reference><Reference><Citation>Slager RE, Newton TL, Vlangos CN, Finucane B, Elsea SH. Mutations in RAI1 associated with Smith-Magenis syndrome. Nat Genet. 2003;33:466&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">12652298</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CH, Della NG, Chew CE, Zack DJ. Rin, a neuron-specific and calmodulin-binding small G-protein, and Rit define a novel subfamily of ras proteins. J Neurosci. 1996;16:6784&#x2013;6794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579259</ArticleId><ArticleId IdType="pubmed">8824319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron. 2009;62:218&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677560</ArticleId><ArticleId IdType="pubmed">19409267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson GD, Chen XN, Korenberg JR, Herschman HR. The human synaptotagmin IV gene defines an evolutionary break point between syntenic mouse and human chromosome regions but retains ligand inducibility and tissue specificity. J Biol Chem. 2000;275:36920&#x2013;36926.</Citation><ArticleIdList><ArticleId IdType="pubmed">10938284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson GD, Anagnostaras SG, Silva AJ, Herschman HR. Deficits in memory and motor performance in synaptotagmin IV mutant mice. Proc Natl Acad Sci USA. 2000;97:5598&#x2013;5603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25874</ArticleId><ArticleId IdType="pubmed">10792055</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh DP, Scoles DR, Nguyen D, Pulst SM. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum Mol Genet. 2003;12:2587&#x2013;2597.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925569</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Schrodi S, Rowland C, Tacey K, Catanese J, et al. Genetic evidence for ubiquitinspecific proteases USP24 and USP40 as candidate genes for late-onset Parkinson disease. Hum Mutat. 2006;27:1017&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917932</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010;67:1116&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329730</ArticleId><ArticleId IdType="pubmed">20837857</ArticleId></ArticleIdList></Reference><Reference><Citation>Moilanen JS, Autere JM, Myllyla VV, Majamaa K. Complex segregation analysis of Parkinson's disease in the Finnish population. Hum Genet. 2001;108:184&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">11354627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Visscher PM, Wray NR. Sporadic cases are the norm for complex disease. Eur J Hum Genet. 2010;18:1039&#x2013;1043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987426</ArticleId><ArticleId IdType="pubmed">19826454</ArticleId></ArticleIdList></Reference><Reference><Citation>Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol. 1994;36:659&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shino MY, McGuire V, Van Den Eeden SK, Tanner CM, Popat R, et al. Familial aggregation of Parkinson's disease in a multiethnic community-based case-control study. Mov Disord. 2010;25:2587&#x2013;2594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978761</ArticleId><ArticleId IdType="pubmed">20842689</ArticleId></ArticleIdList></Reference><Reference><Citation>Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics. 2003;164:1567&#x2013;1587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1462648</ArticleId><ArticleId IdType="pubmed">12930761</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson N, Macpherson JM, Tung JY, Hon LS, Naughton B, et al.  Web-based, participantdriven studies yield novel genetic associations for common traits. PLoS Genet. 2010;6:e1000993. doi: 10.1371/journal.pgen.1000993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000993</ArticleId><ArticleId IdType="pmc">PMC2891811</ArticleId><ArticleId IdType="pubmed">20585627</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung HC, Scholz S, Matarin M, Simon-Sanchez J, Hernandez D, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006;5:911&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">17052657</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Sanchez J, Scholz S, Fung HC, Matarin M, Hernandez D, et al. Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet. 2007;16:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116639</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet. 2005;76:887&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1199378</ArticleId><ArticleId IdType="pubmed">15789306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindorff L, Junkins H, Hall P, Mehta J, Manolio T. A catalog of published genome-wide association studies.  Available at:  www.genome.gov/gwastudies. Accessed Nov. 18, 2010.</Citation></Reference><Reference><Citation>Freidlin B, Zheng G, Li Z, Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered. 2002;53:146&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">12145550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou H, Hastie T. Regularization and variable selection via the Elastic Net. Journal of the Royal Statistical Society B. 2005;67:301&#x2013;320.</Citation></Reference><Reference><Citation>Cho S, Kim H, Oh S, Kim K, Park T. Elastic-net regularization approaches for genome-wide association studies of rheumatoid arthritis. BMC Proc. 2009;3(Suppl 7):S25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795922</ArticleId><ArticleId IdType="pubmed">20018015</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzzetta G, Jurman G, Furlanello C. A machine learning pipeline for quantitative phenotype prediction from genotype data. BMC Bioinformatics. 2010;11(Suppl 8):S3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966290</ArticleId><ArticleId IdType="pubmed">21034428</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman RJ, Sung YJ. Multistage analysis strategies for genome-wide association studies: summary of group 3 contributions to Genetic Analysis Workshop 16. Genet Epidemiol. 2009;33(Suppl 1):19&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996886</ArticleId><ArticleId IdType="pubmed">19924712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoggart CJ, Whittaker JC, De Iorio M, Balding DJ. Simultaneous analysis of all SNPs in genome-wide and re-sequencing association studies. PLoS Genet. 2008;4:e1000130. doi: 10.1371/journal.pgen.1000130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000130</ArticleId><ArticleId IdType="pmc">PMC2464715</ArticleId><ArticleId IdType="pubmed">18654633</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">17309939</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepe MS, Janes HE. Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer. J Natl Cancer Inst. 2008;100:978&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132154</ArticleId><ArticleId IdType="pubmed">18612128</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575184</ArticleId><ArticleId IdType="pubmed">20010215</ArticleId></ArticleIdList></Reference><Reference><Citation>Hand DJ. Evaluating diagnostic tests: The area under the ROC curve and the balance of errors. Stat Med. 2010;29:1502&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pubmed">20087877</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens AC, Khoury MJ. Assessment of improved prediction beyond traditional risk factors:when does a difference make a difference? Circ Cardiovasc Genet. 2010;3:3&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160189</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet. 2010;42:565&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232052</ArticleId><ArticleId IdType="pubmed">20562875</ArticleId></ArticleIdList></Reference><Reference><Citation>Genz A. Numerical computation of multivariate normal probabilities. J Comput Graph Stat. 1992;1:141&#x2013;149.</Citation></Reference><Reference><Citation>Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37:120&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamza TH, Payami H. The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors. J Hum Genet. 2010;55:241&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947819</ArticleId><ArticleId IdType="pubmed">20203693</ArticleId></ArticleIdList></Reference><Reference><Citation>Payami H, Zareparsi S, James D, Nutt J. Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. Arch Neurol. 2002;59:848&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020270</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21738488</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1553-7404</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>PLoS genetics</Title><ISOAbbreviation>PLoS Genet</ISOAbbreviation></Journal><ArticleTitle>A two-stage meta-analysis identifies several new loci for Parkinson's disease.</ArticleTitle><Pagination><StartPage>e1002142</StartPage><MedlinePgn>e1002142</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002142</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgen.1002142</ELocationID><Abstract><AbstractText>A previous genome-wide association (GWA) meta-analysis of 12,386 PD cases and 21,026 controls conducted by the International Parkinson's Disease Genomics Consortium (IPDGC) discovered or confirmed 11 Parkinson's disease (PD) loci. This first analysis of the two-stage IPDGC study focused on the set of loci that passed genome-wide significance in the first stage GWA scan. However, the second stage genotyping array, the ImmunoChip, included a larger set of 1,920 SNPs selected on the basis of the GWA analysis. Here, we analyzed this set of 1,920 SNPs, and we identified five additional PD risk loci (combined p&lt;5&#xd7;10(-10), PARK16/1q32, STX1B/16p11, FGF20/8p22, STBD1/4q21, and GPNMB/7p15). Two of these five loci have been suggested by previous association studies (PARK16/1q32, FGF20/8p22), and this study provides further support for these findings. Using a dataset of post-mortem brain samples assayed for gene expression (n&#x200a;=&#x200a;399) and methylation (n&#x200a;=&#x200a;292), we identified methylation and expression changes associated with PD risk variants in PARK16/1q32, GPNMB/7p15, and STX1B/16p11 loci, hence suggesting potential molecular mechanisms and candidate genes at these risk loci.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>International Parkinson's Disease Genomics Consortium (IPDGC)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Wellcome Trust Case Control Consortium 2 (WTCCC2)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0501560</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0802462</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G0901330</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400017</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>085475/B/08/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS075321</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089698</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS041509</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-0909</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100479</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000949-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900627</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>091157</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>J-0804</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA HG200336</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G1100616</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>F-1202</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0800784</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 ES101986</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0700943</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_G1000735</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>090532</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>J-0901</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_09003</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>085475/Z/08/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Genet</MedlineTA><NlmUniqueID>101239074</NlmUniqueID><ISSNLinking>1553-7390</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease.</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Plagnol</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nalls</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>Manu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheerin</LastName><ForeName>Una-Marie</ForeName><Initials>UM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saad</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sim&#xf3;n-S&#xe1;nchez</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schulte</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sveinbj&#xf6;rnsd&#xf3;ttir</LastName><ForeName>Sigurlaug</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arepalli</LastName><ForeName>Sampath</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Band</LastName><ForeName>Gavin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>Roger A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellinguez</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben-Shlomo</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berendse</LastName><ForeName>Henk W</ForeName><Initials>HW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Kailash</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Bie</LastName><ForeName>Rob M A</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biffi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bloem</LastName><ForeName>Bas</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bochdanovits</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonin</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockmann</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burn</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charlesworth</LastName><ForeName>Gavin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Honglei</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chinnery</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chong</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Carl E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>J Mark</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Counsell</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Panos</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deuschl</LastName><ForeName>G&#xfc;nther</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dexter</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Karin D</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillman</LastName><ForeName>Allissa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durif</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>D&#xfc;rr</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edkins</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Jonathan R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foltynie</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freeman</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gao</LastName><ForeName>Jianjun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardner</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xfa;stafsson</LastName><ForeName>&#xd3;mar</ForeName><Initials>&#xd3;</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Clare</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellenthal</LastName><ForeName>Garrett</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Jacobus J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hollenbeck</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holton</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huber</LastName><ForeName>Heiko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Gavin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huttenlocher</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Illig</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xf3;nsson</LastName><ForeName>P&#xe1;lmi V</ForeName><Initials>PV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langford</LastName><ForeName>Cordelia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtner</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Limousin</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Grisel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorenz</LastName><ForeName>Delia</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McNeill</LastName><ForeName>Alisdair</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moorby</LastName><ForeName>Catriona</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Huw</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudanohwo</LastName><ForeName>Ese</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Sullivan</LastName><ForeName>Sean S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearson</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearson</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>Joel S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe9;tursson</LastName><ForeName>Hj&#xf6;rvar</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pirinen</LastName><ForeName>Matti</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollak</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Post</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravina</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riess</LastName><ForeName>Olaf</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivadeneira</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzu</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sawcer</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schapira</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheffer</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoulson</LastName><ForeName>Ira</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sidransky</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Silva</LastName><ForeName>Rohan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spencer</LastName><ForeName>Chris C A</ForeName><Initials>CC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stef&#xe1;nsson</LastName><ForeName>Hreinn</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stockton</LastName><ForeName>Joanna D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strange</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Su</LastName><ForeName>Zhan</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanner</LastName><ForeName>Carlie M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tashakkori-Ghanbaria</LastName><ForeName>Avazeh</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tison</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andr&#xe9; G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandrovcova</LastName><ForeName>Jana</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velseboer</LastName><ForeName>Daan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vidailhet</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vukcevic</LastName><ForeName>Damjan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>van de Warrenburg</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weale</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wickremaratchi</LastName><ForeName>Mirdhu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Nigel</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams-Gray</LastName><ForeName>Caroline H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winder-Rhodes</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stef&#xe1;nsson</LastName><ForeName>K&#xe1;ri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wood</LastName><ForeName>Nicholas W</ForeName><Initials>NW</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21738488</ArticleId><ArticleId IdType="pmc">PMC3128098</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1002142</ArticleId><ArticleId IdType="pii">PGENETICS-D-11-00446</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zimprich A, M&#xfc;ller-Myhsok B, Farrer M, Leitner P, Sharma M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. American journal of human genetics. 2004;74:11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181898</ArticleId><ArticleId IdType="pubmed">14691730</ArticleId></ArticleIdList></Reference><Reference><Citation>Pais&#xe1;n-Ru&#xed;z C, Jain S, Evans W, Gilks W, Sim&#xf3;n J, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Abou-Sleiman P, Caputo V, Muqit M, Harvey K, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304:1158&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati V, Rizzu P, van Baren M, Schaap O, Breedveld G, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446870</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, Schulte C, Bras J, Sharma M, Gibbs R, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics. 2009;41:1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787725</ArticleId><ArticleId IdType="pubmed">19915575</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genetics. 2009;41:1303&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">19915576</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad M, Lesage S, Saint-Pierre A, Corvol J-C, Zelenika D, et al. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as risk loci for Parkinson's disease in the European population. Human Molecular Genetics. 2011;20:615&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">21084426</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Sanchez J, van Hilten J, van de Warrenburg B, Post B, Berendse H, et al. Genome-wide association study confirms extant PD risk loci among the Dutch. European Journal of Human Genetics aop 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110043</ArticleId><ArticleId IdType="pubmed">21248740</ArticleId></ArticleIdList></Reference><Reference><Citation>Dissection of the genetics of Parkinson's disease identifies an additional association 5&#x2032; of SNCA and multiple associated haplotypes at 17q21. Human Molecular Genetics. 2011;20:345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3005904</ArticleId><ArticleId IdType="pubmed">21044948</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N, Wilk J, Latourelle J, DeStefano A, Halter C, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Human genetics. 2009;124:593&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627511</ArticleId><ArticleId IdType="pubmed">18985386</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamza T, Zabetian C, Tenesa A, Laederach A, Montimurro J, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nature Genetics. 2010;42:781&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930111</ArticleId><ArticleId IdType="pubmed">20711177</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Willer C, Ding J, Scheet P, Abecasis G. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genetic epidemiology. 2010;34:816&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175618</ArticleId><ArticleId IdType="pubmed">21058334</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls M, Plagnol V, Hernandez D, Sharma M, Sheerin U-M, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696507</ArticleId><ArticleId IdType="pubmed">21292315</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Walt J, Noureddine M, Kittappa R, Hauser M, Scott W, et al. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. American journal of human genetics. 2004;74:1121&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182076</ArticleId><ArticleId IdType="pubmed">15122513</ArticleId></ArticleIdList></Reference><Reference><Citation>Smirnova T, Stinnakre J, Mallet J. Characterization of a presynaptic glutamate receptor. Science. 1993;262:430&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">8105537</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, van der Walt J, Mayhew G, Li Y-J, Z&#xfc;chner S, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. American journal of human genetics. 2008;82:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427225</ArticleId><ArticleId IdType="pubmed">18252210</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C, Dachsel J, Soto A, Heckman M, Diehl N, et al. FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. Movement disorders. 2009;24:455&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875476</ArticleId><ArticleId IdType="pubmed">19133659</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilks W, Abou-Sleiman P, Gandhi S, Jain S, Singleton A, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005;365:415&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">15680457</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner S, Pritchard J. Overcoming the winner's curse: estimating penetrance parameters from case-control data. American journal of human genetics. 2007;80:605&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852705</ArticleId><ArticleId IdType="pubmed">17357068</ArticleId></ArticleIdList></Reference><Reference><Citation>Plagnol V, Smyth D, Todd J, Clayton D. Statistical independence of the colocalized association signals for type 1 diabetes and RPS26 gene expression on chromosome 12q13. Biostatistics (Oxford, England) 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648905</ArticleId><ArticleId IdType="pubmed">19039033</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu F, Katagiri T, Suzuki M, Watanabe TK, Okuno S, et al. Cloning and chromosome assignment to 1q32 of a human cDNA (RAB7L1) encoding a small GTP-binding protein, a member of the RAS superfamily. Cytogenetics and cell genetics. 1997;77:261&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">9284931</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshimura K, Ohue T, Akiyama Y, Itoh A, Miwa S. L-dopa administration enhances exocytotic dopamine release in vivo in the rat striatum. Life sciences. 1992;51:747&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">1325018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabin D, Shimazu K, Murphy D, Cole N, Gottschalk W, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. The Journal of neuroscience. 2002;22:8797&#x2013;8807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757677</ArticleId><ArticleId IdType="pubmed">12388586</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundt K, Haga IV, Aleporou-Marinou V, Drosos Y, Wanvik B, et al. Characterisation of the NUCKS gene on human chromosome 1q32.1 and the presence of a homologous gene in different species. Biochemical and biophysical research communications. 2004;323:796&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">15381070</ArticleId></ArticleIdList></Reference><Reference><Citation>Helton T, Otsuka T, Lee M-C, Mu Y, Ehlers M. Pruning and loss of excitatory synapses by the parkin ubiquitin ligase. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:19492&#x2013;19497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614788</ArticleId><ArticleId IdType="pubmed">19033459</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarimon J, Xiromerisiou G, Eerola J, Gourbali V, Hellstr&#xf6;m O, et al. Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients. BMC neurology. 2005;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183215</ArticleId><ArticleId IdType="pubmed">15967032</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffers M, Shimkets R, Prayaga S, Boldog F, Yang M, et al. Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer research. 2001;61:3131&#x2013;3138.</Citation><ArticleIdList><ArticleId IdType="pubmed">11306498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmachi S, Mikami T, Konishi M, Miyake A, Itoh N. Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. J Neurosci Res. 2003;72:436&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">12704805</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucci A, Nalls M, Houlden H, Revesz T, Singleton A, et al. Genetic variability at the PARK16 locus. European journal of human genetics : EJHG. 2010;18:1356&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3002857</ArticleId><ArticleId IdType="pubmed">20683486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson S, Wang K, Krantz I, Hakonarson H, Goldstein D. Rare Variants Create Synthetic Genome-Wide Associations. PLoS Biol. 2010;8:e1000294. doi: 10.1371/journal.pbio.1000294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000294</ArticleId><ArticleId IdType="pmc">PMC2811148</ArticleId><ArticleId IdType="pubmed">20126254</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. American journal of human genetics. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Price A, Patterson N, Plenge R, Weinblatt M, Shadick N, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nature Genetics. 2006;38:904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042601</ArticleId><ArticleId IdType="pubmed">20981092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21753171</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Proinflammatory cytokines, sickness behavior, and Alzheimer disease.</ArticleTitle><Pagination><StartPage>212</StartPage><EndPage>218</EndPage><MedlinePgn>212-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e318225ae07</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In Alzheimer disease (AD), systemic inflammation is known to give rise to a delirium. However, systemic inflammation also gives rise to other centrally mediated symptoms in the absence of a delirium, a concept known as sickness behavior. Systemic inflammation is characterized by the systemic production of the proinflammatory cytokines tumor necrosis factor-&#x3b1; (TNF&#x3b1;) and interleukin-6 (IL-6) that mediate immune to brain communication and the development of sickness behavior.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine if raised serum TNF&#x3b1; or IL-6 are associated with the presence of sickness behavior symptoms, independent of the development of delirium, in a prospective cohort study of subjects with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 300 subjects with mild to severe AD were cognitively assessed at baseline and a blood sample taken for inflammatory markers. Cognitive assessments, including assessments to detect the development of a delirium, and blood samples were repeated at 2, 4, and 6 months. The development of neuropsychiatric symptoms in the subject with AD over the 6-month follow-up period was assessed independently by carer interview at 2, 4, and 6 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Raised serum TNF&#x3b1; and IL-6, but not CRP, were associated with an approximately 2-fold increased frequency of neuropsychiatric symptoms characteristic of sickness behavior. These relationships are independent of the development of delirium.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased serum proinflammatory cytokines are associated with the presence of symptoms characteristic of sickness behavior, which are common neuropsychiatric features found in AD. This association was independent of the presence of delirium.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Southampton, Memory Assessment and Research Centre, Botley Rd, Southampton, UK, SO30 3JB. ch4@soton.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zotova</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Culliford</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>V H</ForeName><Initials>VH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>090907</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2011 Jul 19;77(3):206-7. doi: 10.1212/WNL.0b013e31822550af.</RefSource><PMID Version="1">21753168</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055809" MajorTopicYN="N">Illness Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21753171</ArticleId><ArticleId IdType="pmc">PMC3136056</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318225ae07</ArticleId><ArticleId IdType="pii">WNL.0b013e318225ae07</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kent S, Bluthe RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992;13:24&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">1542935</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 2009;29:247&#x2013;264</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740752</ArticleId><ArticleId IdType="pubmed">19389580</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988;12:123&#x2013;137</Citation><ArticleIdList><ArticleId IdType="pubmed">3050629</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007;21:153&#x2013;160</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850954</ArticleId><ArticleId IdType="pubmed">17088043</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 2005;25:9275&#x2013;9284</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725757</ArticleId><ArticleId IdType="pubmed">16207887</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Campion S, Lunnon K, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 2009;65:304&#x2013;312</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633437</ArticleId><ArticleId IdType="pubmed">18801476</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:788&#x2013;789</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738504</ArticleId><ArticleId IdType="pubmed">12754353</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009;73:768&#x2013;774</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848584</ArticleId><ArticleId IdType="pubmed">19738171</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939&#x2013;944</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356&#x2013;1364</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308&#x2013;2314</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method: a new method for detection of delirium. Ann Intern Med 1990;113:941&#x2013;948</Citation><ArticleIdList><ArticleId IdType="pubmed">2240918</ArticleId></ArticleIdList></Reference><Reference><Citation>Piser TM. Linking the cytokine and neurocircuitry hypotheses of depression: a translational framework for discovery and development of novel anti-depressants. Brain Behav Immun 2010;24:515&#x2013;524</Citation><ArticleIdList><ArticleId IdType="pubmed">20193757</ArticleId></ArticleIdList></Reference><Reference><Citation>Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643&#x2013;652</Citation><ArticleIdList><ArticleId IdType="pubmed">11927189</ArticleId></ArticleIdList></Reference><Reference><Citation>Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004;56:819&#x2013;824</Citation><ArticleIdList><ArticleId IdType="pubmed">15576057</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DR, O'Connor JC, Dantzer R, Freund GG. Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness. Proc Natl Acad Sci USA 2005;102:15184&#x2013;15189</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1257721</ArticleId><ArticleId IdType="pubmed">16217019</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919277</ArticleId><ArticleId IdType="pubmed">18073775</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. Washington, DC: American Psychiatric Association; 1987</Citation></Reference><Reference><Citation>Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS. Confusion assessment method in the diagnostics of delirium among aged hospital patients: would it serve better in screening than as a diagnostic instrument? Int J Geriatr Psychiatry 2002;17:1112&#x2013;1119</Citation><ArticleIdList><ArticleId IdType="pubmed">12461759</ArticleId></ArticleIdList></Reference><Reference><Citation>Monette J, Galbaud du Fort G, Fung SH, et al. Evaluation of the Confusion Assessment Method (CAM) as a screening tool for delirium in the emergency room. Gen Hosp Psychiatry 2001;23:20&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pubmed">11226553</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994</Citation></Reference><Reference><Citation>Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499&#x2013;511</Citation><ArticleIdList><ArticleId IdType="pubmed">12551878</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann NY Acad Sci 2001;933:222&#x2013;234</Citation><ArticleIdList><ArticleId IdType="pubmed">12000023</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007;7:161&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">17220915</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, Strachan MW, Reynolds RM, et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 2010;59:710&#x2013;713</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828661</ArticleId><ArticleId IdType="pubmed">19959761</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiem U, Niklaus D, Sehlhoff B, et al. C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-acquired pneumonia. Age Ageing 2009;38:693&#x2013;697</Citation><ArticleIdList><ArticleId IdType="pubmed">19729453</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukardali Y, Oncul O, Kunter E, et al. Community acquired infections in elderly population. Cent Eur J Med 2009;4:171&#x2013;178</Citation></Reference><Reference><Citation>Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP. Delirium in Alzheimer disease. Alzheimer Dis Assoc Disord 1997;11:16&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pubmed">9071440</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong TG, Jones RN, Shi P, et al. Delirium accelerates cognitive decline in Alzheimer disease. Neurology 2009;72:1570&#x2013;1575</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677515</ArticleId><ArticleId IdType="pubmed">19414723</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gool WA, van de Beek D, Eikelenboom P. Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet 2010;375:773&#x2013;775</Citation><ArticleIdList><ArticleId IdType="pubmed">20189029</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, Verhey FR, Boziki M, et al. Neuropsychiatric syndromes in dementia: results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord 2007;24:457&#x2013;463</Citation><ArticleIdList><ArticleId IdType="pubmed">17986816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 2004;18:17&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">15195459</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer K, Di Iulio F, Varsi AE, et al. Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. J Alzheimers Dis 2010;20:175&#x2013;183</Citation><ArticleIdList><ArticleId IdType="pubmed">20164594</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21753176</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Hemoglobin level in older persons and incident Alzheimer disease: prospective cohort analysis.</ArticleTitle><Pagination><StartPage>219</StartPage><EndPage>226</EndPage><MedlinePgn>219-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e318225aaa9</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the hypothesis that level of hemoglobin is associated with incident Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 881 community-dwelling older persons participating in the Rush Memory and Aging Project without dementia and a measure of hemoglobin level underwent annual cognitive assessments and clinical evaluations for AD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During an average of 3.3 years of follow-up, 113 persons developed AD. In a Cox proportional hazards model adjusted for age, sex, and education, there was a nonlinear relationship between baseline level of hemoglobin such that higher and lower levels of hemoglobin were associated with AD risk (hazard ratio [HR] for the quadratic of hemoglobin 1.06, 95% confidence interval [CI] 1.01-1.11). Findings were unchanged after controlling for multiple covariates. When compared to participants with clinically normal hemoglobin (n = 717), participants with anemia (n = 154) had a 60% increased hazard for developing AD (95% CI 1.02-2.52), as did participants with clinically high hemoglobin (n = 10, HR 3.39, 95% CI 1.25-9.20). Linear mixed-effects models showed that lower and higher hemoglobin levels were associated with a greater rate of global cognitive decline (parameter estimate for quadratic of hemoglobin = -0.008, SE -0.002, p &lt; 0.001). Compared to participants with clinically normal hemoglobin, participants with anemia had a -0.061 z score unit annual decline in global cognitive function (SE 0.012, p &lt; 0.001), as did participants with clinically high hemoglobin (-0.090 unit/year, SE 0.038, p = 0.018).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In older persons without dementia, both lower and higher hemoglobin levels are associated with an increased hazard for developing AD and more rapid cognitive decline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>R C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Armour Academic Facility, Suite 1038, 600 South Paulina St., Chicago, IL 60612, USA. Raj_C_Shah@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>A S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Leurgans</LastName><ForeName>S E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG24480</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2011 Jul 19;77(3):206-7. doi: 10.1212/WNL.0b013e31822550af.</RefSource><PMID Version="1">21753168</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018962" MajorTopicYN="N">Phlebotomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21753176</ArticleId><ArticleId IdType="pmc">PMC3136057</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318225aaa9</ArticleId><ArticleId IdType="pii">WNL.0b013e318225aaa9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer's Association 2009 Alzheimer's disease facts and figures. Alzheimers Dement 2009;5:234&#x2013;270</Citation><ArticleIdList><ArticleId IdType="pubmed">19426951</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer's disease in the U.S. population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119&#x2013;1122</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodman R, Ferrucci L, Guralnik J. Anemia in older adults. Curr Opin Hematol 2005;12:123&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pubmed">15725902</ArticleId></ArticleIdList></Reference><Reference><Citation>Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004;104:2263&#x2013;2268</Citation><ArticleIdList><ArticleId IdType="pubmed">15238427</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakai NA, Katz R, Hirsch C, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005;165:2214&#x2013;2220</Citation><ArticleIdList><ArticleId IdType="pubmed">16246985</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny SD, Kuchibhatla MN, Cohen HJ. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 2006;119:327&#x2013;334</Citation><ArticleIdList><ArticleId IdType="pubmed">16564775</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves PH, Carlson MC, Ferrucci L, Guralnik JM, Serba R, Fried LP. Association between mild anemia and executive function impairment in community-dwelling older women: The Women's Health and Aging Study II. J Am Geriatr Soc 2006;54:1429&#x2013;1435</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668150</ArticleId><ArticleId IdType="pubmed">16970654</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah RC, Wilson RS, Tang Y, Dong X, Murray A, Bennett DA. Relation of hemoglobin to level of cognitive function in older persons. Neuroepidemiology 2009;32:40&#x2013;46</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739739</ArticleId><ArticleId IdType="pubmed">19001795</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard CM, Kokmen E, O'Brien PC, Ania BJ, Melton LJ., 3rd Risk of Alzheimer's disease among elderly patients with anemia: population-based investigations in Olmsted County Minnesota. Ann Epidemiol 1997;7:219&#x2013;224</Citation><ArticleIdList><ArticleId IdType="pubmed">9141646</ArticleId></ArticleIdList></Reference><Reference><Citation>Atti AR, Palmer K, Volpato S, Zuliani G, Winblad B, Fratiglioni L. Anemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging 2006;27:278&#x2013;284</Citation><ArticleIdList><ArticleId IdType="pubmed">15893409</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Burch L, Warner J, Beckeet N, Poulter R, Bulpitt C. Hemoglobin, anemia, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr 2008;8:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2529275</ArticleId><ArticleId IdType="pubmed">18691409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology 2005;25:163&#x2013;175</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Aggarwal NT, et al. Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology 2006;27:169&#x2013;176</Citation><ArticleIdList><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939&#x2013;944</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Bennett DA. Mild cognitive impairment in different function domains and incident Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005;76:1479&#x2013;1484</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739422</ArticleId><ArticleId IdType="pubmed">16227534</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Krueger KR, Hoganson G, Bienias JL, Bennett DA. Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc 2005;11:400&#x2013;407</Citation><ArticleIdList><ArticleId IdType="pubmed">16209420</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Nutritional Anemias: Report of a WHO Scientific Group: World Health Organization Tec Rep Ser 405. Geneva: WHO; 1968</Citation><ArticleIdList><ArticleId IdType="pubmed">4975372</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Kidney Disease Educational Program GFR Calculators. Available at: http://www.nkdep.nih.gov/professionals/gfr_calculators/orig_con.htm Accessed February 21, 2007</Citation></Reference><Reference><Citation>Otulana BA, Higenbottam T, Ferrari L, Scott J, Igboaka G, Wallwork J. The use of home spirometry in detecting acute lung rejection and infection following heart-lung transplantation. Chest 1990;97:353&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">2298060</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Wilson RS, Boyle PA, Tang Y, Fleischman DA, Bennett DA. Physical activity and leg strength predict decline in mobility performance in older persons. J Am Geriatr Soc 2007;55:1618&#x2013;1623</Citation><ArticleIdList><ArticleId IdType="pubmed">17697103</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Mendes de Leon CF, Barnes LL, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer's disease. JAMA 2002;287:742&#x2013;748</Citation><ArticleIdList><ArticleId IdType="pubmed">11851541</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhillips JB, Pellettera KM, Barrett-Conner E, Wingard DL, Criqui MH. Exercise patterns in a population of older adults. Am J Prev Med 1989;5:65&#x2013;72</Citation><ArticleIdList><ArticleId IdType="pubmed">2730794</ArticleId></ArticleIdList></Reference><Reference><Citation>Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385&#x2013;401</Citation></Reference><Reference><Citation>Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol 2006;5:406&#x2013;412</Citation><ArticleIdList><ArticleId IdType="pubmed">16632311</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Boyle PA, Wilson RS, Beck TL, Kelly JF, Bennett DA. Apolipoprotein E e4 allele is associated with more rapid motor decline in older persons. Alzheimer Dis Assoc Disord 2009;23:63&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662708</ArticleId><ArticleId IdType="pubmed">19266700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;74:187&#x2013;220</Citation></Reference><Reference><Citation>Laird N, Ware J. Random-effects models for longitudinal data. Biometrics 1982;38:963&#x2013;974</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzitari M, Studenski S, Rosano C, et al. Anemia is associated with the progression of white matter disease in older adults with high blood pressure: the cardiovascular health study. J Am Geriatr Soc 2008;56:1867&#x2013;1872</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897005</ArticleId><ArticleId IdType="pubmed">18811608</ArticleId></ArticleIdList></Reference><Reference><Citation>Nangaku M, Inagi R, Miyata T, Fujita T. Hypoxia and hypoxia-inducible factor in renal disease. Nephron Exp Nephrol 2008;110:e1&#x2013;e7</Citation><ArticleIdList><ArticleId IdType="pubmed">18667839</ArticleId></ArticleIdList></Reference><Reference><Citation>Assaraf MI, Diaz Z, Liberman A, et al. Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. J Neuropathol Exp Neurol 2007;66:389&#x2013;398</Citation><ArticleIdList><ArticleId IdType="pubmed">17483696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 2006;18:132&#x2013;138</Citation><ArticleIdList><ArticleId IdType="pubmed">16628067</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90&#x2013;95</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2254180</ArticleId><ArticleId IdType="pubmed">15632341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hascalovici JR, Vaya J, Khatib S, et al. Brain sterol dysregulation in sporadic AD and MCI: relationship to heme oxygenase-1. J Neurochem 2009;110:1241&#x2013;1253</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2770254</ArticleId><ArticleId IdType="pubmed">19522732</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruppo Italiano Studio Policitemia Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656&#x2013;664</Citation><ArticleIdList><ArticleId IdType="pubmed">7574220</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung WW, Wisnivesky JP, Siu AL, Ross JS. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:134&#x2013;137</Citation><ArticleIdList><ArticleId IdType="pubmed">19423714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortapamuk H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. Ann Nucl Med 2006;20:99&#x2013;106</Citation><ArticleIdList><ArticleId IdType="pubmed">16615418</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21757228</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations.</ArticleTitle><Pagination><StartPage>318</StartPage><EndPage>331</EndPage><MedlinePgn>318-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2011.06.019</ELocationID><Abstract><AbstractText>Patient-specific induced pluripotent stem cells (iPSCs) derived from somatic cells provide a unique tool for the study of human disease, as well as a promising source for cell replacement therapies. One crucial limitation has been the inability to perform experiments under genetically defined conditions. This is particularly relevant for late age onset disorders in which in vitro phenotypes are predicted to be subtle and susceptible to significant effects of genetic background variations. By combining zinc finger nuclease (ZFN)-mediated genome editing and iPSC technology, we provide a generally applicable solution to this problem, generating sets of isogenic disease and control human pluripotent stem cells that differ exclusively at either of two susceptibility variants for Parkinson's disease by modifying the underlying point mutations in the &#x3b1;-synuclein gene. The robust capability to genetically correct disease-causing point mutations in patient-derived hiPSCs represents significant progress for basic biomedical research and an advance toward hiPSC-based cell replacement therapies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soldner</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The Whitehead Institute, 9 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagani&#xe8;re</LastName><ForeName>Jos&#xe9;e</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Albert W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Hockemeyer</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Alagappan</LastName><ForeName>Raaji</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Khurana</LastName><ForeName>Vikram</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Golbe</LastName><ForeName>Lawrence I</ForeName><Initials>LI</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Guschin</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Lauren K</ForeName><Initials>LK</Initials></Author><Author ValidYN="Y"><LastName>Vu</LastName><ForeName>B Joseph</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xiangdong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Urnov</LastName><ForeName>Fyodor D</ForeName><Initials>FD</Initials></Author><Author ValidYN="Y"><LastName>Rebar</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>H Steve</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Jaenisch</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE29774</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01-CA084198</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HD045022</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD045022</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA084198</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076843</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37-HD045022</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Cell. 2011 Aug 19;146(4):659</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2011 Aug 5;9(2):93-4. doi: 10.1016/j.stem.2011.07.011.</RefSource><PMID Version="1">21816359</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005818" MajorTopicYN="N">Genetic Engineering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039904" MajorTopicYN="Y">Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="Y">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21757228</ArticleId><ArticleId IdType="mid">NIHMS312232</ArticleId><ArticleId IdType="pmc">PMC3155290</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2011.06.019</ArticleId><ArticleId IdType="pii">S0092-8674(11)00661-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, Ziller M, Croft GF, Amoroso MW, Oakley DH, et al. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell. 2011;144:439&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063454</ArticleId><ArticleId IdType="pubmed">21295703</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulting GL, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ, Williams DJ, Kahler DJ, Yamaki M, Davidow L, et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol. 2011;29:279&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229307</ArticleId><ArticleId IdType="pubmed">21293464</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, Li Y, Mu Y, Chen G, Yu D, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392969</ArticleId><ArticleId IdType="pubmed">21490598</ArticleId></ArticleIdList></Reference><Reference><Citation>Capecchi MR. Altering the genome by homologous recombination. Science. 1989;244:1288&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pubmed">2660260</ArticleId></ArticleIdList></Reference><Reference><Citation>Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell. 2008;132:544&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295571</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Ko HS, Dawson VL. Genetic Animal Models of Parkinson&#x2019;s Disease. Neuron. 2010;66:646&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917798</ArticleId><ArticleId IdType="pubmed">20547124</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimos J, Rodolfa K, Niakan K, Weisenthal L, Mitsumoto H, Chung W, Croft G, Saphier G, Leibel R, Goland R, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321:1218&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669821</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, Amora R, Hocking TD, Zhang L, Rebar EJ, et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nature Biotechnology. 2008;26:702&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674762</ArticleId><ArticleId IdType="pubmed">18500334</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, Xia DF, Miller JC, Urnov FD, Gregory PD, Holmes MC. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods. 2010:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21131970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert A, Yu J, Rose F, Mattis V, Lorson C, Thomson J, Svendsen C. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009;457:277&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659408</ArticleId><ArticleId IdType="pubmed">19098894</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott B, Richardson C, Winderbaum J, Nickoloff JA, Jasin M. Gene conversion tracts from double-strand break repair in mammalian cells. Mol Cell Biol. 1998;18:93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC121458</ArticleId><ArticleId IdType="pubmed">9418857</ArticleId></ArticleIdList></Reference><Reference><Citation>Golbe LI, Di Iorio G, Sanges G, Lazzarini AM, La Sala S, Bonavita V, Duvoisin RC. Clinical genetic analysis of Parkinson&#x2019;s disease in the Contursi kindred. Ann Neurol. 1996;40:767&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8957018</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S, Dewell S, Law M, Guo X, Li X, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell. 2010;140:678&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885838</ArticleId><ArticleId IdType="pubmed">20211137</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011;471:63&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074107</ArticleId><ArticleId IdType="pubmed">21368825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920&#x2013;1923.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, Dekelver RC, Katibah GE, Amora R, Boydston EA, Zeitler B, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol. 2009;27:851&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142824</ArticleId><ArticleId IdType="pubmed">19680244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hockemeyer D, Soldner F, Cook EG, Gao Q, Mitalipova M, Jaenisch R. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell. 2008;3:346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4097107</ArticleId><ArticleId IdType="pubmed">18786421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E, Ng S, Sourour M, Hamalainen R, Olsson C, et al. Copy number variation and selection during reprogramming to pluripotency. Nature. 2011;471:58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">21368824</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21240260</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, Lynch C, Harness JV, Lee S, Barrero MJ, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell. 2011;8:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3043464</ArticleId><ArticleId IdType="pubmed">21211785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009;461:402&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784695</ArticleId><ArticleId IdType="pubmed">19693009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lees AJ, Hardy J, Revesz T. Parkinson&#x2019;s disease. The Lancet. 2010;373:2055&#x2013;2066.</Citation><ArticleIdList><ArticleId IdType="pubmed">19524782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lengner CJ, Gimelbrant AA, Erwin JA, Cheng AW, Guenther MG, Welstead GG, Alagappan R, Frampton GM, Xu P, Muffat J, et al. Derivation of Pre-X Inactivation Human Embryonic Stem Cells under Physiological Oxygen Concentrations. Cell. 2010;141:872&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">20471072</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto MCN, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, Chen G, Gage FH, Muotri AR. A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells. Cell. 2010;143:527&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003590</ArticleId><ArticleId IdType="pubmed">21074045</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol. 2007;25:778&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">17603475</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery SB, Sammeth M, Gutierrez-Arcelus M, Lach RP, Ingle C, Nisbett J, Guigo R, Dermitzakis ET. Transcriptome genetics using second generation sequencing in a Caucasian population. Nature. 2010;464:773&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836232</ArticleId><ArticleId IdType="pubmed">20220756</ArticleId></ArticleIdList></Reference><Reference><Citation>Narva E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, Borghese L, Itskovitz-Eldor J, Rasool O, Dvorak P, et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol. 2010;28:371&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">20351689</ArticleId></ArticleIdList></Reference><Reference><Citation>Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633781</ArticleId><ArticleId IdType="pubmed">18691744</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nature Biotechnology. 2008;26:808&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422503</ArticleId><ArticleId IdType="pubmed">18587387</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickrell JK, Marioni JC, Pai AA, Degner JF, Engelhardt BE, Nkadori E, Veyrieras JB, Stephens M, Gilad Y, Pritchard JK. Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature. 2010;464:768&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3089435</ArticleId><ArticleId IdType="pubmed">20220758</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Radecke F, Peter I, Radecke S, Gellhaus K, Schwarz K, Cathomen T. Targeted chromosomal gene modification in human cells by single-stranded oligodeoxynucleotides in the presence of a DNA double-strand break. Mol Ther. 2006;14:798&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904944</ArticleId></ArticleIdList></Reference><Reference><Citation>Radecke S, Radecke F, Cathomen T, Schwarz K. Zinc-finger nuclease-induced gene repair with oligodeoxynucleotides: wanted and unwanted target locus modifications. Mol Ther. 2010;18:743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862519</ArticleId><ArticleId IdType="pubmed">20068556</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest. 2010;120:3127&#x2013;3136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929734</ArticleId><ArticleId IdType="pubmed">20739751</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson C, Jasin M. Coupled homologous and nonhomologous repair of a double-strand break preserves genomic integrity in mammalian cells. Mol Cell Biol. 2000;20:9068&#x2013;9075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86559</ArticleId><ArticleId IdType="pubmed">11074004</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell. 2009;5:584&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2921621</ArticleId><ArticleId IdType="pubmed">19951687</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JB. Update on the pathogenesis of Parkinson&#x2019;s disease. J Neurol. 2008;255(Suppl 5):3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18787877</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, et al. Parkinson&#x2019;s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009;136:964&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787236</ArticleId><ArticleId IdType="pubmed">19269371</ArticleId></ArticleIdList></Reference><Reference><Citation>Summers KM. Relationship between genotype and phenotype in monogenic diseases: relevance to polygenic diseases. Hum Mutat. 1996;7:283&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">8723677</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005;435:646&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">15806097</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel G. Stem cells. Diseases in a dish take off. Science. 2010;330:1172&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">21109645</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S, Nie J, Jonsdottir G, Ruotti V, Stewart R, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917&#x2013;1920.</Citation><ArticleIdList><ArticleId IdType="pubmed">18029452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J, Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S, Chou BK, Chen G, Ye Z, Park IH, Daley GQ, et al. Gene Targeting of a Disease-Related Gene in Human Induced Pluripotent Stem and Embryonic Stem Cells. Stem Cell. 2009;5:97&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720132</ArticleId><ArticleId IdType="pubmed">19540188</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21764118</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>378</Volume><Issue>9789</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>403</StartPage><EndPage>411</EndPage><MedlinePgn>403-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(11)60830-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Depression is common in dementia but the evidence base for appropriate drug treatment is sparse and equivocal. We aimed to assess efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We undertook the parallel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use of Antidepressants for Depression in Dementia (HTA-SADD) trial in participants from old-age psychiatry services in nine centres in England. Participants were eligible if they had probable or possible Alzheimer's disease, depression (lasting &#x2265;4 weeks), and a Cornell scale for depression in dementia (CSDD) score of 8 or more. Participants were ineligible if they were clinically critical (eg, suicide risk), contraindicated to study drugs, on antidepressants, in another trial, or had no carer. The clinical trials unit at King's College London (UK) randomly allocated participants with a computer-generated block randomisation sequence, stratified by centre, with varying block sizes, in a 1:1:1 ratio to receive sertraline (target dose 150 mg per day), mirtazapine (45 mg), or placebo (control group), all with standard care. The primary outcome was reduction in depression (CSDD score) at 13 weeks (outcomes to 39 weeks were also assessed), assessed with a mixed linear-regression model adjusted for baseline CSDD, time, and treatment centre. This study is registered, number ISRCTN88882979 and EudraCT 2006-000105-38.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Decreases in depression scores at 13 weeks did not differ between 111 controls and 107 participants allocated to receive sertraline (mean difference 1&#xb7;17, 95% CI -0&#xb7;23 to 2&#xb7;58; p=0&#xb7;10) or mirtazapine (0&#xb7;01, -1&#xb7;37 to 1&#xb7;38; p=0&#xb7;99), or between participants in the mirtazapine and sertraline groups (1&#xb7;16, -0&#xb7;25 to 2&#xb7;57; p=0&#xb7;11); these findings persisted to 39 weeks. Fewer controls had adverse reactions (29 of 111 [26%]) than did participants in the sertraline group (46 of 107, 43%; p=0&#xb7;010) or mirtazapine group (44 of 108, 41%; p=0&#xb7;031), and fewer serious adverse events rated as severe (p=0&#xb7;003). Five patients in every group died by week 39.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Because of the absence of benefit compared with placebo and increased risk of adverse events, the present practice of use of these antidepressants, with usual care, for first-line treatment of depression in Alzheimer's disease should be reconsidered.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">UK National Institute of Health Research HTA Programme.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Sube</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Health Services and Population Research Department, King's College London, London, UK. sube.banerjee@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellier</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dewey</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Romeo</LastName><ForeName>Renee</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bentham</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Katona</LastName><ForeName>Cornelius</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Knapp</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lawton</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lindesay</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>McCrae</LastName><ForeName>Niall</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Moniz-Cook</LastName><ForeName>Esme</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Joanna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Nurock</LastName><ForeName>Shirley</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Orrell</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Poppe</LastName><ForeName>Michaela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Walwyn</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN88882979</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>04/11/02</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>250PJI13LM</RegistryNumber><NameOfSubstance UI="D008803">Mianserin</NameOfSubstance></Chemical><Chemical><RegistryNumber>A051Q2099Q</RegistryNumber><NameOfSubstance UI="D000078785">Mirtazapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>QUC7NX6WMB</RegistryNumber><NameOfSubstance UI="D020280">Sertraline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2011 Jul 30;378(9789):375-6. doi: 10.1016/S0140-6736(11)61031-3.</RefSource><PMID Version="1">21764117</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Curr Neurol Neurosci Rep. 2011 Dec;11(6):520-2. doi: 10.1007/s11910-011-0222-y.</RefSource><PMID Version="1">21909654</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2012 Feb;15(1):17. doi: 10.1136/ebmh.2011.100256.</RefSource><PMID Version="1">22096088</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2012 Jan 21;379(9812):220. doi: 10.1016/S0140-6736(12)60102-0.</RefSource><PMID Version="1">22265630</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Aust N Z J Psychiatry. 2012 Jul;46(7):595-7. doi: 10.1177/0004867412449061.</RefSource><PMID Version="1">22735635</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008803" MajorTopicYN="N">Mianserin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078785" MajorTopicYN="N">Mirtazapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020280" MajorTopicYN="N">Sertraline</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21764118</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(11)60830-1</ArticleId><ArticleId IdType="pii">S0140-6736(11)60830-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21771893</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3679</ISSN><JournalIssue CitedMedium="Internet"><Volume>171</Volume><Issue>14</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Archives of internal medicine</Title><ISOAbbreviation>Arch Intern Med</ISOAbbreviation></Journal><ArticleTitle>Activity energy expenditure and incident cognitive impairment in older adults.</ArticleTitle><Pagination><StartPage>1251</StartPage><EndPage>1257</EndPage><MedlinePgn>1251-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archinternmed.2011.277</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Studies suggest that physically active people have reduced risk of incident cognitive impairment in late life. However, these studies are limited by reliance on self-reports of physical activity, which only moderately correlate with objective measures and often exclude activity not readily quantifiable by frequency and duration. The objective of this study was to investigate the relationship between activity energy expenditure (AEE), an objective measure of total activity, and incidence of cognitive impairment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We calculated AEE as 90% of total energy expenditure (assessed during 2 weeks using doubly labeled water) minus resting metabolic rate (measured using indirect calorimetry) in 197 men and women (mean age, 74.8 years) who were free of mobility and cognitive impairments at study baseline (1998-1999). Cognitive function was assessed at baseline and 2 or 5 years later using the Modified Mini-Mental State Examination. Cognitive impairment was defined as a decline of at least 1.0 SD (9 points) between baseline and follow-up evaluations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After adjustment for baseline Modified Mini-Mental State Examination scores, demographics, fat-free mass, sleep duration, self-reported health, and diabetes mellitus, older adults in the highest sex-specific tertile of AEE had lower odds of incident cognitive impairment than those in the lowest tertile (odds ratio, 0.09; 95% confidence interval, 0.01-0.79). There was also a significant dose response between AEE and incidence of cognitive impairment (P&#xa0;=&#xa0;.05 for trend over tertiles).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings indicate that greater AEE may be protective against cognitive impairment in a dose-response manner. The significance of overall activity in contrast to vigorous or light activity should be determined.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Heart and Stroke Foundation Centre for Stroke Recovery, Sunnybrook Research Institute, 2075 Bayview Ave, A421, Toronto, ON M4N 3M5, Canada. Middleton_l@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manini</LastName><ForeName>Todd M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Simonsick</LastName><ForeName>Eleanor M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Tamara B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Deborah E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Tylavsky</LastName><ForeName>Frances</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Brach</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Everhart</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01-AG-6-2101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AG-6-2103</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01-AG-024069</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AG-6-2106</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG026766-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 AG062101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG024069</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG026766</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG028740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Intern Med</MedlineTA><NlmUniqueID>0372440</NlmUniqueID><ISSNLinking>0003-9926</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Intern Med. 2011 Jul 25;171(14):1258-9. doi: 10.1001/archinternmed.2011.273.</RefSource><PMID Version="1">21771895</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Intern Med. 2012 Jan 9;172(1):83; author reply 84. doi: 10.1001/archinternmed.2011.615.</RefSource><PMID Version="1">22232159</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001481" MajorTopicYN="Y">Basal Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001823" MajorTopicYN="N">Body Composition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="Y">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005082" MajorTopicYN="Y">Physical Exertion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012494" MajorTopicYN="N">Sampling Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012647" MajorTopicYN="N">Self-Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None of the authors report a conflict of interest relevant to the current study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21771893</ArticleId><ArticleId IdType="mid">NIHMS352199</ArticleId><ArticleId IdType="pmc">PMC3923462</ArticleId><ArticleId IdType="doi">10.1001/archinternmed.2011.277</ArticleId><ArticleId IdType="pii">archinternmed.2011.277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol. 2009 Oct;66:1210&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762111</ArticleId><ArticleId IdType="pubmed">19822776</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med. 2006 Jan 17;144:73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16418406</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol. 2001 Mar;58:498&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255456</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Middleton L. Physical activity and the maintenance of cognitive function. Alzheimers Dement. 2007 Apr;3:S38&#x2013;S44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595973</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovio S, Kareholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005 Nov;4:705&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239176</ArticleId></ArticleIdList></Reference><Reference><Citation>Lytle ME, Vander Bilt J, Pandav RS, Dodge HH, Ganguli M. Exercise level and cognitive decline: the MoVIES project. Alzheimer Dis Assoc Disord. 2004;18:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249848</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuit AJ, Feskens EJ, Launer LJ, Kromhout D. Physical activity and cognitive decline, the role of the apolipoprotein e4 allele. Med Sci Sports Exerc. 2001 May;33:772&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">11323547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Barnes D, Nevitt M, Lui LY, Covinsky K. A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med. 2001 Jul 23;161:1703&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">11485502</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerterp KR. Assessment of physical activity: a critical appraisal. Eur J Appl Physiol. 2009 Feb 12;105:823&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">19205725</ArticleId></ArticleIdList></Reference><Reference><Citation>Donahoo WT, Levine JA, Melanson EL. Variability in energy expenditure and its components. Curr Opin Clin Nutr Metab Care. 2004 Nov;7:599&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534426</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Blackwell T, Stone KL, Goldman SE, Hillier T, Yaffe K. Cognition in older women: the importance of daytime movement. J Am Geriatr Soc. 2008 Sep;56:1658&#x2013;1664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680379</ArticleId><ArticleId IdType="pubmed">18662201</ArticleId></ArticleIdList></Reference><Reference><Citation>Manini TM, Everhart JE, Patel KV, et al. Daily activity energy expenditure and mortality among older adults. JAMA. Dec 7;296:171&#x2013;179. 6 A.D.</Citation><ArticleIdList><ArticleId IdType="pubmed">16835422</ArticleId></ArticleIdList></Reference><Reference><Citation>Manini TM, Everhart JE, Anton SD, et al. Activity energy expenditure and change in body composition in late life. 2009;90:1336&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762160</ArticleId><ArticleId IdType="pubmed">19740971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahar DR, Yu B, Houston DK, et al. Dietary Factors in Relation to Daily Activity Energy Expenditure and Mortality among Older Adults. J Nutr Health Agin. 2009 May;13:414&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757288</ArticleId><ArticleId IdType="pubmed">19390747</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooks RN, Simonsick EM, Miles T, et al. The association of race and socioeconomic status with cardiovascular disease indicators among older adults in the health, aging, and body composition study. J Gerontol B Psychol Sci Soc Sci. 2002 Jul;57:S247&#x2013;S256.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084794</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanc S, Colligan AS, Trabulsi J, et al. Influence of delayed isotopic equilibration in urine on the accuracy of the (2)H(2)(18)O method in the elderly. J Appl Physiol. 2002 Mar;92:1036&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pubmed">11842037</ArticleId></ArticleIdList></Reference><Reference><Citation>Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol. 1949;109:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1392602</ArticleId><ArticleId IdType="pubmed">15394301</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia M, Ritz P, Stubbs RJ. Total energy expenditure in the elderly. Eur J Clin Nutri. 2000 Jun;54:S92&#x2013;S103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11041080</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanc S, Schoeller DA, Bauer D, et al. Energy requirements in the eighth decade of life. Am J Clin Nutr. 2004 Feb;79:303&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">14749238</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloesch D, Schutz Y, Breitenstein E, Jequier E, Felber JP. Thermogenic response to an oral glucose load in man: comparison between young and elderly subjects. J Am Coll Nutr. 1988 Dec;7:471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">3068276</ArticleId></ArticleIdList></Reference><Reference><Citation>Rising R, Harper IT, Fontvielle AM, Ferraro RT, Spraul M, Ravussin E. Determinants of total daily energy expenditure: variability in physical activity. Am J Clin Nutr. 1994 Apr;59:800&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">8147322</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs DR, Jr, Ainsworth BE, Hartman TJ, Leon AS. A simultaneous evaluation of 10 commonly used physical activity questionnaires. Med Sci Sports Exerc. 1993 Jan;25:81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423759</ArticleId></ArticleIdList></Reference><Reference><Citation>Slinde F, Arvidsson D, Sjoberg A, Rossander-Hulthen L. Minnesota leisure time activity questionnaire and doubly labeled water in adolescents. Med Sci Sports Exerc. 2003 Nov;35:1923&#x2013;1928.</Citation><ArticleIdList><ArticleId IdType="pubmed">14600560</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor HL, Jacobs DR, Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis. 1978;31:741&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">748370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993 Jan;25:71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8292105</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987 Aug;48:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Lindquist K, Shlipak MG, et al. Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol. 2008 Jun;63:798&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2584446</ArticleId><ArticleId IdType="pubmed">18496846</ArticleId></ArticleIdList></Reference><Reference><Citation>Radloff LS. A self-report depression scale for research in the general population. 1977;1:385&#x2013;401.</Citation></Reference><Reference><Citation>Middleton L, Kirkland S, Rockwood K. Prevention of CIND by physical activity: different impact on VCI-ND compared with MCI. J Neurol Sci. 2008 Jun 15;269:80&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">18243244</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. 1995 Jun 01;:1161&#x2013;1168. 1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783883</ArticleId></ArticleIdList></Reference><Reference><Citation>Neilson HK, Robson PJ, Friedenreich CM, Csizmadi I. Estimating activity energy expenditure: how valid are physical activity questionnaires? Am J Clin Nutr. 2008 Feb;87:279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">18258615</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder K, van Sluijs EM, Wright A, Whincup P, Wareham NJ, Ekelund U. Is it possible to assess free-living physical activity and energy expenditure in young people by self-report? Am J Clin Nutr. 2009 Mar;89:862&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">19144732</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhillips JB, Pellettera KM, Barrett-Connor E, Wingard DL, Criqui MH. Exercise patterns in a population of older adults. Am J Prev Med. 1989 Mar;5:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">2730794</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Boyle PA, Wilson RS, Tang Y, Bennett DA. Frailty is associated with incident Alzheimer's disease and cognitive decline in the elderly. Psychosom Med. 2007 Jun;69:483&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556640</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Buchman AS, Wilson RS, Leurgans SE, Bennett DA. Physical frailty is associated with incident mild cognitive impairment in community-based older persons. J Am Geriatr Soc. 2010 Feb;58:248&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150526</ArticleId><ArticleId IdType="pubmed">20070417</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007 Aug 31;30:464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">17765329</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Pinilla F, Vaynman S, Ying Z. Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur J Neurosci. 2008 Dec;28:2278&#x2013;2287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805663</ArticleId><ArticleId IdType="pubmed">19046371</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci. 2004 Nov;20:2580&#x2013;2590.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548201</ArticleId></ArticleIdList></Reference><Reference><Citation>Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci. 2005 Apr 27;25:4217&#x2013;4221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725122</ArticleId><ArticleId IdType="pubmed">15858047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesaniemi YK, Danforth E, Jr, Jensen MD, Kopelman PG, Lefebvre P, Reeder BA. Dose-response issues concerning physical activity and health: an evidence-based symposium. Med Sci Sports Exerc. 2001 Jun;33:S351&#x2013;S358.</Citation><ArticleIdList><ArticleId IdType="pubmed">11427759</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794848</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol. 2008 May 6;585:119&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474785</ArticleId><ArticleId IdType="pubmed">18384771</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology. 2004 Aug 24;63:658&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326238</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew MK, Rockwood K. A five-point change in Modified Mini-Mental State Examination was clinically meaningful in community-dwelling elderly people. J Clin Epidemiol. 2008 Aug;61:827&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">18468855</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21771894</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3679</ISSN><JournalIssue CitedMedium="Internet"><Volume>171</Volume><Issue>14</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Archives of internal medicine</Title><ISOAbbreviation>Arch Intern Med</ISOAbbreviation></Journal><ArticleTitle>Physical activity and cognition in women with vascular conditions.</ArticleTitle><Pagination><StartPage>1244</StartPage><EndPage>1250</EndPage><MedlinePgn>1244-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archinternmed.2011.282</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Individuals with vascular disease or risk factors have substantially higher rates of cognitive decline, yet little is known about means of maintaining cognition in this group.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined the relation between physical activity and cognitive decline in participants of the Women's Antioxidant Cardiovascular Study, a cohort of women with prevalent vascular disease or at least 3 coronary risk factors. Recreational physical activity was assessed at baseline (October 1995 through June 1996) and every 2 years thereafter. Between December 1998 and July 2000, a total of 2809 women 65 years or older underwent a cognitive battery by telephone interview, including 5 tests of global cognition, verbal memory, and category fluency. Tests were administered 3 additional times over 5.4 years. We used multivariable-adjusted general linear models for repeated measures to compare the annual rates of cognitive score changes across levels of total physical activity and energy expended in walking, as assessed at Women's Antioxidant Cardiovascular Study baseline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found a significant trend (P &lt; .001 for trend) toward decreasing rates of cognitive decline with increasing energy expenditure. Compared with the bottom quintile of total physical activity, significant differences in rates of cognitive decline were observed from the fourth quintile (P = .04 for the fourth quintile and P &lt; .001 for the fifth quintile), or the equivalent of daily 30-minute walks at a brisk pace. This was equivalent to the difference in cognitive decline observed for women who were 5 to 7 years younger. Regularly walking for exercise was strongly related to slower rates of cognitive decline (P = .003 for trend).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Regular physical activity, including walking, was associated with better preservation of cognitive function in older women with vascular disease or risk factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vercambre</LastName><ForeName>Marie-No&#xeb;l</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Foundation of Public Health, Mutuelle Generale de l'Education Nationale, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grodstein</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Manson</LastName><ForeName>JoAnn E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Stampfer</LastName><ForeName>Meir J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jae H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG015933</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL046959</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15933</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL046959</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Intern Med</MedlineTA><NlmUniqueID>0372440</NlmUniqueID><ISSNLinking>0003-9926</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Intern Med. 2011 Jul 25;171(14):1258-9. doi: 10.1001/archinternmed.2011.273.</RefSource><PMID Version="1">21771895</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Intern Med. 2012 Jan 9;172(1):83; author reply 84. doi: 10.1001/archinternmed.2011.615.</RefSource><PMID Version="1">22232159</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001642" MajorTopicYN="N">Bicycling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003615" MajorTopicYN="N">Dancing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007590" MajorTopicYN="N">Jogging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005082" MajorTopicYN="Y">Physical Exertion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012420" MajorTopicYN="N">Running</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013550" MajorTopicYN="N">Swimming</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013689" MajorTopicYN="N">Telephone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016387" MajorTopicYN="N">Women's Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015013" MajorTopicYN="N">Yoga</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21771894</ArticleId><ArticleId IdType="mid">NIHMS314477</ArticleId><ArticleId IdType="pmc">PMC3153432</ArticleId><ArticleId IdType="doi">10.1001/archinternmed.2011.282</ArticleId><ArticleId IdType="pii">archinternmed.2011.282</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de la Torre JC. How do heart disease and stroke become risk factors for Alzheimer&#x2019;s disease? Neurol Res. 2006;28(6):637&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">16945216</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tang M-X, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. A summary risk score for the prediction of Alzheimer Disease in elderly persons. Arch Neurol. 2010;67(7):835&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068839</ArticleId><ArticleId IdType="pubmed">20625090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics--2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">19075105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Barnes D, Nevitt M, Lui LY, Covinsky K. A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med. 2001;161(14):1703&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">11485502</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuit AJ, Feskens EJ, Launer LJ, Kromhout D. Physical activity and cognitive decline, the role of the apolipoprotein e4 allele. Med Sci Sports Exerc. 2001;33(5):772&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">11323547</ArticleId></ArticleIdList></Reference><Reference><Citation>Weuve J, Kang JH, Manson JE, Breteler MM, Ware JH, Grodstein F. Physical activity, including walking, and cognitive function in older women. JAMA. 2004;292(12):1454&#x2013;1461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15383516</ArticleId></ArticleIdList></Reference><Reference><Citation>Podewils LJ, Guallar E, Kuller LH, et al. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol. 2005;161(7):639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">15781953</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassilhas RC, Viana VA, Grassmann V, et al. The impact of resistance exercise on the cognitive function of the elderly. Med Sci Sports Exerc. 2007;39(8):1401&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pubmed">17762374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300(9):1027&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">18768414</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton LE, Mitnitski A, Fallah N, Kirkland SA, Rockwood K. Changes in cognition and mortality in relation to exercise in late life: a population based study. PLoS One. 2008;3(9):e3124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518854</ArticleId><ArticleId IdType="pubmed">18769616</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol. 2010;67(1):71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056436</ArticleId><ArticleId IdType="pubmed">20065132</ArticleId></ArticleIdList></Reference><Reference><Citation>Etgen T, Sander D, Huntgeburth U, Poppert H, Forstl H, Bickel H. Physical activity and incident cognitive impairment in elderly persons: the INVADE study. Arch Intern Med. 2010;170(2):186&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">20101014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2000;(4):CD001800.</Citation><ArticleIdList><ArticleId IdType="pubmed">11034729</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women&#x2019;s Antioxidant Cardiovascular Study. Arch Intern Med. 2007;167(15):1610&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034519</ArticleId><ArticleId IdType="pubmed">17698683</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299(17):2027&#x2013;2036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684623</ArticleId><ArticleId IdType="pubmed">18460663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Cook N, Manson J, Buring JE, Albert CM, Grodstein F. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr. 2008;88(6):1602&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3470481</ArticleId><ArticleId IdType="pubmed">19064521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Cook NR, Manson JE, Buring JE, Albert CM, Grodstein F. Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women&#x2019;s Antioxidant and Cardiovascular Study. Circulation. 2009;119(21):2772&#x2013;2780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752297</ArticleId><ArticleId IdType="pubmed">19451353</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;25(1):71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8292105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol. 1994;23(5):991&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">7860180</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt J, Folstein MF. Telephone Interview for Cognitive Status: Professional Manual. Lutz, FL: Psychological Assessment Resources, Inc; 2003.</Citation></Reference><Reference><Citation>Scherr PA, Albert MS, Funkenstein HH, et al. Correlates of cognitive function in an elderly community population. Am J Epidemiol. 1988;128:1084&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">3189282</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer&#x2019;s disease. Neurology. 1989;39:1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Fratiglioni L, Viitanen M, Winblad B, Backman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population based sample. Arch Neurol. 2000;57:839&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867781</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien JT. Vascular cognitive impairment. Am J Geriatr Psychiatry. 2006;14(9):724&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">16943169</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmond DW. The neuropsychology of vascular cognitive impairment: is there a specific cognitive deficit? J Neurol Sci. 2004;226(1&#x2013;2):3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537510</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanne D, Freimark D, Poreh A, et al. Cognitive functions in severe congestive heart failure before and after an exercise training program. Int J Cardiol. 2005;103(2):145&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">16080972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploughman M, McCarthy J, Bosse M, Sullivan HJ, Corbett D. Does treadmill exercise improve performance of cognitive or upper-extremity tasks in people with chronic stroke? A randomized cross-over trial. Arch Phys Med Rehabil. 2008;89(11):2041&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">18996231</ArticleId></ArticleIdList></Reference><Reference><Citation>Devore EE, Kang JH, Okereke O, Grodstein F. Physical Activity Levels and Cognition in Women With Type 2 Diabetes. Am J Epidemiol. 2009;170(8):1040&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765365</ArticleId><ArticleId IdType="pubmed">19729385</ArticleId></ArticleIdList></Reference><Reference><Citation>Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, Vanhees L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2008;(3):CD005381.</Citation><ArticleIdList><ArticleId IdType="pubmed">18646126</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Ambrose T, Nagamatsu LS, Graf P, Beattie BL, Ashe MC, Handy TC. Resistance Training and Executive Functions: A 12-Month Randomized Controlled Trial. Arch Intern Med. 2010;170(2):170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448565</ArticleId><ArticleId IdType="pubmed">20101012</ArticleId></ArticleIdList></Reference><Reference><Citation>Klusmann V, Evers A, Schwarzer R, et al. Complex mental and physical activity in older women and cognitive performance: a 6-month randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2010;65(6):680&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">20418350</ArticleId></ArticleIdList></Reference><Reference><Citation>Solfrizzi V, Capurso C, D&#x2019;Introno A, et al. Lifestyle-related factors in predementia and dementia syndromes. Expert Rev Neurother. 2008;8(1):133&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">18088206</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30(9):464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">17765329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer AF, Erickson KI. Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function. Trends Cogn Sci. 2007;11(8):342&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">17629545</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3(6):343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">15157849</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Cronk BB, Anderson HS, et al. Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology. 2008;71(3):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657657</ArticleId><ArticleId IdType="pubmed">18625967</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108(7):3017&#x2013;3022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041121</ArticleId><ArticleId IdType="pubmed">21282661</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PD, Buchner D, Pina IL, et al. Exercise and Physical Activity in the Prevention and Treatment of Atherosclerotic Cardiovascular Disease: A Statement From the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) Circulation. 2003;107(24):3109&#x2013;3116.</Citation><ArticleIdList><ArticleId IdType="pubmed">12821592</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosano C, Newman AB. Cardiovascular disease and risk of Alzheimer&#x2019;s disease. Neurol Res. 2006;28(6):612&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">16945212</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">18039117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamer M, Stamatakis E. Physical activity and risk of cardiovascular disease events: inflammatory and metabolic mechanisms. Med Sci Sports Exerc. 2009;41(6):1206&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">19461547</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance DE, Wadley VG, Ball KK, Roenker DL, Rizzo M. The effects of physical activity and sedentary behavior on cognitive health in older adults. J Aging Phys Act. 2005;13(3):294&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">16192657</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudreau SA, O&#x2019;Hara R. The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adults. Psychol Aging. 2009;24(2):507&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725021</ArticleId><ArticleId IdType="pubmed">19485667</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21775587</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>29</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice.</ArticleTitle><Pagination><StartPage>10427</StartPage><EndPage>10431</EndPage><MedlinePgn>10427-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1459-11.2011</ELocationID><Abstract><AbstractText>Previous studies suggested that the cellular prion protein (PrP(c)) plays a critical role in the pathogenesis of Alzheimer's disease (AD). Specifically, amyloid-&#x3b2; (A&#x3b2;) oligomers were proposed to cause synaptic and cognitive dysfunction by binding to PrP(c). To test this hypothesis, we crossed human amyloid precursor protein (hAPP) transgenic mice from line J20 onto a PrP(c)-deficient background. Ablation of PrP(c) did not prevent the premature mortality and abnormal neural network activity typically seen in hAPPJ20 mice. Furthermore, hAPPJ20 mice with or without PrP(c) expression showed comparably robust abnormalities in learning and memory and in other behavioral domains at 6-8 months of age. Notably, these abnormalities are not refractory to therapeutic manipulations in general: they can be effectively prevented by interventions that prevent A&#x3b2;-dependent neuronal dysfunction also in other lines of hAPP transgenic mice. Thus, at least in this model, PrP(c) is not an important mediator of A&#x3b2;-induced neurological impairments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ciss&#xe9;</LastName><ForeName>Moustapha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Pascal E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR18928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018620">PrPSc Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurosci. 2011 Sep 28;31(39):14046</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018620" MajorTopicYN="N">PrPSc Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21775587</ArticleId><ArticleId IdType="mid">NIHMS312961</ArticleId><ArticleId IdType="pmc">PMC3314063</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1459-11.2011</ArticleId><ArticleId IdType="pii">31/29/10427</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Baumann F, Bremer J. The prion's elusive reason for being. Annu Rev Neurosci. 2008;31:439&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">18558863</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron. 2010;66:631&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956420</ArticleId><ArticleId IdType="pubmed">20547123</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G. Synthetic amyloid-{beta} oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A. 2010;107:2295&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836680</ArticleId><ArticleId IdType="pubmed">20133875</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;eler H, Fischer M, Lang Y, Bluethmann H, Lipp H, DeArmond S, Prusiner S, Aguet M, Weissmann C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 1992;356:577&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">1373228</ArticleId></ArticleIdList></Reference><Reference><Citation>Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med. 2010;2:306&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962809</ArticleId><ArticleId IdType="pubmed">20665634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliv&#xe4;li J, Lesn&#xe9; S, Ashe KH, Muchowski PJ, Mucke L. Accelerating amyloid-&#x3b2; fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Yu G-Q, Kojima N, Masliah E, Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004;24:4692&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729387</ArticleId><ArticleId IdType="pubmed">15140940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005;25:9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciss&#xe9; M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu G-Q, Mucke L. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Bell KA, Bui D, Sweatt JD. b-Amyloid peptide activates a7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem. 2002;277:25056&#x2013;25061.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983690</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laur&#xe9;n J, Gimbel ZA, Strittmatter SM. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010;30:6367&#x2013;6374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323924</ArticleId><ArticleId IdType="pubmed">20445063</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E, Mucke L. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci. 2010;30:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064502</ArticleId><ArticleId IdType="pubmed">20053918</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A&#x3b2;42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Nguyen LN, Nabavi S, Malinow R. The prion protein as a receptor for amyloid-beta. Nature. 2010;466:E3&#x2013;E4. discussion E4&#x2013;E5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057871</ArticleId><ArticleId IdType="pubmed">20703260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi DT, Chen KS. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 2005;4:173&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15810905</ArticleId></ArticleIdList></Reference><Reference><Citation>Laur&#xe9;n J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, Yu G-Q, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K, Mucke L. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2008;28:5007&#x2013;5017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315282</ArticleId><ArticleId IdType="pubmed">18463254</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ, Mucke L. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic A&#x3b2; oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci. 2009;29:1977&#x2013;1986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768427</ArticleId><ArticleId IdType="pubmed">19228952</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, F&#xfc;l&#xf6;p L, Penke B, Zilberter Y, Harkany T, Pitk&#xe4;nen A, Tanila H. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29:3453&#x2013;3462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665248</ArticleId><ArticleId IdType="pubmed">19295151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Origlia N, Arancio O, Domenici L, Yan SS. MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. Expert Rev Neurother. 2009;9:1635&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8965749</ArticleId><ArticleId IdType="pubmed">19903023</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu G-Q, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel A, Burgaya F, Gav&#xed;n R, Soriano E, Aguzzi A, Del R&#xed;o JA. Enhanced susceptibility of Prnp-deficient mice to kainate-induced seizures, neuronal apoptosis, and death: role of AMPA/kainate receptors. J Neurosci Res. 2007;85:2741&#x2013;2755.</Citation><ArticleIdList><ArticleId IdType="pubmed">17304577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratt&#xe9; S, Vreugdenhil M, Boult JK, Patel A, Asante EA, Collinge J, Jefferys JG. Threshold for epileptiform activity is elevated in prion knockout mice. Neuroscience. 2011;179:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">21277354</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010;66:739&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111138</ArticleId><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G-Q, Mucke L. Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu G-Q, Palop JJ, Noebels JL, Mucke L. Amyloid-&#x3b2;/Fyn-induced synaptic, network, and cognitive impairments depend on Tau levels in multiple mouse models of Alzheimer's disease. J Neurosci. 2011;31:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L. Levels and alternative splicing of amyloid b protein precursor (APP) transcripts in brains of transgenic mice and humans with Alzheimer's disease. J Biol Chem. 1995;270:28257&#x2013;28267.</Citation><ArticleIdList><ArticleId IdType="pubmed">7499323</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 2010;277:1348&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pubmed">20148964</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Mejia RO, Newman JW, Toh S, Yu G-Q, Zhou Y, Halabisky B, Ciss&#xe9; M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L. Phospholipase A2 reduction ameliorates cognitive deficits in mouse model of Alzheimer's disease. Nat Neurosci. 2008;11:1311&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597064</ArticleId><ArticleId IdType="pubmed">18931664</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011;7:208&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414557</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz R, Amaral OB, Rockenbach IC, Roesler R, Izquierdo I, Cavalheiro EA, Martins VR, Brentani RR. Increased sensitivity to seizures in mice lacking cellular prion protein. Epilepsia. 1999;40:1679&#x2013;1682.</Citation><ArticleIdList><ArticleId IdType="pubmed">10612329</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz R, Castro RM, Velasco TR, Carlotti CG, Jr, Sakamoto AC, Brentani RR, Martins VR. Cellular prion protein: implications in seizures and epilepsy. Cell Mol Neurobiol. 2002;22:249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11533873</ArticleId><ArticleId IdType="pubmed">12469868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21784978</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>32</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Constitutive cAMP response element binding protein (CREB) activation by Alzheimer's disease presenilin-driven inositol trisphosphate receptor (InsP3R) Ca2+ signaling.</ArticleTitle><Pagination><StartPage>13293</StartPage><EndPage>13298</EndPage><MedlinePgn>13293-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1109297108</ELocationID><Abstract><AbstractText>Mutations in presenilins (PS) account for most early-onset familial Alzheimer's disease (FAD). Accumulating evidence suggests that disrupted Ca(2+) signaling may play a proximal role in FAD specifically, and Alzheimer's disease (AD) more generally, but its links to the pathogenesis of AD are obscure. Here we demonstrate that expression of FAD mutant PS constitutively activates the transcription factor cAMP response element binding protein (CREB) and CREB target gene expression in cultured neuronal cells and AD mouse models. Constitutive CREB activation was associated with and dependent on constitutive activation of Ca(2+)/CaM kinase kinase &#x3b2; and CaM kinase IV (CaMKIV). Depletion of endoplasmic reticulum Ca(2+) stores or plasma membrane phosphatidylinositol-bisphosphate and pharmacologic inhibition or knockdown of the expression of the inositol trisphosphate receptor (InsP(3)R) Ca(2+) release channel each abolished FAD PS-associated constitutive CaMKIV and CREB phosphorylation. CREB and CaMKIV phosphorylation and CREB target gene expression, including nitric oxide synthase and c-fos, were enhanced in brains of M146V-KI and 3xTg-AD mice expressing FAD mutant PS1 knocked into the mouse locus. FAD mutant PS-expressing cells demonstrated enhanced cell death and sensitivity to A&#x3b2; toxicity, which were normalized by interfering with the InsP(3)R-CAMKIV-CREB pathway. Thus, constitutive CREB phosphorylation by exaggerated InsP(3)R Ca(2+) signaling in FAD PS-expressing cells may represent a signaling pathway involved in the pathogenesis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Marioly</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C&#xe1;rdenas</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>King-Ho</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Foskett</LastName><ForeName>J Kevin</ForeName><Initials>JK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK056328</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059937</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM/DK56328</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH059937</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053496">Inositol 1,4,5-Trisphosphate Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.17</RegistryNumber><NameOfSubstance UI="D054734">Calcium-Calmodulin-Dependent Protein Kinase Type 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.17</RegistryNumber><NameOfSubstance UI="C517685">Camk4 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="Y">Calcium Signaling</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054734" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinase Type 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053496" MajorTopicYN="N">Inositol 1,4,5-Trisphosphate Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21784978</ArticleId><ArticleId IdType="pmc">PMC3156223</ArticleId><ArticleId IdType="doi">10.1073/pnas.1109297108</ArticleId><ArticleId IdType="pii">1109297108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge MJ. Neuronal calcium signaling. Neuron. 1998;21:13&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9697848</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, et al. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci. 2006;26:5180&#x2013;5189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674246</ArticleId><ArticleId IdType="pubmed">16687509</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, et al. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann N Y Acad Sci. 2007;1097:265&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008;31:454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, LaFerla FM. Linking calcium to A&#x3b2; and Alzheimer's disease. Neuron. 2008;59:190&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667147</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, et al. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid &#x3b2; production. J Gen Physiol. 2008;132:1107&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">18663130</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson O, et al. Familial Alzheimer disease&#x2013;linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest. 2007;117:1230&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847535</ArticleId><ArticleId IdType="pubmed">17431506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, et al. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease&#x2013;linked presenilin mutants in human cells and mouse neurons. Sci Signal. 2010;3:ra22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898196</ArticleId><ArticleId IdType="pubmed">20332427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, et al. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron. 2008;58:871&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2495086</ArticleId><ArticleId IdType="pubmed">18579078</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkbeiner S, et al. CREB: A major mediator of neuronal neurotrophin responses. Neuron. 1997;19:1031&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9390517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Chawla S, Johnson CM, Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature. 1997;385:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">9000075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu GY, Deisseroth K, Tsien RW. Activity-dependent CREB phosphorylation: Convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA. 2001;98:2808&#x2013;2813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30221</ArticleId><ArticleId IdType="pubmed">11226322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Bading H. Calcium as a versatile second messenger in the control of gene expression. Microsc Res Tech. 1999;46:348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">10504212</ArticleId></ArticleIdList></Reference><Reference><Citation>West AE, et al. Calcium regulation of neuronal gene expression. Proc Natl Acad Sci USA. 2001;98:11024&#x2013;11031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58677</ArticleId><ArticleId IdType="pubmed">11572963</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Valero J. The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Rev Neurosci. 2011;22:153&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">21476939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaimovich E, et al. Xestospongin B, a competitive inhibitor of IP3-mediated Ca2+ signaling in cultured rat myotubes, isolated myonuclei, and neuroblastoma (NG108-15) cells. FEBS Lett. 2005;579:2051&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">15811317</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton CL, Mignery GA, S&#xfc;dhof TC. Co-expression in vertebrate tissues and cell lines of multiple inositol 1,4,5-trisphosphate (InsP3) receptors with distinct affinities for InsP3. J Biol Chem. 1994;269:28613&#x2013;28619.</Citation><ArticleIdList><ArticleId IdType="pubmed">7961809</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer PL, Greenberg ME. From synapse to nucleus: Calcium-dependent gene transcription in the control of synapse development and function. Neuron. 2008;59:846&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">18817726</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol Rev. 2009;89:121&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883056</ArticleId><ArticleId IdType="pubmed">19126756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002;35:605&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">12194863</ArticleId></ArticleIdList></Reference><Reference><Citation>Varnai P, Thyagarajan B, Rohacs T, Balla T. Rapidly inducible changes in phosphatidylinositol 4,5-bisphosphate levels influence multiple regulatory functions of the lipid in intact living cells. J Cell Biol. 2006;175:377&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064515</ArticleId><ArticleId IdType="pubmed">17088424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bok J, Wang Q, Huang J, Green SH. CaMKII and CaMKIV mediate distinct prosurvival signaling pathways in response to depolarization in neurons. Mol Cell Neurosci. 2007;36:13&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040167</ArticleId><ArticleId IdType="pubmed">17651987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bito H, Deisseroth K, Tsien RW. CREB phosphorylation and dephosphorylation: A Ca(2+)- and stimulus duration&#x2013;dependent switch for hippocampal gene expression. Cell. 1996;87:1203&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980227</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcoran EE, Means AR. Defining Ca2+/calmodulin-dependent protein kinase cascades in transcriptional regulation. J Biol Chem. 2001;276:2975&#x2013;2978.</Citation><ArticleIdList><ArticleId IdType="pubmed">11096122</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert A, et al. Alzheimer's disease&#x2013;like alterations in peripheral cells from presenilin-1 transgenic mice. Neurobiol Dis. 2001;8:331&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">11300728</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, et al. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid &#x3b2;-peptide. Neuroreport. 1996;8:379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9051814</ArticleId></ArticleIdList></Reference><Reference><Citation>Janicki S, Monteiro MJ. Increased apoptosis arising from increased expression of the Alzheimer's disease&#x2013;associated presenilin-2 mutation (N141I) J Cell Biol. 1997;139:485&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2139804</ArticleId><ArticleId IdType="pubmed">9334350</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xe1;rdenas C, et al. Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell. 2010;142:270&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911450</ArticleId><ArticleId IdType="pubmed">20655468</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MY, Park JH, Choi EJ, Park HS. Presenilin acts as a positive regulator of basal level activity of ERK through the Raf-MEK1 signaling pathway. Biochem Biophys Res Commun. 2005;332:609&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">15896720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, et al. Evidence of A&#x3b2;- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models. J Neurochem. 2007;103:1594&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527620</ArticleId><ArticleId IdType="pubmed">17760871</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisseroth K, Heist EK, Tsien RW. Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons. Nature. 1998;392:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">9515967</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhauser JM, et al. CREB transcriptional activity in neurons is regulated by multiple, calcium-specific phosphorylation events. Neuron. 2002;34:221&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">11970864</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Wang JQ. Glutamate cascade to cAMP response element&#x2013;binding protein phosphorylation in cultured striatal neurons through calcium-coupled group I metabotropic glutamate receptors. Mol Pharmacol. 2002;62:473&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181423</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosethorne EM, Nahorski SR, Challiss RA. Regulation of cyclic AMP response element&#x2013;binding protein (CREB) by Gq/11-protein&#x2013;coupled receptors in human SH-SY5Y neuroblastoma cells. Biochem Pharmacol. 2008;75:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593902</ArticleId><ArticleId IdType="pubmed">18036509</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleichmann M, Mattson MP. Alzheimer's disease and neuronal network activity. Neuromolecular Med. 2010;12:44&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833229</ArticleId><ArticleId IdType="pubmed">19885650</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchenko SM, Yarotskyy VV, Kovalenko TN, Kostyuk PG, Thomas RC. Spontaneously active and InsP3-activated ion channels in cell nuclei from rat cerebellar Purkinje and granule neurones. J Physiol. 2005;565:897&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464565</ArticleId><ArticleId IdType="pubmed">15774532</ArticleId></ArticleIdList></Reference><Reference><Citation>Foskett JK, White C, Cheung KH, Mak DO. Inositol trisphosphate receptor Ca2+ release channels. Physiol Rev. 2007;87:593&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901638</ArticleId><ArticleId IdType="pubmed">17429043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Partin J, Begley JG. Amyloid &#x3b2;-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. 1998;807:167&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">9757026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium. 2003;34:385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">12909083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginty DD, et al. Regulation of CREB phosphorylation in the suprachiasmatic nucleus by light and a circadian clock. Science. 1993;260:238&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">8097062</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank DA, Greenberg ME. CREB: A mediator of long-term memory from mollusks to mammals. Cell. 1994;79:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7923377</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlezon WA, Jr, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci. 2005;28:436&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">15982754</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2010;107:22687&#x2013;22692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012497</ArticleId><ArticleId IdType="pubmed">21149712</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisseroth K, Bito H, Tsien RW. Signaling from synapse to nucleus: Postsynaptic CREB phosphorylation during multiple forms of hippocampal synaptic plasticity. Neuron. 1996;16:89&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">8562094</ArticleId></ArticleIdList></Reference><Reference><Citation>Viosca J, et al. Chronic enhancement of CREB activity in the hippocampus interferes with the retrieval of spatial information. Learn Mem. 2009;16:198&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661251</ArticleId><ArticleId IdType="pubmed">19237642</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos BP, et al. Dysregulation of protein kinase A signaling in the aged prefrontal cortex: New strategy for treating age-related cognitive decline. Neuron. 2003;40:835&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez de Armentia M, et al. cAMP response element&#x2013;binding protein&#x2013;mediated gene expression increases the intrinsic excitability of CA1 pyramidal neurons. J Neurosci. 2007;27:13909&#x2013;13918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673625</ArticleId><ArticleId IdType="pubmed">18077703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Hirsch EC, Damier P, Duyckaerts C, Javoy-Agid F. c-fos protein-like immunoreactivity: Distribution in the human brain and over-expression in the hippocampus of patients with Alzheimer's disease. Neuroscience. 1992;46:9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">1594107</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson AJ, Cummings BJ, Cotman CW. Increased immunoreactivity for Jun- and Fos-related proteins in Alzheimer's disease: Association with pathology. Exp Neurol. 1994;125:286&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">8313943</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus DL, et al. Quantitative neuronal c-fos and c-jun expression in Alzheimer's disease. Neurobiol Aging. 1998;19:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">9880041</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan JI, Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci. 1991;14:421&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">1903243</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyne RJ, et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature. 1993;363:166&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">8483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4:E131&#x2013;E136.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson VL, Dawson TM. Nitric oxide in neurodegeneration. Prog Brain Res. 1998;118:215&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou QG, et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem. 2007;103:1843&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">17854383</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC, et al. Hippocampal nitric oxide upregulation precedes memory loss and A&#x3b2; 1&#x2013;40 accumulation after chronic brain hypoperfusion in rats. Neurol Res. 2003;25:635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">14503018</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratic&#xf2; D. Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. Trends Pharmacol Sci. 2008;29:609&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">18838179</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, et al. Disruption of neurogenesis by amyloid &#x3b2;-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem. 2002;83:1509&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472904</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A&#x3b2; and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhein V, et al. Amyloid-&#x3b2; leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol. 2009;29:1063&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11506282</ArticleId><ArticleId IdType="pubmed">19350381</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. ER calcium and Alzheimer's disease: In a state of flux. Sci Signal. 2010;3:pe10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091478</ArticleId><ArticleId IdType="pubmed">20332425</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21795536</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>30</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>LRAD3, a novel low-density lipoprotein receptor family member that modulates amyloid precursor protein trafficking.</ArticleTitle><Pagination><StartPage>10836</StartPage><EndPage>10846</EndPage><MedlinePgn>10836-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5065-10.2011</ELocationID><Abstract><AbstractText>We have identified a novel low-density lipoprotein (LDL) receptor family member, termed LDL receptor class A domain containing 3 (LRAD3), which is expressed in neurons. The LRAD3 gene encodes an &#x223c;50 kDa type I transmembrane receptor with an ectodomain containing three LDLa repeats, a transmembrane domain, and a cytoplasmic domain containing a conserved dileucine internalization motif and two polyproline motifs with potential to interact with WW-domain-containing proteins. Immunohistochemical analysis of mouse brain reveals LRAD3 expression in the cortex and hippocampus. In the mouse hippocampal-derived cell line HT22, LRAD3 partially colocalizes with amyloid precursor protein (APP) and interacts with APP as revealed by coimmunoprecipitation experiments. To identify the portion of APP that interacts with LRAD3, we used solid-phase binding assays that demonstrated that LRAD3 failed to bind to a soluble APP fragment (sAPP&#x3b1;) released after &#x3b1;-secretase cleavage. In contrast, C99, the &#x3b2;-secretase product that remains cell associated, coprecipitated with LRAD3, confirming that regions within this portion of APP are important for associating with LRAD3. The association of LRAD3 with APP increases the amyloidogenic pathway of APP processing, resulting in a decrease in sAPP&#x3b1; production and increased A&#x3b2; peptide production. Pulse-chase experiments confirm that LRAD3 expression significantly decreases the cellular half-life of mature APP. These results reveal that LRAD3 influences APP processing and raises the possibility that LRAD3 alters APP function in neurons, including its downstream signaling.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ranganathan</LastName><ForeName>Sripriya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Vascular and Inflammatory Diseases and the Departments of Surgery and Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noyes</LastName><ForeName>Nathaniel C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Migliorini</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Winkles</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Battey</LastName><ForeName>Frances D</ForeName><Initials>FD</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Yepes</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mikhailenko</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Strickland</LastName><ForeName>Dudley K</ForeName><Initials>DK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL050784</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007698</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL054710</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL54710</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049478</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS49478</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS055126</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL50784</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C561588">LDLRAD3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020539" MajorTopicYN="N">Sequence Analysis, Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21795536</ArticleId><ArticleId IdType="mid">NIHMS314781</ArticleId><ArticleId IdType="pmc">PMC3189500</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5065-10.2011</ArticleId><ArticleId IdType="pii">31/30/10836</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bacskai BJ, Xia MQ, Strickland DK, Rebeck GW, Hyman BT. The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-d-aspartate receptors. Proc Natl Acad Sci U S A. 2000;97:11551&#x2013;11556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17238</ArticleId><ArticleId IdType="pubmed">11016955</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates P, Young JA, Varmus HE. A receptor for subgroup A Rous sarcoma virus is related to the low density lipoprotein receptor. Cell. 1993;74:1043&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">8402880</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol. 2004;340:783&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">15223320</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg JP, Yang Y, De Tadd&#xe9;o-Borg M, Margolis B, Turner RS. The X11alpha protein slows cellular amyloid precursor protein processing and reduces Abeta40 and Abeta42 secretion. J Biol Chem. 1998;273:14761&#x2013;14766.</Citation><ArticleIdList><ArticleId IdType="pubmed">9614075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bork P, Sudol M. The WW domain: a signalling site in dystrophin? Trends Biochem Sci. 1994;19:531&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">7846762</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell. 2000;100:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693756</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, S&#xfc;dhof TC. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293 [Erratum (2001) 293:1436]:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HI, Sudol M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci U S A. 1995;92:7819&#x2013;7823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41237</ArticleId><ArticleId IdType="pubmed">7644498</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen GB, Ren R, Baltimore D. Modular binding domains in signal transduction proteins. Cell. 1995;80:237&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">7834743</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CG, Goldstein JL, S&#xfc;dhof TC, Anderson RG, Russell DW, Brown MS. Acid-dependent ligand dissociation and recylcing of LDL receptor mediated by growth factor homology region. Nature. 1987;326:760&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">3494949</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittrich E, Haft CR, Muys L, Heinrich PC, Graeve L. A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J Biol Chem. 1996;271:5487&#x2013;5494.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher C, Beglova N, Blacklow SC. Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors. Mol Cell. 2006;22:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630895</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzGerald DJ, Fryling CM, Zdanovsky A, Saelinger CB, Kounnas M, Winkles JA, Strickland D, Leppla S. Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein. J Cell Biol. 1995;129:1533&#x2013;1541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291175</ArticleId><ArticleId IdType="pubmed">7790352</ArticleId></ArticleIdList></Reference><Reference><Citation>Haft CR, Klausner RD, Taylor SI. Involvement of dileucine motifs in the internalization and degradation of the insulin receptor. J Biol Chem. 1994;269:26286&#x2013;26294.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamer I, Haft CR, Paccaud JP, Maeder C, Taylor S, Carpentier JL. Dual role of a dileucine motif in insulin receptor endocytosis. J Biol Chem. 1997;272:21685&#x2013;21691.</Citation><ArticleIdList><ArticleId IdType="pubmed">9268295</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001;108:779&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC200939</ArticleId><ArticleId IdType="pubmed">11560943</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res. 2004;64:8968&#x2013;8972.</Citation><ArticleIdList><ArticleId IdType="pubmed">15604260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem. 2006;281:2120&#x2013;2127.</Citation><ArticleIdList><ArticleId IdType="pubmed">16303771</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunziker W, Fumey C. A di-leucine motif mediates endocytosis and basolateral sorting of macrophage IgG Fc receptors in MDCK cells. EMBO J. 1994;13:2963&#x2013;2969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395183</ArticleId><ArticleId IdType="pubmed">8039492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, Whelan CM, Smith CJ, Mikhailenko I, Rebeck GW, Strickland DK, Hyman BT. Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65. J Neurosci. 2001;21:8354&#x2013;8361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762817</ArticleId><ArticleId IdType="pubmed">11606623</ArticleId></ArticleIdList></Reference><Reference><Citation>Knauer MF, Orlando RA, Glabe CG. Cell surface APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related protein (LRP) Brain Res. 1996;740:6&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8973792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK. LDL receptor-related protein, a multifunctional apoE receptor, binds secreted &#x3b2;-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543026</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol. 2001;305:567&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152613</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23:2947&#x2013;2948.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D, Walsh JD, Mikhailenko I, Yu P, Migliorini M, Wu Y, Krueger S, Curtis JE, Harris B, Lockett S, Blacklow SC, Strickland DK, Wang YX. RAP uses a histidine switch to regulate its interaction with LRP in the ER and Golgi. Mol Cell. 2006;22:423&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678114</ArticleId></ArticleIdList></Reference><Reference><Citation>Letourneur F, Klausner RD. A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell. 1992;69:1143&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">1535555</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron. 2007;56:66&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045076</ArticleId><ArticleId IdType="pubmed">17920016</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhailenko I, Kounnas MZ, Strickland DK. Low density lipoprotein receptor-related protein/&#x3b1;2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans. J Biol Chem. 1995;270:9543&#x2013;9549.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhailenko I, Considine W, Argraves KM, Loukinov D, Hyman BT, Strickland DK. Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms. J Cell Sci. 1999;112:3269&#x2013;3281.</Citation><ArticleIdList><ArticleId IdType="pubmed">10504332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhailenko I, Battey FD, Migliorini M, Ruiz JF, Argraves K, Moayeri M, Strickland DK. Recognition of alpha 2-macroglobulin by the low density lipoprotein receptor-related protein requires the cooperation of two ligand binding cluster regions. J Biol Chem. 2001;276:39484&#x2013;39491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11507091</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra UK, Chu CT, Gawdi G, Pizzo SV. Evidence for a second alpha 2-macroglobulin receptor. J Biol Chem. 1994;269:12541&#x2013;12547.</Citation><ArticleIdList><ArticleId IdType="pubmed">7513689</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton CS, Loukinova E, Mikhailenko I, Ranganathan S, Gao Y, Haudenschild C, Strickland DK. Platelet-derived growth factor receptor-beta (PDGFR-beta) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function. J Biol Chem. 2005;280:27872&#x2013;27878.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944146</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF- 7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem. 1998;273:8502&#x2013;8507.</Citation><ArticleIdList><ArticleId IdType="pubmed">9525964</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuki T, Ota T, Nishikawa T, Hayashi K, Suzuki Y, Yamamoto J, Wakamatsu A, Kimura K, Sakamoto K, Hatano N, Kawai Y, Ishii S, Saito K, Kojima S, Sugiyama T, Ono T, Okano K, Yoshikawa Y, Aotsuka S, Sasaki N, et al. Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries. DNA Res. 2005;12:117&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">16303743</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawson T. Protein modules and signalling networks. Nature. 1995;373:573&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">7531822</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawson T, Scott JD. Signaling through scaffold, anchoring, and adaptor proteins. Science. 1997;278:2075&#x2013;2080.</Citation><ArticleIdList><ArticleId IdType="pubmed">9405336</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 2002;21:5691&#x2013;5700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC131065</ArticleId><ArticleId IdType="pubmed">12411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci. 2004;24:4259&#x2013;4265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729272</ArticleId><ArticleId IdType="pubmed">15115822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Liu CX, Migliorini MM, Von Arnim CA, Peltan ID, Mikhailenko I, Hyman BT, Strickland DK. Serine and threonine phosphorylation of the low density lipoprotein receptor-related protein by protein kinase Calpha regulates endocytosis and association with adaptor molecules. J Biol Chem. 2004;279:40536&#x2013;40544.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272003</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the l-arginine:nitric oxide pathway. Implications for vascular disease. J Biol Chem. 1997;272:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">8995232</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudenko G, Henry L, Henderson K, Ichtchenko K, Brown MS, Goldstein JL, Deisenhofer J. Structure of the LDL receptor extracellular domain at endosomal pH. Science. 2002;298:2353&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pubmed">12459547</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Lanier LM, Ikin AF, Khorkova O, Sahasrabudhe S, Greengard P, Buxbaum JD. Regulation of &#x3b2;-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem. 1999;274:7952&#x2013;7957.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonbaum CP, Lee S, Mahowald AP. The Drosophila yolkless gene encodes a vitellogenin receptor belonging to the low density lipoprotein receptor superfamily. Proc Natl Acad Sci U S A. 1995;92:1485&#x2013;1489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42544</ArticleId><ArticleId IdType="pubmed">7878005</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh H, Isacke CM. A di-hydrophobic Leu-Val motif regulates the basolateral localization of CD44 in polarized Madin-Darby canine kidney epithelial cells. J Biol Chem. 1996;271:12185&#x2013;12190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8647812</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, Price DL. Role of the &#x3b2;-amyloid protein in Alzheimer's disease. FASEB J. 1995;9:366&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">7896005</ArticleId></ArticleIdList></Reference><Reference><Citation>Strickland DK, Ashcom JD, Williams S, Battey F, Behre E, McTigue K, Battey JF, Argraves WS. Primary structure of &#x3b1;2-macroglobulin receptor-associated protein. Human homologue of a Heymann nephritis antigen. J Biol Chem. 1991;266:13364&#x2013;13369.</Citation><ArticleIdList><ArticleId IdType="pubmed">1712782</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudol M. Structure and function of the WW domain. Prog Biophys Mol Biol. 1996;65:113&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029943</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, Strickland DK. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that lrp contributes to the pathogenesis of alzheimer's disease. J Biol Chem. 2000;275:7410&#x2013;7415.</Citation><ArticleIdList><ArticleId IdType="pubmed">10702315</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley HS, Cunningham DD. The endocytotic rate constant. A cellular parameter for quantitating receptor-mediated endocytosis. J Biol Chem. 1982;257:4222&#x2013;4229.</Citation><ArticleIdList><ArticleId IdType="pubmed">6279628</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Orth K, Herz J. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein. J Biol Chem. 1994;269:15827&#x2013;15832.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515061</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Rohlmann A, Horton J, Otani H, Braun JR, Hammer RE, Herz J. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J. 1996;15:2632&#x2013;2639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC450198</ArticleId><ArticleId IdType="pubmed">8654360</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Nykjaer A, Herz J. Lipoprotein receptors: new roles for ancient proteins. Nat Cell Biol. 1999;1:E157&#x2013;E162.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559979</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, Russell DW. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984;39:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">6091915</ArticleId></ArticleIdList></Reference><Reference><Citation>Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest. 2003;112:1533&#x2013;1540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC259131</ArticleId><ArticleId IdType="pubmed">14617754</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21796118</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>476</Volume><Issue>7359</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Neuronal basis of age-related working memory decline.</ArticleTitle><Pagination><StartPage>210</StartPage><EndPage>213</EndPage><MedlinePgn>210-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature10243</ELocationID><Abstract><AbstractText>Many of the cognitive deficits of normal ageing (forgetfulness, distractibility, inflexibility and impaired executive functions) involve prefrontal cortex (PFC) dysfunction. The PFC guides behaviour and thought using working memory, which are essential functions in the information age. Many PFC neurons hold information in working memory through excitatory networks that can maintain persistent neuronal firing in the absence of external stimulation. This fragile process is highly dependent on the neurochemical environment. For example, elevated cyclic-AMP signalling reduces persistent firing by opening HCN and KCNQ potassium channels. It is not known if molecular changes associated with normal ageing alter the physiological properties of PFC neurons during working memory, as there have been no in vivo recordings, to our knowledge, from PFC neurons of aged monkeys. Here we characterize the first recordings of this kind, revealing a marked loss of PFC persistent firing with advancing age that can be rescued by restoring an optimal neurochemical environment. Recordings showed an age-related decline in the firing rate of DELAY neurons, whereas the firing of CUE neurons remained unchanged with age. The memory-related firing of aged DELAY neurons was partially restored to more youthful levels by inhibiting cAMP signalling, or by blocking HCN or KCNQ channels. These findings reveal the cellular basis of age-related cognitive decline in dorsolateral PFC, and demonstrate that physiological integrity can be rescued by addressing the molecular needs of PFC circuits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamo</LastName><ForeName>Nao J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Lu E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiao-Jing</ForeName><Initials>XJ</Initials></Author><Author ValidYN="Y"><LastName>Laubach</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mazer</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Daeyeol</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Arnsten</LastName><ForeName>Amy F T</ForeName><Initials>AF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG030004</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG030004</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058647">Adrenergic alpha-2 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054815">Cyclic Nucleotide-Gated Cation Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064428">Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051656">KCNQ Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015221">Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018341">Receptors, Adrenergic, alpha-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>30OMY4G3MK</RegistryNumber><NameOfSubstance UI="D016316">Guanfacine</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0399OZS9N</RegistryNumber><NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 Aug 19;12(9):490-1. doi: 10.1038/nrn3096.</RefSource><PMID Version="1">21852796</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2011 Aug 31;10(9):660. doi: 10.1038/nrd3541.</RefSource><PMID Version="1">21878979</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058647" MajorTopicYN="N">Adrenergic alpha-2 Receptor Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024803" MajorTopicYN="N">Biomedical Enhancement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003463" MajorTopicYN="N">Cues</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054815" MajorTopicYN="N">Cyclic Nucleotide-Gated Cation Channels</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016316" MajorTopicYN="N">Guanfacine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064428" MajorTopicYN="N">Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051656" MajorTopicYN="N">KCNQ Potassium Channels</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="Y">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015221" MajorTopicYN="N">Potassium Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018341" MajorTopicYN="N">Receptors, Adrenergic, alpha-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21796118</ArticleId><ArticleId IdType="mid">NIHMS326846</ArticleId><ArticleId IdType="pmc">PMC3193794</ArticleId><ArticleId IdType="doi">10.1038/nature10243</ArticleId><ArticleId IdType="pii">nature10243</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>West RL. An application of prefrontal cortex function theory to cognitive aging. Psychol Bull. 1996;120:272&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">8831298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeza R, Anderson ND, Houle S, Mangels JA, Nyberg L. Age-related differences in neural activity during item and temporal-order memory retrieval: a positron emission tomography study. J Cogn Neurosci. 2000;12:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaley A, Cooney JW, Rissman J, D&#x2019;Esposito M. Top-down suppression deficit underlies working memory impairment in normal aging. Nat Neurosci. 2005:1298&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">16158065</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash RS, et al. Age-related differences in the involvement of the prefrontal cortex in attentional control. Brain Cogn. 2009;71:328&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783271</ArticleId><ArticleId IdType="pubmed">19699019</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman-Rakic PS. In: Handbook of Physiology, The Nervous System, Higher Functions of the Brain. Plum F, editor. V. American Physiological Society; 1987. pp. 373&#x2013;417.</Citation></Reference><Reference><Citation>Goldman-Rakic PS. Cellular basis of working memory. Neuron. 1995;14:477&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695894</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci. 2009;32:267&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2863127</ArticleId><ArticleId IdType="pubmed">19555290</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, et al. &#x3b1;2A-adrenoceptor stimulation strengthens working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129:397&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448997</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Paspalas CD, Gamo NJYY, Wang M. Dynamic Network Connectivity: A new form of neuroplasticity. Trends Cog Sci. 2010;14:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914830</ArticleId><ArticleId IdType="pubmed">20554470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles RP, Salthouse TA. Assessing the age-related effects of proactive interference on working memory tasks using the Rasch model. Psychol Aging. 2003;18:608&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">14518820</ArticleId></ArticleIdList></Reference><Reference><Citation>Royall DR, Palmer R, Chiodo LK, Polk MJ. Normal rates of cognitive change in successful aging: the freedom house study. J Int Neuropsychol Soc. 2005;11:899&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16519269</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke SN, Barnes CA. Neural plasticity in the ageing brain. Nat Rev Neurosci. 2006;7:30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappell KA, Gmeindl L, Reuter-Lorenz PA. Age differences in prefontal recruitment during verbal working memory maintenance depend on memory load. Cortex. 2010;46:462&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853232</ArticleId><ArticleId IdType="pubmed">20097332</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HP, et al. Lexical priming deficits as a function of age. Behav Neurosci. 1990;104:286&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">2346624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucur B, Madden DJ. Effects of adult age and blood pressure on executive function and speed of processing. Exp Aging Res. 2010;36:153&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837518</ArticleId><ArticleId IdType="pubmed">20209419</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, Martin LJ, Walker LC, Borchelt DR, Price DL. Cellular and molecular biology of Alzheimer&#x2019;s disease and animal models. Neuroimaging Clin N Am. 1995;5:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">7743085</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore TL, Killiany RJ, Herndon JG, Rosene DL, Moss MB. Executive system dysfunction occurs as early as middle-age in the rhesus monkey. Neurobiol Aging. 2006;27:1484&#x2013;1493.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183172</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp PR, Amaral DG. Evidence for task-dependent memory dysfunction in the aged monkey. J Neurosci. 1989;9:3568&#x2013;3576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569903</ArticleId><ArticleId IdType="pubmed">2795141</ArticleId></ArticleIdList></Reference><Reference><Citation>Herndon JG, Moss MB, Rosene DL, Killiany RJ. Patterns of cognitive decline in aged rhesus monkeys. Behavioural Brain Research. 1997;87:25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9331471</ArticleId></ArticleIdList></Reference><Reference><Citation>Rypma B, D&#x2019;Esposito M. Isolating the neural mechanisms of age-related changes in human working memory. Nat Neurosci. 2000:509&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769393</ArticleId></ArticleIdList></Reference><Reference><Citation>George MS, Abbott LF, Siegelbaum SA. Hyperpolarization-activated HCN channels inhibit subthreshold EPSPs through voltage-dependent interacations with M-type K+ channels. Nature Neuroscience. 2009;12:577&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674138</ArticleId><ArticleId IdType="pubmed">19363490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos B, et al. Dysregulation of protein kinase A signaling in the aged prefrontal cortex: New strategy for treating age-related cognitive decline. Neuron. 2003;40:835&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622586</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore TL, et al. Cognitive impairment in aged rhesus monkeys associated with monoamine receptors in the prefrontal cortex. Behav Brain Res. 2005;160:208&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">15863218</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs JL, et al. Orexin neuronal changes in the locus coeruleus of the aging rhesus macaque. Neurobiol Aging. 2006 Jul 24; Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">16870307</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenbaum G, Setlow B, Saddoris MP, Gallagher M. Encoding changes in orbitofrontal cortex in reversal-impaired aged rats. J Neurophysiol. 2006;95:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430623</ArticleId><ArticleId IdType="pubmed">16338994</ArticleId></ArticleIdList></Reference><Reference><Citation>Luebke JI, Chang YM. Effects of aging on the electrophysiological properties of layer 5 pyramidal cells in the monkey prefrontal cortex. Neuroscience. 2007;150:556&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2410025</ArticleId><ArticleId IdType="pubmed">17981400</ArticleId></ArticleIdList></Reference><Reference><Citation>Luebke J, Barbas H, Peters A. Effects of normal aging on prefrontal area 46 in the rhesus monkey. Brain Res Rev. 2010;62:212&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822043</ArticleId><ArticleId IdType="pubmed">20005254</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GE, et al. Age-related regional network of magnetic resonance imaging gray matter in the rhesus macaque. J Neurosci. 2008;28:2710&#x2013;2718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670689</ArticleId><ArticleId IdType="pubmed">18337400</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, et al. Neurobiological bases of age-related cognitive decline in the rhesus monkey. J Neuropathol Exp Neurol. 1996;55:861&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">8759775</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitriu D, et al. Selective changes in thin spine density and morphology in monkey prefrontal cortex correlate with aging-related cognitive impairment. J Neurosci. 2010;30:7507&#x2013;7515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892969</ArticleId><ArticleId IdType="pubmed">20519525</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21813692</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>31</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Opposing synaptic regulation of amyloid-&#x3b2; metabolism by NMDA receptors in vivo.</ArticleTitle><Pagination><StartPage>11328</StartPage><EndPage>11337</EndPage><MedlinePgn>11328-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0607-11.2011</ELocationID><Abstract><AbstractText>The concentration of amyloid-&#x3b2; (A&#x3b2;) within the brain extracellular space is one determinant of whether the peptide will aggregate into toxic species that are important in Alzheimer's disease (AD) pathogenesis. Some types of synaptic activity can regulate A&#x3b2; levels. Here we demonstrate two distinct mechanisms that are simultaneously activated by NMDA receptors and regulate brain interstitial fluid (ISF) A&#x3b2; levels in opposite directions in the living mouse. Depending on the dose of NMDA administered locally to the brain, ISF A&#x3b2; levels either increase or decrease. Low doses of NMDA increase action potentials and synaptic transmission which leads to an elevation in synaptic A&#x3b2; generation. In contrast, high doses of NMDA activate signaling pathways that lead to ERK (extracellular-regulated kinase) activation, which reduces processing of APP into A&#x3b2;. This depression in A&#x3b2; via APP processing occurs despite dramatically elevated synaptic activity. Both of these synaptic mechanisms are simultaneously active, with the balance between them determining whether ISF A&#x3b2; levels will increase or decrease. NMDA receptor antagonists increase ISF A&#x3b2; levels, suggesting that basal activity at these receptors normally suppresses A&#x3b2; levels in vivo. This has implications for understanding normal A&#x3b2; metabolism as well as AD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verges</LastName><ForeName>Deborah K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Restivo</LastName><ForeName>Jessica L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Goebel</LastName><ForeName>Whitney D</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG568127</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002614">Chelating Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047309">Flavones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026941">Sodium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>139890-68-9</RegistryNumber><NameOfSubstance UI="C070379">1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>4368-28-9</RegistryNumber><NameOfSubstance UI="D013779">Tetrodotoxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>526U7A2651</RegistryNumber><NameOfSubstance UI="D004533">Egtazic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6384-92-5</RegistryNumber><NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>98Y1I8ZD4M</RegistryNumber><NameOfSubstance UI="C050592">3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>BXO86P3XXW</RegistryNumber><NameOfSubstance UI="D011280">Pregnanolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>R8OE3P6O5S</RegistryNumber><NameOfSubstance UI="C010739">ifenprodil</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058256" MajorTopicYN="N">Brain Waves</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002614" MajorTopicYN="N">Chelating Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004533" MajorTopicYN="N">Egtazic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047309" MajorTopicYN="N">Flavones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016202" MajorTopicYN="N">N-Methylaspartate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011280" MajorTopicYN="N">Pregnanolone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026941" MajorTopicYN="N">Sodium Channel Blockers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013779" MajorTopicYN="N">Tetrodotoxin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21813692</ArticleId><ArticleId IdType="mid">NIHMS315866</ArticleId><ArticleId IdType="pmc">PMC3329800</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0607-11.2011</ArticleId><ArticleId IdType="pii">31/31/11328</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bading H, Greenberg ME. Stimulation of protein tyrosine phosphorylation by NMDA receptor activation. Science. 1991;253:912&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715095</ArticleId></ArticleIdList></Reference><Reference><Citation>Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Le&#x15b;kiewicz M, Tetich M, Otczyk M, Kubera M, Laso&#x144; W. Effects of neurosteroids on glucocorticoid receptor-mediated gene transcription in LMCAT cells&#x2014;a possible interaction with psychotropic drugs. Eur Neuropsychopharmacol. 2007;17:37&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581232</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordji K, Becerril-Ortega J, Nicole O, Buisson A. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-&#x3b2; production. J Neurosci. 2010;30:15927&#x2013;15942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633754</ArticleId><ArticleId IdType="pubmed">21106831</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulton TG, Cobb MH. Identification of multiple extracellular signal-regulated kinases (ERKs) with antipeptide antibodies. Cell Regul. 1991;2:357&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC361802</ArticleId><ArticleId IdType="pubmed">1654126</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandler LJ, Sutton G, Dorairaj NR, Norwood D. N-Methyl D-aspartate receptor-mediated bidirectional control of extracellular signal-regulated kinase activity in cortical neuronal cultures. J Biol Chem. 2001;276:2627&#x2013;2636.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062237</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowen DS. Serotonin and neuronal growth factors&#x2014;a convergence of signaling pathways. J Neurochem. 2007;101:1161&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286594</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci. 2010;30:4190&#x2013;4196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855655</ArticleId><ArticleId IdType="pubmed">20335454</ArticleId></ArticleIdList></Reference><Reference><Citation>Duva MA, Tomkins EM, Moranda LM, Kaplan R, Sukhaseum A, Jimenez A, Stanley BG. Reverse microdialysis of N-methyl-D-aspartic acid into the lateral hypothalamus of rats: effects on feeding and other behaviors. Brain Res. 2001;921:122&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11720718</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazeli MS, Breen K, Errington ML, Bliss TV. Increase in extracellular NCAM and amyloid precursor protein following induction of long-term potentiation in the dentate gyrus of anaesthetized rats. Neurosci Lett. 1994;169:77&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8047297</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon-Krajcer W, Sali&#x144;ska E, Lazarewicz JW. N-Methyl-d-aspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: in vitro&#x2014;superfusion study. Folia Neuropathol. 2002;40:13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">12121034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimwood S, Wafford KA, Macaulay A, Hutson PH. N-Methyl-D-aspartate receptor subtype-selectivity of homoquinolinate: an electrophysiological and radioligand binding study using both native and recombinant receptors. J Neurochem. 2002;82:794&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. A hundred years of Alzheimer's disease research. Neuron. 2006;52:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015223</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P, Lo I, Yu GQ, Palop JJ, Masliah E, Mucke L. Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010;68:428&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetman M, Kanning K, Cavanaugh JE, Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J Biol Chem. 1999;274:22569&#x2013;22580.</Citation><ArticleIdList><ArticleId IdType="pubmed">10428835</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Maddalena A, Raschig A, M&#xfc;ller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, M&#xfc;ller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid. 2003;10:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12762134</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoey SE, Williams RJ, Perkinton MS. Synaptic NMDA receptor activation stimulates &#x3b1;-secretase amyloid precursor protein processing and inhibits amyloid-&#x3b2; production. J Neurosci. 2009;29:4442&#x2013;4460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665739</ArticleId><ArticleId IdType="pubmed">19357271</ArticleId></ArticleIdList></Reference><Reference><Citation>Huettner JE, Bean BP. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc Natl Acad Sci U S A. 1988;85:1307&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC279756</ArticleId><ArticleId IdType="pubmed">2448800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, Medina I. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol. 2006;572:789&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779993</ArticleId><ArticleId IdType="pubmed">16513670</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki Y, Kohno T, Zhuang ZY, Brenner GJ, Wang H, Van Der Meer C, Befort K, Woolf CJ, Ji RR. Ionotropic and metabotropic receptors, protein kinase A, protein kinase C, and Src contribute to C-fiber-induced ERK activation and cAMP response element-binding protein phosphorylation in dorsal horn neurons, leading to central sensitization. J Neurosci. 2004;24:8310&#x2013;8321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729681</ArticleId><ArticleId IdType="pubmed">15385614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009;64:632&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Dunah AW, Wang YT, Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron. 2005;46:745&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">15924861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW, Mook-Jung I. ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J. 2006;20:157&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">16293708</ArticleId></ArticleIdList></Reference><Reference><Citation>Klafki HW, Lewczuk P, Kamrowski-Kruck H, Maler JM, M&#xfc;ller K, Peters O, Heuser I, Jessen F, Popp J, Fr&#xf6;lich L, Wolf S, Prinz B, Luckhaus C, Schr&#xf6;der J, Pantel J, Gertz HJ, K&#xf6;lsch H, M&#xfc;ller BW, Esselmann H, Bibl M, et al. Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. J Alzheimers Dis. 2009;18:613&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">19625747</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res. 2006;326:439&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojro E, Postina R, Buro C, Meiringer C, Gehrig-Burger K, Fahrenholz F. The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J. 2006;20:512&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401644</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Krapivinsky G, Krapivinsky L, Manasian Y, Ivanov A, Tyzio R, Pellegrino C, Ben-Ari Y, Clapham DE, Medina I. The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron. 2003;40:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurino M, Fukunaga K, Ushio Y, Miyamoto E. Activation of mitogen-activated protein kinase in cultured rat hippocampal neurons by stimulation of glutamate receptors. J Neurochem. 1995;65:1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">7643105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A. 1999;96:3922&#x2013;3927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22396</ArticleId><ArticleId IdType="pubmed">10097139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, Ali C, Gabriel C, Croci N, MacKenzie ET, Glabe CG, Plotkine M, Marchand-Verrecchia C, Vivien D, Buisson A. NMDA receptor activation inhibits &#x3b1;-secretase and promotes neuronal amyloid-&#x3b2; production. J Neurosci. 2005;25:9367&#x2013;9377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725703</ArticleId><ArticleId IdType="pubmed">16221845</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomakin A, Teplow DB, Kirschner DA, Benedek GB. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci U S A. 1997;94:7942&#x2013;7947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21534</ArticleId><ArticleId IdType="pubmed">9223292</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcello E, Gardoni F, Mauceri D, Romorini S, Jeromin A, Epis R, Borroni B, Cattabeni F, Sala C, Padovani A, Di Luca M. Synapse-associated protein-97 mediates &#x3b1;-secretase ADAM10 trafficking and promotes its activity. J Neurosci. 2007;27:1682&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673742</ArticleId><ArticleId IdType="pubmed">17301176</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M, Boncristiano S, Mathews PM, Mercken M, Abramowski D, Staufenbiel M, Jucker M. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 2000;48:913&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">11117548</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW, Sharpe LG. Brain lesions in an infant rhesus monkey treated with monsodium glutamate. Science. 1969;166:386&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">5812037</ArticleId></ArticleIdList></Reference><Reference><Citation>Patneau DK, Mayer ML. Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-d-aspartate and quisqualate receptors. J Neurosci. 1990;10:2385&#x2013;2399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570388</ArticleId><ArticleId IdType="pubmed">2165523</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AK, Holbrook N, Siedlak SL, Harris PL, Smith MA. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport. 1999;10:2411&#x2013;2415.</Citation><ArticleIdList><ArticleId IdType="pubmed">10439473</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouyss&#xe9;gur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol. 2002;64:755&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">12213567</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Xu GM, Price DL, Borchelt DR, Markowska AL. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol Dis. 2003;12:194&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742740</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem. 2001;76:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145972</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung YT, Hsu WM, Wang BJ, Wu SY, Yen CT, Hu MK, Liao YF. Sodium selenite inhibits gamma-secretase activity through activation of ERK. Neurosci Lett. 2008;440:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">18547722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13:190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Z, Dudek H, Miranti CK, Greenberg ME. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J Neurosci. 1996;16:5425&#x2013;5436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578897</ArticleId><ArticleId IdType="pubmed">8757255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706&#x2013;10714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain. 2011;4:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3022812</ArticleId><ArticleId IdType="pubmed">21214928</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21825135</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>34</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1.</ArticleTitle><Pagination><StartPage>E559</StartPage><EndPage>E568</EndPage><MedlinePgn>E559-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1100745108</ELocationID><Abstract><AbstractText>Amyloid &#x3b2; (A&#x3b2;) peptides, the primary constituents of senile plaques and a hallmark in Alzheimer's disease pathology, are generated through the sequential cleavage of amyloid precursor protein (APP) by &#x3b2;-site APP cleaving enzyme 1 (BACE1) and &#x3b3;-secretase. The early endosome is thought to represent a major compartment for APP processing; however, the mechanisms of how BACE1 encounters APP are largely unknown. In contrast to APP internalization, which is clathrin-dependent, we demonstrate that BACE1 is sorted to early endosomes via a route controlled by the small GTPase ADP ribosylation factor 6 (ARF6). Altering ARF6 levels or its activity affects endosomal sorting of BACE1, and consequently results in altered APP processing and A&#x3b2; production. Furthermore, sorting of newly internalized BACE1 from ARF6-positive towards RAB GTPase 5 (RAB5)-positive early endosomes depends on its carboxyterminal short acidic cluster-dileucine motif. This ARF6-mediated sorting of BACE1 is confined to the somatodendritic compartment of polarized neurons in agreement with A&#x3b2; peptides being primarily secreted from here. These results demonstrate a spatial separation between APP and BACE1 during surface-to-endosome transport, suggesting subcellular trafficking as a regulatory mechanism for this proteolytic processing step. It thereby provides a novel avenue to interfere with A&#x3b2; production through a selective modulation of the distinct endosomal transport routes used by BACE1 or APP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sannerud</LastName><ForeName>Ragna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Membrane Trafficking, Center for Human Genetics, Catholic University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Declerck</LastName><ForeName>Ilse</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Peric</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Raemaekers</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Menendez</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lujia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Veerle</LastName><ForeName>Baert</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Coen</LastName><ForeName>Katrijn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Munck</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Schiavo</LastName><ForeName>Giampietro</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Annaert</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089982">ADP-Ribosylation Factor 6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018957">CD59 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020727">ADP-Ribosylation Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="C000715348">ARF6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="C000715727">Arf6 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="C000715349">Arf6 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020691">rab GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000089982" MajorTopicYN="N">ADP-Ribosylation Factor 6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020727" MajorTopicYN="N">ADP-Ribosylation Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018957" MajorTopicYN="N">CD59 Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002451" MajorTopicYN="N">Cell Compartmentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016764" MajorTopicYN="N">Cell Polarity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020691" MajorTopicYN="N">rab GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21825135</ArticleId><ArticleId IdType="pmc">PMC3161548</ArticleId><ArticleId IdType="doi">10.1073/pnas.1100745108</ArticleId><ArticleId IdType="pii">1100745108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: Regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29:12787&#x2013;12794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Chang WP, Koelsch G, Tang J. Memapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: Implications on the endocytosis mechanism of memapsin 2. FEBS Lett. 2002;524:183&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135764</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahle T, et al. GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. Mol Cell Neurosci. 2005;29:453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15886016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino JS. The GGA proteins: Adaptors on the move. Nat Rev Mol Cell Biol. 2004;5:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">14708007</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, et al. Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med. 2004;10:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286784</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron. 2007;54:721&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada H, et al. Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing. FASEB J. 2010;24:2783&#x2013;2794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909280</ArticleId><ArticleId IdType="pubmed">20354142</ArticleId></ArticleIdList></Reference><Reference><Citation>Grbovic OM, et al. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J Biol Chem. 2003;278:31261&#x2013;31268.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou L, et al. Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization. Cell Res. 2007;17:389&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325690</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey RM, Balcz BA, Lopez-Coviella I, Slack BE. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 2005;6:30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1208872</ArticleId><ArticleId IdType="pubmed">16095541</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyung JH, Selkoe DJ. Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J Biol Chem. 2003;278:51035&#x2013;51043.</Citation><ArticleIdList><ArticleId IdType="pubmed">14525989</ArticleId></ArticleIdList></Reference><Reference><Citation>Traub LM. Tickets to ride: Selecting cargo for clathrin-regulated internalization. Nat Rev Mol Cell Biol. 2009;10:583&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">19696796</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, et al. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem. 1999;274:18851&#x2013;18856.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383380</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson JG, Porat-Shliom N, Cohen LA. Clathrin-independent endocytosis: A unique platform for cell signaling and PM remodeling. Cell Signal. 2009;21:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754696</ArticleId><ArticleId IdType="pubmed">18647649</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant BD, Donaldson JG. Pathways and mechanisms of endocytic recycling. Nat Rev Mol Cell Biol. 2009;10:597&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038567</ArticleId><ArticleId IdType="pubmed">19696797</ArticleId></ArticleIdList></Reference><Reference><Citation>Howes MT, et al. Clathrin-independent carriers form a high capacity endocytic sorting system at the leading edge of migrating cells. J Cell Biol. 2010;190:675&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928008</ArticleId><ArticleId IdType="pubmed">20713605</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslavsky N, Weigert R, Donaldson JG. Characterization of a nonclathrin endocytic pathway: membrane cargo and lipid requirements. Mol Biol Cell. 2004;15:3542&#x2013;3552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC491817</ArticleId><ArticleId IdType="pubmed">15146059</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyster CA, et al. Discovery of new cargo proteins that enter cells through clathrin-independent endocytosis. Traffic. 2009;10:590&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854272</ArticleId><ArticleId IdType="pubmed">19302270</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos PV, et al. Sorting of the Alzheimer's disease amyloid precursor protein mediated by the AP-4 complex. Dev Cell. 2010;18:425&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841041</ArticleId><ArticleId IdType="pubmed">20230749</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA. 2006;103:11172&#x2013;11177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="pubmed">16837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H, et al. Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J. 1994;13:1287&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394944</ArticleId><ArticleId IdType="pubmed">8137813</ArticleId></ArticleIdList></Reference><Reference><Citation>Rink J, Ghigo E, Kalaidzidis Y, Zerial M. Rab conversion as a mechanism of progression from early to late endosomes. Cell. 2005;122:735&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">16143105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegner CS, et al. Ultrastructural characterization of giant endosomes induced by GTPase-deficient Rab5. Histochem Cell Biol. 2010;133:41&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">19830447</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, et al. Phosphorylation regulates intracellular trafficking of beta-secretase. J Biol Chem. 2001;276:14634&#x2013;14641.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, et al. Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J Biol Chem. 2011;286:8677&#x2013;8687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048749</ArticleId><ArticleId IdType="pubmed">21209097</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, et al. Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J Neurosci. 2008;28:2874&#x2013;2882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670660</ArticleId><ArticleId IdType="pubmed">18337418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzetti L, Palamidessi A, Areces L, Scita G, Di Fiore PP. Rab5 is a signalling GTPase involved in actin remodelling by receptor tyrosine kinases. Nature. 2004;429:309&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15152255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettlen M, et al. Src triggers circular ruffling and macropinocytosis at the apical surface of polarized MDCK cells. Traffic. 2006;7:589&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">16643281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, et al. Expression of auxilin or AP180 inhibits endocytosis by mislocalizing clathrin: Evidence for formation of nascent pits containing AP1 or AP2 but not clathrin. J Cell Sci. 2001;114:353&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148137</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown FD, Rozelle AL, Yin HL, Balla T, Donaldson JG. Phosphatidylinositol 4,5-bisphosphate and Arf6-regulated membrane traffic. J Cell Biol. 2001;154:1007&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196179</ArticleId><ArticleId IdType="pubmed">11535619</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslavsky N, Weigert R, Donaldson JG. Convergence of non-clathrin- and clathrin-derived endosomes involves Arf6 inactivation and changes in phosphoinositides. Mol Biol Cell. 2003;14:417&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149982</ArticleId><ArticleId IdType="pubmed">12589044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1:345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Frittoli E, et al. The primate-specific protein TBC1D3 is required for optimal macropinocytosis in a novel ARF6-dependent pathway. Mol Biol Cell. 2008;19:1304&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291429</ArticleId><ArticleId IdType="pubmed">18199687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino L, Ikin AF, Nairn AC, Pursnani A, Buxbaum JD. The carboxyl-terminus of BACE contains a sorting signal that regulates BACE trafficking but not the formation of total A(beta) Mol Cell Neurosci. 2002;19:175&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">11860271</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem. 2000;275:33729&#x2013;33737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, et al. Maturation and pro-peptide cleavage of beta-secretase. J Biol Chem. 2000;275:30849&#x2013;30854.</Citation><ArticleIdList><ArticleId IdType="pubmed">10801872</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai B, Katafiasz D, Horejsi V, Naslavsky N. Pre-sorting endosomal transport of the GPI-anchored protein, CD59, is regulated by EHD1. Traffic. 2011;12:102&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961375</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, et al. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem. 2005;280:25892&#x2013;25900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201532</ArticleId><ArticleId IdType="pubmed">15886206</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Christie G, Hussain I, Dingwall C. Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol. 2001;11:1288&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160:113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai T, et al. Membrane microdomain switching: A regulatory mechanism of amyloid precursor protein processing. J Cell Biol. 2008;183:339&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2568028</ArticleId><ArticleId IdType="pubmed">18936252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA. 2000;97:1456&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, et al. Biochemical and structural characterization of the interaction of memapsin 2 (beta-secretase) cytosolic domain with the VHS domain of GGA proteins. Biochemistry. 2003;42:12174&#x2013;12180.</Citation><ArticleIdList><ArticleId IdType="pubmed">14567678</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorkin A, von Zastrow M. Endocytosis and signalling: Intertwining molecular networks. Nat Rev Mol Cell Biol. 2009;10:609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895425</ArticleId><ArticleId IdType="pubmed">19696798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould GW, Lippincott-Schwartz J. New roles for endosomes: From vesicular carriers to multi-purpose platforms. Nat Rev Mol Cell Biol. 2009;10:287&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690957</ArticleId><ArticleId IdType="pubmed">19277045</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhard C, H&#xe9;bert SS, De Strooper B. The amyloid-beta precursor protein: Integrating structure with biological function. EMBO J. 2005;24:3996&#x2013;4006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356301</ArticleId><ArticleId IdType="pubmed">16252002</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615&#x2013;29619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigismund S, et al. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell. 2008;15:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">18694561</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishige M, et al. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat Cell Biol. 2008;10:85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18084281</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasubramanian N, Scott DW, Castle JD, Casanova JE, Schwartz MA. Arf6 and microtubules in adhesion-dependent trafficking of lipid rafts. Nat Cell Biol. 2007;9:1381&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715295</ArticleId><ArticleId IdType="pubmed">18026091</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabe H. Requirement for Arf6 in cell adhesion, migration, and cancer cell invasion. J Biochem. 2003;134:485&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">14607973</ArticleId></ArticleIdList></Reference><Reference><Citation>Walseng E, Bakke O, Roche PA. Major histocompatibility complex class II-peptide complexes internalize using a clathrin- and dynamin-independent endocytosis pathway. J Biol Chem. 2008;283:14717&#x2013;14727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386912</ArticleId><ArticleId IdType="pubmed">18378669</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, et al. A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci. 2007;27:14459&#x2013;14469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673432</ArticleId><ArticleId IdType="pubmed">18160654</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev. 2008;3:15&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442059</ArticleId><ArticleId IdType="pubmed">18573216</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang EL, Cameron AN, Piazza F, Walker KR, Tesco G. Ubiquitin regulates GGA3-mediated degradation of BACE1. J Biol Chem. 2010;285:24108&#x2013;24119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911305</ArticleId><ArticleId IdType="pubmed">20484053</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweitzer JK, Sedgwick AE, D'Souza-Schorey C. ARF6-mediated endocytic recycling impacts cell movement, cell division and lipid homeostasis. Semin Cell Dev Biol. 2011;22:39&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457924</ArticleId><ArticleId IdType="pubmed">20837153</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski J. ARF6 in the nervous system. Eur J Cell Biol. 2007;86:513&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">17559968</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S, et al. ARF6 and EFA6A regulate the development and maintenance of dendritic spines. J Neurosci. 2006;26:4811&#x2013;4819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674147</ArticleId><ArticleId IdType="pubmed">16672654</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakagami H, Matsuya S, Nishimura H, Suzuki R, Kondo H. Somatodendritic localization of the mRNA for EFA6A, a guanine nucleotide exchange protein for ARF6, in rat hippocampus and its involvement in dendritic formation. Eur J Neurosci. 2004;19:863&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, G&#xf6;tz J. Amyloid-&#x3b2; and tau&#x2014;a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011;12:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Novel research horizons for presenilins and &#x3b3;-secretases in cell biology and disease. Annu Rev Cell Dev Biol. 2010;26:235&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009;78:857&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">19317650</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson JG, Jackson CL. ARF family G proteins and their regulators: roles in membrane transport, development and disease. Nat Rev Mol Cell Biol. 2011;12:362&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245550</ArticleId><ArticleId IdType="pubmed">21587297</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyster CA, et al. Discovery of new cargo proteins that enter cells through clathrin-independent endocytosis. Traffic. 2009;10:590&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854272</ArticleId><ArticleId IdType="pubmed">19302270</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21828324</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>306</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women.</ArticleTitle><Pagination><StartPage>613</StartPage><EndPage>619</EndPage><MedlinePgn>613-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2011.1115</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Sleep-disordered breathing (characterized by recurrent arousals from sleep and intermittent hypoxemia) is common among older adults. Cross-sectional studies have linked sleep-disordered breathing to poor cognition; however, it remains unclear whether sleep-disordered breathing precedes cognitive impairment in older adults.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the prospective relationship between sleep-disordered breathing and cognitive impairment and to investigate potential mechanisms of this association.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Prospective sleep and cognition study of 298 women without dementia (mean [SD] age: 82.3 [3.2] years) who had overnight polysomnography measured between January 2002 and April 2004 in a substudy of the Study of Osteoporotic Fractures. Sleep-disordered breathing was defined as an apnea-hypopnea index of 15 or more events per hour of sleep. Multivariate logistic regression was used to determine the independent association of sleep-disordered breathing with risk of mild cognitive impairment or dementia, adjusting for age, race, body mass index, education level, smoking status, presence of diabetes, presence of hypertension, medication use (antidepressants, benzodiazepines, or nonbenzodiazepine anxiolytics), and baseline cognitive scores. Measures of hypoxia, sleep fragmentation, and sleep duration were investigated as underlying mechanisms for this relationship.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Adjudicated cognitive status (normal, dementia, or mild cognitive impairment) based on data collected between November 2006 and September 2008.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the 193 women without sleep-disordered breathing, the 105 women (35.2%) with sleep-disordered breathing were more likely to develop mild cognitive impairment or dementia (31.1% [n = 60] vs 44.8% [n = 47]; adjusted odds ratio [AOR], 1.85; 95% confidence interval [CI], 1.11-3.08). Elevated oxygen desaturation index (&#x2265;15 events/hour) and high percentage of sleep time (&gt;7%) in apnea or hypopnea (both measures of disordered breathing) were associated with risk of developing mild cognitive impairment or dementia (AOR, 1.71 [95% CI, 1.04-2.83] and AOR, 2.04 [95% CI, 1.10-3.78], respectively). Measures of sleep fragmentation (arousal index and wake after sleep onset) or sleep duration (total sleep time) were not associated with risk of cognitive impairment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among older women, those with sleep-disordered breathing compared with those without sleep-disordered breathing had an increased risk of developing cognitive impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Francisco, San Francisco, CA 94121, USA. kristine.yaffe@ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laffan</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Stephanie Litwack</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Redline</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Spira</LastName><ForeName>Adam P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Ensrud</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Ancoli-Israel</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Katie L</ForeName><Initials>KL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG008415</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR035583</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05394</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1K01AG033195</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2 R01 AG027574-22A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR035582</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2 R01 AG005394-22A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05407</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR35582</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026720</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR035584</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24AG031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG005407</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027576-22</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR35583</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG033195</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08415</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG005394</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR35584</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG026720</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2011 Aug 10;306(6):654-5. doi: 10.1001/jama.2011.1124.</RefSource><PMID Version="1">21828331</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2011 Nov 2;306(17):1863; author reply 1863. doi: 10.1001/jama.2011.1582.</RefSource><PMID Version="1">22045763</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045422" MajorTopicYN="N">Continuous Positive Airway Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012891" MajorTopicYN="N">Sleep Apnea Syndromes</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of Interest/Disclosures: Dr Yaffe reported that she is a consultant for Novartis Inc; serves on data and safety monitoring boards for Pfizer, Medivation, and the National Institute of Mental Health; is a board member for Beeson Scientific Advisory; has grants pending with the National Institutes of Health, the Alzheimer Association, the Department of Defense, and the American Health Assistance Foundation; and has received funding for expenses unrelated to the activities listed from the Alzheimer Association, the National Institutes of Health, Beeson Scientific, Japan Geriatrics Society, Wake Forest University, and the State of California Department of Human Services. Dr Laffan reported that she received salary support and was reimbursed for travel to professional society meetings from the National Institutes of Health. Dr Redline reported that her institution received a California Pacific Medical Center subcontract via a National Institutes of Health grant; she is a board member for the American Academy of Sleep Medicine; her institution has received an endowment for a professorship in sleep medicine from Dr Peter Farrell, CEO of RosMed Inc; and has multiple grants pending with the National Institutes of Health on sleep apnea. Dr Spira reported that he has received honoraria as a clinical editor for the International Journal of Sleep and Wakefulness&#x2014;Primary Care, which receives pharmaceutical industry support. Dr Ancoli-Israel reported that she is a consultant for Johnson &amp; Johnson, Merck, Purdue Pharma LP, sanofi-aventis, and Pfizer and has grants pending with the National Institutes of Health. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21828324</ArticleId><ArticleId IdType="mid">NIHMS352297</ArticleId><ArticleId IdType="pmc">PMC3600944</ArticleId><ArticleId IdType="doi">10.1001/jama.2011.1115</ArticleId><ArticleId IdType="pii">306/6/613</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ancoli-Israel S, Kripke DF, Klauber MR, Mason WJ, Fell R, Kaplan O. Sleep-disordered breathing in community-dwelling elderly. Sleep. 1991 Dec;14(6):486&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756990</ArticleId><ArticleId IdType="pubmed">1798880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip MSM, Lam B, Ng MMT, Lam WK, Tsang KWT, Lam KSL. Obstructive Sleep Apnea Is Independently Associated with Insulin Resistance. Am J Respir Crit Care Med. 2002 Mar 1;165(5):670&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11874812</ArticleId></ArticleIdList></Reference><Reference><Citation>Young T, Peppard P. Sleep-disordered breathing and cardiovascular disease: epidemiologic evidence for a relationship. Sleep. 2000 Jun 15;23(Suppl 4):S122&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">10893084</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjabi NM, Shahar E, Redline S, et al. Sleep-Disordered Breathing, Glucose Intolerance, and Insulin Resistance. Am J Epidemiol. 2004 Sep 15;160(6):521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">15353412</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahar E, Whitney CW, Redline S, et al. Sleep-disordered Breathing and Cardiovascular Disease. Cross-sectional Results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001 Jan 1;163(1):19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11208620</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Blackwell T, Stone KL, et al. Sleep-Disordered Breathing and Cognition in Older Women. J Am Geriatr Soc. 2008;56(1):45&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18047498</ArticleId></ArticleIdList></Reference><Reference><Citation>Dealberto MJ, Pajot N, Courbon D, Alperovitch A. Breathing disorders during sleep and cognitive performance in an older community sample: the EVA Study. J Am Geriatr Soc. 1996 Nov;44(11):1287&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancoli-Israel S, Klauber MR, Butters N, Parker L, Kripke DF. Dementia in institutionalized elderly: relation to sleep apnea. J Am Geriatr Soc. 1991 Mar;39(3):258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">2005339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan C, Berthon-Jones M, Issa F, Eves L. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. The Lancet. 1981;317(8225):862&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">6112294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings SR, Nevitt MC, Browner WS, et al. Risk Factors for Hip Fracture in White Women. N Engl J Med. 1995;332(12):767&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">7862179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System For Sleep Stages of Human Subjects. Washington, D.C: Government Printing Office; 1968.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999 Aug 1;22(5):667&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">10450601</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Battery: Theory and Clinical Interpretation. Tuscon, AZ: Neuropsychology Press; 1985.</Citation></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987 Aug;48(8):314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>McDowell I, Kristjansson B, Hill GB, Hebert R. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin Epidemiol. 1997 Apr;50(4):377&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9179095</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test - (CVLT-II) Second. San Antonio, TX: Psychological Corporation; 2000.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation; 1988.</Citation></Reference><Reference><Citation>Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms and Commentary. New York: Oxford University Press; 1991.</Citation></Reference><Reference><Citation>Yaffe K, Middleton L, Lui L-Y, et al. Mild cognitive impairment, dementia and subtypes among oldest old women. Arch Neurol. 2011;68(5):631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108074</ArticleId><ArticleId IdType="pubmed">21555638</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med Nov. 1989;19(4):1015&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">2594878</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth. Washington, DC: American Psychiatric Association; 2000. Text Revision.</Citation></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol Dec. 2001;58(12):1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999 Mar;56(3):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol. 1994;10(4):405&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">7843344</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley DJ, Masaki K, White L, Larkin EK, Monjan A, Redline S. Sleep-disordered breathing and cognitive impairment in elderly Japanese-American men. Sleep. 2003 Aug 1;26(5):596&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">12938814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sforza E, Roche F, Thomas-Anterion C, et al. Cognitive function and sleep related breathing disorders in a healthy elderly population: the SYNAPSE study. Sleep. 2010 Apr 1;33(4):515&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849791</ArticleId><ArticleId IdType="pubmed">20394321</ArticleId></ArticleIdList></Reference><Reference><Citation>Born J, Wilhelm I. System consolidation of memory during sleep. Psychological Research. 2011 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278619</ArticleId><ArticleId IdType="pubmed">21541757</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloia MS, Arnedt JT, Davis JD, Riggs RL, Byrd D. Neuropsychological sequelae of obstructive sleep apnea-hypopnea syndrome: A critical review. J Int Neuropsychol Soc. 2004;10(05):772&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">15327723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingshott RN, Cosway RJ, Deary IJ, Douglas NJ. The effect of sleep fragmentation on cognitive processing using computerized topographic brain mapping. J Sleep Res. 2000;9(4):353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386203</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepanski EJ. The effect of sleep fragmentation on daytime function. Sleep. 2002 May 1;25(3):268&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">12003157</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas RJ, Tamisier R, Boucher J, et al. Nocturnal hypoxia exposure with simulated altitude for 14 days does not significantly alter working memory or vigilance in humans. Sleep. 2007 Sep 1;30(9):1195&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978402</ArticleId><ArticleId IdType="pubmed">17910391</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MD, Tamisier R, Boucher J, et al. A pilot study of sleep, cognition, and respiration under 4 weeks of intermittent nocturnal hypoxia in adult humans. Sleep Med. 2009;10(7):739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891502</ArticleId><ArticleId IdType="pubmed">19282237</ArticleId></ArticleIdList></Reference><Reference><Citation>Row BW. Intermittent hypoxia and cognitive function: implications from chronic animal models. Adv Exp Med Biol. 2007;618:51&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18269188</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beek AHEA, Claassen JAHR, Rikkert MGMO, Jansen RWMM. Cerebral autoregulation: an overview of current concepts and methodology with special focus on the elderly. J Cereb Blood Flow Metab. 2008;28(6):1071&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">18349877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancoli-Israel S, Palmer BW, Cooke JR, et al. Cognitive Effects of Treating Obstructive Sleep Apnea in Alzheimer&#x2019;s Disease: A Randomized Controlled Study. J Am Geriatr Soc. 2008;56(11):2076&#x2013;2081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585146</ArticleId><ArticleId IdType="pubmed">18795985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke JR, Ayalon L, Palmer BW, et al. Sustained use of CPAP slows deterioration of cognition, sleep, and mood in patients with Alzheimer&#x2019;s disease and obstructive sleep apnea: a preliminary study. J Clin Sleep Med. 2009 Aug 15;5(4):305&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725246</ArticleId><ArticleId IdType="pubmed">19968005</ArticleId></ArticleIdList></Reference><Reference><Citation>Canessa N, Castronovo V, Cappa SF, et al. Obstructive Sleep Apnea: Brain Structural Changes and Neurocognitive Function Before and After Treatment. Am J Respir Crit Care Med. 2010 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">21037021</ArticleId></ArticleIdList></Reference><Reference><Citation>Dematteis M, Godin-Ribuot D, Arnaud C, et al. Cardiovascular consequences of sleep-disordered breathing: Contribution of animal models to understanding the human disease. ILAR Journal. 2009;50(3):262&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">19506313</ArticleId></ArticleIdList></Reference><Reference><Citation>Drager LF, Jun JC, Polotsky VY. Metabolic consequences of intermittent hypoxia: Relevance to obstructive sleep apnea. Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism. 2010;24(5):843&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011976</ArticleId><ArticleId IdType="pubmed">21112030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghegan MD, Angelos PC, Stonebraker AC, Gillespie MB. Laboratory versus Portable Sleep Studies: A Meta-Analysis. The Laryngoscope. 2006;116(6):859&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">16735890</ArticleId></ArticleIdList></Reference><Reference><Citation>Iber C, Redline S, Kaplan Gilpin AM, et al. Polysomnography performed in the unattended home versus the attended laboratory setting--Sleep Heart Health Study methodology. Sleep. 2004;27(3):536&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">15164911</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan SF, Griswold ME, Iber C, et al. Sleep Heart Health Study (SHHS) Research Group: Short-term variability of respiration and sleep during unattended nonlaboratory polysomnography&#x2013;the Sleep Heart Health Study. Sleep. 2002;25:843&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">12489889</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21841774</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Presenilin 1 regulates homeostatic synaptic scaling through Akt signaling.</ArticleTitle><Pagination><StartPage>1112</StartPage><EndPage>1114</EndPage><MedlinePgn>1112-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2893</ELocationID><Abstract><AbstractText>Neurons adapt to long-lasting changes in network activity, both in vivo and in vitro, by adjusting their synaptic strengths to stabilize firing rates. We found that homeostatic scaling of excitatory synapses was impaired in hippocampal neurons derived from mice lacking presenilin 1 (Psen1(-/-) mice) or expressing a familial Alzheimer's disease-linked Psen1 mutation (Psen1(M146V)). These findings suggest that deficits in synaptic homeostasis may contribute to brain dysfunction in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Kara G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Physiology &amp; Biophysics, University of Washington School of Medicine, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Jane M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS055804</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS55804</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026941">Sodium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>4368-28-9</RegistryNumber><NameOfSubstance UI="D013779">Tetrodotoxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>AE28F7PNPL</RegistryNumber><NameOfSubstance UI="D008715">Methionine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>HG18B9YRS7</RegistryNumber><NameOfSubstance UI="D014633">Valine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001703" MajorTopicYN="N">Biophysics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008715" MajorTopicYN="N">Methionine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051058" MajorTopicYN="N">Oncogene Protein v-akt</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026941" MajorTopicYN="N">Sodium Channel Blockers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013779" MajorTopicYN="N">Tetrodotoxin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21841774</ArticleId><ArticleId IdType="mid">NIHMS309526</ArticleId><ArticleId IdType="pmc">PMC3164917</ArticleId><ArticleId IdType="doi">10.1038/nn.2893</ArticleId><ArticleId IdType="pii">nn.2893</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Strooper B. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Neuron. 2001;32:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683989</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP. Trends Neurosci. 2008;31:454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano GG. Cell. 2008;135:422&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834419</ArticleId><ArticleId IdType="pubmed">18984155</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozo K, Goda Y. Neuron. 2010;66:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3021747</ArticleId><ArticleId IdType="pubmed">20471348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibata K, Sun Q, Turrigiano GG. Neuron. 2008;57:819&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">18367083</ArticleId></ArticleIdList></Reference><Reference><Citation>Goold CP, Nicoll RA. Neuron. 2010;68:512&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111089</ArticleId><ArticleId IdType="pubmed">21040851</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, et al. Nat Med. 1999;5:101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Baki L, et al. J Neurosci. 2008;28:483&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670519</ArticleId><ArticleId IdType="pubmed">18184791</ArticleId></ArticleIdList></Reference><Reference><Citation>Baki L, et al. Embo J. 2004;23:2586&#x2013;2596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC449766</ArticleId><ArticleId IdType="pubmed">15192701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, et al. J Biol Chem. 2005;280:31537&#x2013;31547.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Q, Zhang D, Jarzylo L, Huganir RL, Man HY. Proc Natl Acad Sci U S A. 2008;105:775&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206612</ArticleId><ArticleId IdType="pubmed">18174334</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y, et al. Genes Dev. 2005;19:2000&#x2013;2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1199571</ArticleId><ArticleId IdType="pubmed">16107614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. Nat Neurosci. 2011;14:5&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21187847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21844361</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>34</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide.</ArticleTitle><Pagination><StartPage>14330</StartPage><EndPage>14335</EndPage><MedlinePgn>14330-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1105172108</ELocationID><Abstract><AbstractText>The activity of Cdk5 and its regulatory subunit p35 is thought to be important in both normal brain function and neurodegenerative disease pathogenesis. Increased Cdk5 activity, via proteolytic cleavage of p35 to a p25 fragment by the calcium-activated protease calpain or by phosphorylation at Cdk5(Tyr15), can contribute to neurotoxicity. Nonetheless, our knowledge of regulation of Cdk5 activity in disease states is still emerging. Here we demonstrate that Cdk5 is activated by S-nitrosylation or reaction of nitric oxide (NO)-related species with the thiol groups of cysteine residues 83 and 157, to form SNO-Cdk5. We then show that S-nitrosylation of Cdk5 contributes to amyloid-&#x3b2; (A&#x3b2;) peptide-induced dendritic spine loss. Furthermore, we observed significant levels of SNO-Cdk5 in postmortem Alzheimer's disease (AD) but not in normal human brains. These findings suggest that S-nitrosylation of Cdk5 is an aberrant regulatory mechanism of enzyme activity that may contribute to the pathogenesis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Emily A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>McKercher</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Stuart A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY009024</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY005477</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057096</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HD029587</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 ES016738</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HD29587</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY05477</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY09024</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>6384-92-5</RegistryNumber><NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495905">CDK5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="D034281">Dynamins</NameOfSubstance></Chemical><Chemical><RegistryNumber>K848JZ4886</RegistryNumber><NameOfSubstance UI="D003545">Cysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034281" MajorTopicYN="N">Dynamins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016202" MajorTopicYN="N">N-Methylaspartate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015538" MajorTopicYN="N">Nitrosation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: S.A.L. is the named inventor on numerous patents in territories worldwide for the use of memantine in neurodegenerative disorders. He has no direct ownership in the drug, which is currently clinically approved and marketed for moderate to severe Alzheimer&#x2019;s disease under the name Namenda. Under the rules of Harvard University, his former institution where the work was initially performed, S.A.L. participates in a royalty-sharing plan administered by Harvard Medical School and Children&#x2019;s Hospital, Boston.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21844361</ArticleId><ArticleId IdType="pmc">PMC3161554</ArticleId><ArticleId IdType="doi">10.1073/pnas.1105172108</ArticleId><ArticleId IdType="pii">1105172108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lew J, et al. A brain-specific activator of cyclin-dependent kinase 5. Nature. 1994;371:423&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">8090222</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Delalle I, Caviness VS, Jr, Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 1994;371:419&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">8090221</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, et al. An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J Biol Chem. 1995;270:26897&#x2013;26903.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima T, et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA. 1996;93:11173&#x2013;11178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38303</ArticleId><ArticleId IdType="pubmed">8855328</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Sanada K, Samuels BA, Shih H, Tsai LH. Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration. Cell. 2003;114:469&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">12941275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, et al. Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature. 2006;442:814&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862120</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Larivi&#xe8;re RC, Julien JP. Deregulation of Cdk5 in a mouse model of ALS: Toxicity alleviated by perikaryal neurofilament inclusions. Neuron. 2001;30:135&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">11343650</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PD, et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson&#x2019;s disease. Proc Natl Acad Sci USA. 2003;100:13650&#x2013;13655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263868</ArticleId><ArticleId IdType="pubmed">14595022</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu D, et al. Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson&#x2019;s disease. Neuron. 2007;55:37&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">17610816</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, et al. Dopaminergic and glutamatergic signaling crosstalk in Huntington&#x2019;s disease neurodegeneration: The role of p25/cyclin-dependent kinase 5. J Neurosci. 2008;28:10090&#x2013;10101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671267</ArticleId><ArticleId IdType="pubmed">18829967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405:360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Strocchi P, Pession A, Dozza B. Up-regulation of cDK5/p35 by oxidative stress in human neuroblastoma IMR-32 cells. J Cell Biochem. 2003;88:758&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">12577309</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano CA, Ega&#xf1;a JT, N&#xfa;&#xf1;ez MT, Maccioni RB, Gonz&#xe1;lez-Billault C. Oxidative stress promotes tau dephosphorylation in neuronal cells: The roles of cdk5 and PP1. Free Radic Biol Med. 2004;36:1393&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">15135175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:8843&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725603</ArticleId><ArticleId IdType="pubmed">16192374</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahlgren CM, et al. A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell death. EMBO J. 2006;25:4808&#x2013;4819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618100</ArticleId><ArticleId IdType="pubmed">17036052</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron. 2005;48:825&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Lipton SA. Emerging roles of S-nitrosylation in protein misfolding and neurodegenerative diseases. Antioxid Redox Signal. 2008;10:87&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">17961071</ArticleId></ArticleIdList></Reference><Reference><Citation>Uehara T, et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature. 2006;441:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">16724068</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho DH, et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science. 2009;324:102&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823371</ArticleId><ArticleId IdType="pubmed">19342591</ArticleId></ArticleIdList></Reference><Reference><Citation>Asada A, et al. Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear localization of active cyclin-dependent kinase 5 complexes. J Neurochem. 2008;106:1325&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pubmed">18507738</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster MW, Forrester MT, Stamler JS. A protein microarray-based analysis of S-nitrosylation. Proc Natl Acad Sci USA. 2009;106:18948&#x2013;18953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776442</ArticleId><ArticleId IdType="pubmed">19864628</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, et al. S-nitrosylation of cyclin-dependent kinase 5 (cdk5) regulates its kinase activity and dendrite growth during neuronal development. J Neurosci. 2010;30:14366&#x2013;14370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634798</ArticleId><ArticleId IdType="pubmed">20980593</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian B, Yang Q, Mao Z. Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death. Nat Cell Biol. 2009;11:211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760486</ArticleId><ArticleId IdType="pubmed">19151707</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamler JS, Toone EJ, Lipton SA, Sucher NJ. (S)NO signals: Translocation, regulation, and a consensus motif. Neuron. 1997;18:691&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">9182795</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino SM, Gladyshev VN. Structural analysis of cysteine S-nitrosylation: A modified acid-based motif and the emerging role of trans-nitrosylation. J Mol Biol. 2010;395:844&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061812</ArticleId><ArticleId IdType="pubmed">19854201</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S-nitrosylation: A physiological signal for neuronal nitric oxide. Nat Cell Biol. 2001;3:193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">11175752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Liu S, Fu Y, Wang JH, Lu Y. Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat Neurosci. 2003;6:1039&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">14502288</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer L, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997;243:527&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">9030781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawasli AH, et al. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat Neurosci. 2007;10:880&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910113</ArticleId><ArticleId IdType="pubmed">17529984</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer&#x2019;s disease? Biochim Biophys Acta. 2004;1697:137&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023356</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkany T, et al. beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci. 2000;12:2735&#x2013;2745.</Citation><ArticleIdList><ArticleId IdType="pubmed">10971616</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia P, Chen HSV, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30:11246&#x2013;11250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932667</ArticleId><ArticleId IdType="pubmed">20720132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat Rev Drug Discov. 2006;5:160&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">16424917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer&#x2019;s disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer&#x2019;s disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, et al. Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol Cell. 2010;39:184&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924818</ArticleId><ArticleId IdType="pubmed">20670888</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsoum MJ, et al. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 2006;25:3900&#x2013;3911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1553198</ArticleId><ArticleId IdType="pubmed">16874299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: Purview and parameters. Nat Rev Mol Cell Biol. 2005;6:150&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">15688001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell DA, Marletta MA. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nat Chem Biol. 2005;1:154&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">16408020</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuer K, et al. Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis. Cell Death Differ. 2007;14:651&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">17218957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko J, et al. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci. 2001;21:6758&#x2013;6771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763073</ArticleId><ArticleId IdType="pubmed">11517264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed TM, et al. Specific role of neuronal nitric-oxide synthase when tethered to the plasma membrane calcium pump in regulating the beta-adrenergic signal in the myocardium. J Biol Chem. 2009;284:12091&#x2013;12098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673278</ArticleId><ArticleId IdType="pubmed">19278978</ArticleId></ArticleIdList></Reference><Reference><Citation>Minegishi S, et al. Membrane association facilitates degradation and cleavage of the cyclin-dependent kinase 5 activators p35 and p39. Biochemistry. 2010;49:5482&#x2013;5493.</Citation><ArticleIdList><ArticleId IdType="pubmed">20518484</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin C, Miyaguchi K, Segal M. Dendritic spine density and LTP induction in cultured hippocampal slices. J Neurophysiol. 1997;77:1614&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pubmed">9084624</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu WY, et al. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. Nat Neurosci. 2007;10:67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">17143272</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 1993;336:417&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">8282104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21849536</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>33</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>APP is phosphorylated by TrkA and regulates NGF/TrkA signaling.</ArticleTitle><Pagination><StartPage>11756</StartPage><EndPage>11761</EndPage><MedlinePgn>11756-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1960-11.2011</ELocationID><Abstract><AbstractText>The pathogenic model of Alzheimer's disease (AD) posits that aggregates of amyloid &#x3b2;, a product of amyloid precursor protein (APP) processing, cause dementia. However, alterations of normal APP functions could contribute to AD pathogenesis, and it is therefore important to understand the role of APP. APP is a member of a gene family that shows functional redundancy as documented by the evidence that single knock-out mice are viable, whereas mice with combined deletions of APP family genes die shortly after birth. A residue in the APP intracellular region, Y(682), is indispensable for these essential functions of APP. It is therefore important to identify pathways that regulate phosphorylation of Y(682) as well as the role of Y(682) in vivo. TrkA is associated with both phosphorylation of APP-Y(682) and alteration of APP processing, suggesting that tyrosine phosphorylation of APP links APP processing and neurotrophic signaling to intracellular pathways associated with cellular differentiation and survival. Here we have tested whether the NGF/TrkA signaling pathway is a physiological regulator of APP phosphorylation. We find that NGF induces tyrosine phosphorylation of APP, and that APP interacts with TrkA and this interaction requires Y(682). Unpredictably, we also uncover that APP, and specifically Y(682), regulates activation of the NGF/TrkA signaling pathway in vivo, the subcellular distribution of TrkA and the sensitivity of neurons to the trophic action of NGF. This evidence suggests that these two membrane protein's functions are strictly interconnected and that the NGF/TrkA signaling pathway is involved in AD pathogenesis and can be used as a therapeutic target.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matrone</LastName><ForeName>Carmela</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Cellular Biology and Neurobiology, National Council of Research of Rome, 00143 Rome, Italy. c.matrone@inmm.cnr.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbagallo</LastName><ForeName>Alessia P M</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>La Rosa</LastName><ForeName>Luca R</ForeName><Initials>LR</Initials></Author><Author ValidYN="Y"><LastName>Florenzano</LastName><ForeName>Fulvio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ciotti</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Mercanti</LastName><ForeName>Delio</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Moses V</ForeName><Initials>MV</Initials></Author><Author ValidYN="Y"><LastName>Calissano</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>D'Adamio</LastName><ForeName>Luciano</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS21072</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS021072</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025970</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025970</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG027139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS021072</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9061-61-4</RegistryNumber><NameOfSubstance UI="D020932">Nerve Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020917">Receptor, trkA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020932" MajorTopicYN="N">Nerve Growth Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020917" MajorTopicYN="N">Receptor, trkA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21849536</ArticleId><ArticleId IdType="mid">NIHMS318923</ArticleId><ArticleId IdType="pmc">PMC3319322</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1960-11.2011</ArticleId><ArticleId IdType="pii">31/33/11756</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barbagallo AP, Weldon R, Tamayev R, Zhou D, Giliberto L, Foreman O, D'Adamio L. Tyr682 in the intracellular domain of APP regulates amyloidogenic APP processing in vivo. PLoS One. 2010;5:e15503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982846</ArticleId><ArticleId IdType="pubmed">21103325</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbagallo AP, Wang Z, Zheng H, D'Adamio L. A single tyrosine residue in the amyloid precursor protein intracellular domain is essential for developmental function. J Biol Chem. 2011;286:8717&#x2013;8721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059018</ArticleId><ArticleId IdType="pubmed">21266574</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand E, Brouillet E, Caill&#xe9; I, Bouillot C, Cole GM, Prochiantz A, Allinquant B. A short cytoplasmic domain of the amyloid precursor protein induces apoptosis in vitro and in vivo. Mol Cell Neurosci. 2001;18:503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11922141</ArticleId></ArticleIdList></Reference><Reference><Citation>Giliberto L, Zhou D, Weldon R, Tamagno E, De Luca P, Tabaton M, D'Adamio L. Evidence that the amyloid beta precursor protein-intracellular domain lowers the stress threshold of neurons and has a &#x201c;regulated&#x201d; transcriptional role. Mol Neurodegener. 2008;3:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538519</ArticleId><ArticleId IdType="pubmed">18764939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartikka J, Hefti F. Comparison of nerve growth factor's effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro. J Neurosci Res. 1988;21:352&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">3216428</ArticleId></ArticleIdList></Reference><Reference><Citation>King GD, Scott Turner R. Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk? Exp Neurol. 2004;185:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736502</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wang Z, Wang B, Guo Q, Dolios G, Tabuchi K, Hammer RE, S&#xfc;dhof TC, Wang R, Zheng H. Genetic dissection of the amyloid precursor protein in developmental function and amyloid pathogenesis. J Biol Chem. 2010;285:30598&#x2013;30605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945554</ArticleId><ArticleId IdType="pubmed">20693289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS, Koo EH, Bredesen DE. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med. 2000;6:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10742146</ArticleId></ArticleIdList></Reference><Reference><Citation>Madeira A, Pommet JM, Prochiantz A, Allinquant B. SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain. FASEB J. 2005;19:1905&#x2013;1907.</Citation><ArticleIdList><ArticleId IdType="pubmed">16162853</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrone C, Ciotti MT, Mercanti D, Marolda R, Calissano P. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc Natl Acad Sci U S A. 2008;105:13139&#x2013;13144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525562</ArticleId><ArticleId IdType="pubmed">18728191</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrone C, Marolda R, Ciafr&#xe8; S, Ciotti MT, Mercanti D, Calissano P. Tyrosine kinase nerve growth factor receptor switches from prosurvival to proapoptotic activity via Abeta-mediated phosphorylation. Proc Natl Acad Sci U S A. 2009;106:11358&#x2013;11363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699376</ArticleId><ArticleId IdType="pubmed">19549834</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Passer B, Pellegrini L, Russo C, Siegel RM, Lenardo MJ, Schettini G, Bachmann M, Tabaton M, D'Adamio L. Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor. J Alzheimers Dis. 2000;2:289&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214090</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopal R, Chen Z-Y, Lee FS, Chao MV. Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. J Neuroscience. 2004;24:6650&#x2013;6658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729703</ArticleId><ArticleId IdType="pubmed">15282267</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, Dolcini V, Salis S, Venezia V, Zambrano N, Russo T, Schettini G. Signal transduction through tyrosine-phosphorylated C-terminal fragments of amyloid precursor protein via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. J Biol Chem. 2002;277:35282&#x2013;35288.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084708</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet. 2002;3:67&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142353</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. Basic neurochemistry: molecular, cellular and medical aspects. 6th Ed. Philadelphia: Lippincott Williams &amp; Wilkins; 1999.</Citation></Reference><Reference><Citation>Tamayev R, Zhou D, D'Adamio L. The interactome of the Amyloid betaeta Precursor Protein family members is shaped by phosphorylation of their intracellular domains. Mol Neurodegener. 2009;4:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723102</ArticleId><ArticleId IdType="pubmed">19602287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarr PE, Roncarati R, Pelicci G, Pelicci PG, D'Adamio L. Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc. J Biol Chem. 2002a;277:16798&#x2013;16804.</Citation><ArticleIdList><ArticleId IdType="pubmed">11877420</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarr PE, Contursi C, Roncarati R, Noviello C, Ghersi E, Scheinfeld MH, Zambrano N, Russo T, D'Adamio L. Evidence for a role of the nerve growth factor receptor TrkA in tyrosine phosphorylation and processing of beta-APP. Biochem Biophys Res Commun. 2002b;295:324&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150951</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano N, Bruni P, Minopoli G, Mosca R, Molino D, Russo C, Schettini G, Sudol M, Russo T. The beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells expressing a constitutively active form of the Abl protoncogene. J Biol Chem. 2001;276:19787&#x2013;19792.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279131</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Noviello C, D'Ambrosio C, Scaloni A, D'Adamio L. Growth factor receptor-bound protein 2 interaction with the tyrosine-phosphorylated tail of amyloid beta precursor protein is mediated by its Src homology 2 domain. J Biol Chem. 2004;279:25374&#x2013;25380.</Citation><ArticleIdList><ArticleId IdType="pubmed">15054097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Zambrano N, Russo T, D'Adamio L. Phosphorylation of a tyrosine in the amyloid-beta protein precursor intracellular domain inhibits Fe65 binding and signaling. J Alzheimers Dis. 2009;16:301&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">19221419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21865451</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>34</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Synaptic autoregulation by metalloproteases and &#x3b3;-secretase.</ArticleTitle><Pagination><StartPage>12083</StartPage><EndPage>12093</EndPage><MedlinePgn>12083-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2513-11.2011</ELocationID><Abstract><AbstractText>The proteolytic machinery comprising metalloproteases and &#x3b3;-secretase, an intramembrane aspartyl protease involved in Alzheimer's disease, cleaves several substrates in addition to the extensively studied amyloid precursor protein. Some of these substrates, such as N-cadherin, are synaptic proteins involved in synapse remodeling and maintenance. Here we show, in rats and mice, that metalloproteases and &#x3b3;-secretase are physiologic regulators of synapses. Both proteases are synaptic, with &#x3b3;-secretase tethered at the synapse by &#x3b4;-catenin, a synaptic scaffolding protein that also binds to N-cadherin and, through scaffolds, to AMPA receptor and a metalloprotease. Activity-dependent proteolysis by metalloproteases and &#x3b3;-secretase takes place at both sides of the synapse, with the metalloprotease cleavage being NMDA receptor-dependent. This proteolysis decreases levels of synaptic proteins and diminishes synaptic transmission. Our results suggest that activity-dependent substrate cleavage by synaptic metalloproteases and &#x3b3;-secretase modifies synaptic transmission, providing a novel form of synaptic autoregulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Restituito</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, New York University Langone Medical Center, New York, New York 10016, USA. restis01@nyumc.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khatri</LastName><ForeName>Latika</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ninan</LastName><ForeName>Ipe</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Ziff</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS35527</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013620</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013620</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG13620</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS035527</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051177">Catenins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D045726">Metalloproteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000095002">Delta Catenin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurosci. 2011 Sep 21;31(38):13695</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051177" MajorTopicYN="N">Catenins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045726" MajorTopicYN="N">Metalloproteases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013570" MajorTopicYN="N">Synaptic Membranes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095002" MajorTopicYN="N">Delta Catenin</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21865451</ArticleId><ArticleId IdType="mid">NIHMS320277</ArticleId><ArticleId IdType="pmc">PMC3169340</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2513-11.2011</ArticleId><ArticleId IdType="pii">31/34/12083</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Auffret A, Gautheron V, Repici M, Kraftsik R, Mount HT, Mariani J, Rovira C. Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease. J Neurosci. 2009;29:10144&#x2013;10152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6664983</ArticleId><ArticleId IdType="pubmed">19675248</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao J, Lin H, Ouyang Y, Lei D, Osman A, Kim TW, Mei L, Dai P, Ohlemiller KK, Ambron RT. Activity-dependent transcription regulation of PSD-95 by neuregulin-1 and Eos. Nat Neurosci. 2004;7:1250&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494726</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;ckner K, Pablo Labrador J, Scheiffele P, Herb A, Seeburg PH, Klein R. EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Neuron. 1999;22:511&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartier AE, Djakovic SN, Salehi A, Wilson SM, Masliah E, Patrick GN. Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J Neurosci. 2009;29:7857&#x2013;7868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748938</ArticleId><ArticleId IdType="pubmed">19535597</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalva MB, McClelland AC, Kayser MS. Cell adhesion molecules: signalling functions at the synapse. Nat Rev Neurosci. 2007;8:206&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756920</ArticleId><ArticleId IdType="pubmed">17299456</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunah AW, Hueske E, Wyszynski M, Hoogenraad CC, Jaworski J, Pak DT, Simonetta A, Liu G, Sheng M. LAR receptor protein tyrosine phosphatases in the development and maintenance of excitatory synapses. Nat Neurosci. 2005;8:458&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD. Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron. 2000;28:511&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144360</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, N&#xe4;slund J. Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem. 2003;278:24277&#x2013;24284.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697771</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakopoulos A, Marambaud P, Friedrich VL, Jr, Shioi J, Efthimiopoulos S, Robakis NK. Presenilin-1: a component of synaptic and endothelial adherens junctions. Ann NY Acad Sci. 2000;920:209&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193152</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakopoulos A, Litterst C, Ghersi E, Baki L, Xu C, Serban G, Robakis NK. Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. EMBO J. 2006;25:1242&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422162</ArticleId><ArticleId IdType="pubmed">16511561</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo A, Kim DY, Carey BW, Turunen MK, Pettingell WH, Kovacs DM. Presenilin/gamma-secretase-mediated cleavage regulates association of leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase with beta-catenin. J Biol Chem. 2007;282:9063&#x2013;9072.</Citation><ArticleIdList><ArticleId IdType="pubmed">17259169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hass MR, Sato C, Kopan R, Zhao G. Presenilin: RIP and beyond. Semin Cell Dev Biol. 2009;20:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693421</ArticleId><ArticleId IdType="pubmed">19073272</ArticleId></ArticleIdList></Reference><Reference><Citation>Israely I, Costa RM, Xie CW, Silva AJ, Kosik KS, Liu X. Deletion of the neuron-specific protein delta-catenin leads to severe cognitive and synaptic dysfunction. Curr Biol. 2004;14:1657&#x2013;1663.</Citation><ArticleIdList><ArticleId IdType="pubmed">15380068</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan BA, Fernholz BD, Boussac M, Xu C, Grigorean G, Ziff EB, Neubert TA. Identification and verification of novel rodent postsynaptic density proteins. Mol Cell Proteomics. 2004;3:857&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">15169875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Haass C, Steiner H. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis. 2006;3:275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">17047368</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in Alzheimer's disease. Mol Neurobiol. 2008;37:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18438727</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Donahue CP, Israely I, Liu X, Ochiishi T. Delta-catenin at the synaptic-adherens junction. Trends Cell Biol. 2005;15:172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">15752981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouchi Z, Barthet G, Serban G, Georgakopoulos A, Shioi J, Robakis NK. p120 catenin recruits cadherins to &#x3b3;-secretase and inhibits production of A&#x3b2; peptide. J Biol Chem. 2009;284:1954&#x2013;1961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629097</ArticleId><ArticleId IdType="pubmed">19008223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lah JJ, Heilman CJ, Nash NR, Rees HD, Yi H, Counts SE, Levey AI. Light and electron microscopic localization of presenilin-1 in primate brain. J Neurosci. 1997;17:1971&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793763</ArticleId><ArticleId IdType="pubmed">9045726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, Kameyama K, Huganir RL, Bear MF. NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus. Neuron. 1998;21:1151&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856470</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonoudakis D, Conti LR, Radeke CM, McGuire LM, Vandenberg CA. A multiprotein trafficking complex composed of SAP97, CASK, Veli, and Mint1 is associated with inward rectifier Kir2 potassium channels. J Biol Chem. 2004;279:19051&#x2013;19063.</Citation><ArticleIdList><ArticleId IdType="pubmed">14960569</ArticleId></ArticleIdList></Reference><Reference><Citation>Levesque G, Yu G, Nishimura M, Zhang DM, Levesque L, Yu H, Xu D, Liang Y, Rogaeva E, Ikeda M, Duthie M, Murgolo N, Wang L, VanderVere P, Bayne ML, Strader CD, Rommens JM, Fraser PE, St George-Hyslop P. Presenilins interact with armadillo proteins including neural-specific plakophilin-related protein and beta-catenin. J Neurochem. 1999;72:999&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037471</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Shafer JA, Gardell SJ. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A. 2000;97:6138&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabb AM, Ehlers MD. Ubiquitination in postsynaptic function and plasticity. Annu Rev Cell Dev Biol. 2010;26:179&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163670</ArticleId><ArticleId IdType="pubmed">20604708</ArticleId></ArticleIdList></Reference><Reference><Citation>Macaskill AF, Rinholm JE, Twelvetrees AE, Arancibia-Carcamo IL, Muir J, Fransson A, Aspenstrom P, Attwell D, Kittler JT. Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses. Neuron. 2009;61:541&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670979</ArticleId><ArticleId IdType="pubmed">19249275</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinverno M, Carta M, Epis R, Marcello E, Verpelli C, Cattabeni F, Sala C, Mulle C, Di Luca M, Gardoni F. Synaptic localization and activity of ADAM10 regulate excitatory synapses through N-cadherin cleavage. J Neurosci. 2010;30:16343&#x2013;16355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634827</ArticleId><ArticleId IdType="pubmed">21123580</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell. 2003;114:635&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678586</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcello E, Gardoni F, Mauceri D, Romorini S, Jeromin A, Epis R, Borroni B, Cattabeni F, Sala C, Padovani A, Di Luca M. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J Neurosci. 2007;27:1682&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673742</ArticleId><ArticleId IdType="pubmed">17301176</ArticleId></ArticleIdList></Reference><Reference><Citation>Matteoli M, Takei K, Perin MS, S&#xfc;dhof TC, De Camilli P. Exo-endocytotic recycling of synaptic vesicles in developing processes of cultured hippocampal neurons. J Cell Biol. 1992;117:849&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289460</ArticleId><ArticleId IdType="pubmed">1577861</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy JV, Twomey C, Wujek P. Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci. 2009;66:1534&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11131470</ArticleId><ArticleId IdType="pubmed">19189053</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller CC, McLoughlin DM, Lau KF, Tennant ME, Rogelj B. The X11 proteins, Abeta production and Alzheimer's disease. Trends Neurosci. 2006;29:280&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">16545469</ArticleId></ArticleIdList></Reference><Reference><Citation>Monea S, Jordan BA, Srivastava S, DeSouza S, Ziff EB. Membrane localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding protein and cleavage of cadherins. J Neurosci. 2006;26:2300&#x2013;2312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674808</ArticleId><ArticleId IdType="pubmed">16495457</ArticleId></ArticleIdList></Reference><Reference><Citation>Osten P, Srivastava S, Inman GJ, Vilim FS, Khatri L, Lee LM, States BA, Einheber S, Milner TA, Hanson PI, Ziff EB. The AMPA receptor GluR2 C terminus can mediate a reversible, ATP-dependent interaction with NSF and alpha- and beta-SNAPs. Neuron. 1998;21:99&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">9697855</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent AT, Barnes NY, Taniguchi Y, Thinakaran G, Sisodia SS. Presenilin attenuates receptor-mediated signaling and synaptic function. J Neurosci. 2005;25:1540&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725985</ArticleId><ArticleId IdType="pubmed">15703408</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiretti F, Deprez-Beauclair P, Bonardo B, Aubert H, Juhan-Vague I, Nalbone G. Identification of SAP97 as an intracellular binding partner of TACE. J Cell Sci. 2003;116:1949&#x2013;1957.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668732</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips GR, Huang JK, Wang Y, Tanaka H, Shapiro L, Zhang W, Shan WS, Arndt K, Frank M, Gordon RE, Gawinowicz MA, Zhao Y, Colman DR. The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron. 2001;32:63&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11604139</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R. A closer look at alpha-secretase. Current Alzheimer research. 2008;5:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">18393803</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozo K, Goda Y. Unraveling mechanisms of homeostatic synaptic plasticity. Neuron. 2010;66:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3021747</ArticleId><ArticleId IdType="pubmed">20471348</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt KG, Zhu P, Watari H, Cook DG, Sullivan JM. A novel role for {gamma}-secretase: selective regulation of spontaneous neurotransmitter release from hippocampal neurons. J Neurosci. 2011;31:899&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632921</ArticleId><ArticleId IdType="pubmed">21248114</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P. ADAM10 cleavage of N-cadherin and regulation of cell&#x2013;celladhesion and beta-catenin nuclear signalling. EMBO J. 2005;24:742&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549617</ArticleId><ArticleId IdType="pubmed">15692570</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, Kandel ER, Duff K, Kirkwood A, Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal M. Dendritic spines and long-term plasticity. Nat Rev Neurosci. 2005;6:277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">15803159</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman JB, Restituito S, Lu W, Lee-Edwards L, Khatri L, Ziff EB. Synaptic anchorage of AMPA receptors by cadherins through neural plakophilin-related arm protein AMPA receptor-binding protein complexes. J Neurosci. 2007;27:8505&#x2013;8516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672939</ArticleId><ArticleId IdType="pubmed">17687028</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai CY, Mysore SP, Chiu C, Schuman EM. Activity-regulated N-cadherin endocytosis. Neuron. 2007;54:771&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">17553425</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanahashi H, Tabira T. Isolation of human delta-catenin and its binding specificity with presenilin 1. Neuroreport. 1999;10:563&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">10208590</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Shan W, Phillips GR, Arndt K, Bozdagi O, Shapiro L, Huntley GW, Benson DL, Colman DR. Molecular modification of N-cadherin in response to synaptic activity. Neuron. 2000;25:93&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">10707975</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615&#x2013;29619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura K, Kihara T, Kuzuya A, Okawa K, Nishimoto T, Ninomiya H, Sugimoto H, Kinoshita A, Shimohama S. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci Lett. 2006;402:278&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">16687212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wierenga CJ, Walsh MF, Turrigiano GG. Temporal regulation of the expression locus of homeostatic plasticity. J Neurophysiol. 2006;96:2127&#x2013;2133.</Citation><ArticleIdList><ArticleId IdType="pubmed">16760351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A. 2006;103:6901&#x2013;6906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458991</ArticleId><ArticleId IdType="pubmed">16641105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Liyanage U, Medina M, Ho C, Simmons AD, Lovett M, Kosik KS. Presenilin 1 interaction in the brain with a novel member of the Armadillo family. Neuroreport. 1997;8:2085&#x2013;2090.</Citation><ArticleIdList><ArticleId IdType="pubmed">9223106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21865539</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>97</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.</ArticleTitle><Pagination><StartPage>97ra81</StartPage><MedlinePgn>97ra81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3002473</ELocationID><Abstract><AbstractText>A valine-to-isoleucine mutation at position 122 of the serum protein transthyretin (TTR), found in 3 to 4% of African Americans, alters its stability, leading to amyloidogenesis and cardiomyopathy. In addition, 10 to 15% of individuals older than 65 years develop senile systemic amyloidosis and cardiac TTR deposits because of wild-type TTR amyloidogenesis. Although several drugs are in development, no approved therapies for TTR amyloid cardiomyopathy are yet available, so the identification of additional compounds that prevent amyloid-mediated cardiotoxicity is needed. To this aim, we developed a fluorescence polarization-based high-throughput screen and used it to identify several new chemical scaffolds that target TTR. These compounds were potent kinetic stabilizers of TTR and prevented TTR tetramer dissociation, partial unfolding, and aggregation of both wild type and the most common cardiomyopathy-associated TTR mutant, V122I-TTR. High-resolution co-crystal structures and characterization of the binding energetics revealed how these diverse structures bound to tetrameric TTR. These compounds effectively inhibited the proteotoxicity of V122I-TTR toward human cardiomyocytes. Several of these ligands stabilized TTR in human serum more effectively than diflunisal, which is a well-studied inhibitor of TTR aggregation, and may be promising leads for the treatment or prevention of TTR-mediated cardiomyopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alhamadsheh</LastName><ForeName>Mamoun M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University Medical School, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connelly</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Ahryon</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Reixach</LastName><ForeName>Nat&#xe0;lia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Powers</LastName><ForeName>Evan T</ForeName><Initials>ET</Initials></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Dorothy W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Ian A</ForeName><Initials>IA</Initials></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Jeffery W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Graef</LastName><ForeName>Isabella A</ForeName><Initials>IA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG032285</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5PN2EY016525</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI 42266</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032285</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI042266</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PN2 EY016525</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK 46335</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK046335</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 DK046335</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AI042266</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001577">Benzophenones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011228">Prealbumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>125628-97-9</RegistryNumber><NameOfSubstance UI="C071721">Ro 41-0960</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2011 Oct 14;10(11):816. doi: 10.1038/nrd3586.</RefSource><PMID Version="1">21997752</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001577" MajorTopicYN="N">Benzophenones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="N">Cardiomyopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005454" MajorTopicYN="N">Fluorescence Polarization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011228" MajorTopicYN="N">Prealbumin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21865539</ArticleId><ArticleId IdType="mid">NIHMS337580</ArticleId><ArticleId IdType="pmc">PMC3227540</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3002473</ArticleId><ArticleId IdType="pii">3/97/97ra81</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426:900&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685251</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature. 2003;426:905&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685252</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SM, et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res. 2005;38:911&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">16359163</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science. 1995;268:1039&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">7754382</ArticleId></ArticleIdList></Reference><Reference><Citation>Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302305</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants. Amyloid. 2003;10:160&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">14640030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet. 1990;47:127&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683748</ArticleId><ArticleId IdType="pubmed">2349941</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166:1805&#x2013;1813.</Citation><ArticleIdList><ArticleId IdType="pubmed">17000935</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev. 2010;18:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">20010333</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermark P, Sletten K, Johansson B, Cornwell GG., 3rd Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA. 1990;87:2843&#x2013;2845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53787</ArticleId><ArticleId IdType="pubmed">2320592</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapezzi C, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479782</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson DR, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336:466&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">9017939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Buxbaum JN, Kelly JW. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA. 2001;98:14943&#x2013;14948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC64963</ArticleId><ArticleId IdType="pubmed">11752443</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors LH, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158:607&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">19781421</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum J, et al. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J. 2010;159:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865207</ArticleId><ArticleId IdType="pubmed">20435197</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol. 2010;20:54&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830738</ArticleId><ArticleId IdType="pubmed">20133122</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammarstrom P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293:2459&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pubmed">11577236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299:713&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">12560553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473048</ArticleId><ArticleId IdType="pubmed">16740558</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein M. J. Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. Hypertens. 2002;(Suppl 20):S17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12683423</ArticleId></ArticleIdList></Reference><Reference><Citation>Marnett LJ, Kalgutka AS. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci. 1999;20:465&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace JL. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol. 2001;15:691&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566035</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">11509060</ArticleId></ArticleIdList></Reference><Reference><Citation>Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160:777&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchheiner J, Brockm&#xf6;ller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15637526</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005;33:1567&#x2013;1575.</Citation><ArticleIdList><ArticleId IdType="pubmed">16118328</ArticleId></ArticleIdList></Reference><Reference><Citation>Prapunpoj P, Leelawatwatana L, Schreiber G, Richardson SJ. Change in structure of the N-terminal region of transthyretin produces change in affinity of transthyretin to T4 and T3. FEBS J. 2006;273:4013&#x2013;4023.</Citation><ArticleIdList><ArticleId IdType="pubmed">16879610</ArticleId></ArticleIdList></Reference><Reference><Citation>Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 1992;31:8654&#x2013;8660.</Citation><ArticleIdList><ArticleId IdType="pubmed">1390650</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem. 2004;47:355&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">14711308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiseman RL, et al. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc. 2005;127:5540&#x2013;5551.</Citation><ArticleIdList><ArticleId IdType="pubmed">15826192</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 1999;4:67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10838414</ArticleId></ArticleIdList></Reference><Reference><Citation>Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci USA. 2005;102:14545&#x2013;14550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1253540</ArticleId><ArticleId IdType="pubmed">16195386</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgulya J, Bruderer H, Bernauer K, Z&#xfc;rcher G, Da Prada M. Catechol-O-methyltransferase-Inhibiting Pyrocatechol Derivatives: Synthesis and Structure-Activity Studies. Helvetica Chimica Acta. 1989;72:952&#x2013;968.</Citation></Reference><Reference><Citation>Trivella DB, et al. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: Implications to tetramer stability and ligand-binding. J Struct Biol. 2010;170:522&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">20211733</ArticleId></ArticleIdList></Reference><Reference><Citation>Leavitt S, Freire E. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr Opin Struct Biol. 2001;11:560&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">11785756</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SM, Connelly S, Wilson IA, Kelly JW. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem. 2008;51:6348&#x2013;6358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587341</ArticleId><ArticleId IdType="pubmed">18811132</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3145458</ArticleId><ArticleId IdType="pubmed">21557933</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson MM, et al. Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell Cardiol. 2005;39:133&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15913645</ArticleId></ArticleIdList></Reference><Reference><Citation>Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA. 2004;101:2817&#x2013;2822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365703</ArticleId><ArticleId IdType="pubmed">14981241</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004;84:545&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">14968122</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsen E, Suhr OB, Tashima K, Athlin E. Early liver transplantation is essential for familial amyloidotic polyneuropathy patients&#x2019; quality of life. Amyloid. 2001;8:52&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamour IM, et al. Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant. 2008;8:1056&#x2013;1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">18318779</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ. Small transthyretin TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord. 2005;4:587&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">16266291</ArticleId></ArticleIdList></Reference><Reference><Citation>McCutchen SL, Colon W, Kelly JW. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry. 1993;32:12119&#x2013;12127.</Citation><ArticleIdList><ArticleId IdType="pubmed">8218290</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintas A, Saraiva MJ, Brito RM. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett. 1997;418:297&#x2013; 300.</Citation><ArticleIdList><ArticleId IdType="pubmed">9428731</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho T, et al. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met 30 and TTR Met 119. J Rheumatol. 1993;120:179.</Citation></Reference><Reference><Citation>Kolstoe SE, Wood SP. Drug targets for amyloidosis. Biochem Soc Trans. 2010;38:466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">20298204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi S, Takahashi K, Naito M, Tashiro F, Wakasugi S, Maeda S, Shimada K, Yamamura K, Araki S. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am J Pathol. 1991;138:403&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886191</ArticleId><ArticleId IdType="pubmed">1992765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohno K, Palha JA, Miyakawa K, Saraiva MJ, Ito S, Mabuchi T, Blaner WS, Iijima H, Tsukahara S, Episkopou V, Gottesman ME, Shimada K, Takahashi K, Yamamura K, Maeda S. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol. 1997;150:1497&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858187</ArticleId><ArticleId IdType="pubmed">9095004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr. 1994;14:495&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">7946531</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison&#x2019;s Principles of Internal Medicine. 17. Vol. 1448. 2008. p. 1763.p. 1770.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21873225</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>36</Issue><PubDate><Year>2011</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Serotonin signaling is associated with lower amyloid-&#x3b2; levels and plaques in transgenic mice and humans.</ArticleTitle><Pagination><StartPage>14968</StartPage><EndPage>14973</EndPage><MedlinePgn>14968-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1107411108</ELocationID><Abstract><AbstractText>Aggregation of amyloid-&#x3b2; (A&#x3b2;) as toxic oligomers and amyloid plaques within the brain appears to be the pathogenic event that initiates Alzheimer's disease (AD) lesions. One therapeutic strategy has been to reduce A&#x3b2; levels to limit its accumulation. Activation of certain neurotransmitter receptors can regulate A&#x3b2; metabolism. We assessed the ability of serotonin signaling to alter brain A&#x3b2; levels and plaques in a mouse model of AD and in humans. In mice, brain interstitial fluid (ISF) A&#x3b2; levels were decreased by 25% following administration of several selective serotonin reuptake inhibitor (SSRI) antidepressant drugs. Similarly, direct infusion of serotonin into the hippocampus reduced ISF A&#x3b2; levels. Serotonin-dependent reductions in A&#x3b2; were reversed if mice were pretreated with inhibitors of the extracellular regulated kinase (ERK) signaling cascade. Chronic treatment with an SSRI, citalopram, caused a 50% reduction in brain plaque load in mice. To test whether serotonin signaling could impact A&#x3b2; plaques in humans, we retrospectively compared brain amyloid load in cognitively normal elderly participants who were exposed to antidepressant drugs within the past 5 y to participants who were not. Antidepressant-treated participants had significantly less amyloid load as quantified by positron emission tomography (PET) imaging with Pittsburgh Compound B (PIB). Cumulative time of antidepressant use within the 5-y period preceding the scan correlated with less plaque load. These data suggest that serotonin signaling was associated with less A&#x3b2; accumulation in cognitively normal individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. cirritoj@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Disabato</LastName><ForeName>Brianne M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Restivo</LastName><ForeName>Jessica L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Verges</LastName><ForeName>Deborah K</ForeName><Initials>DK</Initials></Author><Author ValidYN="Y"><LastName>Goebel</LastName><ForeName>Whitney D</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>Sathyan</LastName><ForeName>Anshul</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hayreh</LastName><ForeName>Davinder</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>D'Angelo</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hyejin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungsu</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Sheline</LastName><ForeName>Yvette I</ForeName><Initials>YI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 MH079510</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH77124</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS069329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH077124</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MHO79510</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):E1007; author reply E1008. doi: 10.1073/pnas.1114219108.</RefSource><PMID Version="1">22042836</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21873225</ArticleId><ArticleId IdType="pmc">PMC3169155</ArticleId><ArticleId IdType="doi">10.1073/pnas.1107411108</ArticleId><ArticleId IdType="pii">1107411108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>St George-Hyslop PH, Morris JC. Will anti-amyloid therapies work for Alzheimer's disease? Lancet. 2008;372:180&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640437</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomakin A, Teplow DB, Kirschner DA, Benedek GB. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci USA. 1997;94:7942&#x2013;7947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21534</ArticleId><ArticleId IdType="pubmed">9223292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoey SE, Williams RJ, Perkinton MS. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. J Neurosci. 2009;29:4442&#x2013;4460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665739</ArticleId><ArticleId IdType="pubmed">19357271</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckols K, et al. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci. 1995;57:1183&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">7674807</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258:304&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">1411529</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease&#x2014;an update. Curr Alzheimer Res. 2007;4:577&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220527</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci. 2010;30:4190&#x2013;4196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855655</ArticleId><ArticleId IdType="pubmed">20335454</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 2000;48:913&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">11117548</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem. 1996;271:4188&#x2013;4194.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626761</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjona AA, Pooler AM, Lee RK, Wurtman RJ. Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Res. 2002;951:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">12231467</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen F, et al. 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. 2011;61:69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">21392515</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker S, et al. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Curr Alzheimer Res. 2006;3:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">16842099</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson RL, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007;205:166&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1979096</ArticleId><ArticleId IdType="pubmed">17368447</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe1;k&#xe1;ski M, et al. Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem Int. 2005;47:190&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955598</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A, et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis. 2005;18:602&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755686</ArticleId></ArticleIdList></Reference><Reference><Citation>Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">17942826</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SK, et al. ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J. 2006;20:157&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">16293708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojro E, et al. The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J. 2006;20:512&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401644</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouyss&#xe9;gur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol. 2002;64:755&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">12213567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetman M, Kanning K, Cavanaugh JE, Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J Biol Chem. 1999;274:22569&#x2013;22580.</Citation><ArticleIdList><ArticleId IdType="pubmed">10428835</ArticleId></ArticleIdList></Reference><Reference><Citation>Basta-Kaim A, et al. Effects of neurosteroids on glucocorticoid receptor-mediated gene transcription in LMCAT cells&#x2014;A possible interaction with psychotropic drugs. Eur Neuropsychopharmacol. 2007;17:37&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581232</ArticleId></ArticleIdList></Reference><Reference><Citation>Krapivinsky G, et al. The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron. 2003;40:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622581</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AM, et al. Catecholaminergic control of mitogen-activated protein kinase signaling in paraventricular neuroendocrine neurons in vivo and in vitro: a proposed role during glycemic challenges. J Neurosci. 2007;27(27):7344&#x2013;7360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794600</ArticleId><ArticleId IdType="pubmed">17611287</ArticleId></ArticleIdList></Reference><Reference><Citation>Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR. Opposing synaptic regulation of amyloid-&#x3b2; metabolism by NMDA receptors in vivo. J Neurosci. 2011;31:11328&#x2013;11337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329800</ArticleId><ArticleId IdType="pubmed">21813692</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowen DS. Serotonin and neuronal growth factors: A convergence of signaling pathways. J Neurochem. 2007;101:1161&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286594</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills J, et al. Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci. 1997;17(24):9415&#x2013;9422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573401</ArticleId><ArticleId IdType="pubmed">9390997</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkeley JL, et al. M1 muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices. Mol Cell Neurosci. 2001;18:512&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">11922142</ArticleId></ArticleIdList></Reference><Reference><Citation>Haring R, et al. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. J Neurochem. 1998;71:2094&#x2013;2103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9798935</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology. 2008;70:1258&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391157</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530614</ArticleId><ArticleId IdType="pubmed">16651510</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, et al. Depression as a risk factor for Alzheimer disease: The MIRAGE Study. Arch Neurol. 2003;60:753&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">12756140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003;15:346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE. Blowing hot and cold over depression and cognitive impairment. Neurology. 2010;75:12&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20603480</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology. 2010;75:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906403</ArticleId><ArticleId IdType="pubmed">20603482</ArticleId></ArticleIdList></Reference><Reference><Citation>Saczynski JS, et al. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology. 2010;75:35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906404</ArticleId><ArticleId IdType="pubmed">20603483</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev. 2005;4:141&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15996533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessing LV, S&#xf8;nderg&#xe5;rd L, Forman JL, Andersen PK. Antidepressants and dementia. J Affect Disord. 2009;117:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">19138799</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, et al. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15:169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584433</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>McConlogue L, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007;282:26326&#x2013;26334.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616527</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706&#x2013;10714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pubmed">12900317</ArticleId></ArticleIdList></Reference><Reference><Citation>Post RM, Roy-Byrne PP, Uhde TW. Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry. 1988;145:844&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">3381929</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21886162</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>477</Volume><Issue>7362</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>The ageing systemic milieu negatively regulates neurogenesis and cognitive function.</ArticleTitle><Pagination><StartPage>90</StartPage><EndPage>94</EndPage><MedlinePgn>90-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature10357</ELocationID><Abstract><AbstractText>In the central nervous system, ageing results in a precipitous decline in adult neural stem/progenitor cells and neurogenesis, with concomitant impairments in cognitive functions. Interestingly, such impairments can be ameliorated through systemic perturbations such as exercise. Here, using heterochronic parabiosis we show that blood-borne factors present in the systemic milieu can inhibit or promote adult neurogenesis in an age-dependent fashion in mice. Accordingly, exposing a young mouse to an old systemic environment or to plasma from old mice decreased synaptic plasticity, and impaired contextual fear conditioning and spatial learning and memory. We identify chemokines--including CCL11 (also known as eotaxin)--the plasma levels of which correlate with reduced neurogenesis in heterochronic parabionts and aged mice, and the levels of which are increased in the plasma and cerebrospinal fluid of healthy ageing humans. Lastly, increasing peripheral CCL11 chemokine levels in vivo in young mice decreased adult neurogenesis and impaired learning and memory. Together our data indicate that the decline in neurogenesis and cognitive impairments observed during ageing can be in part attributed to changes in blood-borne factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villeda</LastName><ForeName>Saul A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mosher</LastName><ForeName>Kira I</ForeName><Initials>KI</Initials></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Bende</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Britschgi</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bieri</LastName><ForeName>Gregor</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Stan</LastName><ForeName>Trisha M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Fainberg</LastName><ForeName>Nina</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Zhaoqing</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Eggel</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lucin</LastName><ForeName>Kurt M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Czirr</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jeong-Soo</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Couillard-Despr&#xe9;s</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Aigner</LastName><ForeName>Ludwig</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ge</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Xinmin S</ForeName><Initials>XS</Initials></Author><Author ValidYN="Y"><LastName>Rando</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI007290</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG08017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH078194</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 F31 AG034045-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG027505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 OD000392</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR056849</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 F31 NS066676-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS066676</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG034045</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054413">Chemokine CCL11</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2011 Aug 31;477(7362):41-2. doi: 10.1038/477041a.</RefSource><PMID Version="1">21886154</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 Sep 20;12(10):547. doi: 10.1038/nrn3116.</RefSource><PMID Version="1">21931332</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054413" MajorTopicYN="N">Chemokine CCL11</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007859" MajorTopicYN="N">Learning Disabilities</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010227" MajorTopicYN="N">Parabiosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests Statement:</b> The authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21886162</ArticleId><ArticleId IdType="mid">NIHMS313001</ArticleId><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="doi">10.1038/nature10357</ArticleId><ArticleId IdType="pii">nature10357</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci. 2005;25 (38):8680&#x2013;8685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360197</ArticleId><ArticleId IdType="pubmed">16177036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage FH. Mammalian neural stem cells. Science. 2000;287 (5457):1433&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pubmed">10688783</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Buylla A, Lim DA. For the long run: maintaining germinal niches in the adult brain. Neuron. 2004;41 (5):683&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003168</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132 (4):645&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295581</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, et al. Functional neurogenesis in the adult hippocampus. Nature. 2002;415 (6875):1030&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci. 11(5):339&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886712</ArticleId><ArticleId IdType="pubmed">20354534</ArticleId></ArticleIdList></Reference><Reference><Citation>Clelland CD, et al. A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science. 2009;325 (5937):210&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997634</ArticleId><ArticleId IdType="pubmed">19590004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang CL, Zou Y, He W, Gage FH, Evans RM. A role for adult TLX-positive neural stem cells in learning and behaviour. Nature. 2008;451 (7181):1004&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">18235445</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxe MD, et al. Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc Natl Acad Sci U S A. 2006;103 (46):17501&#x2013;17506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1859958</ArticleId><ArticleId IdType="pubmed">17088541</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q, et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science. 2004;304 (5675):1338&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">15060285</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpentier PA, Palmer TD. Immune influence on adult neural stem cell regulation and function. Neuron. 2009;64 (1):79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789107</ArticleId><ArticleId IdType="pubmed">19840551</ArticleId></ArticleIdList></Reference><Reference><Citation>Renault VM, et al. FoxO3 regulates neural stem cell homeostasis. Cell Stem Cell. 2009;5 (5):527&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775802</ArticleId><ArticleId IdType="pubmed">19896443</ArticleId></ArticleIdList></Reference><Reference><Citation>Molofsky AV, et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature. 2006;443 (7110):448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586960</ArticleId><ArticleId IdType="pubmed">16957738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie DC, et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005;437 (7063):1370&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009;64 (1):110&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834890</ArticleId><ArticleId IdType="pubmed">19840553</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp PR, Heindel WC. Memory systems in normal and pathological aging. Curr Opin Neurol. 1994;7 (4):294&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">7952236</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10 (12):1538&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361 (6407):31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Conboy IM, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005;433 (7027):760&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">15716955</ArticleId></ArticleIdList></Reference><Reference><Citation>Couillard-Despres S, et al. In vivo optical imaging of neurogenesis: watching new neurons in the intact brain. Mol Imaging. 2008;7 (1):28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">18384721</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302 (5651):1760&#x2013;1765.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615545</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriyama M, et al. Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis. J Neurosci. 31(11):3981&#x2013;3989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071463</ArticleId><ArticleId IdType="pubmed">21411641</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli M, d&#x2019;Adda di Fagagna F. SASPense and DDRama in cancer and ageing. Nat Cell Biol. 2009;11 (8):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">19648977</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, et al. Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J Clin Invest. 2007;117 (11):3306&#x2013;3315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040317</ArticleId><ArticleId IdType="pubmed">17965773</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Smart TG. Modulation of long-term potentiation in rat hippocampal pyramidal neurons by zinc. Pflugers Arch. 1994;427 (5&#x2013;6):481&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">7971146</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1 (4):1671&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487150</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, et al. Irradiation enhances hippocampus-dependent cognition in mice deficient in extracellular superoxide dismutase. Hippocampus. 21(1):72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891276</ArticleId><ArticleId IdType="pubmed">20020436</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129 (4):526&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688655</ArticleId><ArticleId IdType="pubmed">18343778</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One. 2009;4 (5):e5424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671606</ArticleId><ArticleId IdType="pubmed">19412541</ArticleId></ArticleIdList></Reference><Reference><Citation>Couillard-Despres S, et al. Human in vitro reporter model of neuronal development and early differentiation processes. BMC Neurosci. 2008;9:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270856</ArticleId><ArticleId IdType="pubmed">18312642</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckwalter MS, et al. Chronically increased transforming growth factor-beta1 strongly inhibits hippocampal neurogenesis in aged mice. Am J Pathol. 2006;169 (1):154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698757</ArticleId><ArticleId IdType="pubmed">16816369</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21917794</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>37</Issue><PubDate><Year>2011</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice.</ArticleTitle><Pagination><StartPage>13110</StartPage><EndPage>13117</EndPage><MedlinePgn>13110-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2569-11.2011</ELocationID><Abstract><AbstractText>Although tau is a cytoplasmic protein, it is also found in brain extracellular fluids, e.g., CSF. Recent findings suggest that aggregated tau can be transferred between cells and extracellular tau aggregates might mediate spread of tau pathology. Despite these data, details of whether tau is normally released into the brain interstitial fluid (ISF), its concentration in ISF in relation to CSF, and whether ISF tau is influenced by its aggregation are unknown. To address these issues, we developed a microdialysis technique to analyze monomeric ISF tau levels within the hippocampus of awake, freely moving mice. We detected tau in ISF of wild-type mice, suggesting that tau is released in the absence of neurodegeneration. ISF tau was significantly higher than CSF tau and their concentrations were not significantly correlated. Using P301S human tau transgenic mice (P301S tg mice), we found that ISF tau is fivefold higher than endogenous murine tau, consistent with its elevated levels of expression. However, following the onset of tau aggregation, monomeric ISF tau decreased markedly. Biochemical analysis demonstrated that soluble tau in brain homogenates decreased along with the deposition of insoluble tau. Tau fibrils injected into the hippocampus decreased ISF tau, suggesting that extracellular tau is in equilibrium with extracellular or intracellular tau aggregates. This technique should facilitate further studies of tau secretion, spread of tau pathology, the effects of different disease states on ISF tau, and the efficacy of experimental treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Brandon B</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>Lester I</ForeName><Initials>LI</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Marc I</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21917794</ArticleId><ArticleId IdType="mid">NIHMS653771</ArticleId><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2569-11.2011</ArticleId><ArticleId IdType="pii">31/37/13110</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115&#x2013;9129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Braak H, Fischer P, Jellinger KA. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett. 1993;162:179&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8121624</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010;30:16559&#x2013;16566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135981</ArticleId><ArticleId IdType="pubmed">21147995</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging. 1997;18:S85&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330992</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, L&#xe9;ger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol. 1995;131:1327&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120645</ArticleId><ArticleId IdType="pubmed">8522593</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between A&#x3b2;, tau, and &#x3b1;-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30:7281&#x2013;7289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308018</ArticleId><ArticleId IdType="pubmed">20505094</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem. 2002;81:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>Deters N, Ittner LM, G&#xf6;tz J. Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci. 2008;28:137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">18662339</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Hauw JJ. Prevalence, incidence and duration of Braak's stages in the general population: can we know? Neurobiol Aging. 1997;18:362&#x2013;369. discussion 389&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">9380250</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-produced &#x3b1;-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30:6838&#x2013;6851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842464</ArticleId><ArticleId IdType="pubmed">20484626</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah CA, Perreault S, Liazoghli D, Desjardins M, Anton A, Lauzon M, Paiement J, Leclerc N. Tau interacts with Golgi membranes and mediates their association with microtubules. Cell Motil Cytoskeleton. 2006;63:710&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960886</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845&#x2013;12852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990;9:4225&#x2013;4230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552204</ArticleId><ArticleId IdType="pubmed">2124967</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Ramos A, D&#xed;az-Hern&#xe1;ndez M, Cuadros R, Hern&#xe1;ndez F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett. 2006;580:4842&#x2013;4850.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914144</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Ramos A, D&#xed;az-Hern&#xe1;ndez M, Rubio A, Miras-Portugal MT, Avila J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci. 2008;37:673&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">18272392</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, Pratico D, Clark CM, Coslett HB, Chatterjee A, Gee J, Trojanowski JQ, Lee VM. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol. 2005;57:721&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852395</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137759</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G&#xf6;tz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung D, Filliol D, Miehe M, Rendon A. Interaction of brain mitochondria with microtubules reconstituted from brain tubulin and MAP2 or TAU. Cell Motil Cytoskeleton. 1993;24:245&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">8097434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009;64:632&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF. Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis. 2010a;19:647&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Lee S, Hall GF. Secretion of human tau fragments resembling CSF-tau in Alzheimer's disease is modulated by the presence of the exon 2 insert. FEBS Lett. 2010b;584:3085&#x2013;3088.</Citation><ArticleIdList><ArticleId IdType="pubmed">20553717</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A. 1995;92:10369&#x2013;10373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40798</ArticleId><ArticleId IdType="pubmed">7479786</ArticleId></ArticleIdList></Reference><Reference><Citation>Menacherry S, Hubert W, Justice JB., Jr In vivo calibration of microdialysis probes for exogenous compounds. Anal Chem. 1992;64:577&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">1580357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Sch&#xf6;nig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM. The potential for &#x3b2;-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008;28:737&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel W. Pathways of unconventional protein secretion. Curr Opin Biotechnol. 2010;21:621&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">20637599</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem. 2006;281:39413&#x2013;39423.</Citation><ArticleIdList><ArticleId IdType="pubmed">17056594</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, Weber T, Kretzschmar HA, Poser S. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 1997;225:210&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">9147407</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29:10741&#x2013;10749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760256</ArticleId><ArticleId IdType="pubmed">19710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Hansson SF, Tran AJ, Zetterberg H, Grognet P, Vanmechelen E, H&#xf6;glund K, Brinkmalm G, Westman-Brinkmalm A, Nordhoff E, Blennow K, Gobom J. Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res. 2008;7:2114&#x2013;2120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18351740</ArticleId></ArticleIdList></Reference><Reference><Citation>Porzig R, Singer D, Hoffmann R. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun. 2007;358:644&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499212</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, F&#xf6;rstl H, Kurz A. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 2003;8:343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660807</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L. Amyloid-&#x3b2;/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci. 2011;31:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res. 2009;6:446&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891148</ArticleId><ArticleId IdType="pubmed">19874269</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A, Mandelkow EM. &#x2018;Prion-like&#x2019; propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy. Neurodegener Dis. 2010;7:28&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160454</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow EM. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci. 2011;31:2511&#x2013;2525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623704</ArticleId><ArticleId IdType="pubmed">21325519</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma H, Arawaka S, Mori H. Isoforms changes of tau protein during development in various species. Brain Res Dev Brain Res. 2003;142:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">12711363</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E, Mandelkow EM. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci. 2007;27:2896&#x2013;2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Trickler WJ, Miller DW. Use of osmotic agents in microdialysis studies to improve the recovery of macromolecules. J Pharm Sci. 2003;92:1419&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pubmed">12820146</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61:1828&#x2013;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">8228996</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 2000;97:5129&#x2013;5134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 2008;18:253&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095597</ArticleId><ArticleId IdType="pubmed">18363936</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2218531</PMID><DateCompleted><Year>1990</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>250</Volume><Issue>4978</Issue><PubDate><Year>1990</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.</ArticleTitle><Pagination><StartPage>279</StartPage><EndPage>282</EndPage><MedlinePgn>279-82</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid beta protein is deposited in the brains of patients with Alzheimer's disease but its pathogenic role is unknown. In culture, the amyloid beta protein was neurotrophic to undifferentiated hippocampal neurons at low concentrations and neurotoxic to mature neurons at higher concentrations. In differentiated neurons, amyloid beta protein caused dendritic and axonal retraction followed by neuronal death. A portion of the amyloid beta protein (amino acids 25 to 35) mediated both the trophic and toxic effects and was homologous to the tachykinin neuropeptide family. The effects of the amyloid beta protein were mimicked by tachykinin antagonists and completely reversed by specific tachykinin agonists. Thus, the amyloid beta protein could function as a neurotrophic factor for differentiating neurons, but at high concentrations in mature neurons, as in Alzheimer's disease, could cause neuronal degeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>B A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duffy</LastName><ForeName>L K</ForeName><Initials>LK</Initials></Author><Author ValidYN="Y"><LastName>Kirschner</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG08572</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS01240</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015320">Tachykinins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="Y">Neurotoxins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015320" MajorTopicYN="N">Tachykinins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>10</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>10</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2218531</ArticleId><ArticleId IdType="doi">10.1126/science.2218531</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2423512</PMID><DateCompleted><Year>1986</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-924X</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>5</Issue><PubDate><Year>1986</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of biochemistry</Title><ISOAbbreviation>J Biochem</ISOAbbreviation></Journal><ArticleTitle>One of the antigenic determinants of paired helical filaments is related to tau protein.</ArticleTitle><Pagination><StartPage>1541</StartPage><EndPage>1544</EndPage><MedlinePgn>1541-4</MedlinePgn></Pagination><Abstract><AbstractText>Paired helical filaments (PHF) are unusual neuronal fibers which accumulate progressively in the brain in Alzheimer's disease (AD). The insolubility of PHF in various kinds of solvents enabled us to obtain highly purified PHF, but prevented the application of conventional analytical methods to identify their components. Here we report that antibodies against purified PHF recognize tau protein, a brain-specific microtubule-associated protein, suggesting that a portion of PHF is tau protein.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nukina</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ihara</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biochem</MedlineTA><NlmUniqueID>0376600</NlmUniqueID><ISSNLinking>0021-924X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007120" MajorTopicYN="N">Immunochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2423512</ArticleId><ArticleId IdType="doi">10.1093/oxfordjournals.jbchem.a135625</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2424015</PMID><DateCompleted><Year>1986</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>83</Volume><Issue>11</Issue><PubDate><Year>1986</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau).</ArticleTitle><Pagination><StartPage>4040</StartPage><EndPage>4043</EndPage><MedlinePgn>4040-3</MedlinePgn></Pagination><Abstract><AbstractText>The relationship of the neurofibrillary tangle, found in Alzheimer disease and aged brains, to normal or abnormal cytoskeletal proteins remains elusive. Although immunohistochemical studies have yielded disparate results, most antigenic determinants localized to neurofibrillary tangles are cytoskeletal constituents normally present in neuronal perikarya or dendrites. We report light and electron microscopic immunolabeling of neurofibrillary tangles by a monoclonal antibody to the microtubule-associated protein tau (tau). Dephosphorylation of tissue slices not only increased the number of tau-positive tangles but also produced marked positive immunoreactivity of neuritic plaques. The localization of tau, an axonal protein, to neurofibrillary tangles in the perikaryon in particular suggests that abnormal synthesis, modification, or aggregation of tau may induce aberrant cytoskeletal--cell organelle interactions, subsequent interference with axonal flow, and resultant tangle formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Mirra</LastName><ForeName>S S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>N J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>L I</ForeName><Initials>LI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS17731</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A 1986 Dec;83(24):9773</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1986</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2424015</ArticleId><ArticleId IdType="pmc">PMC323661</ArticleId><ArticleId IdType="doi">10.1073/pnas.83.11.4040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Exp Brain Res. 1982;Suppl 5:15-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6185356</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1982 Dec 15;129(2):465-71</Citation><ArticleIdList><ArticleId IdType="pubmed">7151809</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1983 Jan;42(1):69-79</Citation><ArticleIdList><ArticleId IdType="pubmed">6337236</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1983 Aug 25-31;304(5928):727-30</Citation><ArticleIdList><ArticleId IdType="pubmed">6350889</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1983 Dec;113(3):373-81</Citation><ArticleIdList><ArticleId IdType="pubmed">6196977</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1984;62(3):167-77</Citation><ArticleIdList><ArticleId IdType="pubmed">6538056</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1983 Dec;62(1-3):315-26</Citation><ArticleIdList><ArticleId IdType="pubmed">6366122</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1984 Feb;4(2):394-410</Citation><ArticleIdList><ArticleId IdType="pubmed">6699682</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1984;62(4):259-67</Citation><ArticleIdList><ArticleId IdType="pubmed">6428153</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1984 Jun 20;226(2):203-21</Citation><ArticleIdList><ArticleId IdType="pubmed">6736300</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1984 Sep 24;310(2):249-60</Citation><ArticleIdList><ArticleId IdType="pubmed">6207891</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1984 Dec;81(24):7941-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6083566</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(11):3916-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3889918</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(12):4274-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3159022</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Brain Res. 1982;Suppl 5:20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6185357</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1985 Aug 15-21;316(6029):630-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2412124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1985 Oct;101(4):1371-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1985 Aug;120(2):292-303</Citation><ArticleIdList><ArticleId IdType="pubmed">2411143</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1963 Jan 12;197:192-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14032480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1963 Oct;22:629-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14069842</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1975 May;72(5):1858-62</Citation><ArticleIdList><ArticleId IdType="pubmed">1057175</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 1977 Oct 25;116(2):227-47</Citation><ArticleIdList><ArticleId IdType="pubmed">146092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1980 Jan;84(1):66-76</Citation><ArticleIdList><ArticleId IdType="pubmed">6985613</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1981 Aug 25;256(16):8795-800</Citation><ArticleIdList><ArticleId IdType="pubmed">7263687</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1982 Jan;2(1):113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7033478</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1982 Mar 5;215(4537):1243-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6120571</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2423928</PMID><DateCompleted><Year>1986</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>3</Issue><PubDate><Year>1986</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques.</ArticleTitle><Pagination><StartPage>351</StartPage><EndPage>355</EndPage><MedlinePgn>351-5</MedlinePgn></Pagination><Abstract><AbstractText>Paired helical filaments, pathologically changed components of the cytoskeleton of human nerve cells, are demonstrated by a specific silver staining technique, immunostaining and electron microscopy. Accumulations of these filaments are found in the telencephalic cortex of old-aged individuals and patients suffering from Alzheimer's disease. Apart from neurofibrillary tangles and neuritic plaques, paired helical filaments are encountered in neuropil threads. At this third location, pathological filaments occur in small and inconspicuous profiles scattered throughout both allocortical and isocortical areas. The pattern of distribution and packing density of neuropil threads varies between different cortical areas and layers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Grundke-Iqbal</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05892</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG/NS 04220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 18105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance></Chemical><Chemical><RegistryNumber>3M4G523W1G</RegistryNumber><NameOfSubstance UI="D012834">Silver</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007106" MajorTopicYN="N">Immune Sera</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012834" MajorTopicYN="N">Silver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>4</Month><Day>24</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>4</Month><Day>24</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2423928</ArticleId><ArticleId IdType="doi">10.1016/0304-3940(86)90288-0</ArticleId><ArticleId IdType="pii">0304-3940(86)90288-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2424016</PMID><DateCompleted><Year>1986</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>83</Volume><Issue>11</Issue><PubDate><Year>1986</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease.</ArticleTitle><Pagination><StartPage>4044</StartPage><EndPage>4048</EndPage><MedlinePgn>4044-8</MedlinePgn></Pagination><Abstract><AbstractText>The detailed protein composition of the paired helical filaments (PHF) that accumulate in human neurons in aging and Alzheimer disease is unknown. However, the identity of certain components has been surmised by using immunocytochemical techniques. Whereas PHF share epitopes with neurofilament proteins and microtubule-associated protein (MAP) 2, we report evidence that the MAP tau (tau) appears to be their major antigenic component. Immunization of rabbits with NaDodSO4-extracted, partially purified PHF (free of normal cytoskeletal elements, including tau) consistently produces antibodies to tau but not, for example, to neurofilaments. Such PHF antibodies label all of the heterogeneous fetal and mature forms of tau from rat and human brain. Absorption of PHF antisera with heat-stable MAPs (rich in tau) results in almost complete loss of staining of neurofibrillary tangles (NFT) in human brain sections. An affinity-purified antibody to tau specifically labels NFT and the neurites of senile plaques in human brain sections as well as NaDodSO4-extracted NFT. tau-Immunoreactive NFT frequently extend into the apical dendrites of pyramidal neurons, suggesting an aberrant intracellular locus for this axonal protein. tau and PHF antibodies label tau proteins identically on electrophoretic transfer blots and stain the gel-excluded protein representing NaDodSO4-insoluble PHF in homogenates of human brain. The progressive accumulation of altered tau protein in neurons in Alzheimer disease may result in instability of microtubules, consequent loss of effective transport of molecules and organelles, and, ultimately, neuronal death.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>K S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Joachim</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5K07 NS00835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06172</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS23340</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007163" MajorTopicYN="N">Immunosorbent Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1986</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2424016</ArticleId><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="doi">10.1073/pnas.83.11.4044</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neuropathol Exp Neurol. 1967 Jan;26(1):25-39</Citation><ArticleIdList><ArticleId IdType="pubmed">6022163</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1964 Feb;44:269-97</Citation><ArticleIdList><ArticleId IdType="pubmed">14119171</ArticleId></ArticleIdList></Reference><Reference><Citation>J Histochem Cytochem. 1974 Dec;22(12):1077-83</Citation><ArticleIdList><ArticleId IdType="pubmed">4374474</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Biochem. 1978 Jun;56(6):598-604</Citation><ArticleIdList><ArticleId IdType="pubmed">208731</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1978 Dec 1;92(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">729584</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4</Citation><ArticleIdList><ArticleId IdType="pubmed">388439</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1980 Mar 27;284(5754):353-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7360270</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1980 Apr 18;208(4441):297-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7367858</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1981 Apr;89(1):86-95</Citation><ArticleIdList><ArticleId IdType="pubmed">6164682</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1982 Mar 5;215(4537):1243-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6120571</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1982 Feb;92(2):435-42</Citation><ArticleIdList><ArticleId IdType="pubmed">6120944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1982 Jul 1;298(5869):84-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6178036</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1982 Sep 10;217(4564):1053-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7112111</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1982 Dec 15;129(2):465-71</Citation><ArticleIdList><ArticleId IdType="pubmed">7151809</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1983 Apr 14;744(1):36-45</Citation><ArticleIdList><ArticleId IdType="pubmed">6299365</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1983 Jun 6;268(2):249-54</Citation><ArticleIdList><ArticleId IdType="pubmed">6191831</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1983 Aug 25-31;304(5928):727-30</Citation><ArticleIdList><ArticleId IdType="pubmed">6350889</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1983 Dec;113(3):373-81</Citation><ArticleIdList><ArticleId IdType="pubmed">6196977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1984 Mar;98(3):1090-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6421824</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1984 Jan;11(1):156-67</Citation><ArticleIdList><ArticleId IdType="pubmed">6709184</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1984 Mar;81(6):1875-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6584922</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1984;62(4):268-75</Citation><ArticleIdList><ArticleId IdType="pubmed">6730905</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1984 Sep;81(17):5613-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6591209</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1984 Sep 24;310(2):249-60</Citation><ArticleIdList><ArticleId IdType="pubmed">6207891</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1984 Dec;81(24):7941-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6083566</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1984 Nov 19;322(1):194-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6083822</ArticleId></ArticleIdList></Reference><Reference><Citation>J Submicrosc Cytol. 1985 Jan;17(1):89-96</Citation><ArticleIdList><ArticleId IdType="pubmed">3973960</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(11):3916-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3889918</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(12):4274-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3159022</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1985 Aug;120(2):282-91</Citation><ArticleIdList><ArticleId IdType="pubmed">2411142</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1985 Oct;101(4):1371-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1985 Dec 6;230(4730):1179-81</Citation><ArticleIdList><ArticleId IdType="pubmed">4071042</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1986 Jan;45(1):56-64</Citation><ArticleIdList><ArticleId IdType="pubmed">3510274</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1986 Mar;45(2):161-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2419516</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1986 Jun;46(6):1820-34</Citation><ArticleIdList><ArticleId IdType="pubmed">3517233</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Jun;83(11):4040-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1970 Aug 15;227(5259):680-5</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2457949</PMID><DateCompleted><Year>1988</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>241</Volume><Issue>4869</Issue><PubDate><Year>1988</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Amyloid protein precursor messenger RNAs: differential expression in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1080</StartPage><EndPage>1084</EndPage><MedlinePgn>1080-4</MedlinePgn></Pagination><Abstract><AbstractText>In situ hybridization was used to assess total amyloid protein precursor (APP) messenger RNA and the subset of APP mRNA containing the Kunitz protease inhibitor (KPI) insert in 11 Alzheimer's disease (AD) and 7 control brains. In AD, a significant twofold increase was observed in total APP mRNA in nucleus basalis and locus ceruleus neurons but not in hippocampal subicular neurons, neurons of the basis pontis, or occipital cortical neurons. The increase in total APP mRNA in locus ceruleus and nucleus basalis neurons was due exclusively to an increase in APP mRNA lacking the KPI domain. These findings suggest that increased production of APP lacking the KPI domain in nucleus basalis and locus ceruleus neurons may play an important role in the deposition of cerebral amyloid that occurs in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palmert</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>T E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Gusella</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Usiak</LastName><ForeName>M F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>L H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>S G</ForeName><Initials>SG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5T32GM07250</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06656</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH43444</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018075">RNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014361">Trypsin Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010582" MajorTopicYN="N">Bacteriophage lambda</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009693" MajorTopicYN="N">Nucleic Acid Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009875" MajorTopicYN="N">Operator Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018075" MajorTopicYN="N">RNA, Complementary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014361" MajorTopicYN="N">Trypsin Inhibitors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>8</Month><Day>26</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>8</Month><Day>26</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2457949</ArticleId><ArticleId IdType="doi">10.1126/science.2457949</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2453810</PMID><DateCompleted><Year>1988</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0305-1846</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>1988</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Neuropathology and applied neurobiology</Title><ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Neuropil threads occur in dendrites of tangle-bearing nerve cells.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>44</EndPage><MedlinePgn>39-44</MedlinePgn></Pagination><Abstract><AbstractText>Transparent Golgi preparations counterstained for Alzheimer's neurofibrillary changes rendered possible the demonstration of neuropil threads in defined cellular processes. Only dendrites of tangle-bearing cortical nerve cells were found to contain neuropil threads. Processes of glial cells as well as axons present in the material were devoid of neuropil threads.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anatomy, J. W. Goethe University of Frankfurt, West Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropathol Appl Neurobiol</MedlineTA><NlmUniqueID>7609829</NlmUniqueID><ISSNLinking>0305-1846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3M4G523W1G</RegistryNumber><NameOfSubstance UI="D012834">Silver</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012834" MajorTopicYN="N">Silver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2453810</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2990.1988.tb00864.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2466390</PMID><DateCompleted><Year>1989</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-6322</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><Issue>3</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain.</ArticleTitle><Pagination><StartPage>314</StartPage><EndPage>319</EndPage><MedlinePgn>314-9</MedlinePgn></Pagination><Abstract><AbstractText>We studied senile plaques (SP) in the cerebella of six autopsied subjects with Alzheimer-type dementia (ATD) and ten non-ATD autopsied subjects between the ages of 78 and 90. Neither SP nor amyloid angiopathy (AA) was observed in any of the non-ATD subjects. In the four of the six ATD subjects, diffuse plaques in the molecular layer were seen as ill-defined areas of fine fibrillar materials by beta protein immunostaining with formic acid pretreatment, the modified Bielschowsky stain, and periodic acid-methenamine silver (PAM) stain. The plaques were not visible with Bodian, Congo red, or periodic acid-Schiff stains. Compact plaques in the Purkinje cell or in the granular cell layers were found in three of the six subjects. Their amyloid core was often surrounded by areolar amyloid deposits. AA was observed in three of the six subjects. The argyrophilia of the diffuse and compact plaques, demonstrated by the modified Bielschowsky and PAM stains, became undetectable when the sections were first treated with formic acid. Such treatment made the plaques immunoreactive with beta protein antiserum. The findings suggested that cerebellar diffuse plaques and compact plaques consist mainly of an amyloid component, and are characteristic of ATD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>College of Medical Care and Technology, Gunma University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirai</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Morimatsu</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shoji</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nakazato</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005561">Formates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance></Chemical><Chemical><RegistryNumber>0YIW783RG1</RegistryNumber><NameOfSubstance UI="C030544">formic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005561" MajorTopicYN="N">Formates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006098" MajorTopicYN="N">Granulocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007106" MajorTopicYN="N">Immune Sera</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2466390</ArticleId><ArticleId IdType="doi">10.1007/BF00687584</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brain. 1979 Mar;102(1):177-92</Citation><ArticleIdList><ArticleId IdType="pubmed">427529</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1988;76(6):541-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3059748</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1984 May 16;120(3):885-90</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1985 Nov;4(11):2757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Dec;82(24):8729-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2934737</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 1986 Jan-Feb;12(1):3-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2422580</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1980 Aug;30(8):820-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7191064</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1986 Jul 24;68(2):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3748453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lab Invest. 1987 Aug;57(2):230-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2441141</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Feb 20;235(4791):873-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3544219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Feb 19-25;325(6106):733-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2474201</PMID><DateCompleted><Year>1989</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>245</Volume><Issue>4916</Issue><PubDate><Year>1989</Year><Month>Jul</Month><Day>28</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>417</StartPage><EndPage>420</EndPage><MedlinePgn>417-20</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid deposition in senile plaques and the cerebral vasculature is a marker of Alzheimer's disease. Whether amyloid itself contributes to the neurodegenerative process or is simply a by-product of that process is unknown. Pheochromocytoma (PC12) and fibroblast (NIH 3T3) cell lines were transfected with portions of the gene for the human amyloid precursor protein. Stable PC12 cell transfectants expressing a specific amyloid-containing fragment of the precursor protein gradually degenerated when induced to differentiate into neuronal cells with nerve growth factor. Conditioned medium from these cells was toxic to neurons in primary hippocampal cultures, and the toxic agent could be removed by immunoabsorption with an antibody directed against the amyloid polypeptide. Thus, a peptide derived from the amyloid precursor may be neurotoxic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>B A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawes</LastName><ForeName>L R</ForeName><Initials>LR</Initials></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Villa-Komaroff</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Oster-Granite</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Neve</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>HD 18655</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD 18658</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 01240</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009693" MajorTopicYN="N">Nucleic Acid Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010673" MajorTopicYN="N">Pheochromocytoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015183" MajorTopicYN="N">Restriction Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>7</Month><Day>28</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>7</Month><Day>28</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2474201</ArticleId><ArticleId IdType="doi">10.1126/science.2474201</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2475254</PMID><DateCompleted><Year>1989</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>4</Issue><PubDate><Year>1989</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts.</ArticleTitle><Pagination><StartPage>615</StartPage><EndPage>622</EndPage><MedlinePgn>615-22</MedlinePgn></Pagination><Abstract><AbstractText>Fibroblasts that harbor an antisense construct of amyloid beta protein precursor (ABPP) cDNA, A-1, produced less ABPP mRNA and ABPP and grew poorly. Normal growth was restored when either parent cell conditioned medium (CM) or purified ABPP was provided. The capacity of the CM to restore cell growth was abolished by passage through an anti-ABPP immunoaffinity column; the activity was in the bound fraction. A Mr 90,000 protein recognized by the anti-ABPP antibody was diminished in the CM of A-1. CM from ABPP cDNA-transfected cells expressing high levels of ABPP was more potent than that from non-transfected parent cells in restoring A-1 growth. These results indicate that ABPP is released from cells into the medium and has an autocrine function in growth regulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saitoh</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, School of Medicine, University of California at San Diego, La Jolla 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundsmo</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Roch</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Schubert</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Oltersdorf</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006133">Growth Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016372">RNA, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002451" MajorTopicYN="N">Cell Compartmentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002455" MajorTopicYN="Y">Cell Division</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006133" MajorTopicYN="N">Growth Substances</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016372" MajorTopicYN="N">RNA, Antisense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>8</Month><Day>25</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>8</Month><Day>25</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2475254</ArticleId><ArticleId IdType="doi">10.1016/0092-8674(89)90096-2</ArticleId><ArticleId IdType="pii">0092-8674(89)90096-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2494667</PMID><DateCompleted><Year>1989</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>7</Issue><PubDate><Year>1989</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor.</ArticleTitle><Pagination><StartPage>2478</StartPage><EndPage>2482</EndPage><MedlinePgn>2478-82</MedlinePgn></Pagination><Abstract><AbstractText>We have isolated genomic and cDNA clones for a Drosophila gene resembling the human beta-amyloid precursor protein (APP). This gene produces a nervous system-enriched 6.5-kilobase transcript. Sequencing of cDNAs derived from the 6.5-kilobase transcript predicts an 886-amino acid polypeptide. This polypeptide contains a putative transmembrane domain and exhibits strong sequence similarity to cytoplasmic and extracellular regions of the human beta-amyloid precursor protein. There is a high probability that this Drosophila gene corresponds to the essential Drosophila locus vnd, a gene required for embryonic nervous system development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>D R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Biology, Brandeis University, Waltham, MA 02254.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Morris</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>L Q</ForeName><Initials>LQ</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>J04516</AccessionNumber><AccessionNumber>J04546</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>GM-33205</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS-07292</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005796" MajorTopicYN="Y">Genes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1989</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2494667</ArticleId><ArticleId IdType="pmc">PMC286936</ArticleId><ArticleId IdType="doi">10.1073/pnas.86.7.2478</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 1987 Jul 3;237(4810):77-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3299701</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1987 Feb 25;15(4):1353-61</Citation><ArticleIdList><ArticleId IdType="pubmed">3822832</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1988 Feb 11;331(6156):530-2</Citation><ArticleIdList><ArticleId IdType="pubmed">2893291</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Feb 20;235(4791):880-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2949367</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1972 Jun;69(6):1408-12</Citation><ArticleIdList><ArticleId IdType="pubmed">4504350</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Jul 8;241(4862):223-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2968652</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 1982 May 5;157(1):105-32</Citation><ArticleIdList><ArticleId IdType="pubmed">7108955</ArticleId></ArticleIdList></Reference><Reference><Citation>Genetics. 1983 Jul;104(3):433-48</Citation><ArticleIdList><ArticleId IdType="pubmed">6411520</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1984 May 16;120(3):885-90</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1985 Nov;4(11):2757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1984 May;3(5):1003-13</Citation><ArticleIdList><ArticleId IdType="pubmed">6329730</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1988 May;7(5):1365-70</Citation><ArticleIdList><ArticleId IdType="pubmed">2900758</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurogenet. 1987 Jun;4(4):179-200</Citation><ArticleIdList><ArticleId IdType="pubmed">3112354</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1986 Sep;5(9):2313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3023069</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7</Citation><ArticleIdList><ArticleId IdType="pubmed">271968</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1988 Apr;7(4):949-57</Citation><ArticleIdList><ArticleId IdType="pubmed">2900137</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1987 Feb;6(2):425-31</Citation><ArticleIdList><ArticleId IdType="pubmed">3107982</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Jun 10;240(4858):1453-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3131880</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Feb 20;235(4791):877-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3810169</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1979 Nov 15;282(5736):310-2</Citation><ArticleIdList><ArticleId IdType="pubmed">116132</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1980 Oct;21(3):729-38</Citation><ArticleIdList><ArticleId IdType="pubmed">6777047</ArticleId></ArticleIdList></Reference><Reference><Citation>Genetics. 1978 Mar;88(3):469-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17248807</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1988 Feb 11;331(6156):528-30</Citation><ArticleIdList><ArticleId IdType="pubmed">2893290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 1970 Mar;48(3):443-53</Citation><ArticleIdList><ArticleId IdType="pubmed">5420325</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1988 Feb 11;331(6156):525-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2893289</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Feb 19-25;325(6106):733-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1983;2(6):927-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16453459</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1987 Jun;84(12):4190-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3035574</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurogenet. 1985 Jun;2(3):197-218</Citation><ArticleIdList><ArticleId IdType="pubmed">3926976</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Biol. 1980 Dec;80(2):332-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6778748</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2483104</PMID><DateCompleted><Year>1990</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>9</Issue><PubDate><Year>1988</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Epitopes that span the tau molecule are shared with paired helical filaments.</ArticleTitle><Pagination><StartPage>817</StartPage><EndPage>825</EndPage><MedlinePgn>817-25</MedlinePgn></Pagination><Abstract><AbstractText>Tau protein has been shown to be an integral component of Alzheimer paired helical filaments (PHF). However, the extent to which tau is incorporated into PHF has not been clear because the antibodies used to label PHF generally do not have precisely defined epitopes. Here we define the antigenic sites for five monoclonal antibodies that react with tau and cross-react with SDS-extracted neurofibrillary tangles. The reactive sites were determined by screening a lambda gt11 sublibrary expressing small fragments of the tau sequence. The mapped epitopes were found to span almost the entire length of tau, suggesting that PHF contains tau in its entirety or nearly in its entirety. One antibody was found to cross-react with microtubule-associated protein 2, implying some degree of homology between the two proteins.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>K S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orecchio</LastName><ForeName>L D</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>V M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG06172</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS00835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="Y">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2483104</ArticleId><ArticleId IdType="doi">10.1016/0896-6273(88)90129-8</ArticleId><ArticleId IdType="pii">0896-6273(88)90129-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2506449</PMID><DateCompleted><Year>1989</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>341</Volume><Issue>6238</Issue><PubDate><Year>1989</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II.</ArticleTitle><Pagination><StartPage>144</StartPage><EndPage>147</EndPage><MedlinePgn>144-7</MedlinePgn></Pagination><Abstract><AbstractText>The A4 protein (or beta-protein) is a 42- or 43-amino-acid peptide present in the extracellular neuritic plaques in Alzheimer's disease and is derived from a membrane-bound amyloid protein precursor (APP). Three forms of APP have been described and are referred to as APP695, APP751 and APP770, reflecting the number of amino acids encoded for by their respective complementary DNAs. The two larger APPs contain a 57-amino-acid insert with striking homology to the Kunitz family of protease inhibitors. Here we report that the deduced amino-terminal sequence of APP is identical to the sequence of a cell-secreted protease inhibitor, protease nexin-II (PN-II). To confirm this finding, APP751 and APP695 cDNAs were over-expressed in the human 293 cell line, and the secreted N-terminal extracellular domains of these APPs were purified to near homogeneity from the tissue-culture medium. The relative molecular mass and high-affinity binding to dextran sulphate of secreted APP751 were consistent with that of PN-II. Functionally, secreted APP751 formed stable, non-covalent, inhibitory complexes with trypsin. Secreted APP695 did not form complexes with trypsin. We conclude that the secreted form of APP with the Kunitz protease inhibitor domain is PN-II.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oltersdorf</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Athena Neurosciences, Inc., South San Francisco, California 94080.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fritz</LastName><ForeName>L C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Lieberburg</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Johnson-Wood</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Beattie</LastName><ForeName>E C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Blacher</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Dovey</LastName><ForeName>H F</ForeName><Initials>HF</Initials></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.4</RegistryNumber><NameOfSubstance UI="D014357">Trypsin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014357" MajorTopicYN="N">Trypsin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>9</Month><Day>14</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>9</Month><Day>14</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2506449</ArticleId><ArticleId IdType="doi">10.1038/341144a0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2518372</PMID><DateCompleted><Year>1990</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>1989</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>The regulation of amyloid beta protein precursor secretion and its modulatory role in cell adhesion.</ArticleTitle><Pagination><StartPage>689</StartPage><EndPage>694</EndPage><MedlinePgn>689-94</MedlinePgn></Pagination><Abstract><AbstractText>The regulation and function of two forms of the amyloid beta protein precursor (ABPP) that are released into the growth-conditioned medium of the PC12 nerve cell line were examined. Nerve growth factor increases the release of the form of ABPP without the protease-inhibitor domain relative to the protein containing the protease inhibitor and increases the overall rate of ABPP secretion 2-fold. In contrast, fibroblast growth factor increases the rate of ABPP secretion approximately 7-fold. Both forms of the secreted ABPP molecule are, in turn, able to stimulate adhesion of PC12 cells to substrata to which they are adsorbed about 10-fold more efficiently on a molar basis than Iaminin.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schubert</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Salk Institute For Biological Studies, San Diego, California 92138.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>L W</ForeName><Initials>LW</Initials></Author><Author ValidYN="Y"><LastName>Saitoh</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>62031-54-3</RegistryNumber><NameOfSubstance UI="D005346">Fibroblast Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron 1990 May;4(5):813</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005346" MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2518372</ArticleId><ArticleId IdType="doi">10.1016/0896-6273(89)90237-7</ArticleId><ArticleId IdType="pii">0896-6273(89)90237-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2529544</PMID><DateCompleted><Year>1989</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>19</Issue><PubDate><Year>1989</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.</ArticleTitle><Pagination><StartPage>7611</StartPage><EndPage>7615</EndPage><MedlinePgn>7611-5</MedlinePgn></Pagination><Abstract><AbstractText>Interleukin 1, an immune response-generated cytokine that stimulates astrocyte proliferation and reactivity (astrogliosis), was present in up to 30 times as many glial cells in tissue sections of brain from patients with Down syndrome and Alzheimer disease compared with age-matched control subjects. Most interleukin 1-immunoreactive glia in Down syndrome and Alzheimer disease were classified as microglia. The number of interleukin 1 immunoreactive neurons did not appear to differ in Down syndrome and Alzheimer disease compared with control brain. Numerous temporal lobe astrocytes in Alzheimer disease and postnatal Down syndrome were intensely interleukin 1-, S-100-, and glial fibrillary acidic protein-immunoreactive and had reactive structure. Interleukin 1 levels in Alzheimer disease temporal lobe homogenates were elevated, as were the levels of S-100 and glial fibrillary acidic protein, two proteins reportedly elevated in reactive astrocytes. These data suggest that increased expression of S-100 in Down syndrome, resulting from duplication of the gene on chromosome 21 that encodes the beta subunit of S-100, may be augmented by elevation of interleukin 1. As a corollary, the astrogliosis in Alzheimer disease may be promoted by elevation of interleukin 1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>W S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock 72205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanley</LastName><ForeName>L C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>MacLeod</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Perrot</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>C L</ForeName><Initials>CL</Initials><Suffix>3rd</Suffix></Author><Author ValidYN="Y"><LastName>Araoz</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05537</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI 14663</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009418">S100 Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009418" MajorTopicYN="N">S100 Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1990</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2529544</ArticleId><ArticleId IdType="pmc">PMC298116</ArticleId><ArticleId IdType="doi">10.1073/pnas.86.19.7611</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropatol Pol. 1986;24(3):365-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3561797</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1985 Nov;42(11):1097-105</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1985 Oct 17;842(2-3):146-50</Citation><ArticleIdList><ArticleId IdType="pubmed">4052452</ArticleId></ArticleIdList></Reference><Reference><Citation>Lymphokine Res. 1986 Spring;5(2):77-85</Citation><ArticleIdList><ArticleId IdType="pubmed">3010001</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1986 Mar;17(3):857-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2422599</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1986 Aug 1;164(2):594-604</Citation><ArticleIdList><ArticleId IdType="pubmed">3487617</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1986;70(1):17-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3727931</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1986 Nov;78(5):1349-54</Citation><ArticleIdList><ArticleId IdType="pubmed">2429991</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1988 Feb 26;52(4):487-501</Citation><ArticleIdList><ArticleId IdType="pubmed">3257719</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 1988 Feb;2(2):108-15</Citation><ArticleIdList><ArticleId IdType="pubmed">3277884</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Mar 11;239(4845):1311-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2964086</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Apr 15;240(4850):321-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3258444</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 1988 Mar;23(2):173-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3357357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 1988 May;43(2):99-136</Citation><ArticleIdList><ArticleId IdType="pubmed">2969441</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1989 Jun 1;320(22):1446-52</Citation><ArticleIdList><ArticleId IdType="pubmed">2566117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1988 Jul;8(7):2485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">2470873</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1989 Jul 3;101(3):288-92</Citation><ArticleIdList><ArticleId IdType="pubmed">2549464</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Oct;86(19):7606-10</Citation><ArticleIdList><ArticleId IdType="pubmed">2508093</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1971 Aug;68(8):1762-6</Citation><ArticleIdList><ArticleId IdType="pubmed">5288762</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1974 Feb;24(2):101-6</Citation><ArticleIdList><ArticleId IdType="pubmed">4272520</ArticleId></ArticleIdList></Reference><Reference><Citation>Humangenetik. 1974 Jan 22;21(1):99-101</Citation><ArticleIdList><ArticleId IdType="pubmed">4276065</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1976 Jan 20;420(1):142-54</Citation><ArticleIdList><ArticleId IdType="pubmed">2294</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1980 Jul;30(7 Pt 1):778-82</Citation><ArticleIdList><ArticleId IdType="pubmed">7190246</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1981 Mar;40(2):95-101</Citation><ArticleIdList><ArticleId IdType="pubmed">7007585</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Immunol. 1980 May;17(5):571-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6971397</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1982 Dec;129(6):2413-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6982921</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1983;61(1):76-80</Citation><ArticleIdList><ArticleId IdType="pubmed">6353837</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1984 Nov;43(5):1494-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6387052</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1984 Dec;81(24):7907-11</Citation><ArticleIdList><ArticleId IdType="pubmed">6083565</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1985 Apr 26;228(4698):497-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3872478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1985 Mar;17(3):278-82</Citation><ArticleIdList><ArticleId IdType="pubmed">3158266</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1985 Sep;45(3):700-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4031854</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2560640</PMID><DateCompleted><Year>1990</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>1989</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Developmentally regulated expression of specific tau sequences.</ArticleTitle><Pagination><StartPage>1389</StartPage><EndPage>1397</EndPage><MedlinePgn>1389-97</MedlinePgn></Pagination><Abstract><AbstractText>Tau protein undergoes a shift in its molecular mass and its electrophoretic complexity during early postnatal development. We have sequenced a tau cDNA from an adult rat brain expression library and have found two inserted sequences. One of these inserts predicts a fourth repeated sequence homologous to the other three in the carboxyl end of tau that have the property of microtubule binding. Oligonucleotide probes directed against the insert hybridized only to tau mRNA at postnatal time points, even though tau is first expressed as early as embryonic day 13. A probe directed against the junction revealed expression of non-insert-containing tau mRNA from embryonic day 14 until postnatal day 8, after which time there was an abrupt decline in the expression of this immature form. Comparison of the developmentally expressed tau sequences with those sequences obtained directly from Alzheimer paired helical filaments revealed the presence of both the mature and the immature tau mRNA sequences.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>K S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Neurology (Neuroscience), Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orecchio</LastName><ForeName>L D</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Bakalis</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Neve</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG06172</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-HD18655</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.17</RegistryNumber><NameOfSubstance UI="D017871">Calcium-Calmodulin-Dependent Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017871" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005796" MajorTopicYN="N">Genes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005809" MajorTopicYN="Y">Genes, Regulator</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005812" MajorTopicYN="Y">Genes, Switch</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005810" MajorTopicYN="N">Multigene Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012091" MajorTopicYN="N">Repetitive Sequences, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2560640</ArticleId><ArticleId IdType="doi">10.1016/0896-6273(89)90077-9</ArticleId><ArticleId IdType="pii">0896-6273(89)90077-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2570916</PMID><DateCompleted><Year>1989</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>8664</Issue><PubDate><Year>1989</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Early marker for Alzheimer's disease: the atrophic hippocampus.</ArticleTitle><Pagination><StartPage>672</StartPage><EndPage>673</EndPage><MedlinePgn>672-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Stylopoulos</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2570916</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(89)90911-2</ArticleId><ArticleId IdType="pii">S0140-6736(89)90911-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2690101</PMID><DateCompleted><Year>1990</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0361-7742</ISSN><JournalIssue CitedMedium="Print"><Volume>317</Volume><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Progress in clinical and biological research</Title><ISOAbbreviation>Prog Clin Biol Res</ISOAbbreviation></Journal><ArticleTitle>The stage specific temporal course of Alzheimer's disease: functional and behavioral concomitants based upon cross-sectional and longitudinal observation.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>41</EndPage><MedlinePgn>23-41</MedlinePgn></Pagination><Abstract><AbstractText>A series of studies published over the past 6 years now permit a relatively precise description of the temporal course of Alzheimer's disease (AD). Initially, 7 global stages of CNS aging and AD were described. Subsequently, data on the stage specific relationship between these stages and widely employed mental status, psychometric, and other assessment measures were collected. Longitudinal studies helped to clarify the borders between normal CNS aging and AD using these measures. Other studies described functioning and self-care correlates of the 7 global stages. These were ultimately divisible into 16 clearly defined, ordinal functional stages. Empirical longitudinal observations permitted the description of the mean temporal course of each of the 16 functional stages of aging and AD. The cross-sectional stage specific data on mental status and other measures can now be applied to the mean temporal course observations and the validity of the temporal estimates forwarded can be investigated in detail. Etiologic hypotheses based upon the observed phenomenologic and temporal course of AD are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Medical Center, New York 10016.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Kluger</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Franssen</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Borenstein</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Alba</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prog Clin Biol Res</MedlineTA><NlmUniqueID>7605701</NlmUniqueID><ISSNLinking>0361-7742</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>24</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2690101</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2817839</PMID><DateCompleted><Year>1989</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>1989</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Microtubular reorganization and dendritic growth response in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>652</StartPage><EndPage>659</EndPage><MedlinePgn>652-9</MedlinePgn></Pagination><Abstract><AbstractText>Cytoskeletal disruption is a key pathological feature of Alzheimer's disease (AD). We used refined immunocytochemical techniques to define the range of abnormalities affecting the microtubule system in AD hippocampus. Minimal tau and tubulin immunoreactivity was granular and accumulated in otherwise normal neuronal perikarya. As tau-reactive neurofibrillary tangles formed, granular tau and tubulin staining diminished, and ubiquitin reactivity developed. In regions of high neurofibrillary tangle density, microtubule-associated protein 2 (MAP2) histochemical features of remaining nontangled neurons included apical dendritic degeneration with proliferation of basal dendrites. In addition to perisomatic dendritic proliferation, there was massive sprouting of tau-immunoreactive distal dystrophic neurites. Sprouting proximal dendrites and dystrophic neurites often demonstrated growth-cone-like lamellipodia and filopodia. Degeneration of the perisomatic proliferating dendrites was characterized by the accumulation of fibrillar tau immunoreactivity. The colocalization of MAP2 and tau in growth structures recapitulated their codistribution in developing neurites. The data suggest that extensive plasticity and growth response occur in tandem with neuronal degeneration in AD, and that reorganization of the cytoskeletal microtubule system may underlie these proliferative changes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Massachusetts General Hospital, Boston 02114.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>N W</ForeName><Initials>NW</Initials></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>K S</ForeName><Initials>KS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 01368-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2817839</ArticleId><ArticleId IdType="doi">10.1002/ana.410260511</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2808689</PMID><DateCompleted><Year>1989</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-5728</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>1989</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neuroimmunology</Title><ISOAbbreviation>J Neuroimmunol</ISOAbbreviation></Journal><ArticleTitle>Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease.</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>182</EndPage><MedlinePgn>173-82</MedlinePgn></Pagination><Abstract><AbstractText>The relationship of microglia and astrocytes to deposits of beta-amyloid protein (BAP) was studied in Alzheimer's disease by immunohistochemistry. BAP was detected in forms varying from diffuse amorphous deposits to compact spherical masses. These latter corresponded in frequency and distribution to senile plaques revealed by Bielschowsky and thioflavine S staining. Approximately half the diffuse deposits had no human leukocyte antigen (HLA)-DR-positive reactive microglia associated with them while nearly all compact deposits had single or multiple HLA-DR-positive reactive microglia embedded in their core. Electron microscopy showed these reactive microglia to be in intimate contact with amyloid fibrils. These data suggest that amyloid deposition may precede the activation of microglia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Itagaki</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of British Columbia, Department of Psychiatry, Kinsmen Laboratory of Neurological Research, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>P L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neuroimmunol</MedlineTA><NlmUniqueID>8109498</NlmUniqueID><ISSNLinking>0165-5728</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006684" MajorTopicYN="N">HLA-DR Antigens</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId><ArticleId IdType="doi">10.1016/0165-5728(89)90115-x</ArticleId><ArticleId IdType="pii">0165-5728(89)90115-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2874414</PMID><DateCompleted><Year>1986</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>8504</Issue><PubDate><Year>1986</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Defective brain microtubule assembly in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>421</StartPage><EndPage>426</EndPage><MedlinePgn>421-6</MedlinePgn></Pagination><Abstract><AbstractText>Brains obtained within 2-4 hours post mortem and histopathologically confirmed for Alzheimer's disease and non-Alzheimer brains from age-matched controls were examined for in-vitro assembly of microtubules and neurofilaments. Microtubule assembly was observed only in control but not in Alzheimer brains, and neurofilaments were obtained from both types of brain. The microtubule-associated protein tau, which stimulates assembly of microtubules from tubulin, was abnormally phosphorylated in Alzheimer but not in control brain microtubule preparations. Alzheimer brains did not show the presence of any inhibitor of microtubule assembly or any abnormality of tubulin. DEAE-dextran, a polycation which mimics tau in stimulating microtubule assembly, induced the assembly of microtubules in Alzheimer brain. Tubulin from both normal and Alzheimer brains was labelled on western blots by a monoclonal antibody to the tyrosinylated carboxy-terminal epitope of alpha tubulin. These studies suggest that in Alzheimer's disease tubulin can be assembled into brain microtubules, but the process is defective, probably because of abnormal phosphorylation of tau. This post-translational alteration of tau might be the cause of the neurofibrillary abnormality in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Grundke-Iqbal</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Zaidi</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Merz</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>G Y</ForeName><Initials>GY</Initials></Author><Author ValidYN="Y"><LastName>Shaikh</LastName><ForeName>S S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Alafuzoff</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG/NS 04220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 17487</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 18105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014404">Tubulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9015-73-0</RegistryNumber><NameOfSubstance UI="D003637">DEAE-Dextran</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet 1986 Nov 15;2(8516):1174</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003637" MajorTopicYN="N">DEAE-Dextran</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014404" MajorTopicYN="N">Tubulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2874414</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(86)92134-3</ArticleId><ArticleId IdType="pii">S0140-6736(86)92134-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2880399</PMID><DateCompleted><Year>1987</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>235</Volume><Issue>4791</Issue><PubDate><Year>1987</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>The genetic defect causing familial Alzheimer's disease maps on chromosome 21.</ArticleTitle><Pagination><StartPage>885</StartPage><EndPage>890</EndPage><MedlinePgn>885-90</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease is a leading cause of morbidity and mortality among the elderly. Several families have been described in which Alzheimer's disease is caused by an autosomal dominant gene defect. The chromosomal location of this defective gene has been discovered by using genetic linkage to DNA markers on chromosome 21. The localization on chromosome 21 provides an explanation for the occurrence of Alzheimer's disease-like pathology in Down syndrome. Isolation and characterization of the gene at this locus may yield new insights into the nature of the defect causing familial Alzheimer's disease and possibly, into the etiology of all forms of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>P H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Polinsky</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Nee</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Pollen</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Drachman</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>ADRC P50 AGO5134</GrantID><Acronym>AD</Acronym><Agency>ADAMHA HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS20012</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS22031</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002891" MajorTopicYN="Y">Chromosomes, Human, Pair 21</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012150" MajorTopicYN="N">Polymorphism, Restriction Fragment Length</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>2</Month><Day>20</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>2</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2880399</ArticleId><ArticleId IdType="doi">10.1126/science.2880399</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2881985</PMID><DateCompleted><Year>1987</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3069</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>3</Issue><PubDate><Year>1987</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles.</ArticleTitle><Pagination><StartPage>262</StartPage><EndPage>268</EndPage><MedlinePgn>262-8</MedlinePgn></Pagination><Abstract><AbstractText>Senile dementia of the Alzheimer type (SDAT) is typified pathologically by neuritic plaques (NP) and neurofibrillary tangles (NFT) in the neocortex and hippocampus. However, in a large series of cases (60) over age 74 a significant minority (30%) lacked neocortical tangles. In order to determine if these latter cases (Group B) otherwise differ from the majority which have both neocortical plaques and tangles (Group A), various clinical and neuropathological parameters were measured for both groups and the results compared. The following indices were examined: degree of dementia, rate of progression of dementia, age at death, brain weight, cerebral hemispheric weight, cortical cell counts from the frontal, temporal, and parietal lobes, the number of neocortical NP, the number of hippocampal NP and NFT, and the levels of neocortical choline acetyltransferase and somatostatin. The two groups showed no statistically significant differences in any of these categories except for increased numbers of neocortical NP in Group A in midfrontal and superior temporal regions. However, cases in Group A showed greater pathologic abnormality in nearly every parameter, albeit without attaining statistical significance. We conclude that SDAT with neocortical NFT is the same disease as SDAT without them, although the presence of such tangles is associated with a tendency towards greater severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Terry</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>DeTeresa</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Tobias</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Katzman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AGO5131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AGO5386</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance UI="D013004">Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013004" MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2881985</ArticleId><ArticleId IdType="doi">10.1097/00005072-198705000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2900758</PMID><DateCompleted><Year>1988</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0261-4189</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>1988</Year><Month>May</Month></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact.</ArticleTitle><Pagination><StartPage>1365</StartPage><EndPage>1370</EndPage><MedlinePgn>1365-70</MedlinePgn></Pagination><Abstract><AbstractText>The cloned cDNA encoding the rat cognate of the human A4 amyloid precursor protein was isolated from a rat brain library. The predicted primary structure of the 695-amino acid-long protein displays 97% identity to its human homologue shown previously to resemble an integral membrane protein. The protein was detected in rodent brain and muscle by Western blot analysis. Using in situ hybridization and immunocytochemistry on rat brain sections, we discovered that rat amyloidogenic glycoprotein (rAG) and its mRNA are ubiquitously and abundantly expressed in neurons indicating a neuronal original for the amyloid deposits observed in humans with Alzheimer's disease (AD). The protein appears in patches on or near the plasma membranes of neurons suggesting a role for this protein in cell contact. Highest expression was seen in rat brain regions where amyloid is deposited in AD but also in areas which do not contain deposits in AD. Since amyloid deposits are rarely observed in rat brain, we conclude that high expression of AG is not the sole cause of amyloidosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shivers</LastName><ForeName>B D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Zentrum f&#xfc;r Molekulare Biologie, Universit&#xe4;t Heidelberg, FRG.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilbich</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Multhaup</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Salbaum</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Beyreuther</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Seeburg</LastName><ForeName>P H</ForeName><Initials>PH</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>X07648</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1989</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2900758</ArticleId><ArticleId IdType="pmc">PMC458385</ArticleId><ArticleId IdType="doi">10.1002/j.1460-2075.1988.tb02952.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 1970 Aug 15;227(5259):680-5</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1988 Feb;7(2):367-72</Citation><ArticleIdList><ArticleId IdType="pubmed">2896589</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1981 Jul;40(4):472-87</Citation><ArticleIdList><ArticleId IdType="pubmed">7195927</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1984 Aug 16;122(3):1131-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6236805</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1985 Nov;4(11):2757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 1986;124:497-510</Citation><ArticleIdList><ArticleId IdType="pubmed">3754925</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Feb 20;235(4791):873-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3544219</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Feb 20;235(4791):877-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3810169</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Feb 19-25;325(6106):733-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Mar 13;235(4794):1390-2</Citation><ArticleIdList><ArticleId IdType="pubmed">2950593</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Mar 27;235(4796):1641-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3029875</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Jul 3;237(4810):77-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3299701</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Sep 10-16;329(6135):153-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3306405</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Sep 10-16;329(6135):156-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2888020</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1987 Dec 1;6(12):3627-32</Citation><ArticleIdList><ArticleId IdType="pubmed">3322812</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4</Citation><ArticleIdList><ArticleId IdType="pubmed">388439</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2950593</PMID><DateCompleted><Year>1987</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>235</Volume><Issue>4794</Issue><PubDate><Year>1987</Year><Month>Mar</Month><Day>13</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Beta amyloid gene duplication in Alzheimer's disease and karyotypically normal Down syndrome.</ArticleTitle><Pagination><StartPage>1390</StartPage><EndPage>1392</EndPage><MedlinePgn>1390-2</MedlinePgn></Pagination><Abstract><AbstractText>With the recently cloned complementary DNA probe, lambda Am4 for the chromosome 21 gene encoding brain amyloid polypeptide (beta amyloid protein) of Alzheimer's disease, leukocyte DNA from three patients with sporadic Alzheimer's disease and two patients with karyotypically normal Down syndrome was found to contain three copies of this gene. Because a small region of chromosome 21 containing the ets-2 gene is duplicated in patients with Alzheimer's disease, as well as in karyotypically normal Down syndrome, duplication of a subsection of the critical segment of chromosome 21 that is duplicated in Down syndrome may be the genetic defect in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delabar</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Goldgaber</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lamour</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Nicole</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Huret</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>de Grouchy</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gajdusek</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Sinet</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002891" MajorTopicYN="Y">Chromosomes, Human, Pair 21</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007962" MajorTopicYN="N">Leukocytes</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005810" MajorTopicYN="Y">Multigene Family</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>3</Month><Day>13</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>3</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2950593</ArticleId><ArticleId IdType="doi">10.1126/science.2950593</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2960019</PMID><DateCompleted><Year>1987</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>238</Volume><Issue>4827</Issue><PubDate><Year>1987</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Gene dosage of the amyloid beta precursor protein in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>669</StartPage><EndPage>671</EndPage><MedlinePgn>669-71</MedlinePgn></Pagination><Abstract><AbstractText>The progressive deposition in the human brain of amyloid filaments composed of the amyloid beta protein is a principal feature of Alzheimer's disease (AD). Densitometric analysis of Southern blots probed with a complementary DNA for the amyloid protein has been carried out to determine the relative dosage of this gene in genomic DNA of 14 patients with AD, 12 aged normal subjects, and 10 patients with trisomy 21 (Down syndrome). Whereas patients in the last group showed the expected 1.5-fold increase in dosage of this gene, none of the patients with AD had a gene dosage higher than that of the normal controls. These results do not support the hypothesis that the genetic defect in AD involves duplication of a segment of chromosome 21 containing the amyloid gene. Alternative mechanisms for the brain-specific increase in amyloid protein deposition in AD should be considered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Podlisny</LastName><ForeName>M B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AGO2741</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AGO6173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002891" MajorTopicYN="N">Chromosomes, Human, Pair 21</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005796" MajorTopicYN="N">Genes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007962" MajorTopicYN="N">Leukocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>10</Month><Day>30</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>10</Month><Day>30</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2960019</ArticleId><ArticleId IdType="doi">10.1126/science.2960019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2968652</PMID><DateCompleted><Year>1988</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>241</Volume><Issue>4862</Issue><PubDate><Year>1988</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta protein precursor is possibly a heparan sulfate proteoglycan core protein.</ArticleTitle><Pagination><StartPage>223</StartPage><EndPage>226</EndPage><MedlinePgn>223-6</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid beta protein peptide is a major constituent of amyloid plaque cores in Alzheimer's disease and is apparently derived from a higher molecular weight precursor. It is now shown that the core protein of a heparan sulfate proteoglycan secreted from a nerve cell line (PC12) has an amino acid sequence and a size very similar to those of the amyloid beta protein precursor and that these molecules are antigenically related. This amyloid beta protein precursor-related protein is not found in the conditioned medium of a variant cell line (F3 PC12) that does not secrete heparan sulfate proteoglycan. The synaptic localization and metabolism of this class of proteoglycans are consistent with its potential involvement in central nervous system dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schubert</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Salk Institute for Biological Studies, San Diego, CA 92138.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>LaCorbiere</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Saitoh</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F2 AG 05424A</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 09658</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011508">Chondroitin Sulfate Proteoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006025">Glycosaminoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019812">Heparan Sulfate Proteoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011509">Proteoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014758">Viral Core Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011508" MajorTopicYN="N">Chondroitin Sulfate Proteoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006025" MajorTopicYN="N">Glycosaminoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019812" MajorTopicYN="N">Heparan Sulfate Proteoglycans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="N">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007158" MajorTopicYN="N">Immunologic Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011509" MajorTopicYN="N">Proteoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014758" MajorTopicYN="N">Viral Core Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>7</Month><Day>8</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>7</Month><Day>8</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2968652</ArticleId><ArticleId IdType="doi">10.1126/science.2968652</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3029875</PMID><DateCompleted><Year>1987</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>235</Volume><Issue>4796</Issue><PubDate><Year>1987</Year><Month>Mar</Month><Day>27</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Ubiquitin is a component of paired helical filaments in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1641</StartPage><EndPage>1644</EndPage><MedlinePgn>1641-4</MedlinePgn></Pagination><Abstract><AbstractText>Paired helical filaments (PHF), which constitute a distinct type of pathological neuronal fiber, are the principal constituent of neurofibrillary tangles that occur in the brain of patients with Alzheimer's disease. Their insolubility in sodium dodecyl sulfate and urea has prevented the analysis of their subunit composition by gel electrophoresis. A monoclonal antibody (DF2) was isolated that specifically labeled PHF at both the light and electron microscopic levels. It labeled a small polypeptide (5 kilodaltons) that was shown to be ubiquitin in immunoblots of the soluble fraction of brain homogenates. To obtain direct evidence that ubiquitin is a component of PHF, PHF were treated with concentrated formic acid and digested with lysylendopeptidase; ubiquitin-derived peptides were then identified by reversed-phase high-performance liquid chromatography. Two fragments in the PHF digest were identified as derived from ubiquitin by protein sequencing. This procedure should make possible definitive identification of other PHF components.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ihara</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014452">Ubiquitins</NameOfSubstance></Chemical><Chemical><RegistryNumber>368GB5141J</RegistryNumber><NameOfSubstance UI="D012967">Sodium Dodecyl Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>8W8T17847W</RegistryNumber><NameOfSubstance UI="D014508">Urea</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012967" MajorTopicYN="N">Sodium Dodecyl Sulfate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014452" MajorTopicYN="N">Ubiquitins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014508" MajorTopicYN="N">Urea</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>3</Month><Day>27</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>3</Month><Day>27</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3029875</ArticleId><ArticleId IdType="doi">10.1126/science.3029875</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3033674</PMID><DateCompleted><Year>1987</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>84</Volume><Issue>9</Issue><PubDate><Year>1987</Year><Month>May</Month></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.</ArticleTitle><Pagination><StartPage>3033</StartPage><EndPage>3036</EndPage><MedlinePgn>3033-6</MedlinePgn></Pagination><Abstract><AbstractText>Neurofibrillary tangles (NFT) and neurites associated with senile plaques (SP) in Alzheimer disease-affected brain tissues were specifically immunostained with affinity-purified antibody preparations directed against ubiquitin. In addition, a class of neurites seen in brain regions containing NFT and SP were also specifically stained. Cross-reactivity of the ubiquitin antisera for tau protein, neurofilament proteins, and high molecular weight microtubule-associated proteins (MAPs) were ruled out by (i) the inability of the ubiquitin antisera to stain these proteins in immunoblotting experiments and (ii) the inability of tau, neurofilament, and MAP preparations, when preincubated with the ubiquitin antisera, to inhibit the selective neurofibrillar staining observed. Our results are consistent with the suggestion that ubiquitin is covalently associated with the insoluble neurofibrillary material of NFT and SP. We propose that the ubiquitin-mediated degradative pathway may be ineffective in removing these fibrillar structures in Alzheimer disease brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Chau</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG00795</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM 35803</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS22695</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000936">Antigen-Antibody Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014452">Ubiquitins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000936" MajorTopicYN="N">Antigen-Antibody Complex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014452" MajorTopicYN="N">Ubiquitins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1987</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3033674</ArticleId><ArticleId IdType="pmc">PMC304795</ArticleId><ArticleId IdType="doi">10.1073/pnas.84.9.3033</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neuropathol Exp Neurol. 1968 Apr;27(2):167-82</Citation><ArticleIdList><ArticleId IdType="pubmed">5646193</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1978 Dec 1;92(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">729584</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 1980 Apr;126(2):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">6153988</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1980 Jun 12;302(24):1333-43</Citation><ArticleIdList><ArticleId IdType="pubmed">6990257</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1980 Apr;77(4):1783-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6990414</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1980 Aug 25;255(16):7525-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6249802</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1980 Nov 1;191(2):543-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7195199</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1982 Mar 5;215(4537):1243-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6120571</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Biochem. 1982;51:335-64</Citation><ArticleIdList><ArticleId IdType="pubmed">6287917</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1983 Aug;34(1):11-2</Citation><ArticleIdList><ArticleId IdType="pubmed">6309404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1983 Aug 25-31;304(5928):727-30</Citation><ArticleIdList><ArticleId IdType="pubmed">6350889</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1982 Oct;79(19):5857-61</Citation><ArticleIdList><ArticleId IdType="pubmed">6310549</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1984 Mar;81(6):1619-23</Citation><ArticleIdList><ArticleId IdType="pubmed">6324208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1984 Apr 25;259(8):5301-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6425287</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1984 May;37(1):57-66</Citation><ArticleIdList><ArticleId IdType="pubmed">6327060</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1985 May 10;260(9):5232-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2985583</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(11):3916-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3889918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1985 Oct 15;260(23):12464-73</Citation><ArticleIdList><ArticleId IdType="pubmed">2995377</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1985 Nov;42(11):1097-105</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 1985 Sep;31(3):213-55</Citation><ArticleIdList><ArticleId IdType="pubmed">3906293</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1986 May 5;261(13):6084-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1986 Feb;5(2):269-76</Citation><ArticleIdList><ArticleId IdType="pubmed">2423324</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1986 Apr 24;65(3):351-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2423928</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Jun;83(11):4040-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Jun;83(11):4044-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1986 Nov 5;261(31):14365-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3021736</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cell Biol. 1986 Oct;42(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3539605</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3035574</PMID><DateCompleted><Year>1987</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>84</Volume><Issue>12</Issue><PubDate><Year>1987</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides.</ArticleTitle><Pagination><StartPage>4190</StartPage><EndPage>4194</EndPage><MedlinePgn>4190-4</MedlinePgn></Pagination><Abstract><AbstractText>Deposits of amyloid fibers are found in large numbers in the walls of blood vessels and in neuritic plaques in the brains of patients with Alzheimer disease and adults with Down syndrome. We used the amino acid sequence of the amyloid peptide to synthesize oligonucleotide probes specific for the gene encoding this peptide. When a human brain cDNA library was screened with this probe, a clone was found with a 1.7-kilobase insert that contains a long open reading frame coding for 412 amino acid residues including the 28 amino acids of the amyloid peptide. RNA gel blots revealed that a 3.3-kilobase mRNA species was present in the brains of individuals with Alzheimer disease, with Down syndrome, or with no apparent neurological disorders. Southern blots showed that homologous genes are present in the genomic DNA of humans, rabbits, sheep, hamsters, and mice, suggesting that this gene has been conserved through mammalian evolution. Localization of the corresponding genomic sequences on human chromosome 21 suggests a genetic relationship between Alzheimer disease and Down syndrome, and it may explain the early appearance of large numbers of neuritic plaques in adult Down syndrome patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robakis</LastName><ForeName>N K</ForeName><Initials>NK</Initials></Author><Author ValidYN="Y"><LastName>Ramakrishna</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>M16765</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>AG04220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009838">Oligodeoxyribonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.21.-</RegistryNumber><NameOfSubstance UI="D004262">DNA Restriction Enzymes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A 1987 Oct;84(20):7221</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="Y">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004262" MajorTopicYN="N">DNA Restriction Enzymes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005796" MajorTopicYN="Y">Genes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009838" MajorTopicYN="N">Oligodeoxyribonucleotides</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1987</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3035574</ArticleId><ArticleId IdType="pmc">PMC305050</ArticleId><ArticleId IdType="doi">10.1073/pnas.84.12.4190</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1972 Jun;69(6):1408-12</Citation><ArticleIdList><ArticleId IdType="pubmed">4504350</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 1975 Nov 5;98(3):503-17</Citation><ArticleIdList><ArticleId IdType="pubmed">1195397</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7</Citation><ArticleIdList><ArticleId IdType="pubmed">271968</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Genet. 1978 Jul;8(4):315-31</Citation><ArticleIdList><ArticleId IdType="pubmed">567976</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1978 Dec;15(4):1157-74</Citation><ArticleIdList><ArticleId IdType="pubmed">728996</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1980 Jun 5;302(23):1283-92</Citation><ArticleIdList><ArticleId IdType="pubmed">6154243</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1980 Mar;77(3):1496-500</Citation><ArticleIdList><ArticleId IdType="pubmed">6929499</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1980 Apr 11;8(7):1499-504</Citation><ArticleIdList><ArticleId IdType="pubmed">6253938</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1980 Sep;77(9):5201-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6159641</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1981 Jan 25;256(2):1023-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6161125</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1981 Jan 10;9(1):r43-74</Citation><ArticleIdList><ArticleId IdType="pubmed">7208352</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1981 Jan 24;9(2):309-21</Citation><ArticleIdList><ArticleId IdType="pubmed">6259625</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1981 Nov;120(2):275-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7318825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1981 Dec;10(6):517-22</Citation><ArticleIdList><ArticleId IdType="pubmed">7198888</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 1982 May 5;157(1):105-32</Citation><ArticleIdList><ArticleId IdType="pubmed">7108955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1983 Dec;35(2 Pt 1):349-58</Citation><ArticleIdList><ArticleId IdType="pubmed">6418385</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1984 Feb;3(2):361-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6232133</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1984 May 16;120(3):885-90</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1984 Jul 27;225(4660):437-40</Citation><ArticleIdList><ArticleId IdType="pubmed">6377496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1984 Aug;38(1):287-97</Citation><ArticleIdList><ArticleId IdType="pubmed">6088071</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1985 Apr;40(4):735-46</Citation><ArticleIdList><ArticleId IdType="pubmed">2859120</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1985 Jul;35(7):957-61</Citation><ArticleIdList><ArticleId IdType="pubmed">3159974</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1985 Nov;4(11):2757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Dec;82(24):8729-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2934737</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1986 May 5;261(13):6084-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1986 Jun;38(6):793-804</Citation><ArticleIdList><ArticleId IdType="pubmed">3014865</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Sep;83(17):6377-81</Citation><ArticleIdList><ArticleId IdType="pubmed">3529083</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Med Virol. 1986;33:78-98</Citation><ArticleIdList><ArticleId IdType="pubmed">3092282</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1986 Oct 30;140(2):758-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2877664</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1987 Feb 14;1(8529):384-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2880184</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Feb 20;235(4791):877-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3810169</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Feb 20;235(4791):880-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2949367</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Feb 19-25;325(6106):733-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3059748</PMID><DateCompleted><Year>1989</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-6322</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>6</Issue><PubDate><Year>1988</Year></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining.</ArticleTitle><Pagination><StartPage>541</StartPage><EndPage>549</EndPage><MedlinePgn>541-9</MedlinePgn></Pagination><Abstract><AbstractText>We studied cerebral amyloid deposits in the hippocampal area immunohistochemically, using antiserum to synthetic beta peptide (1-28) in 66 patients with or without dementia and aged 17 to 91 years old. Senile plaques (SP) and amyloid angiopathy (AA) were detected in 36 (55%) and 19 (29%) patients, respectively. Also, cerebral amyloid deposits from the brains of seven patients with dementia and five patients without were studied in serial sections stained with Bodian, modified Bielschowsky, Congo red, and beta protein immunostain. In the patients with Alzheimer-type dementia (ATD) diffuse plaques, typical of this group, were stained with beta protein antiserum but not with Bodian stain, because the plaques were devoid of abnormally swollen neuritic processes. The diffuse plaques often contained one or more neuronal cell bodies. As well as primitive and classic plaques and AA, the beta protein immunostain demonstrated small deposits among the SP, small stellate deposits of layer 1, subpial fibrillar deposits, and focal cribriform deposits of parasubiculum, which may be new types of amyloid deposits. Amyloid plaques within the subcortical white matter were only found in ATD brains. In the non-demented patients various kinds of SP, including diffuse and compact ones, were immunostained. They tended to be small and few. beta protein immunostain with formic acid pretreatment is a useful method for the identification of a variety of senile cerebral amyloid deposits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>College of Medical Care and Technology, Gunma University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirai</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Morimatsu</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shoji</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ihara</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3059748</ArticleId><ArticleId IdType="doi">10.1007/BF00689591</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Psychiatry. 1968 Jul;114(512):797-811</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1986;70(3-4):202-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2945355</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Jul 3;237(4810):77-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3299701</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1987;74(2):133-41</Citation><ArticleIdList><ArticleId IdType="pubmed">3673504</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinsho Shinkeigaku. 1987 May;27(5):617-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3621759</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1984 May 16;120(3):885-90</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1987 May 29;145(1):241-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3593340</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1985 Nov;4(11):2757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Dec;82(24):8729-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2934737</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1975 Sep;23(9):390-406</Citation><ArticleIdList><ArticleId IdType="pubmed">50338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1985 Mar;17(3):273-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3994315</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 1986 Jan-Feb;12(1):3-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2422580</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1968 Sep-Oct;7(2):331-56</Citation><ArticleIdList><ArticleId IdType="pubmed">5707082</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 1983 Sep-Oct;9(5):379-89</Citation><ArticleIdList><ArticleId IdType="pubmed">6646345</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1986 Jul 24;68(2):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3748453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lab Invest. 1987 Aug;57(2):230-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2441141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1983 Aug 25-31;304(5928):727-30</Citation><ArticleIdList><ArticleId IdType="pubmed">6350889</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Feb 20;235(4791):873-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3544219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Feb 19-25;325(6106):733-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>